

Pembrolizumab for the Treatment of Non-“Small-Cell

New England Journal of Medicine

372, 2018-2028

DOI: [10.1056/nejmoa1501824](https://doi.org/10.1056/nejmoa1501824)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current state of immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 196-211.	1.3	150
2	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 178-185.	1.3	21
3	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <i>Translational Lung Cancer Research</i> , 2007, 6, 169-177.	1.3	4
4	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 220-229.	1.3	10
5	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 113-118.	1.3	13
6	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Nonâ€“Small Cell Carcinoma of the Lung. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 171-174.	1.2	20
7	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 13110.	1.6	310
8	Immune Checkpoint Blockade in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2015, 4, 201-207.	4.2	40
12	Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 319.	1.8	27
14	JITC launches a new section: commentary and editorials. , 2015, 3, 28.		0
15	Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. <i>Melanoma Research</i> , 2015, 25, 555-558.	0.6	35
16	An update on current standards and clinical trials in systemic therapy for stage III NSCLC. <i>Lung Cancer Management</i> , 2015, 4, 289-297.	1.5	0
17	From Uniplex to Multiplex Molecular Profiling in Advanced Nonâ€“Small Cell Lung Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 413-424.	1.0	3
18	Recent advances in antibodyâ€“based therapies for Hodgkin Lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 171-178.	1.2	4
19	Immunotherapy for Advanced Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 383-391.	1.0	10
20	Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. <i>Pharmacotherapy</i> , 2015, 35, 963-976.	1.2	183
22	The Evolution of Therapies in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2015, 7, 1815-1846.	1.7	107
23	Antiâ€“PD-1/PD-L1 therapy of human cancer: past, present, and future. <i>Journal of Clinical Investigation</i> , 2015, 125, 3384-3391.	3.9	1,112

#	ARTICLE	IF	CITATIONS
24	The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastro­intestinal tract cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 2617.	1.0	28
25	Evaluaci3n positiva de medicamentos: marzo/abril/mayo 2015. <i>Sanidad Militar</i> , 2015, 71, 186-195.	0.0	0
26	Low Elderly Participation in Non-Small Cell Lung Cancer Clinical Trials. <i>Journal of Gerontology & Geriatric Research</i> , 2015, s4, .	0.1	1
27	Drug Development for Metastasis Prevention. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 449-473.	0.2	48
28	Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. <i>Vaccines</i> , 2015, 3, 662-685.	2.1	225
29	Targeting C-Type Lectin Receptors for Cancer Immunity. <i>Frontiers in Immunology</i> , 2015, 6, 408.	2.2	80
30	Novel Immune Check-Point Regulators in Tolerance Maintenance. <i>Frontiers in Immunology</i> , 2015, 6, 421.	2.2	37
31	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. <i>Frontiers in Immunology</i> , 2015, 6, 582.	2.2	73
32	Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells. <i>Frontiers in Immunology</i> , 2015, 6, 633.	2.2	12
33	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015, 10, e0130142.	1.1	390
34	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. <i>PLoS ONE</i> , 2015, 10, e0136023.	1.1	202
35	Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. <i>OncoTargets and Therapy</i> , 2015, 8, 2949.	1.0	7
36	Immunotherapy in Tumors. <i>Deutsches A&#x0308;rztblatt International</i> , 2015, 112, 809-15.	0.6	31
37	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
38	New & Emerging Drugs for Squamous Cell Lung Cancer. <i>Chemotherapy</i> , 2015, 05, .	0.0	0
39	Checkpoint blockade in lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 69-73.	0.9	11
40	IMCT-01PEMBROLIZUMAB: FIRST EXPERIENCE WITH RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2015, 17, v107.1-v107.	0.6	2
41	Reply to D.A. Palma et al and A. Addeo et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 2929-2930.	0.8	2

#	ARTICLE	IF	CITATIONS
42	Screening for Lung Cancer: What Comes Next?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3847-3848.	0.8	9
43	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1308-1315.	1.6	114
44	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. <i>Cancer Immunology Research</i> , 2015, 3, 1292-1298.	1.6	38
45	Promise of Immunotherapy in Lung Cancer. <i>Progress in Tumor Research</i> , 2015, 42, 95-109.	0.1	2
46	Immunotherapy: the third wave in lung cancer treatment. <i>Lancet Respiratory Medicine</i> , 2015, 3, 923-924.	5.2	4
47	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1033-1043.	0.9	30
48	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1396-1403.	0.5	76
49	Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC. <i>Current Breast Cancer Reports</i> , 2015, 7, 203-209.	0.5	2
50	ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. <i>Journal of Hematology and Oncology</i> , 2015, 8, 129.	6.9	223
51	New hope on the horizon for patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2015, 4, 229-239.	0.8	0
53	Combination cancer immunotherapy and new immunomodulatory targets. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 561-584.	21.5	1,058
54	Update in Lung Cancer 2014. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 283-294.	2.5	36
55	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 ^{-/-} /IL2R ^β null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.4	137
56	Immune therapy of non-small cell lung cancer. The future. <i>Pharmacological Research</i> , 2015, 99, 217-222.	3.1	20
57	Challenges and future perspectives of T cell immunotherapy in cancer. <i>Immunology Letters</i> , 2015, 166, 117-133.	1.1	41
58	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	12.8	576
59	Pembrolizumab "is the writing on the wall for cancer?". <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 371-371.	12.5	0
60	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	13.9	7,973

#	ARTICLE	IF	CITATIONS
61	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. <i>Annals of Oncology</i> , 2015, 26, 2375-2391.	0.6	1,136
62	What are the options for non-small-cell lung cancer patients post second-line therapy?. <i>Future Oncology</i> , 2015, 11, 2379-2382.	1.1	1
63	Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique. <i>Oncologie</i> , 2015, 17, 379-389.	0.2	0
64	Immunomodulation: checkpoint blockade etc.: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii26-vii31.	0.6	26
65	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <i>Molecular Oncology</i> , 2015, 9, 2043-2053.	2.1	87
66	Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials. <i>Clinical Cancer Research</i> , 2015, 21, 4545-4551.	3.2	33
68	Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1609-1621.	2.0	42
70	Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2015, 75, 1925-1934.	4.9	23
71	AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. <i>Journal of Hematology and Oncology</i> , 2015, 8, 96.	6.9	84
72	Immunological landscape and immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 681-700.	8.2	478
73	Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. <i>British Journal of Cancer</i> , 2015, 113, 1343-1349.	2.9	54
74	Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. <i>Seminars in Oncology</i> , 2015, 42, S19-S28.	0.8	17
75	ASCO update 2015: lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 213-215.	0.3	0
76	The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Oncologist</i> , 2015, 20, 1253-1260.	1.9	40
77	Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas. <i>European Journal of Cancer</i> , 2015, 51, 2698-2707.	1.3	150
78	Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, S11-S18.	0.8	55
79	Efficacy of a Cancer Vaccine against <i>ALK</i> -Rearranged Lung Tumors. <i>Cancer Immunology Research</i> , 2015, 3, 1333-1343.	1.6	42
81	Immunogénicité de la chimiothérapie. <i>Oncologie</i> , 2015, 17, 345-353.	0.2	0

#	ARTICLE	IF	CITATIONS
82	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. <i>Trends in Cancer</i> , 2015, 1, 66-75.	3.8	101
83	Update on Mucin-1 immunotherapy in cancer: a clinical perspective. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1773-1787.	1.4	36
84	Endocrine resistance in breast cancer – An overview and update. <i>Molecular and Cellular Endocrinology</i> , 2015, 418, 220-234.	1.6	280
85	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3488-3515.	0.8	606
86	Pembrolizumab. , 2015, 3, 36.		171
87	Management of Dermatologic Complications of Lung Cancer Therapies. <i>Current Treatment Options in Oncology</i> , 2015, 16, 50.	1.3	13
88	Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015, 42, 55-66.	0.1	151
89	Immunopharmacogenomics. , 2015, , .		3
90	Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. <i>Drugs</i> , 2015, 75, 1757-1771.	4.9	11
91	Advancing pharmacological treatment options for advanced gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2293-2305.	0.9	10
93	Landscape of Tumor Antigens in T Cell Immunotherapy. <i>Journal of Immunology</i> , 2015, 195, 5117-5122.	0.4	124
94	Crizotinib: an orphan drug for treating non-small-cell lung cancer. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1209-1218.	0.5	1
95	Nivolumab for treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1789-1797.	1.4	27
96	Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma. <i>Journal of Oral and Maxillofacial Surgery</i> , 2015, 73, S107-S115.	0.5	6
97	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 104.	6.9	139
98	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 868-876.	3.4	358
99	Battling regional (stage III) lung cancer: bumpy road of a cancer survivor in the immunotherapy age. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215304.	0.2	2
100	Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016216426.	0.2	20

#	ARTICLE	IF	CITATIONS
101	Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. Journal of Thoracic Disease, 2016, 8, E1348-E1350.	0.6	6
102	Immuno-oncology. , 2016, , .		0
103	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget, 2016, 7, 56233-56240.	0.8	48
104	Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biology and Medicine, 2016, 13, 171-193.	1.4	98
105	Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget, 2016, 7, 52810-52817.	0.8	305
106	Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. Reviews on Recent Clinical Trials, 2016, 11, 87-92.	0.4	3
107	The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget, 2016, 7, 3477-3488.	0.8	73
108	Clinical significance of <i>PD-L1</i> and <i>PD-L2</i> copy number gains in non-small-cell lung cancer. Oncotarget, 2016, 7, 32113-32128.	0.8	100
109	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. OncoTargets and Therapy, 2016, Volume 9, 5855-5866.	1.0	11
110	A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. OncoTargets and Therapy, 2016, Volume 9, 7275-7283.	1.0	49
111	Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?. Cancer Biology and Medicine, 2016, 13, 157-170.	1.4	86
112	Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedalscience, 2016, 10, 648.	0.6	29
113	Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?. Reviews on Recent Clinical Trials, 2016, 11, 81-86.	0.4	12
114	Combined Modality Therapy for Thoracic and head and Neck Cancers: A Review of Updated Literature Based on a Consensus Meeting. Tumori, 2016, 102, 459-471.	0.6	11
115	Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer. OncoTargets and Therapy, 2016, 9, 3187.	1.0	11
116	New targeted treatments for non-small-cell lung cancer – role of nivolumab. Biologics: Targets and Therapy, 2016, Volume 10, 103-117.	3.0	23
117	Análise da expressão de PD-L1 no microambiente do câncer de pulmão de não pequenas células e de seu papel como potencial marcador preditivo. , 2016, 95, 76.	0.0	0
118	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. Journal of Gastrointestinal Oncology, 2016, 7, 771-788.	0.6	84

#	ARTICLE	IF	CITATIONS
119	Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast. <i>Oncotarget</i> , 2016, 7, 1707-1716.	0.8	25
120	Seeking New Approaches to Patients With Small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e477-e482.	1.8	2
121	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 34-42.	1.8	85
122	Biomarkers for Immunotherapy: Current Developments and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e493-e503.	1.8	85
123	PD-L1 expression in lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 3053-3055.	0.6	2
124	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives. <i>Translational Lung Cancer Research</i> , 2016, 5, 628-636.	1.3	15
125	Pembrolizumab as first-line treatment for non-small cell lung cancer—“a game changer?”. <i>Translational Lung Cancer Research</i> , 2016, 5, 538-542.	1.3	4
126	Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature. <i>Translational Lung Cancer Research</i> , 2016, 5, 720-726.	1.3	32
127	Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases. <i>Journal of Thoracic Disease</i> , 2016, 8, E535-E537.	0.6	21
128	Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 479-486.	0.6	21
129	Advances in targeted therapy and immunotherapy for treatment of lung cancer. <i>Annals of Cancer Research and Therapy</i> , 2016, 24, 1-6.	0.1	1
130	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	0.8	100
131	Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	0.9	17
132	Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer. <i>Disease Markers</i> , 2016, 2016, 1-12.	0.6	26
133	Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). <i>Medical Journal of Australia</i> , 2016, 205, 418-424.	0.8	29
134	PD-1 blockade enhances the vaccination-induced immune response in glioma. <i>JCI Insight</i> , 2016, 1, .	2.3	128
135	Toxicity management of immunotherapy for patients with metastatic melanoma. <i>Annals of Translational Medicine</i> , 2016, 4, 272-272.	0.7	92
136	Potential role of immunotherapy in advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 21-30.	1.0	46

#	ARTICLE	IF	CITATIONS
137	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. <i>Theranostics</i> , 2016, 6, 1629-1640.	4.6	167
138	An update on clinical oncology for the non-oncologist. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 294-299.	0.3	2
139	Monitoring of the Immune Dysfunction in Cancer Patients. <i>Vaccines</i> , 2016, 4, 29.	2.1	15
140	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	2.2	409
141	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 621.	2.2	132
142	Systemic Immunotherapy for the Treatment of Brain Metastases. <i>Frontiers in Oncology</i> , 2016, 6, 49.	1.3	66
143	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 233.	1.3	148
144	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. <i>Frontiers in Oncology</i> , 2016, 6, 256.	1.3	39
145	Biomarkers for immune therapy in colorectal cancer: mismatch-repair deficiency and others. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 713-720.	0.6	45
146	Advances in Cancer Immunotherapy in Solid Tumors. <i>Cancers</i> , 2016, 8, 106.	1.7	131
147	First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma—An Update on Patient Selection and Response Evaluation. <i>Diagnostics</i> , 2016, 6, 44.	1.3	11
148	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. <i>PLoS ONE</i> , 2016, 11, e0153954.	1.1	73
149	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3153-3161.	2.0	29
150	Immune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5101-5116.	1.0	27
151	Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. <i>OncoTargets and Therapy</i> , 2016, 9, 3711.	1.0	98
152	PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. <i>OncoTargets and Therapy</i> , 2016, 9, 489.	1.0	43
153	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 215-215.	0.7	13
154	Immunotherapy in non-small cell lung cancer: the clinical impact of immune response and targeting. <i>Annals of Translational Medicine</i> , 2016, 4, 268-268.	0.7	16

#	ARTICLE	IF	CITATIONS
155	Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix. <i>Oncotarget</i> , 2016, 7, 75379-75393.	0.8	27
156	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 73068-73079.	0.8	76
157	Checkpoint Inhibition. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 17-22.	1.0	17
158	Chemoradiotherapy of locally advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 104-109.	1.1	16
159	Adjuvant therapy for nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 150-158.	1.1	6
160	Checkpoint inhibitors and gastrointestinal immune-related adverse events. <i>Current Opinion in Oncology</i> , 2016, 28, 264-268.	1.1	35
161	Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. <i>Lung Cancer</i> , 2016, 98, 114-117.	0.9	127
162	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
163	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 974-980.	1.9	64
164	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. <i>Immunotherapy</i> , 2016, 8, 809-819.	1.0	44
165	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016, 8, 907-921.	1.0	20
167	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (<i>LSL^{Kras}G12D/+</sup>;LSL^{Trp53}R172H/+</sup>;Pdx¹Cre</i>), Its Variants, and Their Application in Immunotherapy Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2016, 73, 14.39.1-14.39.20.	4.0	141
168	Severe Psoriasis Flare After Anti-Programmed Death Ligand 1 (PD-L1) Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC). <i>Journal of Immunotherapy</i> , 2016, 39, 202-204.	1.2	33
169	Immune Checkpoint Therapy in Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 81-91.	1.0	11
170	Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. <i>Lung Cancer</i> , 2016, 98, 51-58.	0.9	110
171	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2016, 22, 4309-4321.	3.2	182
172	Multispectral Imaging of T and B Cells in Murine Spleen and Tumor. <i>Journal of Immunology</i> , 2016, 196, 3943-3950.	0.4	63
173	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. <i>Journal of Neuro-Oncology</i> , 2016, 129, 453-460.	1.4	82

#	ARTICLE	IF	CITATIONS
174	Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. <i>Current Opinion in Oncology</i> , 2016, 28, 254-263.	1.1	213
175	PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 663-670.	0.7	85
176	Targeted therapies for treatment of non-small cell lung cancer—Recent advances and future perspectives. <i>International Journal of Cancer</i> , 2016, 138, 2549-2561.	2.3	155
177	Immune-mediated respiratory adverse events of checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 269-277.	1.1	39
178	Rare side-effects of checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 295-305.	1.1	7
179	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1484-1499.	1.0	75
180	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1346.	3.4	667
181	Low density of CD204-positive M2-type tumor-associated macrophages in Epstein-Barr virus-associated gastric cancer: a clinicopathologic study with digital image analysis. <i>Human Pathology</i> , 2016, 56, 74-80.	1.1	30
182	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.	0.8	397
183	Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2953-2955.	0.8	13
184	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. <i>Modern Pathology</i> , 2016, 29, 1165-1172.	2.9	340
185	Immune checkpoint inhibitors side effects and management. <i>Immunotherapy</i> , 2016, 8, 799-807.	1.0	62
186	Immune Checkpoint Therapies in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 117-120.	1.0	46
187	Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. <i>Onc Immunology</i> , 2016, 5, e1204504.	2.1	19
188	Ocular and orbital side-effects of checkpoint inhibitors: a review article. <i>Current Opinion in Oncology</i> , 2016, 28, 288-294.	1.1	117
189	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Onc Immunology</i> , 2016, 5, e1186323.	2.1	2
190	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 255-264.	2.3	335
191	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1213-1224.	2.3	93

#	ARTICLE	IF	CITATIONS
192	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. <i>ESMO Open</i> , 2016, 1, e000122.	2.0	55
193	Immunotherapy for breast cancer: past, present, and future. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 525-546.	2.7	49
194	AACR Cancer Progress Report 2016. <i>Clinical Cancer Research</i> , 2016, 22, S1-S137.	3.2	29
195	What does PD-L1 positive or negative mean?. <i>Journal of Experimental Medicine</i> , 2016, 213, 2835-2840.	4.2	263
196	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I "pre-analytical and analytical validation. ", 2016, 4, 76.		155
197	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. <i>Npj Genomic Medicine</i> , 2016, 1, .	1.7	103
198	Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 191-200.	0.3	6
199	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e542-e551.	5.1	1,274
200	Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. <i>Immunotherapy</i> , 2016, 8, 1383-1391.	1.0	16
203	PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. <i>Breast Care</i> , 2016, 11, 385-390.	0.8	20,872
204	Knockdown of Upregulated Gene 11 (URG11) Inhibits Proliferation, Invasion, and β -Catenin Expression in Non-Small Cell Lung Cancer Cells. <i>Oncology Research</i> , 2016, 24, 197-204.	0.6	6
205	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
206	Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma. <i>Oncology Nursing Forum</i> , 2016, 43, 219-226.	0.5	18
207	Perspectives of immunotherapy in hepatocellular carcinoma (HCC). <i>Zeitschrift Fur Gastroenterologie</i> , 2016, 54, 1334-1342.	0.2	18
208	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, .		0
209	A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, 16025.	7.1	35
210	Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. <i>Immunotherapy</i> , 2016, 8, 1363-1369.	1.0	34
211	Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. <i>Immunotherapy</i> , 2016, 8, 1437-1446.	1.0	25

#	ARTICLE	IF	CITATIONS
212	Immune checkpoint inhibitors renal side effects and management. <i>Immunotherapy</i> , 2016, 8, 1417-1425.	1.0	13
213	Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine. <i>Genome Medicine</i> , 2016, 8, 136.	3.6	64
214	Renal effects of immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw382.	0.4	67
215	A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 379-385.	0.4	5
216	Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies. <i>Journal of Translational Medicine</i> , 2016, 14, 173.	1.8	103
217	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. <i>Scientific Reports</i> , 2016, 6, 25952.	1.6	36
218	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 336-342.	0.5	9
219	Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2016, 24, 392-397.	0.6	261
220	Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients. , 2016, 4, 84.		94
221	Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. <i>BMJ Open</i> , 2016, 6, e013904.	0.8	63
222	Programmed death-ligand 1 expression in rectal cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2016, 48, 352-356.	0.3	15
224	Toxicités matologiques et digestives en cancérologie thoracique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2016, 8, 478-488.	0.0	0
225	Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. <i>Onc Immunology</i> , 2016, 5, e1255394.	2.1	62
226	Learning from the "tsunami" of immune checkpoint inhibitors in 2015. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 213-220.	2.0	39
227	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. <i>European Journal of Cancer</i> , 2016, 59, 160-170.	1.3	78
228	Immune checkpoint inhibitors in lung cancer: past, present and future. <i>Future Oncology</i> , 2016, 12, 1151-1163.	1.1	26
230	Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 347-354.	1.2	57
231	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 44.	1.2	40

#	ARTICLE	IF	CITATIONS
232	High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. <i>European Journal of Cancer</i> , 2016, 59, 152-159.	1.3	174
233	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 895-901.	1.4	20
234	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 47.	6.9	271
235	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. <i>Lancet Oncology</i> , 2016, 17, 956-965.	5.1	1,369
236	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <i>Drugs</i> , 2016, 76, 925-945.	4.9	123
237	Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. <i>American Journal of Kidney Diseases</i> , 2016, 68, 287-291.	2.1	253
238	<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Nonâ€“Small Cell Lung Cancer: A Retrospective Analysis. <i>Clinical Cancer Research</i> , 2016, 22, 4585-4593.	3.2	977
239	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 31.	1.3	57
240	Inhibitory immunologiczných punktÅ³w kontrolnych podziaÅ³u komÅ³rki w leczeniu chorÅ³b nowotworowych. <i>Acta Haematologica Polonica</i> , 2016, 47, 155-162.	0.1	1
241	Patient-Physician Communication in the 21st Century. <i>Trends in Immunology</i> , 2016, 37, 347-349.	2.9	1
242	PD-L1 Expression in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 964-975.	0.5	329
243	Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2016, 76, 969-978.	4.9	34
244	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016, 44, 1069-1078.	6.6	418
245	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016, 130, 251-277.	1.1	107
246	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480
247	Targeting PD-L1 for non-small-cell lung cancer. <i>Immunotherapy</i> , 2016, 8, 747-758.	1.0	12
248	Endocrinological side-effects of immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 278-287.	1.1	115
249	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <i>Annals of Oncology</i> , 2016, 27, 1492-1504.	0.6	460

#	ARTICLE	IF	CITATIONS
250	The fourth modality: immunotherapy for head and neck cancer hits pay dirt. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 575-577.	0.2	6
251	FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. <i>Oncologist</i> , 2016, 21, 643-650.	1.9	302
252	The Face of the Next Generation in China. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1090-1091.	2.5	4
253	PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy. <i>Translational Oncology</i> , 2016, 9, 64-69.	1.7	77
254	A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 3782-3790.	3.2	116
255	Into the Clinic With Nivolumab and Pembrolizumab. <i>Oncologist</i> , 2016, 21, 527-528.	1.9	17
256	Non-Small Cell Lung Cancer, PD-L1, and the Pathologist. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 249-254.	1.2	83
257	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	12.8	2,133
258	MicroRNAs provide a novel pathway toward combinatorial immune checkpoint blockade. <i>Neuro-Oncology</i> , 2016, 18, 601-602.	0.6	2
259	Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg?. <i>Clinical Cancer Research</i> , 2016, 22, 3422-3424.	3.2	65
260	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 1865-1874.	3.2	700
261	Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 210-225.	1.3	490
262	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	1.3	546
263	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. <i>Tumor Biology</i> , 2016, 37, 7507-7514.	0.8	40
264	Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. <i>Tumor Biology</i> , 2016, 37, 8515-8528.	0.8	47
265	Advances in immunotherapy for melanoma. <i>BMC Medicine</i> , 2016, 14, 20.	2.3	111
266	Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. <i>Clinical Immunology</i> , 2016, 166-167, 48-58.	1.4	45
267	Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. <i>European Journal of Cancer</i> , 2016, 60, 12-25.	1.3	321

#	ARTICLE	IF	CITATIONS
268	Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1286-1291.	0.6	92
269	Biomarkers for PD-1/PD-L1 Blockade Therapy in "Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. <i>Clinical Lung Cancer</i> , 2016, 17, 350-361.	1.1	100
270	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. <i>Oncologist</i> , 2016, 21, 634-642.	1.9	379
271	PD-1 Blockade in Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1573.	3.8	5
272	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	3.8	857
273	Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 25.	1.3	15
274	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
275	Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. <i>Annals of Oncology</i> , 2016, 27, 1178-1179.	0.6	71
276	Programmed Death Ligand-1 Immunohistochemistry " A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 341-344.	1.2	107
277	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. <i>British Journal of Cancer</i> , 2016, 114, 1145-1151.	2.9	25
278	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 2460-2467.	0.8	1,185
279	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 717-726.	5.1	943
280	High co-expression of PD-L1 and HIF-1 \pm correlates with tumour necrosis in pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2016, 60, 125-135.	1.3	91
281	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	12.5	831
282	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 665-674.	1.0	39
283	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. <i>Immunotherapy</i> , 2016, 8, 583-600.	1.0	71
284	Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1291-1298.	0.6	129
285	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798.	1.0	29

#	ARTICLE	IF	CITATIONS
286	Anti-PD-1-associated organizing pneumonia in a responding melanoma patient. <i>Annals of Oncology</i> , 2016, 27, 1649-1650.	0.6	13
287	Primary mucosal melanoma of the oral cavity: current therapy and future directions. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 122, 17-27.	0.2	27
288	Biomarkers associated with checkpoint inhibitors. <i>Annals of Oncology</i> , 2016, 27, 1199-1206.	0.6	142
289	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>International Immunology</i> , 2016, 28, 373-382.	1.8	143
292	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
293	Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 122-129.	1.1	41
294	TG4010: a vaccine with a therapeutic role in cancer. <i>Immunotherapy</i> , 2016, 8, 511-519.	1.0	14
295	PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. <i>Oncolmmunology</i> , 2016, 5, e1131379.	2.1	94
296	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1151595.	2.1	57
297	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. <i>Blood</i> , 2016, 128, 384-394.	0.6	697
298	Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. <i>Blood</i> , 2016, 128, 37-44.	0.6	347
299	Perspectives for immunotherapy in endocrine cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R469-R484.	1.6	12
300	Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology. <i>Diagnostic Cytopathology</i> , 2016, 44, 1000-1009.	0.5	55
301	The PD-1/PD-L1 Axis in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 644-644.	2.5	4
302	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48.		178
303	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 587-600.	1.3	30
304	Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion. <i>Journal of Virology</i> , 2016, 90, 8934-8946.	1.5	69
305	The mucin MUC1 modulates the tumor immunological microenvironment through engagement of the lectin Siglec-9. <i>Nature Immunology</i> , 2016, 17, 1273-1281.	7.0	277

#	ARTICLE	IF	CITATIONS
306	Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2016, 22, 5772-5782.	3.2	279
307	Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 935-941.	0.6	49
308	Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics. <i>Journal of Clinical Oncology</i> , 2016, 34, 3605-3608.	0.8	72
310	Genetics of triple-negative breast cancer: Implications for patient care. <i>Current Problems in Cancer</i> , 2016, 40, 130-140.	1.0	24
312	A genome-wide assessment of variations of primary colorectal cancer maintained in metastases. <i>Gene</i> , 2016, 595, 18-24.	1.0	4
313	Immunotherapy for malignant mesothelioma: reality check. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1167-1176.	1.1	10
314	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	0.8	715
315	A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1863-1868.	0.5	82
316	Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 4431-4439.	1.8	187
317	Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies. <i>Cell Death and Disease</i> , 2016, 7, e2380-e2380.	2.7	38
318	Trends and advances in tumor immunology and lung cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 157.	3.5	50
320	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. <i>Haematologica</i> , 2016, 101, 1144-1158.	1.7	6
321	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , The, 2016, 17, 1497-1508.	5.1	1,279
322	Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. <i>Current Problems in Cancer</i> , 2016, 40, 151-162.	1.0	18
323	Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. <i>BMC Cancer</i> , 2016, 16, 744.	1.1	94
325	Metastatic Lung Cancer: Emerging Therapeutic Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 736-749.	0.8	1
326	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 771-782.	0.8	12
327	Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 760-770.	0.8	50

#	ARTICLE	IF	CITATIONS
328	Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1823-1833.	13.9	7,847
329	Divide and Conquer to Treat Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1892-1893.	13.9	17
330	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Diagnostic Pathology</i> , 2016, 11, 95.	0.9	149
331	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	0.8	528
332	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1479-1489.	1.4	10
333	Genomic insights into head and neck cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, .	6.2	65
334	Targeting Immune Checkpoints in Hematologic Malignancies. <i>Pharmacological Reviews</i> , 2016, 68, 1014-1025.	7.1	36
335	Reliable Entity Subtyping in Non-small Cell Lung Cancer by Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry on Formalin-fixed Paraffin-embedded Tissue Specimens. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3081-3089.	2.5	72
336	Erlotinib-based targeted dual agent versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis of 13 randomized controlled trials. <i>Current Medical Research and Opinion</i> , 2016, 32, 1927-1934.	0.9	0
337	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3638-3647.	0.8	140
338	Molecular Imaging of Immunotherapy Targets in Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1487-1492.	2.8	77
339	Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 99, 79-87.	0.9	108
340	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1490.	3.4	68
341	Metastatic melanoma and immunotherapy. <i>Clinical Immunology</i> , 2016, 172, 105-110.	1.4	43
342	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 903-910.	1.1	6
343	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016, 18, 59.	1.8	35
344	Emerging biological therapies for the treatment of myelodysplastic syndromes. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 283-300.	1.0	15
345	Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy. <i>Cancer Immunology Research</i> , 2016, 4, 755-765.	1.6	36

#	ARTICLE	IF	CITATIONS
346	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. <i>Immunotherapy</i> , 2016, 8, 1011-1019.	1.0	34
347	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <i>Investigational New Drugs</i> , 2016, 34, 677-684.	1.2	30
348	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 910-921.	1.9	58
350	The Molecular Pathology of Lung Cancer. <i>Surgical Pathology Clinics</i> , 2016, 9, 353-378.	0.7	23
351	Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1927-1939.	0.5	63
352	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2567-2578.	1.3	56
353	Chemotherapy remains an essential element of personalized care for persons with lung cancers. <i>Annals of Oncology</i> , 2016, 27, 1829-1835.	0.6	83
354	Pembrolizumab in classical Hodgkin's lymphoma. <i>European Journal of Haematology</i> , 2016, 97, 219-227.	1.1	22
355	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212
356	Immunotherapy for lung cancer. <i>Respirology</i> , 2016, 21, 821-833.	1.3	268
357	PD-1 Pathway Inhibitors: Immunology Agents for Restoring Antitumor Immune Responses. <i>Pharmacotherapy</i> , 2016, 36, 317-334.	1.2	82
358	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. <i>Cancer Science</i> , 2016, 107, 107-115.	1.7	28
359	Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1954-1961.	0.5	10
360	Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. <i>Investigational New Drugs</i> , 2016, 34, 794-796.	1.2	17
361	Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1869-1878.	0.5	81
362	Lymphocyte activation gene-3, an important immune checkpoint in cancer. <i>Cancer Science</i> , 2016, 107, 1193-1197.	1.7	168
363	Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2066-2081.	0.5	49
364	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. , 2016, 4, 36.		90

#	ARTICLE	IF	CITATIONS
365	Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease. <i>Lancet, The</i> , 2016, 388, 1002-1011.	6.3	132
366	New and emerging targeted treatments in advanced non-small-cell lung cancer. <i>Lancet, The</i> , 2016, 388, 1012-1024.	6.3	381
367	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1387-1396.	0.5	6
368	Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. <i>Cancer Research</i> , 2016, 76, 5994-6005.	0.4	191
369	Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1243-1249.	1.2	100
370	PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome. <i>Modern Pathology</i> , 2016, 29, 1552-1564.	2.9	25
371	Cancer Immunotherapy by Checkpoint Blockade. , 2016, , 561-580.		2
372	PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. <i>Annals of Oncology</i> , 2016, 27, 1658-1659.	0.6	3
373	Regulatory circuits of T cell function in cancer. <i>Nature Reviews Immunology</i> , 2016, 16, 599-611.	10.6	445
374	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. <i>Radiotherapy and Oncology</i> , 2016, 120, 185-194.	0.3	99
375	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
377	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	3.2	393
378	Immunotherapy in Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 203-223.	0.2	8
379	Diagnosis and Molecular Classification of Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 25-46.	0.2	172
380	Lung Cancer Staging and Prognosis. <i>Cancer Treatment and Research</i> , 2016, 170, 47-75.	0.2	228
381	Resistance to Therapy. <i>Cancer Treatment and Research</i> , 2016, 170, 183-202.	0.2	10
382	Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer. <i>JAMA Oncology</i> , 2016, 2, 1607.	3.4	600
383	Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. <i>Lung Cancer Management</i> , 2016, 5, 119-122.	1.5	5

#	ARTICLE	IF	CITATIONS
384	Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNAActive® CV9201 immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1249560.	2.1	18
385	Emerging role of immunotherapy in urothelial carcinomaâ€”Advanced disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 538-547.	0.8	41
386	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II â€” clinical validation and regulatory considerations. , 2016, 4, 77.		87
387	Clarification on Tartari et al.: Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients. <i>Cancer Treatment Reviews</i> , 2016, 50, 82.	3.4	3
388	PD-1 blockade in Hodgkinâ€™s lymphoma: learning new tricks from an old teacher. <i>Expert Review of Hematology</i> , 2016, 9, 939-949.	1.0	13
389	Novel immunotherapy in the treatment of advanced non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1571-1581.	1.3	21
390	Update in Lung Cancer 2015. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 661-671.	2.5	13
391	Reply: Disparities in Access to Lung Transplantationâ€”More Than Meets the Eye. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 643-644.	2.5	0
392	Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report. <i>Oncology Letters</i> , 2016, 12, 2023-2027.	0.8	4
393	Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. <i>Oral Oncology</i> , 2016, 61, 166-176.	0.8	11
394	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 460-473.	1.4	30
395	PD-L1 in melanoma: facts and myths. <i>Melanoma Management</i> , 2016, 3, 187-194.	0.1	11
396	Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Antiâ€”Programmed Cell Death 1 and Antiâ€”Programmed Cell Death Ligand 1 Immunotherapy. <i>JAMA Dermatology</i> , 2016, 152, 1128.	2.0	188
397	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	0.8	438
398	PD-L1 expression is associated with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2016, 12, 921-927.	0.8	18
399	Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. <i>Oncology Letters</i> , 2016, 12, 944-950.	0.8	75
400	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmmunology</i> , 2016, 5, e1214790.	2.1	64
401	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. <i>Clinical and Translational Science</i> , 2016, 9, 89-104.	1.5	144

#	ARTICLE	IF	CITATIONS
402	Novel therapeutic targets on the horizon for lung cancer. <i>Lancet Oncology</i> , The, 2016, 17, e347-e362.	5.1	156
403	PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. <i>Human Pathology</i> , 2016, 58, 7-14.	1.1	135
404	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). <i>Journal of Neuro-Oncology</i> , 2016, 130, 19-29.	1.4	107
405	Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1075-1078.	1.4	13
406	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. <i>Modern Pathology</i> , 2016, 29, 1433-1442.	2.9	144
407	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 4550-4555.	3.2	73
408	Advances in the Treatment of Nonâ€“small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. <i>BioDrugs</i> , 2016, 30, 397-405.	2.2	36
409	Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 767-774.	1.0	9
410	Efficacy of Tumor Vaccines and Cellular Immunotherapies in Nonâ€“Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3204-3212.	0.8	46
411	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1209-1223.	1.4	18
412	Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. <i>Oral Oncology</i> , 2016, 63, e1-e3.	0.8	11
413	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2016, 30, 571-584.	2.2	93
414	ImmunothÃ©rapie et cancer du sein. <i>Oncologie</i> , 2016, 18, 551-558.	0.2	2
415	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	5.8	412
416	Cytotoxic T Cells in PD-L1â€“Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016, 4, 1038-1048.	1.6	62
417	A phase I trial of panobinostat (<sc>LBH</sc>589) in patients with metastatic melanoma. <i>Cancer Medicine</i> , 2016, 5, 3041-3050.	1.3	51
418	Programmed Death-1 Culls Peripheral Accumulation of High-Affinity Autoreactive CD4ÂˆT Cells to Protect against Autoimmunity. <i>Cell Reports</i> , 2016, 17, 1783-1794.	2.9	35
419	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. <i>Science Translational Medicine</i> , 2016, 8, 328rv4.	5.8	1,844

#	ARTICLE	IF	CITATIONS
420	The Human Vaccines Project: A roadmap for cancer vaccine development. <i>Science Translational Medicine</i> , 2016, 8, 334ps9.	5.8	162
421	Targeting the PD-1/PD-L1 axis in the treatment of lung cancer. <i>Forum of Clinical Oncology</i> , 2016, 7, 17-27.	0.1	0
423	Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplification. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a001180.	0.5	57
424	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. , 2016, 4, 60.		60
425	Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. <i>Seminars in Oncology</i> , 2016, 43, 638-646.	0.8	45
426	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. <i>Protein and Cell</i> , 2016, 7, 866-877.	4.8	44
427	PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 201-206.	0.3	38
428	Crizotinib resistance: implications for therapeutic strategies. <i>Annals of Oncology</i> , 2016, 27, iii42-iii50.	0.6	109
429	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. <i>Current Treatment Options in Oncology</i> , 2016, 17, 59.	1.3	3
430	Immune checkpoint inhibitors for cancer treatment. <i>Archives of Pharmacal Research</i> , 2016, 39, 1577-1587.	2.7	43
431	Tim-3: Expression on immune cells and roles at the maternal-fetal interface. <i>Journal of Reproductive Immunology</i> , 2016, 118, 92-99.	0.8	43
432	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. <i>Lung Cancer</i> , 2016, 102, 21-27.	0.9	11
433	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 13354.	5.8	224
434	Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338.		0
435	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. <i>Scientific Reports</i> , 2016, 6, 30093.	1.6	213
436	Lung Cancer Subtypes Generate Unique Immune Responses. <i>Journal of Immunology</i> , 2016, 197, 4493-4503.	0.4	115
437	Current Status of Immunotherapy for Non-Small-Cell Lung Cancer. <i>Tumori</i> , 2016, 102, 337-351.	0.6	6
438	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 165-202.	0.2	30

#	ARTICLE	IF	CITATIONS
440	Programmed Death-1 Inhibition in Cancer With a Focus on Non-Small Cell Lung Cancer: Rationale, Nursing Implications, and Patient Management Strategies. <i>Clinical Journal of Oncology Nursing</i> , 2016, 20, 319-326.	0.3	3
441	Immunotherapy for Lung Cancer: Many Questions Yet to Be Answered. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 935-938.	2.3	1
442	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
443	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
444	It's TIME for a biomarker-driven approach to cancer immunotherapy. , 2016, 4, 43.		6
445	Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. <i>BMC Cancer</i> , 2016, 16, 868.	1.1	15
446	Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2016, 95, 1191-1192.	0.8	13
447	Harnessing the antitumor immunity cycle to treat lung cancer. <i>Current Pulmonology Reports</i> , 2016, 5, 40-48.	0.5	0
448	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 984-993.	5.1	689
450	Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1319-1325.	0.5	16
451	Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 411-417.	1.4	98
452	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. <i>Cancer Treatment Reviews</i> , 2016, 48, 20-24.	3.4	118
453	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. <i>Modern Pathology</i> , 2016, 29, 1028-1037.	2.9	84
454	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	1.6	81
455	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. <i>Oncologist</i> , 2016, 21, 804-816.	1.9	208
456	A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1846-1855.	0.5	80
457	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2016, 28, e127-e138.	0.6	35
459	Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 41.	1.3	33

#	ARTICLE	IF	CITATIONS
460	Anaplastic Thyroid Carcinoma: Light at the End of the Tunnel?. Journal of Oncology Practice, 2016, 12, 519-520.	2.5	2
461	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. Journal of Thoracic Oncology, 2016, 11, 1819-1836.	0.5	31
462	Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1879-1890.	0.5	156
463	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. Seminars in Oncology, 2016, 43, 501-513.	0.8	10
464	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology, 2016, 12, 1805-1822.	1.1	6
465	PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology, 2016, 5, e1176653.	2.1	59
466	Challenges & Perspectives of Immunotherapy Biomarkers & The HistoOncoImmuneâ„¢ Methodology. Expert Review of Precision Medicine and Drug Development, 2016, 1, 9-24.	0.4	5
467	Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer, 2016, 97, 73-80.	0.9	122
468	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 976-983.	5.1	846
469	Trends in immunotherapy for brain metastases. Lancet Oncology, The, 2016, 17, 859-860.	5.1	8
470	Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. Cancer Treatment Communications, 2016, 6, 20-23.	0.4	27
471	Prognostic Significance of PD-L1 in Patients with Nonâ€“Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. Journal of Thoracic Oncology, 2016, 11, 1003-1011.	0.5	130
472	Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches. Oral Oncology, 2016, 58, 49-51.	0.8	0
473	Nivolumab and Pembrolizumab for Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 3713-3717.	3.2	62
474	Checkpoint Inhibitors and Their Application in Breast Cancer. Breast Care, 2016, 11, 108-115.	0.8	45
475	Genomic determinants of cancer immunotherapy. Current Opinion in Immunology, 2016, 41, 32-38.	2.4	27
476	Nintedanib in NSCLC: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology, 2016, 8, 188-197.	1.4	19
477	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. Journal of Nuclear Medicine, 2016, 57, 1607-1611.	2.8	105

#	ARTICLE	IF	CITATIONS
478	Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung. <i>Clinical Lung Cancer</i> , 2016, 17, 391-397.	1.1	75
479	The Utility of Exercise Testing in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1397-1410.	0.5	62
480	Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. <i>Lung Cancer</i> , 2016, 99, 4-10.	0.9	81
481	The use of biomarkers in the treatment of non-small cell lung cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 25-36.	0.4	2
482	Targeted Therapy and Immunotherapy for Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 601-609.	0.6	99
483	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1217.	3.4	216
484	Immune Checkpoint Inhibitors in Older Adults. <i>Current Oncology Reports</i> , 2016, 18, 47.	1.8	49
485	Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2016, 39, 353-358.	0.8	6
486	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
487	Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 48.	6.9	28
488	Adjuvant Therapy for Stage I and II Non-Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 585-599.	0.6	11
489	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1511-1521.	0.5	95
490	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. <i>Journal of Clinical Oncology</i> , 2016, 34, 3733-3739.	0.8	586
491	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
492	Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?. <i>Future Oncology</i> , 2016, 12, 429-431.	1.1	3
493	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016, 54, 139-148.	1.3	1,687
494	Doubling the blockade for melanoma immunotherapy. <i>OncImmunology</i> , 2016, 5, e1106127.	2.1	9
495	Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 324-333.	0.5	28

#	ARTICLE	IF	CITATIONS
496	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016, 12, 551-564.	1.1	8
497	Current status of immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 191-203.	0.6	52
498	Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. <i>European Journal of Cancer</i> , 2016, 55, 7-14.	1.3	163
499	Modulation of tumor immunity: a patent evaluation of WO2015026684A1. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 417-425.	2.4	8
500	Treatment of recurrent and platinum-refractory stage IV non-small cell lung cancer with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as a single agent. <i>Medical Oncology</i> , 2016, 33, 13.	1.2	12
501	Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 397-406.	1.4	56
502	Epigenetic Therapeutics: A New Weapon in the War Against Cancer. <i>Annual Review of Medicine</i> , 2016, 67, 73-89.	5.0	285
503	Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2177-2182.	3.2	119
504	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 46.	3.4	693
505	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1540-1550.	6.3	5,456
506	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 57-75.	1.5	46
507	Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2016, 76, 227-238.	0.4	595
508	Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. <i>Future Oncology</i> , 2016, 12, 9-23.	1.1	13
509	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 263-270.e2.	1.1	107
510	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2016, 8, 479-488.	1.0	136
511	Recognizing that the microbiome is part of the human immune system will advance treatment of both cancer and infections. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 772-774.	0.6	5
512	Best Lung Cancer Research, 2015. <i>Oncology Times</i> , 2016, 38, 1.	0.1	0
513	CTLA-4 and PD-1 Pathways. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 98-106.	0.6	1,644

#	ARTICLE	IF	CITATIONS
514	Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. <i>Journal of Biomolecular Screening</i> , 2016, 21, 769-785.	2.6	12
515	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3915-3923.	3.2	91
516	Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung. <i>Oncologist</i> , 2016, 21, 205-213.	1.9	22
517	PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 569.	3.4	5
518	The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 571.	3.4	18
519	A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. <i>Clinical Lung Cancer</i> , 2016, 17, 232-236.e1.	1.1	124
520	Combining Epigenetic and Immunotherapy to Combat Cancer. <i>Cancer Research</i> , 2016, 76, 1683-1689.	0.4	251
521	Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know. <i>Gynecologic Oncology</i> , 2016, 141, 65-71.	0.6	11
522	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	0.8	692
523	Immunotherapy for head and neck cancer: latest developments and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 168-175.	1.4	18
524	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
525	Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 28-37.	0.4	4
526	Immunotherapy of melanoma: efficacy and mode of action. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 28-36.	0.4	16
527	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	1.1	181
528	Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. <i>Journal of Clinical Oncology</i> , 2016, 34, 1676-1688.	0.8	71
529	PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 88-98.	2.0	316
530	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.4	451
531	Novel therapies for advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2016, 12, 659-667.	1.1	11

#	ARTICLE	IF	CITATIONS
532	PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors. <i>Lung Cancer</i> , 2016, 93, 9-16.	0.9	27
533	Immune checkpoint therapy for non-small-cell lung cancer: an update. <i>Immunotherapy</i> , 2016, 8, 279-298.	1.0	56
534	The Herpes Simplex Virus Latency-Associated Transcript Gene Is Associated with a Broader Repertoire of Virus-Specific Exhausted CD8 ⁺ T Cells Retained within the Trigeminal Ganglia of Latently Infected HLA Transgenic Rabbits. <i>Journal of Virology</i> , 2016, 90, 3913-3928.	1.5	32
535	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. <i>Seminars in Immunology</i> , 2016, 28, 73-80.	2.7	56
536	PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 351-354.	1.2	12
537	Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. <i>Cancer Immunology Research</i> , 2016, 4, 345-353.	1.6	214
539	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. <i>Targeted Oncology</i> , 2016, 11, 469-477.	1.7	34
540	The Evolving Role of Nivolumab in Non-“Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Clinical Lung Cancer</i> , 2016, 17, 161-168.	1.1	13
541	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. <i>Nature Communications</i> , 2016, 7, 10501.	5.8	1,163
542	Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2016, 34, 987-1011.	0.8	141
543	Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. <i>Cancer Treatment Reviews</i> , 2016, 45, 7-18.	3.4	354
544	Epithelial-“Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	3.2	353
545	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2016, 22, 2261-2270.	3.2	217
546	Management of toxicities of immune checkpoint inhibitors. <i>Cancer Treatment Reviews</i> , 2016, 44, 51-60.	3.4	706
548	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv414.	3.0	81
549	The race for combined checkpoint inhibition in NSCLC. <i>Lancet Oncology</i> , The, 2016, 17, 259-260.	5.1	6
550	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 326-331.	1.2	118
551	The management of immune-related adverse events associated with immune checkpoint blockade. Expert Review of Quality of Life in Cancer Care, 2016, 1, 89-97.	0.6	15

#	ARTICLE	IF	CITATIONS
552	Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 141-150.	2.7	25
553	The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 18.	1.3	18
554	Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma. <i>European Journal of Cancer</i> , 2016, 57, 91-103.	1.3	120
555	Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 511-525.	1.4	212
557	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	0.5	48
558	Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 75-85.	2.0	105
559	Two cases of immune thrombocytopenia associated with pembrolizumab. <i>European Journal of Cancer</i> , 2016, 54, 172-174.	1.3	52
560	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	12.5	909
561	Immune checkpoint pathways: perspectives on myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 995-1001.	0.6	4
562	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	1.8	39
563	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016, 18, 1137-1145.	0.6	126
564	S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2016, 12, 701-713.	1.1	4
565	Molecular pathology in real time. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 129-140.	2.7	26
566	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1909-1920.	6.3	3,077
567	Predictive Markers for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 976-988.	0.5	197
568	Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 289-293.	1.6	135
569	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 122-136.	2.0	24
570	Emerging immunotherapy for the treatment of esophageal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 667-677.	1.9	32

#	ARTICLE	IF	CITATIONS
571	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1837-1846.	6.3	2,390
572	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 183-193.	1.0	112
573	Express approval of immune checkpoint inhibitors: a conflict between science and finance. <i>Future Oncology</i> , 2016, 12, 1215-1217.	1.1	0
574	Vaccines for established cancer: overcoming the challenges posed by immune evasion. <i>Nature Reviews Cancer</i> , 2016, 16, 219-233.	12.8	580
575	Ocular toxicities of MEK inhibitors and other targeted therapies. <i>Annals of Oncology</i> , 2016, 27, 998-1005.	0.6	72
576	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 4-31.	1.4	40
577	Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1-4.	1.1	5
578	OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. <i>Oral Oncology</i> , 2016, 52, 1-10.	0.8	56
579	Bypassing checkpoints, overcoming resistance, and honing in on new targets. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 75-76.	12.5	9
580	Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 419-428.	1.3	25
581	Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?. <i>Lancet</i> , The, 2016, 387, 1488-1490.	6.3	9
582	Current progress in immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 244-251.	3.2	149
583	Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, 590-599.	0.6	35
584	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 212-223.	5.1	158
585	The changing landscape of phase I trials in oncology. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 106-117.	12.5	84
586	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 5-12.	1.1	13
587	Safety and efficacy of targeted agents monotherapy in advanced NSCLC. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 143-155.	1.3	1
588	Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 131-133.	1.5	52

#	ARTICLE	IF	CITATIONS
589	Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. <i>Pathology and Oncology Research</i> , 2016, 22, 331-339.	0.9	13
590	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , 2016, 27, 214-224.	0.6	86
591	Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 13-20.	1.1	81
592	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1324-1333.	0.6	33
593	Novel immunotherapies in lymphoid malignancies. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 25-40.	12.5	224
594	Perspectives on Cost and Value in Cancer Care. <i>JAMA Oncology</i> , 2016, 2, 19.	3.4	44
595	PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy. <i>Annals of Oncology</i> , 2016, 27, 206-207.	0.6	20
597	From T cell "exhaustion" to anti-cancer immunity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 49-57.	3.3	18
598	Decision support systems for personalized and participative radiation oncology. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 131-153.	6.6	113
599	Integrating chemoradiation and molecularly targeted therapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 74-83.	6.6	22
600	Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer. <i>Lung Cancer</i> , 2017, 107, 50-58.	0.9	45
601	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. <i>Pharmacogenomics Journal</i> , 2017, 17, 528-534.	0.9	9
602	Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 3, 9.	0.5	18
603	FDA approves breakthrough immunotherapy for patients with non-small cell lung cancer. <i>Cancer</i> , 2017, 123, 191-191.	2.0	1
604	Elements of cancer immunity and the cancer "immune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
605	COX2/mPGES1/PGE ₂ pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 1117-1122.	3.3	378
606	Comprehensive screening for PD-L1 expression in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 97-106.	1.6	119
607	Cancer immunotherapy " immune checkpoint blockade and associated endocrinopathies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 195-207.	4.3	515

#	ARTICLE	IF	CITATIONS
608	Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E970-E979.	3.3	172
609	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. Journal of Cancer Research and Practice, 2017, 4, 72-75.	0.2	1
610	High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer, 2017, 104, 1-6.	0.9	144
611	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Modern Pathology, 2017, 30, 530-538.	2.9	92
612	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. Current Medical Research and Opinion, 2017, 33, 749-759.	0.9	65
613	Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. Annals of Hematology, 2017, 96, 919-927.	0.8	20
614	Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 410-414.	1.1	7
615	Renal complications of immune checkpoint blockade. Current Problems in Cancer, 2017, 41, 100-110.	1.0	81
616	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncology, The, 2017, 18, 212-220.	5.1	307
617	EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. Clinical Lung Cancer, 2017, 18, 527-534.e1.	1.1	108
618	Immune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity?. Clinical Oncology, 2017, 29, 207-217.	0.6	6
619	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer, 2017, 73, 1-8.	1.3	397
620	PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. Expert Opinion on Biological Therapy, 2017, 17, 305-312.	1.4	42
621	Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer, 2017, 106, 1-7.	0.9	403
622	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. , 2017, , 309-327.		1
623	Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Annals of Hematology, 2017, 96, 647-651.	0.8	25
624	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Seminars in Immunopathology, 2017, 39, 225-239.	2.8	42
625	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. Expert Opinion on Pharmacotherapy, 2017, 18, 295-304.	0.9	12

#	ARTICLE	IF	CITATIONS
626	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. , 2017, 174, 1-21.		123
627	Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determined by multiparametric single cell mass cytometry analysis. BMC Immunology, 2017, 18, 6.	0.9	31
628	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Communication and Signaling, 2017, 15, 1.	2.7	154
629	Smokeless tobacco product may increase mortality rate in patients with prostate cancer. Cancer, 2017, 123, 190-190.	2.0	0
630	Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 3585-3591.	3.2	264
631	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. Cancer Immunology Research, 2017, 5, 106-117.	1.6	236
632	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World Journal of Urology, 2017, 35, 1401-1407.	1.2	29
633	Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapy. BMJ Open Respiratory Research, 2017, 4, e000163.	1.2	7
634	SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity, 2017, 46, 51-64.	6.6	122
635	Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3 PD-L1 ≥50% Expression in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, 878-883.	0.5	109
636	Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. Lung Cancer, 2017, 105, 17-22.	0.9	48
637	Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro-Oncology, 2017, 19, now287.	0.6	128
638	Harnessing the immunotherapeutic potential of T-lymphocyte co-signaling molecules in transplantation. Immunology Letters, 2017, 183, 8-16.	1.1	10
639	Tailoring Palliative Care to the Changing Needs of People Facing Cancer. Journal of Clinical Oncology, 2017, 35, 813-815.	0.8	9
640	A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). Expert Review of Anticancer Therapy, 2017, 17, 199-201.	1.1	21
641	Medication-associated gastrointestinal tract injury. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 245-266.	1.4	22
643	Immunoprofiling as a predictor of patient's response to cancer therapy promises and challenges. Current Opinion in Immunology, 2017, 45, 60-72.	2.4	39
644	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. European Journal of Cancer, 2017, 75, 141-149.	1.3	84

#	ARTICLE	IF	CITATIONS
645	Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. <i>Nature Communications</i> , 2017, 8, 14572.	5.8	279
646	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 387-394.	1.1	128
647	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <i>OncoImmunology</i> , 2017, 6, e1286437.	2.1	28
648	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	3.2	117
649	Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. <i>Cells Tissues Organs</i> , 2017, 203, 128-138.	1.3	20
650	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
651	Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification. <i>Expert Review of Proteomics</i> , 2017, 14, 351-362.	1.3	10
653	PD-1 and PD-L1 antibodies in cancer: current status and future directions. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 551-564.	2.0	253
654	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. <i>Revue De Medecine Interne</i> , 2017, 38, 513-525.	0.6	36
655	Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 783-791.	1.2	36
656	Response Evaluation in Head and Neck Oncology: Definition and Prediction. <i>Orl</i> , 2017, 79, 14-23.	0.6	7
657	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1051.	3.4	658
658	EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 465-469.	1.0	156
659	Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. <i>Future Oncology</i> , 2017, 13, 1097-1103.	1.1	1
661	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. <i>Lancet Oncology</i> , 2017, 18, 623-630.	5.1	425
662	Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2017, 9, 261-272.	1.0	32
663	Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2017, 92, 283-290.	0.9	36
664	Combination immunotherapy: a road map. , 2017, 5, 16.		325

#	ARTICLE	IF	CITATIONS
665	Targeting the programmed death-1 pathway in lymphoid neoplasms. <i>Cancer Treatment Reviews</i> , 2017, 54, 99-109.	3.4	27
666	Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990-2015: Progress and Opportunities. <i>Oncologist</i> , 2017, 22, 304-310.	1.9	8
667	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , 2017, 18, e143-e152.	5.1	1,612
668	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) <i>TJ ETQq1</i> 1,078,431.4 <i>rgBT /O</i> 0.7 34	0.7	34
669	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. <i>Lung Cancer</i> , 2017, 106, 70-75.	0.9	30
670	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. <i>Nature Communications</i> , 2017, 8, 14369.	5.8	192
671	PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. <i>Oncolmmunology</i> , 2017, 6, e1284722.	2.1	87
672	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	0.6	156
673	Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 44-50.	1.2	12
674	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2017, 12, 814-823.	0.5	192
675	DNA vaccines for prostate cancer. , 2017, 174, 27-42.		36
676	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	3.2	710
677	Applications of Immunogenomics to Cancer. <i>Cell</i> , 2017, 168, 600-612.	13.5	198
678	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. <i>Cancer Treatment Reviews</i> , 2017, 54, 58-67.	3.4	324
679	Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. <i>American Journal of Nephrology</i> , 2017, 45, 160-169.	1.4	10,656
680	Designing nanomedicine for immuno-oncology. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	178
681	Checkpoint Blockade in Lung Cancer and Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 274-282.	2.5	59
682	Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities. <i>JAMA Dermatology</i> , 2017, 153, 285.	2.0	39

#	ARTICLE	IF	CITATIONS
683	The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 850-859.	0.5	83
684	The CD47-SIRP α signaling axis as an innate immune checkpoint in cancer. <i>Immunological Reviews</i> , 2017, 276, 145-164.	2.8	410
685	Emerging challenges of advanced squamous cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000129.	2.0	6
686	Biological therapies in nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2017, 49, 1601520.	3.1	37
687	Gene signature driving invasive mucinous adenocarcinoma of the lung. <i>EMBO Molecular Medicine</i> , 2017, 9, 462-481.	3.3	79
688	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <i>Neurotherapeutics</i> , 2017, 14, 1049-1065.	2.1	20
689	Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. <i>Immunological Reviews</i> , 2017, 276, 9-25.	2.8	13
690	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
691	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. <i>Clinical Lung Cancer</i> , 2017, 18, 572-582.e1.	1.1	46
692	The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 124-132.	2.0	93
693	Cancer Clinical Trials: The Rear-View Mirror and the Crystal Ball. <i>Cell</i> , 2017, 168, 575-578.	13.5	13
694	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 344-351.	0.4	143
695	Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials. <i>Seminars in Oncology</i> , 2017, 44, 3-7.	0.8	83
696	Immune checkpoints and their inhibition in cancer and infectious diseases. <i>European Journal of Immunology</i> , 2017, 47, 765-779.	1.6	418
697	Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. <i>Chemotherapy</i> , 2017, 62, 205-213.	0.8	10
698	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. <i>European Journal of Cancer</i> , 2017, 78, 16-23.	1.3	108
699	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4569-4577.	3.2	96
700	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017, 129, 3419-3427.	0.6	335

#	ARTICLE	IF	CITATIONS
701	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 851-861.	1.2	82
702	Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Oncology</i> , 2017, 93, 62-66.	0.9	14
703	Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. <i>Oncologist</i> , 2017, 22, 700-708.	1.9	11
704	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	1.6	400
705	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. <i>Annals of Oncology</i> , 2017, 28, 1388-1398.	0.6	70
706	Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations. <i>Oncology Research and Treatment</i> , 2017, 40, 7-13.	0.8	9
707	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. <i>Annals of Oncology</i> , 2017, 28, 874-881.	0.6	197
708	Malignant pheochromocytoma—paraganglioma: pathogenesis, TNM staging, and current clinical trials. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 174-183.	1.2	70
709	Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. <i>American Journal of Surgical Pathology</i> , 2017, 41, 643-654.	2.1	146
710	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer. <i>Chest</i> , 2017, 152, 271-281.	0.4	381
711	Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities. <i>Clinical Lung Cancer</i> , 2017, 18, 651-659.	1.1	164
712	Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 105.	6.9	129
713	Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. <i>Journal of Neuro-Oncology</i> , 2017, 133, 561-569.	1.4	43
714	Emerging therapies for breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 98.	6.9	60
715	Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1943-1950.	1.8	86
716	Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. <i>Clinical Lung Cancer</i> , 2017, 18, 682-691.e5.	1.1	74
717	Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1268-1279.	0.5	152
718	PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. <i>Immunotherapy</i> , 2017, 9, 499-506.	1.0	162

#	ARTICLE	IF	CITATIONS
719	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. <i>Immunotherapy</i> , 2017, 9, 507-520.	1.0	12
720	In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	466
721	Checkpoint inhibitors in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 103.	6.9	106
722	Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26613.	0.8	43
723	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma—Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 50.	2.0	10
724	Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 763-769.	15.6	136
725	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. <i>Oncolmmunology</i> , 2017, 6, e1320626.	2.1	89
726	Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma. <i>Muscle and Nerve</i> , 2017, 56, E162-E167.	1.0	18
727	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2017, 133, 331-338.	1.4	107
728	Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e855-e857.	0.9	26
729	CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8 + T EM and CD8 + T RM Cells within Infected Tissues Allows Efficient Protection against Recurrent Herpesvirus Infection and Disease. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
730	Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. <i>Clinical Cancer Research</i> , 2017, 23, 4556-4568.	3.2	149
731	Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. <i>International Journal of Cancer</i> , 2017, 141, 572-582.	2.3	53
732	Enhancement of the adaptive signature design for learning and confirming in a single pivotal trial. <i>Pharmaceutical Statistics</i> , 2017, 16, 312-321.	0.7	7
733	Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. <i>Cancer</i> , 2017, 123, 3285-3290.	2.0	170
734	Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1139-1145.	1.1	63
735	The next generation of immunotherapy: keeping lung cancer in check. <i>Journal of Hematology and Oncology</i> , 2017, 10, 87.	6.9	84
736	Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 29-39.	1.3	66

#	ARTICLE	IF	CITATIONS
737	Immunotherapy in Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 131-141.	0.9	31
738	Systemic Treatment of Brain Metastases. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 157-176.	0.9	8
739	Lung Cancer Biomarkers. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 13-29.	0.9	180
740	Next-Generation Sequencing of Lung Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 1-12.	0.9	12
741	Primary Resistance to PD-1 Blockade Mediated by <i>JAK1/2</i> Mutations. <i>Cancer Discovery</i> , 2017, 7, 188-201.	7.7	997
742	Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. <i>International Journal of Cancer</i> , 2017, 140, 1396-1404.	2.3	48
743	Raising the bar on first-line immunotherapy in lung cancer. <i>Lancet Oncology</i> , The, 2017, 18, 2-3.	5.1	4
744	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. <i>Journal of Thoracic Oncology</i> , 2017, 12, 208-222.	0.5	1,067
745	Real-world data on nivolumab treatment of non-small cell lung cancer. <i>Acta Oncologica</i> , 2017, 56, 438-440.	0.8	42
746	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. <i>Respiration</i> , 2017, 93, 1-14.	1.2	7
747	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3158-3167.	3.2	426
748	Relationship of the Breast Ductal Carcinoma <i>In Situ</i> Immune Microenvironment with Clinicopathological and Genetic Features. <i>Clinical Cancer Research</i> , 2017, 23, 5210-5217.	3.2	61
749	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1248-1260.	1.5	15
750	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1977-1984.	1.2	14
751	More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 685-687.	0.6	1
752	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
753	Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <i>Gastroenterology</i> , 2017, 153, 812-826.	0.6	650
754	PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.	3.0	43

#	ARTICLE	IF	CITATIONS
755	Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Targeted Oncology, 2017, 12, 563-569.	1.7	71
756	Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: AARENAPE study. European Journal of Surgical Oncology, 2017, 43, 1915-1923.	0.5	23
757	Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nature Immunology, 2017, 18, 940-950.	7.0	407
758	Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma—New Therapeutic Targets. American Journal of Surgical Pathology, 2017, 41, 998-1004.	2.1	40
759	Imaging Studies in Immunotherapy. , 2017, , 149-179.		1
760	Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. Clinics in Chest Medicine, 2017, 38, 223-232.	0.8	36
761	Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. Oncologist, 2017, 22, 963-971.	1.9	145
762	Evaluation of dosing strategy for pembrolizumab for oncology indications. , 2017, 5, 43.		189
763	Immunogenomics: using genomics to personalize cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 209-219.	1.4	7
764	Immune Checkpoint Blockade and Gastric Cancer. , 2017, , 115-130.		2
765	Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. New England Journal of Medicine, 2017, 376, 2483-2485.	13.9	31
766	Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2017, 23, 5349-5357.	3.2	191
767	PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. Annals of Oncology, 2017, 28, 882-889.	0.6	105
768	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. Targeted Oncology, 2017, 12, 301-308.	1.7	66
769	Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. OncoImmunology, 2017, 6, e1312240.	2.1	68
770	In Vivo Imaging of the Programmed Death Ligand 1 by ¹⁸ F PET. Journal of Nuclear Medicine, 2017, 58, 1852-1857.	2.8	84
771	Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. Trends in Immunology, 2017, 38, 577-593.	2.9	276
772	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. Current Treatment Options in Oncology, 2017, 18, 33.	1.3	13

#	ARTICLE	IF	CITATIONS
773	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. <i>Lancet Oncology</i> , 2017, 18, 895-903.	5.1	872
774	Programmed cell death-1/Programmed cell death ligand-1 (PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). <i>Cancer Treatment and Research Communications</i> , 2017, 12, 6-13.	0.7	9
775	Checkpoint inhibitors for the treatment of non-small-cell lung cancer: news from the 2016 European Society for Medical Oncology Annual Congress. <i>Drugs and Therapy Perspectives</i> , 2017, 33, 126-132.	0.3	1
776	Immunotherapeutic properties of chemotherapy. <i>Current Opinion in Pharmacology</i> , 2017, 35, 83-88.	1.7	30
777	DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. <i>Lung Cancer</i> , 2017, 110, 26-31.	0.9	59
778	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 70, 34-42.	0.8	38
779	Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 453-459.	0.6	133
780	Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. <i>International Immunopharmacology</i> , 2017, 49, 85-94.	1.7	35
781	Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2017, 10, 511-517.	1.7	47
782	Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. <i>Cancer Science</i> , 2017, 108, 1022-1031.	1.7	100
783	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. <i>Medical Oncology</i> , 2017, 34, 121.	1.2	12
784	Biallelic PMS2 Mutation and Heterozygous DICER1 Mutation Presenting as Constitutional Mismatch Repair Deficiency With Corpus Callosum Agenesis: Case Report and Review of Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e381-e387.	0.3	3
785	Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2017, 44, 403-414.	0.8	103
786	Understanding the checkpoint blockade in lung cancer immunotherapy. <i>Drug Discovery Today</i> , 2017, 22, 1266-1273.	3.2	48
787	Assessment of programmed death-1 ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. <i>Cancer</i> , 2017, 123, 3807-3815.	2.0	135
788	Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. <i>Oncogene</i> , 2017, 36, 5829-5839.	2.6	249
789	Glioblastoma targeted therapy: updated approaches from recent biological insights. <i>Annals of Oncology</i> , 2017, 28, 1457-1472.	0.6	314
790	Pembrolizumab-induced pneumonitis. <i>ERJ Open Research</i> , 2017, 3, 00081-2016.	1.1	35

#	ARTICLE	IF	CITATIONS
791	A Pharmacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	76
792	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 431-439.	1.4	73
793	New insights into the role of EMT in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.	2.1	332
794	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 599-610.	5.1	257
795	Highlights on immune checkpoint inhibitors in non-small cell lung cancer. <i>Tumor Biology</i> , 2017, 39, 101042831769501.	0.8	17
796	Drug-biomarker co-development in oncology – 20 years and counting. <i>Drug Resistance Updates</i> , 2017, 30, 48-62.	6.5	48
797	Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 575-581.	0.2	25
798	Immunomodulation for glioblastoma. <i>Current Opinion in Neurology</i> , 2017, 30, 361-369.	1.8	21
799	Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. <i>Thoracic Cancer</i> , 2017, 8, 275-277.	0.8	17
800	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 559-564.	1.1	12
801	Organizing pneumonia following treatment with pembrolizumab for metastatic malignant melanoma – A case report. <i>Respiratory Medicine Case Reports</i> , 2017, 20, 95-97.	0.2	11
802	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 97-125.	0.8	99
803	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. <i>International Immunopharmacology</i> , 2017, 46, 210-219.	1.7	102
804	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. <i>BMC Medicine</i> , 2017, 15, 55.	2.3	65
805	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. <i>Acta Neuropathologica</i> , 2017, 134, 297-316.	3.9	23
806	Development of CAR T cells designed to improve antitumor efficacy and safety. , 2017, 178, 83-91.		90
807	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
808	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 175-184.	0.8	7

#	ARTICLE	IF	CITATIONS
809	Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?. Lung Cancer, 2017, 108, 90-95.	0.9	10
810	PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 2017, 108, 115-120.	0.9	98
811	Pembrolizumab for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2017, 17, 399-409.	1.1	37
812	Current and Emerging Therapies in Metastatic Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1670-1678.	3.2	114
813	Cancer immunotherapies targeting the PD-1 signaling pathway. Journal of Biomedical Science, 2017, 24, 26.	2.6	501
814	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Annals of Oncology, 2017, 28, 1036-1041.	0.6	207
815	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. Cancer Cell, 2017, 31, 476-485.	7.7	116
816	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. Expert Opinion on Drug Safety, 2017, 16, 573-585.	1.0	21
817	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncology, 2017, 13, 1263-1279.	1.1	113
818	Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncology, The, 2017, 18, 587-598.	5.1	261
820	The high price of anticancer drugs: origins, implications, barriers, solutions. Nature Reviews Clinical Oncology, 2017, 14, 381-390.	12.5	289
821	Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. , 2017, 5, 8.		111
822	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. Journal of Thoracic Oncology, 2017, 12, 932-942.	0.5	129
824	Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection. Biomedicine and Pharmacotherapy, 2017, 90, 24-37.	2.5	45
825	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. Seminars in Radiation Oncology, 2017, 27, 289-298.	1.0	39
826	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomarker Research, 2017, 5, 12.	2.8	149
827	Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. Journal of Thoracic Oncology, 2017, 12, 943-953.	0.5	136
828	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncology, The, 2017, 18, 52-62.	5.1	225

#	ARTICLE	IF	CITATIONS
829	T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. <i>International Journal of Cancer</i> , 2017, 140, 2535-2544.	2.3	42
830	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 583-589.	0.6	510
831	Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138.	1.7	22
832	Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. <i>Lung Cancer</i> , 2017, 103, 44-51.	0.9	91
833	Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. <i>Neuro-Oncology</i> , 2017, 19, i1-i24.	0.6	171
834	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	7.7	706
836	Location Matters: Stage I Non-small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes. <i>Clinical Lung Cancer</i> , 2017, 18, e137-e142.	1.1	21
837	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2017, 29, 218-230.	0.6	49
838	Pharmacological and immunological targeting of tumor mesenchymalization. , 2017, 170, 212-225.		14
839	Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. <i>Current Problems in Cancer</i> , 2017, 41, 111-124.	1.0	37
840	Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3012-3024.	3.2	741
841	Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. <i>Journal of Clinical Oncology</i> , 2017, 35, 243-252.	0.8	19
842	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. <i>Liver Cancer</i> , 2017, 6, 1-12.	4.2	60
843	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 264-272.	21.5	204
844	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.5	317
845	Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. <i>Annals of Oncology</i> , 2017, 28, 673-675.	0.6	87
846	Emerging biomarkers for PD-1 pathway cancer therapy. <i>Biomarkers in Medicine</i> , 2017, 11, 53-67.	0.6	11
847	Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. <i>International Journal of Oncology</i> , 2017, 50, 41-48.	1.4	65

#	ARTICLE	IF	CITATIONS
848	Innate immune signaling and regulation in cancer immunotherapy. <i>Cell Research</i> , 2017, 27, 96-108.	5.7	291
849	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	1.6	126
850	Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12.) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 662	1.0	42
851	Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. <i>Scientific Reports</i> , 2017, 7, 14049.	1.6	37
852	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017, 16, 301-308.	0.1	6
853	Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. <i>Lung Cancer</i> , 2017, 111, 108-115.	0.9	11
854	Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. <i>Lung Cancer</i> , 2017, 113, 93-101.	0.9	38
855	Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5729-5736.	3.2	172
858	Radiomics: the bridge between medical imaging and personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 749-762.	12.5	3,216
859	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. <i>Immunotherapy</i> , 2017, 9, 995-1004.	1.0	14
860	Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. <i>Oncolmunology</i> , 2017, 6, e1386829.	2.1	209
861	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1240-1267.	2.3	220
862	PD-L1 IHC in NSCLC with a global and methodological perspective. <i>Lung Cancer</i> , 2017, 113, 102-105.	0.9	34
863	MACC-1 antibody target therapy suppresses growth and migration of non-small cell lung cancer. <i>Molecular Medicine Reports</i> , 2017, 16, 7329-7336.	1.1	3
864	Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. <i>Clinical Cancer Research</i> , 2017, 23, 7641-7649.	3.2	22
866	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1483-1492.	5.1	1,034
867	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 1-12.	2.0	141
868	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1420-1435.	7.7	507

#	ARTICLE	IF	CITATIONS
869	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. <i>Cancer Cytopathology</i> , 2017, 125, 896-907.	1.4	164
871	Endocrine side effects of cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, T331-T347.	1.6	131
872	Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2017, , 51-68.		0
873	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. <i>Immunological Reviews</i> , 2017, 280, 249-279.	2.8	155
874	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1055-1069.	1.5	24
875	Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma. <i>Journal of Immunotherapy</i> , 2017, 40, 323-333.	1.2	68
876	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	5.8	115
877	Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy. <i>Human Pathology</i> , 2017, 70, 49-54.	1.1	38
878	Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer. <i>Current Pharmacology Reports</i> , 2017, 3, 360-373.	1.5	10
879	Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors. <i>Scientific Reports</i> , 2017, 7, 13682.	1.6	37
880	Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: an overview of the current landscape and challenges ahead. <i>Annals of Oncology</i> , 2017, 28, 2923-2931.	0.6	46
881	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. <i>American Journal of Clinical Pathology</i> , 2017, 148, 441-449.	0.4	19
882	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33
883	Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis. <i>ESMO Open</i> , 2017, 2, e000222.	2.0	11
884	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	1.9	1,779
885	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. <i>Onc Immunology</i> , 2017, 6, e1356150.	2.1	32
886	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017, 84, 212-218.	1.3	132
887	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 353-373.	1.0	28

#	ARTICLE	IF	CITATIONS
888	PD-1/PD-L1 and immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2017, 407, 57-65.	3.2	235
889	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. <i>Drug Resistance Updates</i> , 2017, 32, 1-15.	6.5	132
890	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1654-1663.	0.5	81
891	Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 898-907.	1.6	184
892	Tubulointerstitial nephritis as adverse effect of programmed cell death 1 inhibitor, nivolumab, showed distinct histological findings. <i>CEN Case Reports</i> , 2017, 6, 169-174.	0.5	17
893	Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma. <i>Human Pathology</i> , 2017, 68, 103-111.	1.1	60
894	Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer. <i>International Immunopharmacology</i> , 2017, 52, 7-14.	1.7	68
895	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. <i>British Journal of Cancer</i> , 2017, 117, 913-920.	2.9	145
896	Trial watch: Immune checkpoint blockers for cancer therapy. <i>Oncolmmunology</i> , 2017, 6, e1373237.	2.1	62
897	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. <i>Scientific Reports</i> , 2017, 7, 11671.	1.6	57
898	Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. <i>Cancer Medicine</i> , 2017, 6, 2347-2356.	1.3	39
899	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017, 8, 592.	5.8	166
900	CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. <i>Immunotherapy</i> , 2017, 9, 929-941.	1.0	34
901	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. <i>Medical Molecular Morphology</i> , 2017, 50, 185-194.	0.4	31
902	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. <i>Pharmacoeconomics</i> , 2017, 35, 1195-1209.	1.7	16
903	The Challenge for Development of Valuable Immuno-oncology Biomarkers. <i>Clinical Cancer Research</i> , 2017, 23, 4970-4979.	3.2	76
904	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	3.2	115
905	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. <i>Clinical Cancer Research</i> , 2017, 23, 4992-5002.	3.2	41

#	ARTICLE	IF	CITATIONS
906	PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. <i>Scientific Reports</i> , 2017, 7, 10255.	1.6	160
907	Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade. <i>Clinical Immunology</i> , 2017, 183, 167-173.	1.4	46
908	Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 1512-1520.	2.8	56
909	PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 146-153.	0.9	145
910	Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 3071-3081.	0.7	14
911	The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. <i>American Journal of Pathology</i> , 2017, 187, 2185-2198.	1.9	17
912	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 59, 71-78.	3.4	88
913	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 591-598.	1.1	47
914	Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India. <i>Annals of Diagnostic Pathology</i> , 2017, 31, 56-61.	0.6	16
915	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590
916	Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1238-1246.	0.6	116
918	Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 834-851.	0.2	47
919	Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. <i>International Journal of Cancer</i> , 2017, 141, 1891-1900.	2.3	23
920	Cancer Immunotherapies: Are They as Effective in the Elderly?. <i>Drugs and Aging</i> , 2017, 34, 567-581.	1.3	31
921	Regulation of immune-related diseases by multiple factors of chromatin, exosomes, microparticles, vaccines, oxidative stress, dormancy, protein quality control, inflammation and microenvironment: a meeting report of 2017 International Workshop of the Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine on Tumor Immunology. <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 532-540.	5.7	3
922	Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. <i>Lung Cancer</i> , 2017, 111, 6-11.	0.9	2
923	Programmed death ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice. <i>Cancer Cytopathology</i> , 2017, 125, 521-528.	1.4	11
925	Pan-urollogic cancer genomic subtypes that transcend tissue of origin. <i>Nature Communications</i> , 2017, 8, 199.	5.8	49

#	ARTICLE	IF	CITATIONS
926	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. <i>Scientific Reports</i> , 2017, 7, 5532.	1.6	166
927	Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. <i>ESMO Open</i> , 2017, 2, e000145.	2.0	9
928	Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6487-6497.	3.2	121
929	The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer. <i>Laryngoscope Investigative Otolaryngology</i> , 2017, 2, 99-103.	0.6	14
930	Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1536-1543.	0.5	53
931	First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). <i>Cancer Investigation</i> , 2017, 35, 541-546.	0.6	5
932	Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. <i>ESMO Open</i> , 2017, 2, e000150.	2.0	105
933	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. <i>ESMO Open</i> , 2017, 2, e000200.	2.0	31
934	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 97-104.	1.1	37
935	The importance for immunoregulation for long-term cancer control. <i>Future Oncology</i> , 2017, 13, 1619-1632.	1.1	9
936	Lung cancer as a cardiotoxic state: a review. <i>Medical Oncology</i> , 2017, 34, 159.	1.2	12
937	Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. <i>Future Oncology</i> , 2017, 13, 1649-1663.	1.1	10
938	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1363139.	2.1	60
939	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2310-2325.	3.3	46
940	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. <i>Nature</i> , 2017, 549, 106-110.	13.7	501
941	The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 767-777.	1.6	120
942	Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. <i>Targeted Oncology</i> , 2017, 12, 571-597.	1.7	135
944	PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. <i>Lung Cancer</i> , 2017, 112, 200-215.	0.9	213

#	ARTICLE	IF	CITATIONS
945	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. <i>Current Oncology Reports</i> , 2017, 19, 64.	1.8	106
946	The Expression and Clinical Signification of PD-1 in Lymph Nodes of Patients with Non-small Cell Lung Cancer. <i>Immunological Investigations</i> , 2017, 46, 639-646.	1.0	10
947	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017, 24, 211-239.	2.4	530
948	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immuno-Oncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 225-251.	2.4	469
949	Development of an intervention to support patients and clinicians with advanced lung cancer when considering systematic anticancer therapy: protocol for the PACT study. <i>BMJ Open</i> , 2017, 7, e015277.	0.8	4
950	Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade. <i>OncImmunology</i> , 2017, 6, e1349587.	2.1	56
951	Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 378-382.	0.4	24
952	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 51.	1.3	69
953	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. <i>Annals of Oncology</i> , 2017, 28, 2377-2385.	0.6	631
954	Contrast-enhanced computerized tomography combined with a targeted nanoparticle contrast agent for screening for early-phase non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 5063-5068.	0.8	5
955	Oncogenic RAS Signaling Promotes Tumor Immuno-resistance by Stabilizing PD-L1 mRNA. <i>Immunity</i> , 2017, 47, 1083-1099.e6.	6.6	450
956	Complications rhumatologiques de l'immunothérapie anticancéreuse. <i>Revue Du Rhumatisme (Edition Tijdschrift voor Reumatologie)</i> , 2017, 43, 107-110.	0.0	0
957	Multiplex three-dimensional optical mapping of tumor immune microenvironment. <i>Scientific Reports</i> , 2017, 7, 17031.	1.6	41
958	QuPath: Open source software for digital pathology image analysis. <i>Scientific Reports</i> , 2017, 7, 16878.	1.6	3,854
959	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. <i>Nature Communications</i> , 2017, 8, 1751.	5.8	497
960	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 235-244.	0.6	2
961	Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction Assay Is a Feasible Method for the Relative Quantification of Heregulin Expression in Non-Small Cell Lung Cancer Tissue. <i>Biomarker Insights</i> , 2017, 12, 117727191769985.	1.0	3
962	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <i>Cell</i> , 2017, 171, 1284-1300.e21.	13.5	366

#	ARTICLE	IF	CITATIONS
963	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology</i> , The, 2017, 18, e731-e741.	5.1	568
964	Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. <i>Oncologist</i> , 2017, 22, 1470-1477.	1.9	10
965	Non-“small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. <i>Cancer</i> , 2017, 123, 4800-4807.	2.0	19
966	Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma. <i>Respiratory Medicine Case Reports</i> , 2017, 22, 283-286.	0.2	19
967	Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. <i>Nature Reviews Neurology</i> , 2017, 13, 755-763.	4.9	139
968	Pembrolizumab in the treatment of advanced urothelial cancer. <i>Future Oncology</i> , 2017, 13, 2745-2758.	1.1	4
969	What’s new in chemotherapy for non-small cell lung cancer?. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 123-126.	0.3	0
970	Live Cell Labeling with Terpyridine Derivative Proligands to Measure Cytotoxicity Mediated by Immune Cells. <i>ChemMedChem</i> , 2017, 12, 2006-2013.	1.6	9
971	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 272-294.	0.1	6
972	Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases. <i>American Journal of Kidney Diseases</i> , 2017, 70, 581-585.	2.1	76
973	Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1195-1213.	1.2	20
974	Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. <i>Current Oncology Reports</i> , 2017, 19, 49.	1.8	23
975	Cancer immunotherapy: Breakthrough or “cedeja vu, all over again”? <i>Tumor Biology</i> , 2017, 39, 101042831770776.	0.8	7
976	Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 877-882.	15.6	541
977	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 10-22.	1.0	45
979	Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. <i>European Journal of Cancer</i> , 2017, 82, 34-44.	1.3	146
980	The Use of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Programmed Death Ligand 1 Immunohistochemistry Testing in Non-Small Cell Lung Cancer. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2017, 24, 181-183.	0.8	11
981	Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC. <i>Molecular Cancer Research</i> , 2017, 15, 1354-1365.	1.5	25

#	ARTICLE	IF	CITATIONS
982	Management of infusion reactions to systemic anticancer therapy: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2017, 28, iv100-iv118.	0.6	86
983	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv119-iv142.	0.6	1,744
984	Programmed Death Ligand 1 Expression in Paired Nonâ€“Small Cell Lung Cancer Tumor Samples. <i>Clinical Lung Cancer</i> , 2017, 18, e473-e479.	1.1	35
985	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. <i>Cancer Letters</i> , 2017, 405, 29-37.	3.2	93
986	Tumor Response Dynamics of Advanced Nonâ€“small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. <i>Clinical Cancer Research</i> , 2017, 23, 5737-5744.	3.2	69
987	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. <i>CNS Drugs</i> , 2017, 31, 675-684.	2.7	24
988	Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5948-5958.	3.2	85
989	Patient Reported Outcomes (PROs) as Part of Value-Based Care Can Shape Therapy Guidelines: Impact on Emerging Targeted Agents and Immunotherapy Protocols in Resource-Limited Regions. <i>Oncology and Therapy</i> , 2017, 5, 69-74.	1.0	5
990	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 655-668.	12.5	787
992	Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas. <i>Diagnostic Pathology</i> , 2017, 12, 45.	0.9	93
993	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
994	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. <i>Oncologist</i> , 2017, 22, 1232-1237.	1.9	109
995	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 5-15.	3.2	48
996	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103.	0.3	51
997	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. <i>Modern Pathology</i> , 2017, 30, 1411-1421.	2.9	151
998	Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, e7346.	0.4	27
999	Endocrine dysfunction following immune checkpoint inhibitor therapy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 337-347.	1.2	18
1000	PD-1â€“PD-L1 immune-checkpoint blockade in B-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 203-220.	12.5	358

#	ARTICLE	IF	CITATIONS
1001	Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 28-35.	2.0	120
1002	Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines. <i>Head and Neck Pathology</i> , 2017, 11, 203-211.	1.3	23
1003	Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 458-466.	0.5	120
1004	Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer. <i>Modern Pathology</i> , 2017, 30, 340-349.	2.9	138
1005	Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 843-853.	1.4	51
1006	Gene-expression profiling to predict responsiveness to immunotherapy. <i>Cancer Gene Therapy</i> , 2017, 24, 134-140.	2.2	72
1007	Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 47-59.	1.1	35
1008	Pembrolizumab induced severe sclerodermoid reaction. <i>Annals of Oncology</i> , 2017, 28, 432-433.	0.6	29
1009	Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 119-128.	2.0	89
1010	Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. <i>Annals of Oncology</i> , 2017, 28, 457-467.	0.6	27
1011	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176.	0.7	186
1012	Using Model-Based Learn and Confirm to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 21-28.	1.3	85
1013	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <i>Annals of Oncology</i> , 2017, 28, 57-74.	0.6	45
1014	Re: Atezolizumab in Patients with Locally Advanced and Metastatic Urothelial Carcinoma who have Progressed Following Treatment with Platinum-based Chemotherapy: A Single-arm, Multicenter, Phase 2 Trial. <i>European Urology</i> , 2017, 71, 299-300.	0.9	2
1015	Multiplatform-based molecular subtypes of non-small-cell lung cancer. <i>Oncogene</i> , 2017, 36, 1384-1393.	2.6	118
1016	The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration. <i>International Journal of Cancer</i> , 2017, 140, 888-899.	2.3	75
1017	Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 60-67.	1.1	6
1018	Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine. <i>Cancer Cytopathology</i> , 2017, 125, 155-160.	1.4	4

#	ARTICLE	IF	CITATIONS
1019	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 45-50.	2.0	55
1020	Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 132-140.	1.1	18
1021	A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. <i>JAMA Oncology</i> , 2017, 3, 256.	3.4	164
1022	Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and <sc>SP</sc>142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system. <i>Histopathology</i> , 2017, 70, 253-263.	1.6	37
1023	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2017, 22, 81-88.	1.9	128
1024	Proteomic profiling of human plasma for cancer biomarker discovery. <i>Proteomics</i> , 2017, 17, 1600240.	1.3	82
1025	HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status. <i>Clinical Cancer Research</i> , 2017, 23, 825-832.	3.2	78
1026	Lung cancer: current therapies and new targeted treatments. <i>Lancet, The</i> , 2017, 389, 299-311.	6.3	2,267
1027	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 65-85.	157.7	344
1028	Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. <i>Journal of Medical Economics</i> , 2017, 20, 140-150.	1.0	44
1029	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 602-611.	2.7	76
1030	Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 368-376.	0.6	641
1031	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 7-14.	0.6	39
1032	Assessing PDL-1 and PD-1 in Non-“Small Cell Lung Cancer: A Novel Immunoscore Approach. <i>Clinical Lung Cancer</i> , 2017, 18, 220-233.e8.	1.1	72
1033	Immunotherapy Comes of Age in Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 13-22.	1.1	68
1034	Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 370-378.	3.2	150
1035	Wâ€“ALKâ€“™ Into the Next Stage. <i>Clinical Lung Cancer</i> , 2017, 18, 122-126.	1.1	6
1036	Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3214-3222.	3.2	44

#	ARTICLE	IF	CITATIONS
1037	Estimating Survival in Patients With Lung Cancer and Brain Metastases. <i>JAMA Oncology</i> , 2017, 3, 827.	3.4	543
1038	Immunotherapy approaches in the treatment of malignant brain tumors. <i>Cancer</i> , 2017, 123, 734-750.	2.0	75
1039	Histopathologic diagnosis of brain metastases: current trends in management and future considerations. <i>Brain Tumor Pathology</i> , 2017, 34, 8-19.	1.1	22
1040	Next generation predictive biomarkers for immune checkpoint inhibition. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 179-190.	2.7	84
1041	CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. <i>Oncolmmunology</i> , 2017, 6, e1249558.	2.1	72
1042	Genomic Amplification of <i>CD274</i> (PD-L1) in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1220-1226.	3.2	92
1043	The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. <i>Annual Review of Medicine</i> , 2017, 68, 153-168.	5.0	24
1044	Clinicopathological features of programmed death ligand-1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. <i>Gastric Cancer</i> , 2017, 20, 407-415.	2.7	189
1045	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 110-120.	0.5	108
1046	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	0.8	829
1047	Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion. <i>Cardiology</i> , 2017, 136, 49-51.	0.6	68
1048	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139
1049	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients. <i>Medicine (United States)</i> , 2017, 96, e8931.	0.4	21
1050	RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion. <i>Immunity</i> , 2017, 47, 1007-1009.	6.6	13
1051	The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report. <i>Case Reports in Oncology</i> , 2017, 10, 752-757.	0.3	31
1052	Feeling Exhausted? Tuning Irf4 Energizes Dysfunctional T Cells. <i>Immunity</i> , 2017, 47, 1009-1011.	6.6	8
1053	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	9
1054	Traitement de première ligne et de maintenance dans les CBNPC avancés en l'absence d'addiction oncogénique. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 234-247.	0.0	0

#	ARTICLE	IF	CITATIONS
1055	Cancer bronchique non À petites cellules de stade IV sans addiction oncogÃ©nique : traitements en 2 e ligne et au-delÃ©. Revue Des Maladies Respiratoires Actualites, 2017, 9, 248-258.	0.0	0
1056	ToxicitÃ© pulmonaire de lâ€™immunothÃ©rapie par les inhibiteurs de point de contrÃ©le. Revue Des Maladies Respiratoires Actualites, 2017, 9, 469-474.	0.0	1
1057	Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Molecular and Clinical Oncology, 2017, 8, 310-314.	0.4	22
1058	Adaptive Resistance to Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2017, 1036, 213-227.	0.8	15
1061	The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. Biotarget, 0, 1, 7-7.	0.5	11
1062	Clinical Response to Antiâ€“Programmed Death 1 After Response and Subsequent Progression on Antiâ€“Programmed Death Ligand 1 Therapy. JCO Precision Oncology, 2017, 1, 1-9.	1.5	3
1063	A Case of Secondary Adrenocortical Insufficiency Developed due to ACTH Deficiency After Nivolumab Treatment. Japanese Journal of Lung Cancer, 2017, 57, 226-231.	0.0	1
1064	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. Therapeutics and Clinical Risk Management, 2017, Volume 13, 223-236.	0.9	16
1065	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. Ecanermedicalscience, 2017, 11, 787.	0.6	34
1066	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology, 2017, 8, 49.	1.6	459
1067	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Frontiers in Pharmacology, 2017, 8, 730.	1.6	350
1068	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1259-1271.	0.9	16
1069	Chemotherapy and Targeted Agents. , 2017, , 339-354.		3
1070	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers, 2017, 9, 13.	1.7	40
1071	New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab. Lung Cancer: Targets and Therapy, 2017, Volume 8, 67-78.	1.3	27
1072	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies. OncoTargets and Therapy, 2017, Volume 10, 2349-2363.	1.0	35
1073	Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles. Immune Network, 2017, 17, 378.	1.6	70
1074	The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. Oncotarget, 2017, 8, 57826-57835.	0.8	24

#	ARTICLE	IF	CITATIONS
1075	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 51-71.	2.7	101
1076	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 1-11.	1.3	6
1077	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2537-2549.	2.0	6
1078	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2017, Volume 7, 1-11.	5.5	49
1079	Making cancer immunotherapy a surer bet. <i>Nature</i> , 2017, 552, S72-S73.	13.7	6
1080	Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1517.	1.8	69
1081	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2017, 8, 561.	1.6	1,276
1082	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2017, 18, 645.	1.8	193
1083	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225
1084	Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications. <i>Theranostics</i> , 2017, 7, 3585-3594.	4.6	214
1085	Biologic therapy in esophageal and gastric malignancies: current therapies and future directions. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 418-429.	0.6	20
1086	Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer. <i>Cancers</i> , 2017, 9, 49.	1.7	53
1087	Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer. <i>Cancers</i> , 2017, 9, 164.	1.7	26
1088	Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer. <i>Cells</i> , 2017, 6, 12.	1.8	75
1089	Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. <i>Frontiers in Immunology</i> , 2017, 8, 961.	2.2	93
1090	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. <i>Frontiers in Immunology</i> , 2017, 8, 1547.	2.2	125
1091	Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms. <i>Frontiers in Medicine</i> , 2017, 4, 9.	1.2	14
1092	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 38.	1.3	14

#	ARTICLE	IF	CITATIONS
1093	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 67.	1.3	28
1094	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 197.	1.3	18
1095	Prognostic significance of programmed cell death ligand 1 (pd-l1), cd8+ tumor-infiltrating lymphocytes and p53 in non-small cell lung cancer: an immunohistochemical study. <i>Turk Patoloji Dergisi</i> , 2017, 1, 211-222.	0.1	19
1096	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	65
1097	CD80 Expressed by CD8 ⁺ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8 ⁺ T Cells. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	0.9	33
1098	A population of innate myelolymphoblastoid effector cell expanded by inactivation of mTOR complex 1 in mice. <i>ELife</i> , 2017, 6, .	2.8	5
1099	Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 655-668.	0.7	11
1100	New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2513-2526.	1.0	33
1101	PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 52889-52900.	0.8	82
1102	Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?. <i>Translational Andrology and Urology</i> , 2017, 6, 1067-1080.	0.6	19
1103	Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer. <i>Acta Dermato-Venereologica</i> , 2017, 97, 539-540.	0.6	18
1104	Novel Therapies in Platinum-refractory Metastatic Germ Cell Tumor: A Case Report with a Focus on a PD-1 Inhibitor. <i>Rare Tumors</i> , 2017, 9, 47-49.	0.3	14
1105	PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level. <i>Journal of Cancer</i> , 2017, 8, 3251-3260.	1.2	21
1106	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. <i>Cancer Management and Research</i> , 2017, Volume 9, 207-213.	0.9	128
1107	Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab. <i>Case Reports in Oncology</i> , 2017, 10, 230-234.	0.3	35
1108	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3697-3708.	1.0	6
1109	Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. <i>Current Cancer Therapy Reviews</i> , 2017, 13, .	0.2	0
1110	Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. <i>PLoS ONE</i> , 2017, 12, e0183023.	1.1	73

#	ARTICLE	IF	CITATIONS
1111	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <i>OncImmunology</i> , 2017, 6, e1344805.	2.1	142
1112	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. <i>Tumori</i> , 2017, 103, 405-421.	0.6	52
1113	Addressing the challenges of applying precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 28.	2.3	43
1114	Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis. <i>BMC Cancer</i> , 2017, 17, 690.	1.1	41
1115	PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 146.	6.9	77
1116	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. , 2017, 5, 56.		9
1117	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
1118	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. , 2017, 5, 103.		8
1119	Clinical safety of combined therapy of immune checkpoint inhibitors and <i>Viscum album L.</i> therapy in patients with advanced or metastatic cancer. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 534.	3.7	31
1121	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2017, 6, S8-S20.	1.3	97
1122	Comprehensive Review of PD1/L1 Inhibition in Metastatic Solid Tumors: Safety, efficacy and Resistance. <i>Journal of Biomedical Sciences</i> , 2017, 06, .	0.3	0
1123	Companion Diagnostics: From Biomarkers to Diagnostics. , 2017, , 530-545.		2
1124	Live, Learn, Pass It on. <i>Journal of Patient Experience</i> , 2017, 4, 162-168.	0.4	7
1125	Promoter DNA methylation analysis reveals a combined diagnosis of CpG-based biomarker for prostate cancer. <i>Oncotarget</i> , 2017, 8, 58199-58209.	0.8	10
1126	Prognostic and Predictive Value of PD-L1 in Patients with Lung Cancer. , 0, , .		0
1127	Checkpoint Inhibitors in Nonsmall Cell Lung Cancer. , 2017, , .		0
1128	The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?. <i>Cancer Biology and Medicine</i> , 2017, 14, 341.	1.4	4
1129	Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. <i>Oncotarget</i> , 2017, 8, 67094-67103.	0.8	47

#	ARTICLE	IF	CITATIONS
1130	Improving Molecular Testing and Personalized Medicine in Non-Small-Cell Lung Cancer in Ontario. <i>Current Oncology</i> , 2017, 24, 103-110.	0.9	30
1131	IFN- γ -related mRNA profile predicts clinical response to PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2017, 127, 2930-2940.	3.9	2,560
1132	PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. <i>Oncotarget</i> , 2017, 8, 98524-98532.	0.8	40
1133	Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. <i>Oncotarget</i> , 2017, 8, 57680-57692.	0.8	62
1134	<i>Cancer Immunotherapy</i> . , 2017, , 32-65.		1
1135	PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2017, 9, E384-E386.	0.6	17
1136	Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. <i>Lung Cancer: Targets and Therapy</i> , 2017, Volume 8, 179-190.	1.3	6
1137	Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2851-2860.	2.0	34
1138	<i>Humanized Mice and PDX Models</i> . , 2017, , 75-89.		2
1139	Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. <i>Oncotarget</i> , 2017, 8, 90215-90224.	0.8	68
1140	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. <i>Medical Science Monitor</i> , 2017, 23, 1208-1216.	0.5	49
1141	Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2017, 8, 8910-8920.	0.8	108
1142	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence <i>in situ</i> hybridization (FISH) to select the optimal patients for matched therapy?. <i>Oncotarget</i> , 2017, 8, 100863-100898.	0.8	16
1143	Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 4075-4082.	1.2	7
1144	The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 447-456.	1.1	2
1145	Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. <i>Oncotarget</i> , 2017, 8, 91779-91794.	0.8	298
1146	Addressing the Survivorship Care Needs of Patients Receiving Extended Cancer Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 674-683.	1.8	18
1147	Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. <i>Oncotarget</i> , 2017, 8, 8890-8899.	0.8	48

#	ARTICLE	IF	CITATIONS
1148	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. <i>Oncotarget</i> , 2017, 8, 41932-41946.	0.8	95
1149	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class IIâ€œRestricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. <i>Journal of Clinical Oncology</i> , 2017, 35, 3322-3329.	0.8	204
1150	First Case Report of a Dramatic Radiographic Response to a Checkpoint Inhibitor in a Patient With Proficient Mismatch Repair Gene Expressing Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-4.	1.5	7
1151	Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. <i>JCO Precision Oncology</i> , 2017, 1, 1-12.	1.5	35
1152	Reply to M. Nishino et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1629-1630.	0.8	1
1153	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3823-3829.	0.8	413
1154	Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1â€œPositive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 4050-4056.	0.8	335
1155	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1â€œSelected Advanced Nonâ€œSmall-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	348
1156	Complete Serologic Response to Pembrolizumab in a Woman With Chemoresistant Metastatic Choriocarcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3172-3174.	0.8	43
1157	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	0.8	527
1158	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1â€œPositive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2535-2541.	0.8	383
1159	Biomarkers for Checkpoint Inhibition. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 205-209.	1.8	11
1160	EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 75712-75726.	0.8	119
1161	The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 16421-16429.	0.8	50
1162	Increased PD-L1 expression in erlotinib-resistant NSCLC cells with <i>MET</i> gene amplification is reversed upon MET-TKI treatment. <i>Oncotarget</i> , 2017, 8, 68221-68229.	0.8	31
1163	Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. <i>Journal of Thoracic Disease</i> , 2017, 9, 655-665.	0.6	15
1164	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2579-2586.	0.6	51
1165	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. <i>Translational Lung Cancer Research</i> , 2017, 6, 373-386.	1.3	45

#	ARTICLE	IF	CITATIONS
1166	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 570-587.	1.3	42
1167	Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. <i>Translational Lung Cancer Research</i> , 2017, 6, S39-S40.	1.3	5
1168	Immunotherapy for malignant pleural mesothelioma: current status and future directions. <i>Translational Lung Cancer Research</i> , 2017, 6, 315-324.	1.3	30
1169	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 83986-83994.	0.8	69
1170	Moving more potent and less toxic options to the frontline in the management of advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, 2812-2818.	0.6	1
1171	Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed. <i>Journal of Thoracic Disease</i> , 2017, 9, 4821-4824.	0.6	13
1172	Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?. <i>Translational Lung Cancer Research</i> , 2017, 6, S78-S83.	1.3	9
1173	Reproducibility of PD-L1 assessment in non-small cell lung cancer—know your limits but never stop trying to exceed them. <i>Translational Lung Cancer Research</i> , 2017, 6, S51-S54.	1.3	12
1174	Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, S41-S43.	1.3	2
1175	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	57
1176	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. <i>Oncotarget</i> , 2017, 8, 90123-90131.	0.8	89
1177	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. <i>Oncotarget</i> , 2017, 8, 3197-3205.	0.8	53
1178	A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. <i>Oncotarget</i> , 2017, 8, 29067-29079.	0.8	29
1179	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 77415-77423.	0.8	68
1180	Vaccination-induced skin-resident memory CD8 ⁺ T cells mediate strong protection against cutaneous melanoma. <i>Oncolimmunology</i> , 2018, 7, e1442163.	2.1	62
1181	Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 815-824.	1.4	53
1182	The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. <i>Esophagus</i> , 2018, 15, 103-108.	1.0	14
1183	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	166

#	ARTICLE	IF	CITATIONS
1184	JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 732-739.	1.9	18
1185	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint) <i>Tj ETQq1 1 0.784314 rgBT /Overl</i>	2.8	96
1186	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	8.2	82
1187	Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012. <i>Cancer Science</i> , 2018, 109, 771-776.	1.7	48
1188	Checkpoint inhibitors: raising the bar™ also in brain metastases from non-small-cell lung cancer?. <i>Immunotherapy</i> , 2018, 10, 403-410.	1.0	6
1189	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , 2018, 124, 2010-2017.	2.0	81
1190	Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer. <i>Diagnostic Cytopathology</i> , 2018, 46, 378-383.	0.5	38
1191	The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?. <i>Journal of Thoracic Oncology</i> , 2018, 13, 291-294.	0.5	21
1192	Analysis of middle- and long-term efficacy of thoracoscope-assisted segmental resection of the lung on non-small cell lung cancer in the early stage. <i>Oncology Letters</i> , 2018, 15, 3662-3668.	0.8	1
1193	Time is up for PD-L1 testing standardization in lung cancer. <i>Annals of Oncology</i> , 2018, 29, 791-792.	0.6	2
1194	Systemic immune-inflammation index in germ-cell tumours. <i>British Journal of Cancer</i> , 2018, 118, 831-838.	2.9	70
1195	Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition. <i>Cancer Immunology Research</i> , 2018, 6, 617-627.	1.6	13
1196	Combination Cancer Immunotherapy in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 20-27.	4.2	55
1197	Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. <i>Oncolmmunology</i> , 2018, 7, e1442168.	2.1	64
1198	Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. <i>Cancer Cytopathology</i> , 2018, 126, 342-352.	1.4	102
1199	Combination nivolumab with transcatheter arterial chemoembolization for clinical remission of small cell lung cancer: A case report. <i>Thoracic Cancer</i> , 2018, 9, 646-651.	0.8	4
1200	Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab. <i>Lung Cancer</i> , 2018, 118, 171-172.	0.9	14
1201	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. <i>Annals of Surgical Oncology</i> , 2018, 25, 1814-1827.	0.7	45

#	ARTICLE	IF	CITATIONS
1202	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with nonâ€“small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. Journal of the American Society of Cytopathology, 2018, 7, 133-141.	0.2	56
1203	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. Journal of Neuro-Oncology, 2018, 139, 251-259.	1.4	16
1204	Target Therapy for Esophageal Adenocarcinoma. Methods in Molecular Biology, 2018, 1756, 51-65.	0.4	2
1206	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer, 2018, 120, 137-141.	0.9	29
1207	Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management, 2018, 7, BMT05.	0.2	4
1208	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	13.9	1,495
1209	Pembrolizumab plus Chemotherapy in Metastatic Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	13.9	4,701
1210	Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecologic Oncology Reports, 2018, 24, 1-5.	0.3	10
1211	Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis. Journal of Surgical Oncology, 2018, 117, 1405-1412.	0.8	4
1212	Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Science Advances, 2018, 4, eaao1736.	4.7	269
1213	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876209.	1.4	102
1214	PD-L1 expression testing in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876349.	1.4	120
1215	Radiotherapy and checkpoint inhibitors: a winning new combination?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876824.	1.4	87
1216	Quo Vadisâ€“Do Immunotherapies Have a Role in Glioblastoma?. Current Treatment Options in Neurology, 2018, 20, 14.	0.7	22
1217	The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. Clinica Chimica Acta, 2018, 482, 101-107.	0.5	38
1218	Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 2018, 37, 3686-3697.	2.6	45
1219	Clinical assessment of immune-related adverse events. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591876462.	1.4	101
1220	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell, 2018, 33, 581-598.	7.7	393

#	ARTICLE	IF	CITATIONS
1221	Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know?. <i>Current Pulmonology Reports</i> , 2018, 7, 42-48.	0.5	0
1222	Survival benefit from RetroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinoma. <i>Immunotherapy</i> , 2018, 10, 501-510.	1.0	6
1223	Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. <i>Annals of Oncology</i> , 2018, 29, 1417-1422.	0.6	92
1224	Role of PD-1 during effector CD8 T cell differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4749-4754.	3.3	327
1225	Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. <i>Immunology Letters</i> , 2018, 196, 155-160.	1.1	55
1226	Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage III/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2. <i>Cancer</i> , 2018, 124, 1982-1991.	2.0	12
1228	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. <i>Lancet Oncology</i> , 2018, 19, 347-355.	5.1	290
1229	PD-1 /PD-L1 checkpoint in hematological malignancies. <i>Leukemia Research</i> , 2018, 67, 45-55.	0.4	33
1230	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. <i>Lung Cancer</i> , 2018, 118, 36-40.	0.9	81
1231	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 3.	2.0	83
1232	Combining chemotherapy with PD-1 blockade in NSCLC. , 2018, 186, 130-137.		97
1233	Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2018, 118, 6-12.	0.9	9
1234	Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. <i>Cancer Cytopathology</i> , 2018, 126, 253-263.	1.4	70
1236	Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration. <i>Journal of the National Cancer Institute</i> , 2018, 110, 486-492.	3.0	70
1237	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
1238	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	1.0	60
1239	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
1240	PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations. <i>EBioMedicine</i> , 2018, 28, 97-104.	2.7	55

#	ARTICLE	IF	CITATIONS
1241	Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1 ⁺ Negative Human Lung Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 1954-1964.	3.2	64
1242	The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. <i>Medical Oncology</i> , 2018, 35, 25.	1.2	124
1243	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 1922.	1.6	108
1244	Checkpoint molecule expression by B and T cell lymphomas in dogs. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 352-360.	0.8	25
1245	YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 255-266.	1.6	158
1246	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200
1247	Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. <i>Cancer Immunology Research</i> , 2018, 6, 288-294.	1.6	70
1248	Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775163.	1.4	29
1249	Role of immune-checkpoint inhibitors in lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346581775007.	1.0	88
1250	Cancer Systems Biology. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	8
1251	Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2018, 29, 953-958.	0.6	184
1252	The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 191-194.	1.1	5
1253	Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response. <i>Methods in Molecular Biology</i> , 2018, 1711, 333-349.	0.4	8
1254	Computational immune profiling in lung adenocarcinoma reveals reproducible prognostic associations with implications for immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1431084.	2.1	43
1255	T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 4175-4186.	3.2	402
1256	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 405-415.	5.1	305
1257	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018, 68, 1181-1190.	1.8	372
1258	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. <i>Scientific Reports</i> , 2018, 8, 2592.	1.6	81

#	ARTICLE	IF	CITATIONS
1261	Microsatellite instability status determined by next-generation sequencing and compared with microsatellite instability status and tumor mutational burden in 11,348 patients. <i>Cancer Medicine</i> , 2018, 7, 746-756.	1.3	348
1262	Hypermutated Tumors and Immune Checkpoint Inhibition. <i>Drugs</i> , 2018, 78, 155-162.	4.9	22
1263	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. <i>ESMO Open</i> , 2018, 3, e000257.	2.0	62
1264	Checkpoint Inhibitors, Palliative Care, or Hospice. <i>Current Oncology Reports</i> , 2018, 20, 2.	1.8	8
1265	The differences in the assessments of side effects at an oncology outpatient clinic. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 386-393.	1.0	7
1266	Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays. <i>American Journal of Surgical Pathology</i> , 2018, 42, 687-694.	2.1	31
1267	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1296-1304.	3.2	146
1268	Mechanisms of Resistance to PD-1 and PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 47-53.	1.0	287
1269	PD-1/PD-L1 Axis in Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 15-19.	1.0	61
1270	Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. <i>Clinical and Translational Oncology</i> , 2018, 20, 1072-1079.	1.2	43
1271	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	13.7	2,877
1272	Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. <i>Immunotherapy</i> , 2018, 10, 85-91.	1.0	34
1273	Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. <i>Clinical Lung Cancer</i> , 2018, 19, 280-288.e4.	1.1	45
1274	Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2018, 116, 62-66.	0.9	94
1275	Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 5-11.	0.9	76
1276	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 165-183.	0.5	134
1277	Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 367-376.	0.5	127
1278	Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 377-386.	0.5	50

#	ARTICLE	IF	CITATIONS
1279	Stromal PD-L1 ⁺ Positive Regulatory T cells and PD-1 ⁺ Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, 521-532.	0.5	119
1280	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2018, 13, 510-520.	0.5	77
1281	Pembrolizumab for the treatment of bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 107-114.	1.1	12
1282	Cancer immunotherapy: A need for peripheral immunodynamic monitoring. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12793.	1.2	5
1283	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23
1284	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 106-111.	0.5	203
1285	Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. <i>Gut</i> , 2018, 67, 179-193.	6.1	73
1286	Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. <i>Radiology</i> , 2018, 287, 326-332.	3.6	24
1287	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. , 2018, , 231-246.		0
1288	Immune Checkpoint Inhibition in Lung Cancer. , 2018, , 333-344.		0
1289	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
1290	Immune Therapies in Phase 1 Trials. , 2018, , 547-563.		0
1291	Dermatologic Reactions to Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 345-361.	3.3	426
1292	Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. <i>Lung Cancer</i> , 2018, 126, 217-223.	0.9	89
1293	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 26-38.	4.3	49
1294	Quantitative Biomarkers for Prediction of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer. <i>Translational Oncology</i> , 2018, 11, 94-101.	1.7	101
1295	Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 210.	3.4	437
1296	Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors. <i>OncImmunology</i> , 2018, 7, e1417721.	2.1	33

#	ARTICLE	IF	CITATIONS
1297	Will liquid biopsies become our fluid transition to personalized immunotherapy?. Annals of Oncology, 2018, 29, 11-13.	0.6	7
1298	Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. Oncologist, 2018, 23, 328-336.	1.9	87
1299	Immunotherapy for brain tumors: understanding early successes and limitations. Expert Review of Neurotherapeutics, 2018, 18, 251-259.	1.4	22
1300	Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small cell lung carcinomas. Histopathology, 2018, 72, 1024-1032.	1.6	33
1301	Precision Molecular Pathology of Bladder Cancer. Molecular Pathology Library, 2018, , .	0.1	0
1302	Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response. Molecular Pathology Library, 2018, , 181-194.	0.1	0
1303	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. Expert Opinion on Investigational Drugs, 2018, 27, 163-170.	1.9	5
1305	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clinical Lung Cancer, 2018, 19, e335-e348.	1.1	53
1306	Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. European Journal of Cancer, 2018, 91, 21-29.	1.3	222
1307	Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Oncoimmunology, 2018, 7, e1423182.	2.1	17
1308	KEYNOTE-024: Unlocking a pathway to lung cancer cure?. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1777-1780.	0.4	10
1309	Biomarker Discovery and Validation in HCC Diagnosis, Prognosis, and Therapy. Molecular Pathology Library, 2018, , 95-113.	0.1	1
1310	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 2018, 4, 351.	3.4	599
1311	The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA-4 antibody as a first-line treatment for advanced lung cancer. International Journal of Cancer, 2018, 142, 2344-2354.	2.3	47
1312	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. Annals of Diagnostic Pathology, 2018, 33, 62-68.	0.6	4
1313	Comprehensive analysis of the clinical immuno-oncology landscape. Annals of Oncology, 2018, 29, 84-91.	0.6	422
1314	Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology, 2018, 7, e1395997.	2.1	108
1315	The Basics of Cancer Immunotherapy. , 2018, , .		5

#	ARTICLE	IF	CITATIONS
1316	Significance of Immune Checkpoints in Lung Cancer. , 2018, , 59-77.		0
1317	Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab. Clinical Cancer Research, 2018, 24, 3857-3866.	3.2	150
1318	Updated Correlation of 22C3-PD-L1 ~50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. Journal of Thoracic Oncology, 2018, 13, e81-e83.	0.5	0
1319	The expression of programmed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. Journal of Oral Pathology and Medicine, 2018, 47, 683-690.	1.4	28
1320	Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report. BMC Nephrology, 2018, 19, 48.	0.8	66
1321	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of Hematology and Oncology, 2018, 11, 31.	6.9	256
1322	PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagnostic Pathology, 2018, 13, 12.	0.9	175
1323	The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. , 2018, 6, 15.		22
1324	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
1325	Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-Oncology, 2018, 20, 1566-1572.	0.6	166
1326	Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2018, 13, e79-e81.	0.5	5
1327	Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. Modern Pathology, 2018, 31, 1381-1390.	2.9	41
1328	Pembrolizumab-induced autoimmune type 1 diabetes in a patient with metastatic melanoma. Journal of Pharmacy Practice and Research, 2018, 48, 262-264.	0.5	4
1329	The binding of an anti-PD-1 antibody to Fcγ3R TM has a profound impact on its biological functions. Cancer Immunology, Immunotherapy, 2018, 67, 1079-1090.	2.0	162
1330	A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. OncoImmunology, 2018, 7, e1466016.	2.1	42
1331	CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina, 2018, 38, 1063-1078.	1.0	252
1332	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. Journal of Thoracic Oncology, 2018, 13, 1204-1212.	0.5	46
1333	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. AAPS Journal, 2018, 20, 66.	2.2	10

#	ARTICLE	IF	CITATIONS
1334	Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 621-625.	1.0	44
1335	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2018, , 1461-1505.		0
1336	Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. <i>Annals of Thoracic Surgery</i> , 2018, 106, 178-183.	0.7	96
1337	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Nonâ€“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 831-839.	0.5	94
1338	Liquid Biopsies and Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 78-83.	1.0	18
1339	B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. <i>Clinical Cancer Research</i> , 2018, 24, 2653-2664.	3.2	109
1341	Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis. <i>Cancer Treatment and Research Communications</i> , 2018, 15, 17-20.	0.7	10
1342	Phase Ib Study of Baviximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e481-e487.	1.1	12
1343	Pseudoprogression and hyperprogression after checkpoint blockade. <i>International Immunopharmacology</i> , 2018, 58, 125-135.	1.7	121
1344	Understanding the Hurdles in Lung Cancer Immunotherapy in the Context of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 835-837.	2.5	1
1345	Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Nonâ€“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 926-937.	0.5	27
1346	Management of gastrointestinal adverse events induced by immuneâ€“checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 1-7.	0.9	6
1347	Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape. <i>Immunity</i> , 2018, 48, 399-416.	6.6	442
1348	Recent Developments in Oncology Immunotherapy, Implications for NPs Part 1. <i>Journal for Nurse Practitioners</i> , 2018, 14, 251-258.e1.	0.4	2
1349	Immunological mutational signature in adenocarcinoma of pancreas: an exploratory study of potentially therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 453-461.	1.5	15
1350	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptorâ€“Positive/Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2804-2811.	3.2	249
1351	An overview of the toxicities of checkpoint inhibitors in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 451-458.	0.5	19
1352	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	6.0	4,274

#	ARTICLE	IF	CITATIONS
1353	Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 149, 381-387.	0.6	41
1354	Concepts for Immunotherapies in Gliomas. <i>Seminars in Neurology</i> , 2018, 38, 062-072.	0.5	26
1355	The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 293-302.	1.1	16
1356	Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study. <i>Clinical Lung Cancer</i> , 2018, 19, e405-e415.	1.1	77
1357	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 521-536.	5.1	486
1358	Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. <i>Clinical Lung Cancer</i> , 2018, 19, 315-322.	1.1	36
1359	Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 494-500.	0.5	18
1360	PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. <i>British Journal of Haematology</i> , 2018, 180, 752-755.	1.2	18
1361	Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lung. <i>Clinical Respiratory Journal</i> , 2018, 12, 1106-1117.	0.6	4
1362	Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 638-642.	0.6	33
1363	Current studies of immunotherapy in head and neck cancer. <i>Clinical Otolaryngology</i> , 2018, 43, 13-21.	0.6	63
1364	The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). <i>Breast Cancer</i> , 2018, 25, 34-42.	1.3	88
1365	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. <i>Surgery Today</i> , 2018, 48, 1-8.	0.7	88
1366	Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 489-494.	0.6	38
1367	Tumor infiltrating lymphocytes in early breast cancer. <i>Breast</i> , 2018, 37, 207-214.	0.9	108
1368	The 'Achilles' Heel' of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a027086.	2.9	11
1369	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. <i>Clinical Lung Cancer</i> , 2018, 19, 1-11.	1.1	48
1370	Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 83-93.	0.6	124

#	ARTICLE	IF	CITATIONS
1371	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55
1372	Programmed deathâ€‘ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy. Cancer Cytopathology, 2018, 126, 122-128.	1.4	60
1373	Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Annals of Oncology, 2018, 29, 193-199.	0.6	162
1374	Dendritic cell vaccine induces antigen-specific CD8⁺ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade. Oncolmmunology, 2018, 7, e1395124.	2.1	20
1375	Companion and Complementary Diagnosticsâ€‘Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Nonâ€‘Small Cell Lung Cancer. Therapeutic Drug Monitoring, 2018, 40, 9-16.	1.0	82
1376	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Annals of Oncology, 2018, 29, 71-83.	0.6	253
1377	Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 278-280.	2.5	5
1378	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs, 2018, 36, 601-607.	1.2	90
1379	Looking for the best immuneâ€‘checkpoint inhibitor in preâ€‘treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. International Journal of Cancer, 2018, 142, 1277-1284.	2.3	81
1380	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene. Gene, 2018, 638, 20-25.	1.0	87
1381	Comparison of the toxicity profile of PDâ€‘1 versus PDâ€‘L1 inhibitors in nonâ€‘small cell lung cancer: A systematic analysis of the literature. Cancer, 2018, 124, 271-277.	2.0	265
1382	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. JAMA Oncology, 2018, 4, 173.	3.4	753
1383	Atezolizumab-Induced New Onset Diabetes Mellitus With Ketoacidosis. American Journal of Therapeutics, 2018, 25, e565-e568.	0.5	7
1384	Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, e86-e90.	0.6	8
1385	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncolmmunology, 2018, 7, e1376156.	2.1	14
1386	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. Oncolmmunology, 2018, 7, e1386828.	2.1	36
1387	Clinical significance of programmed cell deathâ€‘ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. International Journal of Cancer, 2018, 142, 822-832.	2.3	55
1388	PD-1 related transcriptome profile and clinical outcome in diffuse gliomas. Oncolmmunology, 2018, 7, e1382792.	2.1	37

#	ARTICLE	IF	CITATIONS
1389	Frequent PD-L1 Expression in Malignant Melanomas of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 477-481.	0.9	10
1390	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	10.6	1,210
1391	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>Oncotarget</i> , 2018, 7, e1385689.	2.1	46
1392	Cholangiocarcinoma "evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 95-111.	12.5	1,051
1393	Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 175-182.	2.0	90
1394	The application and mechanism of PD pathway blockade for cancer therapy. <i>Postgraduate Medical Journal</i> , 2018, 94, 53-60.	0.9	10
1395	Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2018, 12, 221-229.	1.3	27
1396	Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26719.	0.8	39
1397	Microenvironment and Lung Cancer. , 2018, , 121-128.e4.		1
1398	Frontline Systemic Therapy Options in Non-small Cell Lung Cancer. , 2018, , 418-433.e6.		0
1399	Systemic Options for Second-Line Therapy and Beyond. , 2018, , 434-447.e5.		0
1400	Immunotherapy and Lung Cancer. , 2018, , 501-511.e3.		2
1401	Interlaboratory concordance of PD-L1 immunohistochemistry for non-small cell lung cancer. <i>Histopathology</i> , 2018, 72, 449-459.	1.6	71
1402	Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. <i>Leukemia</i> , 2018, 32, 230-233.	3.3	49
1403	⁸⁹ Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 110-120.	3.3	100
1404	Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 325-336.	2.5	77
1405	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. <i>Pathology and Oncology Research</i> , 2018, 24, 701-716.	0.9	17
1406	Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. <i>Modern Pathology</i> , 2018, 31, 101-110.	2.9	38

#	ARTICLE	IF	CITATIONS
1407	Programmed death ligand 1-associated antitumor immunity in early-stage non-small cell lung cancer: Expression of major histocompatibility complex I as a prerequisite. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 393-394.	0.4	0
1408	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. <i>Future Oncology</i> , 2018, 14, 417-430.	1.1	55
1409	Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non-small-cell Lung Cancer: Results of a Phase II Study. <i>Clinical Lung Cancer</i> , 2018, 19, 157-162.	1.1	14
1410	Prognostic value of PD-L1 expression in combination with CD8 ⁺ TILs density in patients with surgically resected non-small cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 32-45.	1.3	48
1411	MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling. <i>Biochemical and Biophysical Research Communications</i> , 2018, 495, 1342-1348.	1.0	42
1412	Evolution of early phase clinical trials in oncology. <i>Journal of Molecular Medicine</i> , 2018, 96, 31-38.	1.7	13
1413	Durvalumab in non-small-cell lung cancer patients: current developments. <i>Future Oncology</i> , 2018, 14, 205-222.	1.1	12
1414	Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. <i>Immunotherapy</i> , 2018, 10, 93-105.	1.0	86
1415	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
1416	Molecular Diagnosis and Targeting for Lung Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 1-32.	0.1	0
1417	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. <i>European Journal of Cancer</i> , 2018, 88, 38-47.	1.3	248
1419	Mechanisms of Tumor Cell Intrinsic Immune Evasion. <i>Annual Review of Cancer Biology</i> , 2018, 2, 213-228.	2.3	65
1420	A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 79-86.	1.6	61
1421	Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. <i>European Journal of Cancer</i> , 2018, 89, 56-63.	1.3	60
1422	CD14 ⁺ HLA-DR ^{low} MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 401-411.	1.1	22
1423	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	1.9	5
1424	Promising immunotherapy for prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 109-120.	1.4	5
1425	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278

#	ARTICLE	IF	CITATIONS
1426	Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 999-1008.	2.3	31
1427	New developments in immunotherapy for pediatric solid tumors. <i>Current Opinion in Pediatrics</i> , 2018, 30, 30-39.	1.0	16
1428	Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 459-470.	2.0	132
1429	Immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Cancer</i> , 2018, 124, 248-261.	2.0	94
1430	Molecular classification and precision therapy of cancer: immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2018, 12, 229-235.	1.5	53
1431	Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. <i>Human Pathology</i> , 2018, 72, 135-143.	1.1	15
1432	Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1562-1573.	3.2	150
1433	Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 178-188.	1.6	121
1434	PD-L1. <i>Journal of Clinical Pathology</i> , 2018, 71, 189-194.	1.0	218
1435	A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. <i>Future Oncology</i> , 2018, 14, 123-136.	1.1	60
1436	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
1437	Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. <i>Oncolmmunology</i> , 2018, 7, e1396403.	2.1	60
1438	Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 78-84.	3.3	150
1439	The Significance of the PD-L1 Expression in Non-small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. <i>Clinical Lung Cancer</i> , 2018, 19, 120-129.	1.1	61
1441	Combinatorial Immunotherapy and Chemotherapy. <i>Current Cancer Research</i> , 2018, , 199-218.	0.2	4
1442	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. <i>Current Cancer Research</i> , 2018, , 243-280.	0.2	0
1443	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
1444	Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 125-133.	1.4	59

#	ARTICLE	IF	CITATIONS
1445	Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 136, 453-461.	1.4	34
1446	PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. <i>Cancer Treatment Reviews</i> , 2018, 62, 39-49.	3.4	94
1447	Humanized mice in studying efficacy and mechanisms of PD-1 targeted cancer immunotherapy. <i>FASEB Journal</i> , 2018, 32, 1537-1549.	0.2	260
1448	Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. <i>Cancer Letters</i> , 2018, 414, 166-173.	3.2	207
1449	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.	1.2	149
1450	Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. <i>Seminars in Cancer Biology</i> , 2018, 52, 166-177.	4.3	11
1451	PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 1-10.	1.6	139
1452	Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD(L)1 inhibitors beyond first line: A meta-analysis. <i>Clinical Respiratory Journal</i> , 2018, 12, 1809-1819.	0.6	25
1453	Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II—The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 26-34.	1.2	30
1454	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. <i>British Journal of Cancer</i> , 2018, 118, 312-324.	2.9	184
1455	Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2018, 6, 59-68.	1.6	26
1456	Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. <i>Immunology Letters</i> , 2018, 193, 1-10.	1.1	13
1457	Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy. <i>Acta Biomaterialia</i> , 2018, 66, 310-324.	4.1	159
1458	Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e177-e184.	1.1	6
1459	Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 32-39.	0.7	92
1460	PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 393-397.	0.6	12
1461	Immunotherapy for thoracic malignancies. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 34, 54-64.	0.2	0
1462	CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous cell and adenocarcinoma patients. <i>Histopathology</i> , 2018, 72, 259-269.	1.6	27

#	ARTICLE	IF	CITATIONS
1463	Pembrolizumab-Related Neuroinflammation: A Case Report and Review of the Literature. <i>Neurographics</i> , 2018, 8, 119-123.	0.2	1
1464	Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma. <i>Medicine (United States)</i> , 2018, 97, e12937.	0.4	4
1465	Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience. <i>Translational Lung Cancer Research</i> , 2018, 7, 404-415.	1.3	54
1466	Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 1008-1018.	1.8	52
1467	The role of immune checkpoint inhibitors in non-small cell lung cancer. <i>Shanghai Chest</i> , 0, 2, 35-35.	0.3	0
1468	Usual Lung Cancers. , 2018, , 534-551.		2
1469	Checkpoint inhibitor-associated autoimmunity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 781-802.	1.4	13
1470	A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis. <i>International Journal of Thyroidology</i> , 2018, 11, 172.	0.1	0
1471	From Choosing Wisely to Using Wisely: Increasing the Value of Cancer Care Through Clinical Research. <i>Journal of Clinical Oncology</i> , 2018, 36, 1387-1388.	0.8	7
1472	Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 737-744.	0.7	21
1473	Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1798-1804.	0.8	27
1474	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
1475	Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 61-67.	0.8	259
1476	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
1477	Keeping Expectations in Check With Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2018, 36, 1654-1657.	0.8	38
1478	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1207-1217.	0.8	23
1479	Patterns of Response and Progression to Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 169-178.	1.8	196
1480	Immune Checkpoint Inhibitors in the Management of Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 682-695.	1.8	35

#	ARTICLE	IF	CITATIONS
1481	Tumor Mutation Burden: Is It Ready for the Clinic?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2978-2979.	0.8	16
1482	Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?. <i>Journal of Thoracic Disease</i> , 2018, 10, 1198-1200.	0.6	6
1483	A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 3575-3584.	0.6	36
1484	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer—where are we?. <i>Translational Lung Cancer Research</i> , 2018, 7, 682-690.	1.3	29
1485	Effects of mdig on proliferation and apoptosis of lung cancer cells. <i>Oncology Letters</i> , 2018, 16, 7146-7151.	0.8	0
1486	Role of immune checkpoint blockers in patients with EGFR mutation. <i>Translational Lung Cancer Research</i> , 2018, 7, S385-S387.	1.3	2
1487	Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?. <i>Translational Lung Cancer Research</i> , 2018, 7, S370-S372.	1.3	2
1488	Developing rational combinations of immune checkpoint inhibitors and radiation therapy for gastrointestinal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 225-230.	0.6	2
1489	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, 219-227.	0.6	6
1490	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1461-S1467.	0.6	25
1491	Immunotherapy in surgically resectable non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S404-S411.	0.6	53
1492	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1564-S1580.	0.6	58
1493	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2018, 10, S422-S432.	0.6	9
1494	Immunotherapy in the Asiatic population: any differences from Caucasian population?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1482-S1493.	0.6	42
1495	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, 180-188.	1.3	28
1496	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. <i>Translational Lung Cancer Research</i> , 2018, 7, 464-486.	1.3	11
1497	Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189. <i>Journal of Thoracic Disease</i> , 2018, 10, 5186-5189.	0.6	1
1498	Immunotherapy in colorectal cancer: for the select few or all?. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 170-179.	0.6	51

#	ARTICLE	IF	CITATIONS
1499	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S433-S450.	0.6	15
1500	Immune checkpoint inhibitors in small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S460-S467.	0.6	46
1501	Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study. Journal of Thoracic Disease, 2018, 10, S1108-S1112.	0.6	15
1502	Methods of measurement for tumor mutational burden in tumor tissue. Translational Lung Cancer Research, 2018, 7, 661-667.	1.3	166
1504	Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy. Translational Lung Cancer Research, 2018, 7, S221-S224.	1.3	2
1505	The evolving toxicity profile of SBRT for lung cancer. Translational Lung Cancer Research, 2018, 8, 48-57.	1.3	39
1506	Development of biomarkers for real precision medicine. Translational Lung Cancer Research, 2018, 7, S228-S231.	1.3	0
1507	Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4082-S4084.	0.6	1
1508	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. Translational Lung Cancer Research, 2018, 7, S198-S201.	1.3	8
1509	Management of Advanced Non-“Small Cell Lung Cancer. , 2018, , 99-115.		1
1510	NIBIT-MESO-1: limitations and clinical perspectives in MPM treatment testing an immune checkpoint blockade combination in a single-arm study. Journal of Thoracic Disease, 2018, 10, S3878-S3881.	0.6	0
1511	Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor. Journal of Thoracic Disease, 2018, 10, 6912-6920.	0.6	13
1512	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. Journal of Thoracic Disease, 2018, 10, S4069-S4072.	0.6	3
1513	Classification of tumor microenvironment immune types based on immune response-associated gene expression. International Journal of Oncology, 2019, 54, 219-228.	1.4	12
1514	The growing role of precision and personalized medicine for cancer treatment. Technology, 2018, 06, 79-100.	1.4	237
1515	Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, S95-S99.	1.3	7
1516	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. Hematologie, 2018, 24, 183-193.	0.0	0
1517	New drugs and new toxicities: pembrolizumab-induced myocarditis. BMJ Case Reports, 2018, 2018, bcr-2017-223252.	0.2	19

#	ARTICLE	IF	CITATIONS
1518	Immunotherapy in Advanced Lung Cancer Treatment. , 2018, , .		0
1521	Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. <i>Radiology and Oncology</i> , 2018, 52, 365-369.	0.6	36
1522	Actionable Gene Alterations in an Asian Population With Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	3
1523	Changes in Numbers of Randomized vs. Non-Randomized Clinical Trials: Recent Evidence of Shifting Cancer Drug Development Pathways. <i>Journal of Clinical Trials</i> , 2018, 08, .	0.1	0
1524	Immunotherapy and new frontiers in the treatment of lung cancer. <i>Shanghai Chest</i> , 0, 2, 77-77.	0.3	0
1526	Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-â€œSmall Cell Lung Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 701-708.	0.6	26
1528	Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. <i>PLoS ONE</i> , 2018, 13, e0206370.	1.1	58
1529	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. <i>BMC Cancer</i> , 2018, 18, 1082.	1.1	42
1530	The adverse kidney effects of cancer immunotherapies. <i>Journal of Onco-Nephrology</i> , 2018, 2, 56-68.	0.3	2
1531	Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1â€œ6 hepatocellular carcinoma model. <i>Cancer Science</i> , 2018, 109, 3993-4002.	1.7	215
1532	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2018, 10, 1303-1313.	1.0	3
1533	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 328.	1.8	12
1534	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 7949-7960.	0.8	49
1535	Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. , 2018, 6, 129.		95
1536	Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. <i>Lung Cancer: Targets and Therapy</i> , 2018, Volume 9, 85-90.	1.3	20
1537	Reporter Genes for PET Imaging of CAR T Cells Offers Insight into Adoptive Cell Transfer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1892-1893.	2.8	4
1538	PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component. <i>Pathology Research and Practice</i> , 2018, 214, 2069-2074.	1.0	19
1539	Combination of PD-1 blockade and RetroNectin^{â€œ}-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. <i>Immunotherapy</i> , 2018, 10, 1315-1323.	1.0	6

#	ARTICLE	IF	CITATIONS
1540	Updates on immunotherapy for colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 160-169.	0.6	126
1541	Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2018, 155, 1936-1950.e17.	0.6	211
1542	β-catenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. <i>BMC Cancer</i> , 2018, 18, 1062.	1.1	20
1543	Linear Endobronchial Ultrasound: What's New?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 649-660.	0.8	5
1544	Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. <i>JCI Insight</i> , 2018, 3, .	2.3	40
1545	New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. <i>Oncotarget</i> , 2018, 9, 10635-10649.	0.8	41
1546	A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the OncoPrint Tumor Mutation Load Assay. <i>Translational Lung Cancer Research</i> , 2018, 7, 616-630.	1.3	41
1547	Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8623-8632.	1.0	13
1548	Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8705-8710.	1.0	6
1549	Current Options and Future Directions in Immune Therapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 578.	1.3	21
1550	Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes. <i>Cancers</i> , 2018, 10, 494.	1.7	68
1551	Comparative Transcriptomics Unravels Prodigiosin's Potential Cancer-Specific Activity Between Human Small Airway Epithelial Cells and Lung Adenocarcinoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 573.	1.3	11
1552	Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases. <i>Cancer Management and Research</i> , 2018, Volume 10, 6421-6429.	0.9	3
1553	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1430.	1.6	88
1554	The Era of Immune Checkpoint Therapy: From Cancer to Viral Infection—A Mini Comment on the 2018 Medicine Nobel Prize. <i>Virologica Sinica</i> , 2018, 33, 467-471.	1.2	9
1555	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. <i>Biomedicines</i> , 2018, 6, 114.	1.4	28
1556	PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 17-32.	3.3	72
1557	Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 65-95.	0.8	49

#	ARTICLE	IF	CITATIONS
1558	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 117-129.	0.8	15
1559	Immune Checkpoint Inhibitors-Induced Colitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 151-157.	0.8	19
1560	Immune Checkpoint Inhibitors-Induced Hepatitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 159-164.	0.8	26
1561	Organoid Modeling of the Tumor Immune Microenvironment. <i>Cell</i> , 2018, 175, 1972-1988.e16.	13.5	870
1562	Immune checkpoint inhibitors in cancer therapy. <i>Journal of Biomedical Research</i> , 2018, 32, 317.	0.7	101
1564	Immune checkpoint inhibitors: recent progress and potential biomarkers. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-11.	3.2	1,410
1565	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, e116-e136.	2.5	49
1567	Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263. <i>Anticancer Research</i> , 2018, 38, 6891-6895.	0.5	18
1568	The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer. <i>Journal of Cancer</i> , 2018, 9, 4325-4333.	1.2	16
1569	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
1570	Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. <i>Case Reports in Oncology</i> , 2018, 11, 688-692.	0.3	7
1572	The Clinical and Biological Significance of Tyrosine Kinases in Gastric Cancer. , 2018, , 29-56.		1
1573	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. <i>Lung Cancer</i> , 2018, 125, 115-120.	0.9	29
1574	Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients. <i>Lung Cancer</i> , 2018, 125, 230-237.	0.9	7
1575	The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. <i>Journal of Translational Medicine</i> , 2018, 16, 273.	1.8	73
1576	Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-L1/PD-L1 inhibitors. <i>Thoracic Cancer</i> , 2018, 9, 1500-1508.	0.8	18
1577	Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. <i>Cancer Research</i> , 2018, 78, 6413-6423.	0.4	33
1578	The role of radiology in the evaluation of the immunotherapy efficacy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1438-S1446.	0.6	22

#	ARTICLE	IF	CITATIONS
1579	Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review. Expert Review of Anticancer Therapy, 2018, 18, 1231-1239.	1.1	18
1580	Response to PD1 inhibition in conventional chondrosarcoma. , 2018, 6, 94.		26
1582	Immunotherapy for Merkel Cell Carcinoma. Current Treatment Options in Oncology, 2018, 19, 57.	1.3	12
1583	Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Lung Cancer, 2018, 125, 150-156.	0.9	152
1584	Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA Lung study). Thoracic Cancer, 2018, 9, 1795-1800.	0.8	3
1585	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends in Biochemical Sciences, 2018, 43, 1014-1032.	3.7	151
1586	Pulmonary Toxicities of Anticancer Treatment. , 2018, , 201-215.		0
1587	Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 167-174.	1.0	0
1588	Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. Lung Cancer, 2018, 125, 212-217.	0.9	114
1589	A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. Journal of Clinical Pathology, 2018, 71, 1078-1083.	1.0	33
1590	Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma. Anticancer Research, 2018, 38, 6003-6008.	0.5	1
1591	Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer, 2018, 18, 946.	1.1	32
1592	Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives. Expert Opinion on Therapeutic Patents, 2018, 28, 813-821.	2.4	5
1593	Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 2040-2051.	13.9	2,676
1594	An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas. Journal of Thoracic Oncology, 2018, 13, 1676-1691.	0.5	21
1595	Key questions about the checkpoint blockade-are microRNAs an answer?. Cancer Biology and Medicine, 2018, 15, 103.	1.4	36
1596	Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients. Journal of Visualized Experiments, 2018, , .	0.2	1
1597	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. Advances in Anatomic Pathology, 2018, 25, 374-386.	2.4	15

#	ARTICLE	IF	CITATIONS
1598	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> , 2018, 362, .	6.0	1,575
1599	Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. <i>Gynecologic Oncology</i> , 2018, 151, 407-413.	0.6	17
1601	Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 114.	0.7	17
1602	Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. <i>Advances in Radiation Oncology</i> , 2018, 3, 486-493.	0.6	48
1603	Inhibition of PD1:PD-L1 interaction by an E.Âcoli-derived optimized PD1 variant. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 731-738.	1.0	1
1604	Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities. <i>Drugs</i> , 2018, 78, 1717-1740.	4.9	62
1605	Predictive biomarkers for tumor immune checkpoint blockade. <i>Cancer Management and Research</i> , 2018, Volume 10, 4501-4507.	0.9	18
1606	Somatic mutation profiling of liver and biliary cancer by targeted next generation sequencing. <i>Oncology Letters</i> , 2018, 16, 6003-6012.	0.8	8
1607	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1733-1742.	0.5	120
1608	Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. <i>ESMO Open</i> , 2018, 3, e000406.	2.0	84
1609	Checkpoint-inhibition in ovarian cancer: rising star or just a dream?. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e93.	1.0	37
1610	Safety of combined PD-1 pathway inhibition and radiation therapy for non-small cell lung cancer: A multicentric retrospective study from the GFPC. <i>Cancer Medicine</i> , 2018, 7, 5505-5513.	1.3	39
1611	Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. <i>Cancer Science</i> , 2018, 109, 3583-3590.	1.7	118
1612	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2018, 119, 950-960.	2.9	133
1613	Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6505-6524.	1.0	47
1614	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018, 71, 47-58.	3.4	37
1615	Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 6525-6537.	1.0	10
1616	The 8th edition AJCC/UICC TNM staging for p16-positive oropharyngeal carcinoma: is there space for improvement?. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 3087-3091.	0.8	17

#	ARTICLE	IF	CITATIONS
1617	Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. <i>Thoracic Cancer</i> , 2018, 9, 1782-1787.	0.8	23
1618	Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients. <i>Journal of the Egyptian National Cancer Institute</i> , 2018, 30, 125-131.	0.6	15
1619	Sarcoidosis-Like Granulomatous Reaction Associated with Pembrolizumab Immunotherapy. <i>Archivos De Bronconeumologia</i> , 2018, 54, 592-593.	0.4	0
1620	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 125-129.	2.0	19
1621	T Cell Senescence and Tumor Immunotherapy. , 2018, , 1-24.		0
1622	Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. <i>Cancer Immunology Research</i> , 2018, 6, 1561-1577.	1.6	151
1623	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1853-1862.	2.0	21
1624	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661879413.	1.0	35
1625	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. , 2018, 6, 82.		30
1626	The nephrotoxicity of immune checkpoint inhibitor-based combinations. <i>European Journal of Cancer</i> , 2018, 103, 274-278.	1.3	5
1627	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 7-16.	1.3	63
1628	Monitoring immunotherapy outcomes with circulating tumor DNA. <i>Immunotherapy</i> , 2018, 10, 1023-1025.	1.0	11
1629	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1511506.	2.1	121
1630	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1692-1704.	0.5	74
1631	Immune Checkpoint Molecules, Personalized Immunotherapy, and Autoimmune Diabetes. <i>Trends in Molecular Medicine</i> , 2018, 24, 931-941.	3.5	34
1633	Roles of the RANKL-RANK axis in antitumour immunity implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 676-693.	12.5	77
1634	The hallmarks of successful anticancer immunotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	419
1635	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. <i>MAbs</i> , 2018, 10, 1301-1311.	2.6	57

#	ARTICLE	IF	CITATIONS
1636	Translational Biomarkers: Application in the Clinical Development of Combination Therapies. , 2018, , 223-248.		0
1637	Pembrolizumab for the first-line treatment of non-small cell lung cancer. Expert Opinion on Biological Therapy, 2018, 18, 1015-1021.	1.4	18
1638	Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer Without EGFR or ALK Mutations is Superior to Chemotherapy Alone. Clinical Pulmonary Medicine, 2018, 25, 194-195.	0.3	0
1639	IMPACT Trial: Triple Versus Dual Therapy for COPD Results in Decreased Rate of Exacerbations. Clinical Pulmonary Medicine, 2018, 25, 195-196.	0.3	1
1640	Selective Inhibition of ADAM28 Suppresses Lung Carcinoma Cell Growth and Metastasis. Molecular Cancer Therapeutics, 2018, 17, 2427-2438.	1.9	12
1641	MEK inhibitors for the treatment of NRAS mutant melanoma. Drug Design, Development and Therapy, 2018, Volume 12, 2553-2565.	2.0	37
1642	A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. Journal of Thoracic Oncology, 2018, 13, 1284-1293.	0.5	30
1643	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Frontiers in Immunology, 2018, 9, 1878.	2.2	127
1644	Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. , 2018, 6, 85.		19
1645	Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. ImmunoTargets and Therapy, 2018, Volume 7, 1-14.	2.7	34
1646	Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer. Medicine (United States), 2018, 97, e11936.	0.4	87
1647	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. Drug Design, Development and Therapy, 2018, Volume 12, 209-215.	2.0	29
1648	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. Pediatric Blood and Cancer, 2018, 65, e27389.	0.8	25
1649	Strategies for Predicting Response to Checkpoint Inhibitors. Current Hematologic Malignancy Reports, 2018, 13, 383-395.	1.2	23
1650	Insights into CD47/SIRP α axis-targeting tumor immunotherapy. Antibody Therapeutics, 2018, 1, 37-42.	1.2	24
1651	Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies. Journal of Immunology Research, 2018, 2018, 1-17.	0.9	147
1652	The Evolution of Phase I Trials, Past, Present, and Future. , 2018, , 17-32.		1
1653	Role of Imaging in Early-Phase Trials. , 2018, , 129-149.		1

#	ARTICLE	IF	CITATIONS
1654	PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1113-1120.	0.5	135
1655	Constrained Combinatorial Libraries of Gp2 Proteins Enhance Discovery of PD-L1 Binders. <i>ACS Combinatorial Science</i> , 2018, 20, 423-435.	3.8	16
1656	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT). <i>American Journal of Surgical Pathology</i> , 2018, 42, 843-854.	2.1	54
1657	Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 856-864.	0.8	21
1658	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108
1659	Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy. <i>Medical Hypotheses</i> , 2018, 116, 111-113.	0.8	19
1660	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
1661	Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 978-986.	0.5	87
1662	Emerging biomarkers for immune checkpoint inhibition in lung cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 269-277.	4.3	67
1663	Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 741-744.	0.5	4
1664	Regulation of innate and adaptive antitumor immunity by IAP antagonists. <i>Immunotherapy</i> , 2018, 10, 787-796.	1.0	51
1665	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.	5.1	1,816
1667	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 426-434.e1.	1.1	102
1668	Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression. <i>Respiratory Investigation</i> , 2018, 56, 361-364.	0.9	18
1669	Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 603-608.	0.6	24
1670	Reacción granulomatosa sarcoidosis-like asociada al tratamiento con inmunoterapia (pembrolizumab). <i>Archivos De Bronconeumología</i> , 2018, 54, 592-593.	0.4	3
1671	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. <i>Anticancer Research</i> , 2018, 38, 3789-3796.	0.5	64
1672	Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. <i>Clinical Lung Cancer</i> , 2018, 19, e823-e830.	1.1	10

#	ARTICLE	IF	CITATIONS
1673	PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes. PLoS ONE, 2018, 13, e0194594.	1.1	19
1674	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. Oncologist, 2018, 23, 1358-1365.	1.9	196
1675	CUP Syndrome. Deutsches Ärzteblatt International, 2018, 115, 157-162.	0.6	25
1676	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. PLoS ONE, 2018, 13, e0198634.	1.1	25
1677	T Lymphocyteâ€“Based Cancer Immunotherapeutics. International Review of Cell and Molecular Biology, 2018, 341, 201-276.	1.6	22
1678	30 Immunotherapy in advanced NSCLCâ€”from the â€˜tsunamiâ€™ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). ESMO Open, 2018, 3, e000298.	2.0	10
1679	The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. Critical Reviews in Oncology/Hematology, 2018, 130, 1-12.	2.0	16
1680	Inhaled TLR9 Agonist Renders Lung Tumors Permissive to PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-cell Interplay. Cancer Research, 2018, 78, 4943-4956.	0.4	49
1681	Systemically Administered Sindbis Virus in Combination with Immune Checkpoint Blockade Induces Curative Anti-tumor Immunity. Molecular Therapy - Oncolytics, 2018, 9, 51-63.	2.0	22
1682	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer, 2018, 123, 91-98.	0.9	35
1683	Immunotherapies: Exploiting the Immune System for Cancer Treatment. Journal of Immunology Research, 2018, 2018, 1-16.	0.9	89
1684	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer, 2018, 119, 153-159.	2.9	329
1685	Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. Journal of the American Society of Nephrology: JASN, 2018, 29, 2039-2052.	3.0	121
1686	Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. Oncoimmunology, 2018, 7, e1484982.	2.1	33
1687	Radioimmunoimaging and targeting treatment in an immunocompetent murine model of tripleâ€“negative breast cancer using radiolabeled antiâ€“programmed deathâ€“ligand 1 monoclonal antibody. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 826-836.	0.5	8
1688	Checkpoint inhibitors as treatment for malignant gliomas: â€œA long way to the topâ€”. Cancer Treatment Reviews, 2018, 69, 121-131.	3.4	46
1689	Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas. PLoS ONE, 2018, 13, e0195958.	1.1	51
1690	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). Journal of UOEH, 2018, 40, 173-189.	0.3	45

#	ARTICLE	IF	CITATIONS
1691	Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 94-102.	0.9	39
1692	Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 68-76.	0.9	11
1693	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 29.	0.7	24
1694	PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study. <i>BMC Cancer</i> , 2018, 18, 652.	1.1	13
1695	KRAS-Mutant non-small cell lung cancer: From biology to therapy. <i>Lung Cancer</i> , 2018, 124, 53-64.	0.9	232
1696	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1645-1657.	2.0	19
1697	A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1138-1145.	0.5	426
1698	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. <i>Journal of Cancer</i> , 2018, 9, 1813-1820.	1.2	41
1699	A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. <i>Journal of Cancer</i> , 2018, 9, 1200-1206.	1.2	31
1700	Concordance of PD-L1 Expression Detection in Non-Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC). <i>American Journal of Clinical Pathology</i> , 2018, 150, 346-352.	0.4	6
1701	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1019-1040.	0.9	55
1702	Immuno-Oncology: Emerging Targets and Combination Therapies. <i>Frontiers in Oncology</i> , 2018, 8, 315.	1.3	244
1703	Construction of an anti-programmed death ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells. <i>Oncology Letters</i> , 2018, 16, 157-166.	0.8	9
1704	AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer. <i>Theranostics</i> , 2018, 8, 676-692.	4.6	69
1705	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4051-4064.	1.0	15
1706	PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2018, 9, 2224-2231.	1.2	17
1707	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018, 101, 201-209.	1.3	41
1708	Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. <i>Immunotherapy</i> , 2018, 10, 851-00.	1.0	27

#	ARTICLE	IF	CITATIONS
1709	Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 232.	2.2	10
1710	Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 552.	2.2	74
1711	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. <i>Frontiers in Immunology</i> , 2018, 9, 727.	2.2	55
1712	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond. <i>Frontiers in Immunology</i> , 2018, 9, 1474.	2.2	174
1713	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. <i>Frontiers in Oncology</i> , 2018, 8, 86.	1.3	926
1714	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
1715	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. <i>Cancer Science</i> , 2018, 109, 2539-2548.	1.7	35
1716	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. , 2018, 6, 46.		135
1717	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. <i>Biomedicines</i> , 2018, 6, 26.	1.4	16
1718	Colorectal Cancers: An Update on Their Molecular Pathology. <i>Cancers</i> , 2018, 10, 26.	1.7	128
1719	Update on Immunohistochemistry for the Diagnosis of Lung Cancer. <i>Cancers</i> , 2018, 10, 72.	1.7	94
1720	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2018, 122, 160-164.	0.9	10
1721	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. <i>Future Oncology</i> , 2018, 14, 2415-2431.	1.1	24
1722	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. <i>Oncolmmunology</i> , 2018, 7, e1480301.	2.1	48
1723	Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. <i>Human Pathology</i> , 2018, 82, 39-45.	1.1	2
1724	High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia. <i>Oncolmmunology</i> , 2018, 7, e1465167.	2.1	15
1725	The Significance of MMP-1 in EGFR-TKI—Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2018, 19, 609.	1.8	21
1726	Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1421.	1.8	46

#	ARTICLE	IF	CITATIONS
1727	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 903-908.	2.3	10
1728	Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. , 2018, 6, 42.		15
1729	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. Immunotherapy, 2018, 10, 797-805.	1.0	20
1730	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers, 2018, 10, 62.	1.7	73
1731	Cardiorenal complications of immune checkpoint inhibitors. Nature Reviews Nephrology, 2018, 14, 571-588.	4.1	80
1732	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). , 2018, 6, 39.		329
1733	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). , 2018, 6, 63.		344
1734	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
1735	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. The Cochrane Library, 0, , .	1.5	6
1736	A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. Clinical and Experimental Medicine, 2018, 18, 555-562.	1.9	25
1737	Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer. Surgical Clinics of North America, 2018, 98, 773-785.	0.5	10
1738	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. Future Oncology, 2018, 14, 41-60.	1.1	12
1740	The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities. Trends in Cancer, 2018, 4, 523-536.	3.8	36
1741	Advances in the Systemic Treatment of Triple-Negative Breast Cancer. Current Oncology, 2018, 25, 142-150.	0.9	241
1742	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. Molecular Imaging and Biology, 2018, 20, 696-704.	1.3	30
1743	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. British Journal of Cancer, 2018, 119, 538-545.	2.9	111
1744	Physical basis of the "magnification rule"™ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer. Diagnostic Pathology, 2018, 13, 19.	0.9	15
1745	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 15.	6.9	155

#	ARTICLE	IF	CITATIONS
1746	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. , 2018, 6, 8.		936
1747	Thoracic Imaging of Solid Tumor Patients Treated with Immune Checkpoint Inhibitors. Current Radiology Reports, 2018, 6, 1.	0.4	1
1748	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. Acta Pharmaceutica Sinica B, 2018, 8, 530-538.	5.7	43
1749	Adoptive T cell therapy: points to consider. Current Opinion in Immunology, 2018, 51, 197-203.	2.4	41
1750	Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials. JAMA Oncology, 2018, 4, e180798.	3.4	86
1751	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocrine Connections, 2018, 7, R196-R211.	0.8	10
1752	Pathway-based dissection of the genomic heterogeneity of cancer hallmarksâ€™™ acquisition with SLAPenrich. Scientific Reports, 2018, 8, 6713.	1.6	24
1753	Combination Immunotherapy in Non-small Cell Lung Cancer. Current Oncology Reports, 2018, 20, 55.	1.8	25
1754	Immunotherapy for pulmonary squamous cell carcinoma and colon carcinoma with pembrolizumab. Medicine (United States), 2018, 97, e0718.	0.4	6
1755	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 104.	6.9	303
1756	Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for nonâ€™small cell lung cancer patients. Experimental and Therapeutic Medicine, 2018, 16, 908-916.	0.8	4
1757	Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. Journal of Emergency Medicine, 2018, 55, 489-502.	0.3	58
1758	Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer. Oncotarget, 2018, 9, 7672-7683.	0.8	14
1759	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Annals of Translational Medicine, 2018, 6, 144-144.	0.7	19
1760	Targeting cysteineâ€™rich angiogenic inducerâ€™61 by antibody immunotherapy suppresses growth and migration of nonâ€™small cell lung cancer. Experimental and Therapeutic Medicine, 2018, 16, 730-738.	0.8	7
1761	Immune Checkpoint Inhibitorâ€™related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 951-953.	2.5	8
1762	CNS cancer immunity cycle and strategies to target this for glioblastoma. Oncotarget, 2018, 9, 22802-22816.	0.8	11
1763	Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. Journal of Cancer, 2018, 9, 129-134.	1.2	11

#	ARTICLE	IF	CITATIONS
1764	A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. <i>Nature Communications</i> , 2018, 9, 3196.	5.8	145
1765	Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. <i>ESMO Open</i> , 2018, 3, e000332.	2.0	55
1766	Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of) <i>Tj ETQq0 0 0 rgBTz/Overlock 10 Tf 50 6</i>	2.0	110
1767	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 1739.	2.2	174
1768	Targeting the Microenvironment in High Grade Serous Ovarian Cancer. <i>Cancers</i> , 2018, 10, 266.	1.7	30
1769	Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 179-188.	0.9	56
1770	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-13.	3.2	152
1771	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
1772	Epigenetic mechanisms of tumor resistance to immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4163-4176.	2.4	27
1773	Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 324-334.	0.9	56
1774	The role of automated cytometry in the new era of cancer immunotherapy (Review). <i>Molecular and Clinical Oncology</i> , 2018, 9, 355-361.	0.4	12
1775	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 46.	1.3	16
1776	Dendritic cell vaccines for high-grade gliomas. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1299-1313.	0.9	42
1777	Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 1713-1723.	1.5	14
1778	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 771-781.	5.2	167
1779	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. <i>Cell</i> , 2018, 174, 1586-1598.e12.	13.5	644
1780	Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. <i>European Journal of Cancer</i> , 2018, 101, 236-243.	1.3	100
1781	First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. <i>Lung Cancer</i> , 2018, 123, 166-171.	0.9	31

#	ARTICLE	IF	CITATIONS
1782	Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4621-4629.	1.0	6
1783	Systemic Treatment of Chest Tumors: Highlighting Some Differences Between Eastern and Western Countries. <i>Current Cancer Therapy Reviews</i> , 2018, 14, 120-136.	0.2	0
1784	Dynamic Macrophages: Understanding Mechanisms of Activation as Guide to Therapy for Atherosclerotic Vascular Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 97.	1.1	21
1785	Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens. <i>Chest</i> , 2018, 154, 827-837.	0.4	50
1786	PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin – case report. <i>BMC Nephrology</i> , 2018, 19, 210.	0.8	30
1787	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2018, 392, 123-133.	6.3	984
1788	A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety. <i>Biochimie</i> , 2018, 151, 54-66.	1.3	13
1789	Safety of combining radiotherapy with immune-checkpoint inhibition. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 477-494.	12.5	208
1790	Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1090-1094.	2.1	27
1792	Driving cars to the clinic for solid tumors. <i>Gene Therapy</i> , 2018, 25, 165-175.	2.3	67
1793	Immune-Related Adverse Toxicities and Clinical Management. , 2018, , 577-589.		0
1794	Innate Immunity in Inflammation. , 2018, , 179-190.		1
1795	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 205-213.	0.4	7
1796	Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1216-1223.	2.1	36
1797	PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1384-1389.	2.1	77
1798	Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma. <i>Internal Medicine</i> , 2018, 57, 3149-3152.	0.3	1
1799	Tissue and Blood Biomarkers in Lung Cancer: A Review. <i>Advances in Clinical Chemistry</i> , 2018, 86, 1-21.	1.8	85
1800	Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial. <i>PLoS ONE</i> , 2018, 13, e0192227.	1.1	78

#	ARTICLE	IF	CITATIONS
1801	Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring. <i>Internal Medicine</i> , 2018, 57, 3157-3162.	0.3	31
1802	Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 3231-3242.	0.5	18
1803	Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. <i>Scientific Reports</i> , 2018, 8, 8810.	1.6	13
1804	The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies: A Case Report and Review of the Literature. <i>Internal Medicine</i> , 2018, 57, 3135-3139.	0.3	23
1805	Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments. <i>International Journal of Clinical Oncology</i> , 2018, 23, 1052-1059.	1.0	27
1806	Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer. <i>Scientific Reports</i> , 2018, 8, 8960.	1.6	14
1807	Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. <i>Cardiology in Review</i> , 2019, 27, 97-107.	0.6	19
1808	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 582-597.	2.3	8
1809	Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 330-337.	1.2	377
1810	A <sc>PK/PD</sc> Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 486-495.	2.3	23
1811	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 736-740.	1.6	90
1812	Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 108-117.	0.4	137
1813	Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 147-154.	2.7	16
1814	Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 957-966.	3.2	37
1815	Comparison of <sc>PD</sc>-1 immunohistochemistry assays and response to <sc>PD</sc>-1/L1 inhibitors in advanced non-small cell lung cancer in clinical practice. <i>Histopathology</i> , 2019, 74, 269-275.	1.6	15
1816	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. <i>Oncogene</i> , 2019, 38, 390-405.	2.6	149
1817	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
1818	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2019, 16, 28-39.	4.8	57

#	ARTICLE	IF	CITATIONS
1819	Cancer immunotherapy for metastasis: past, present and future. <i>Briefings in Functional Genomics</i> , 2019, 18, 140-146.	1.3	10
1820	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 663-673.	0.5	8
1821	Modulating T-cell-based cancer immunotherapy via particulate systems. <i>Journal of Drug Targeting</i> , 2019, 27, 145-163.	2.1	10
1822	PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 1-5.	0.9	27
1823	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019, 52, 144-160.	1.2	10
1824	Analyzing the percentage of different PD-1 + T cell subsets in peripheral blood and bronchoalveolar lavage fluid of small cell lung cancer patients: A prospective study. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 1074-1083.	0.9	2
1825	Imaging of Precision Therapy for Lung Cancer: Current State of the Art. <i>Radiology</i> , 2019, 293, 15-29.	3.6	45
1826	Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 657-665.	1.0	1
1827	Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-13.	3.2	194
1828	Multiparameter Flow Cytometry Assay for Quantification of Immune Cell Subsets, PD-1 Expression Levels and PD-1 Receptor Occupancy by Nivolumab and Pembrolizumab. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 1053-1065.	1.1	14
1829	Tumor mutation burden: from comprehensive mutational screening to the clinic. <i>Cancer Cell International</i> , 2019, 19, 209.	1.8	116
1830	Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. <i>Head and Neck</i> , 2019, 41, 4036-4050.	0.9	3
1831	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1395-1408.	5.1	247
1832	Engineering patient-specific cancer immunotherapies. <i>Nature Biomedical Engineering</i> , 2019, 3, 768-782.	11.6	123
1833	Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. <i>Oncolmmunology</i> , 2019, 8, e1629261.	2.1	40
1834	Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. <i>Annals of Oncology</i> , 2019, 30, 1653-1659.	0.6	220
1835	Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. <i>PLoS ONE</i> , 2019, 14, e0220570.	1.1	20
1836	Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 993-1003.	1.0	16

#	ARTICLE	IF	CITATIONS
1837	Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2541-2546.	1.2	93
1838	A tumor-targeted immune checkpoint blocker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15889-15894.	3.3	21
1839	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2371-2383.	1.1	4
1840	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. <i>Life Sciences</i> , 2019, 233, 116713.	2.0	42
1841	Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 695-708.	1.9	38
1842	The estrogen pathway as a modulator of response to immunotherapy. <i>Immunotherapy</i> , 2019, 11, 1161-1176.	1.0	7
1843	Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society. <i>Lung Cancer</i> , 2019, 136, 65-73.	0.9	8
1844	Recent advances in the vibrational spectroscopic diagnosis of non-small cell lung cancer. <i>Vibrational Spectroscopy</i> , 2019, 104, 102946.	1.2	2
1845	PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. <i>Future Oncology</i> , 2019, 15, 1667-1678.	1.1	13
1846	Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. <i>Cancer</i> , 2019, 125, 4019-4032.	2.0	115
1847	SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. <i>International Immunopharmacology</i> , 2019, 75, 105818.	1.7	58
1848	Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100879.	0.2	6
1849	Phase II study of nedaplatin and amrubicin as first-line treatment for advanced squamous cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 1764-1769.	0.8	3
1850	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. <i>Clinical Chemistry</i> , 2019, 65, 1228-1238.	1.5	178
1851	Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers. <i>Journal of Clinical Medicine</i> , 2019, 8, 998.	1.0	28
1852	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
1853	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019, 36, 168-178.e4.	7.7	240
1854	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	0.9	30

#	ARTICLE	IF	CITATIONS
1855	Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. <i>Translational Lung Cancer Research</i> , 2019, 8, 214-226.	1.3	66
1856	Quantitation of Super Basic Peptides in Biological Matrices by a Generic Perfluoropentanoic Acid-Based Liquid Chromatography-Mass Spectrometry Method. <i>Journal of the American Society for Mass Spectrometry</i> , 2019, 30, 1779-1789.	1.2	3
1857	<p>Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5293-5298.	1.0	20
1858	Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-â€‘Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 1276.	3.4	670
1859	Immune checkpoint inhibitor-induced sarcoidosis-like granulomas. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1171-1181.	1.0	42
1860	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 35-43.	2.0	18
1861	Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019, 2, 100-109.	1.3	11
1862	Smoking history influences the prognostic value of peripheral na~ve CD4+ T cells in advanced non-small cell lung cancer. <i>Cancer Cell International</i> , 2019, 19, 176.	1.8	8
1863	Programmed death-ligand 1 monoclonal antibody-linked immunoliposomes for synergistic efficacy of miR-130a and oxaliplatin in gastric cancers. <i>Nanomedicine</i> , 2019, 14, 1729-1744.	1.7	15
1864	Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites. <i>Lung Cancer</i> , 2019, 134, 202-209.	0.9	35
1865	Design, Synthesis, Evaluation, and Structural Studies of <i>C</i>₂-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Proteinâ€‘Protein Interaction. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7250-7263.	2.9	71
1866	Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 299.	3.5	24
1867	Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. , 2019, 7, 173.		76
1868	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , .		0
1869	Possible Biomarkers for Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 935.	1.7	35
1870	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1â€‘positive advanced non-â€‘small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019, 135, 188-195.	0.9	189
1871	Systemic immuneâ€‘inflammation index, neutrophilâ€‘toâ€‘lymphocyte ratio, plateletâ€‘toâ€‘lymphocyte ratio can predict clinical outcomes in patients with metastatic non-â€‘smallâ€‘cell lung cancer treated with nivolumab. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22964.	0.9	171
1872	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	5.1	193

#	ARTICLE	IF	CITATIONS
1873	Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: A case report. <i>Molecular and Clinical Oncology</i> , 2019, 11, 132-134.	0.4	9
1874	Pembrolizumab for the treatment of head and neck squamous cell cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 879-885.	1.4	8
1875	The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. , 2019, , 65-84.		0
1876	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. <i>Scientific Reports</i> , 2019, 9, 10677.	1.6	37
1877	Macrophage-Mediated Subversion of Anti-Tumour Immunity. <i>Cells</i> , 2019, 8, 747.	1.8	68
1878	The biological functions and clinical applications of exosomes in lung cancer. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4613-4633.	2.4	90
1879	Engineering nanoparticles to locally activate T cells in the tumor microenvironment. <i>Science Immunology</i> , 2019, 4, .	5.6	180
1880	The influence of microenvironment on tumor immunotherapy. <i>FEBS Journal</i> , 2019, 286, 4160-4175.	2.2	64
1881	A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. <i>AAPS Journal</i> , 2019, 21, 79.	2.2	53
1882	<p>Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer</p>. <i>Lung Cancer: Targets and Therapy</i> , 2019, Volume 10, 47-56.	1.3	12
1883	Immunotherapy with hypofractionated radiotherapy in metastatic non-small cell lung cancer: An analysis of the National Cancer Database. <i>Radiotherapy and Oncology</i> , 2019, 138, 75-79.	0.3	11
1884	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. <i>Oncotarget</i> , 2019, 10, 3835-3839.	0.8	8
1885	Immune checkpoint blockade in glioma. , 2019, , 387-396.		0
1886	Germinal immunogenetics as a predictive factor for immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 146-152.	2.0	5
1887	Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. <i>Frontiers in Immunology</i> , 2019, 10, 1337.	2.2	85
1888	Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy. <i>International Immunopharmacology</i> , 2019, 74, 105707.	1.7	11
1889	Commentary: Cell proliferation and immune evasion: A dangerous combination. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 920-921.	0.4	0
1890	KRAS and Immune Checkpoint Inhibitorsâ€”Serendipity Raising Expectations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 951-954.	0.5	4

#	ARTICLE	IF	CITATIONS
1891	The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1378-1389.	0.5	310
1892	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 369-386.	0.6	19
1893	Immunotherapy Toxicities. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 387-401.	0.6	10
1894	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. <i>Modern Pathology</i> , 2019, 32, 1772-1785.	2.9	61
1895	Supporting the stratification of non-small cell lung carcinoma for Anti PD-L1 immunotherapy with digital image registration. , 2019, , .		1
1896	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8 ⁺ T cell responses. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	66
1897	Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. <i>Cancers</i> , 2019, 11, 920.	1.7	10
1898	The macrophage checkpoint CD47 : SIRP α for recognition of α -self TM cells: from clinical trials of blocking antibodies to mechanobiological fundamentals. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019, 374, 20180217.	1.8	32
1899	EGFR Targeted Therapy. <i>Current Cancer Research</i> , 2019, , 1-30.	0.2	2
1900	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
1901	First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2019, 8, e1665977.	2.1	21
1902	Two-stage enrichment clinical trial design with adjustment for misclassification in predictive biomarkers. <i>Statistics in Medicine</i> , 2019, 38, 5445-5469.	0.8	3
1903	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. <i>ESMO Open</i> , 2019, 4, e000472.	2.0	26
1904	Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 170-177.	0.9	3
1905	Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment. <i>Experimental and Molecular Pathology</i> , 2019, 111, 104314.	0.9	19
1906	The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes. <i>Cancer Medicine</i> , 2019, 8, 7207-7218.	1.3	35
1907	Road map to best practices. , 2019, , 241-273.		2
1908	Recent advances in nanotheranostics for triple negative breast cancer treatment. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 430.	3.5	121

#	ARTICLE	IF	CITATIONS
1909	Artificial Intelligence in Lung Cancer Pathology Image Analysis. <i>Cancers</i> , 2019, 11, 1673.	1.7	152
1910	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 36, 597-612.e8.	7.7	100
1911	Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2062-2070.	0.5	49
1912	Immune regulation and cytotoxic T cell activation of IL-10 agonists – Preclinical and clinical experience. <i>Seminars in Immunology</i> , 2019, 44, 101325.	2.7	30
1913	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. <i>Journal of Clinical Oncology</i> , 2019, 37, 3546-3555.	0.8	78
1914	Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target. <i>Cancers</i> , 2019, 11, 1683.	1.7	38
1915	Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 4194-4201.	1.9	6
1916	A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1066.	1.3	43
1917	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. <i>Cancer Cell</i> , 2019, 36, 471-482.	7.7	280
1918	The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis. <i>iScience</i> , 2019, 21, 249-260.	1.9	39
1919	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1040.	1.3	38
1920	Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 1055.	1.3	18
1921	Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2019, . .	1.5	3
1922	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. <i>Antibodies</i> , 2019, 8, 51.	1.2	32
1923	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. <i>European Journal of Cancer</i> , 2019, 122, 72-90.	1.3	97
1924	Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2084-2096.	0.5	48
1925	KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score ≥49%. <i>Journal of Thoracic Disease</i> , 2019, 11, S1963-S1965.	0.6	6
1926	Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. <i>Journal of Thoracic Disease</i> , 2019, 11, 3757-3768.	0.6	29

#	ARTICLE	IF	CITATIONS
1927	Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. <i>Targeted Oncology</i> , 2019, 14, 707-717.	1.7	15
1928	Treatment effect and safety profile of salvage chemotherapy following immune checkpoint inhibitors in lung cancer. <i>Lung Cancer Management</i> , 2019, 8, LMT12.	1.5	10
1929	Evolution of the nonsense-mediated decay pathway is associated with decreased cytolytic immune infiltration. <i>PLoS Computational Biology</i> , 2019, 15, e1007467.	1.5	15
1930	High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 2006-2012.	0.8	52
1931	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR mutant non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 3244-3254.	1.7	32
1932	Novel Biomarkers for Personalized Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1223.	1.7	36
1933	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. <i>Genes and Diseases</i> , 2019, 6, 232-246.	1.5	44
1934	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	12.8	557
1935	Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1250.	1.7	18
1936	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019, 25, 6061-6072.	3.2	58
1937	Pembrolizumab in lung cancer: current evidence and future perspectives. <i>Future Oncology</i> , 2019, 15, 3327-3336.	1.1	4
1938	Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2019, 136, 45-51.	0.9	84
1939	Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Advances in Therapy</i> , 2019, 36, 2600-2617.	1.3	80
1940	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	2.2	46
1941	Inhibition of lung cancer cells and Ras/Raf/MEK/ERK signal transduction by ectonucleoside triphosphate phosphohydrolase-7 (ENTPD7). <i>Respiratory Research</i> , 2019, 20, 194.	1.4	12
1942	Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. , 2019, 7, 227.		58
1943	Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid. <i>Frontiers in Oncology</i> , 2019, 9, 734.	1.3	15
1944	Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 883.	1.3	40

#	ARTICLE	IF	CITATIONS
1945	Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1537-1545.	2.0	10
1946	B7-1 drives TGF- β 2 stimulated pancreatic carcinoma cell migration and expression of EMT target genes. <i>PLoS ONE</i> , 2019, 14, e0222083.	1.1	8
1947	Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. <i>Nature Communications</i> , 2019, 10, 3991.	5.8	409
1948	Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1501-1513.	2.0	39
1949	PD-1 expression and its significance in tumour microenvironment of hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 51-51.	1.5	16
1950	C-reactive protein as an early marker of immune-related adverse events. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2625-2631.	1.2	59
1951	The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2019, 79, 101887.	3.4	49
1952	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74.	1.3	33
1953	Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. <i>Experimental Hematology and Oncology</i> , 2019, 8, 19.	2.0	30
1954	Immunotherapy and urothelial carcinoma: An overview and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 143, 46-55.	2.0	20
1955	The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience. <i>BioMed Research International</i> , 2019, 2019, 1-7.	0.9	20
1956	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	2.2	32
1957	Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation. , 0, , .		7
1958	Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1585-1596.	2.0	37
1959	Transcriptomic Profiling Identifies a DNA Repair-Related Signature as a Novel Prognostic Marker in Lower Grade Gliomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 2079-2086.	1.1	5
1960	High Serum Soluble CD27 Level Correlates with Poor Performance Status and Reduced Survival in Patients with Advanced Lung Cancer. <i>Oncology</i> , 2019, 97, 365-372.	0.9	14
1961	Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. , 2019, 7, 254.		14
1962	Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. <i>European Journal of Cancer</i> , 2019, 119, 44-56.	1.3	26

#	ARTICLE	IF	CITATIONS
1963	Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile. <i>OncImmunity</i> , 2019, 8, e1648170.	2.1	36
1964	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	0.5	69
1965	Niclosamide, an antihelminthic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. , 2019, 7, 245.		66
1966	Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-“Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e948-e956.	2.5	14
1967	PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3055-3065.	1.2	24
1968	Malignant Mesothelioma: Has Anything Changed?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 347-360.	0.8	23
1969	Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. <i>Annals of Oncology</i> , 2019, 30, 1660-1666.	0.6	63
1970	HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 13404.	1.6	103
1971	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
1972	Nanotechnology based therapeutics for lung disease. <i>Thorax</i> , 2019, 74, 965-976.	2.7	64
1973	Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4794.	1.8	29
1974	RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines. <i>Scientific Reports</i> , 2019, 9, 14184.	1.6	32
1975	Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1807-1817.	0.5	27
1976	PD-1 inhibitors monotherapy in hepatocellular carcinoma: Meta-analysis and systematic review. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 505-510.	0.6	30
1977	Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. <i>Drug Resistance Updates</i> , 2019, 46, 100644.	6.5	133
1978	Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1544-1555.	5.1	86
1979	Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150932.	0.7	34
1980	Role of evaluating tumor-“infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. <i>International Journal of Oncology</i> , 2019, 55, 1157-1164.	1.4	13

#	ARTICLE	IF	CITATIONS
1982	Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4624.	1.8	5
1983	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. <i>Translational Lung Cancer Research</i> , 2019, 8, 352-366.	1.3	38
1984	<p>Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7329-7336.	1.0	19
1985	Nanoparticle-mediated internal radioisotope therapy to locally increase the tumor vasculature permeability for synergistically improved cancer therapies. <i>Biomaterials</i> , 2019, 197, 368-379.	5.7	58
1986	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. <i>Nuclear Medicine and Biology</i> , 2019, 68-69, 66-79.	0.3	19
1987	Pembrolizumab resolves adult ashly dermatosis developing in patients with squamous cell carcinoma of the lung. <i>Journal of Dermatology</i> , 2019, 46, 271-273.	0.6	0
1988	Making cold malignant pleural effusions hot: driving novel immunotherapies. <i>Oncolmmunology</i> , 2019, 8, e1554969.	2.1	46
1989	Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 105-109.	0.7	5
1990	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
1991	Challenges with Novel Clinical Trial Designs: Master Protocols. <i>Clinical Cancer Research</i> , 2019, 25, 2049-2057.	3.2	35
1992	Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. <i>Radiation Oncology</i> , 2019, 14, 18.	1.2	41
1993	Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 14.	1.3	33
1994	Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action. <i>Immunotherapy</i> , 2019, 11, 429-441.	1.0	44
1995	Practical Considerations for Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 407-418.	0.6	8
1996	Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?. <i>Immunotherapy</i> , 2019, 11, 161-166.	1.0	5
1997	Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. <i>Neuro-Oncology</i> , 2019, 21, 730-741.	0.6	63
1998	Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491882131.	0.6	7
1999	Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 404-413.	0.9	37

#	ARTICLE	IF	CITATIONS
2000	Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. <i>Frontiers of Medicine</i> , 2019, 13, 32-44.	1.5	25
2001	Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. , 2019, 7, 27.		66
2002	Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 628-640.	0.5	54
2003	T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins. <i>Antibody Therapeutics</i> , 2019, 2, 22-32.	1.2	12
2004	Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is "promoted"! <i>Annals of Oncology</i> , 2019, 30, 165-167.	0.6	5
2005	PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. <i>Cell Proliferation</i> , 2019, 52, e12571.	2.4	94
2006	Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 291-299.	0.9	23
2007	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. <i>Clinical Science</i> , 2019, 133, 181-193.	1.8	51
2008	Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data. <i>Cancer Management and Research</i> , 2019, Volume 11, 4297-4312.	0.9	47
2009	Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab. <i>Medicina (Lithuania)</i> , 2019, 55, 176.	0.8	11
2010	PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays. <i>Human Pathology</i> , 2019, 90, 54-59.	1.1	23
2011	Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails. <i>Frontiers in Pharmacology</i> , 2019, 10, 387.	1.6	15
2012	Poor prognosis of pulmonary sarcomatoid carcinoma with KRAS mutation and ALK fusion. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3321-3325.	1.0	4
2013	Liquid biopsy for lung cancer immunotherapy (Review). <i>Oncology Letters</i> , 2019, 17, 4751-4760.	0.8	14
2014	Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 180-185.	1.0	59
2015	Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 954.	2.2	89
2016	PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 67-76.	1.4	13
2017	Recent advances in the clinical development of immune checkpoint blockade therapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 609-626.	2.1	76

#	ARTICLE	IF	CITATIONS
2018	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. <i>Frontiers in Immunology</i> , 2019, 10, 1181.	2.2	20
2019	Functional T cell activation by smart nanosystems for effective cancer immunotherapy. <i>Nano Today</i> , 2019, 27, 28-47.	6.2	34
2020	Design, synthesis and antitumor study of a series of N-Cyclic sulfamoylaminoethyl substituted 1,2,5-oxadiazol-3-amines as new indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 38-55.	2.6	23
2021	Cell blocks are suitable material for programmed cell death ligand 1 immunohistochemistry: Comparison of cell blocks and matched surgical resection specimens in lung cancer. <i>Cytopathology</i> , 2019, 30, 578-585.	0.4	15
2023	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1859-1868.	3.3	62
2024	Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 1208-1227.	7.7	81
2025	Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1293-1306.	1.6	46
2026	CD8 ⁺ PD-1 ⁺ T-cells and PD-L1 ⁺ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	1.4	13
2027	PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. <i>Journal of Ovarian Research</i> , 2019, 12, 56.	1.3	30
2028	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. <i>Frontiers in Oncology</i> , 2019, 9, 443.	1.3	25
2029	PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 806.	1.7	66
2030	EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1311-1320.	0.6	249
2031	PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2019, 17, 207.	1.8	13
2032	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. <i>Modern Pathology</i> , 2019, 32, 1646-1656.	2.9	16
2033	Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study. <i>Lung Cancer</i> , 2019, 134, 174-179.	0.9	92
2034	A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. <i>International Journal of Cancer</i> , 2019, 145, 2535-2546.	2.3	48
2035	A carrier-free multiplexed gene editing system applicable for suspension cells. <i>Biomaterials</i> , 2019, 217, 119298.	5.7	26
2036	Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. <i>Nature Medicine</i> , 2019, 25, 929-935.	15.2	188

#	ARTICLE	IF	CITATIONS
2037	Molecular profile of non-small cell lung cancer in northeastern Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180181.	0.4	12
2038	Pharmacoeugenetics of Acute Myeloid Leukemia. , 2019, , 541-549.		0
2039	Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. <i>Lung Cancer</i> , 2019, 134, 79-84.	0.9	105
2040	A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. <i>BMC Cancer</i> , 2019, 19, 546.	1.1	30
2041	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. <i>Cancer Cell</i> , 2019, 35, 885-900.e10.	7.7	475
2042	The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1046-1060.	0.5	52
2043	New Perspective in Pancreatic Cancer. , 2019, , 151-161.		0
2044	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , 2019, 66, 1-8.	1.0	19
2045	MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 5193-5200.	0.8	14
2046	Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN γ signaling in non-small cell lung cancer. <i>PLoS ONE</i> , 2019, 14, e0216864.	1.1	11
2048	The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy. <i>Cancer Research</i> , 2019, 79, 5022-5033.	0.4	37
2049	Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy. <i>Cancers</i> , 2019, 11, 754.	1.7	21
2050	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2560.	1.8	72
2051	MALDI Mass Spectrometry Imaging Linked with Top-Down Proteomics as a Tool to Study the Non-Small-Cell Lung Cancer Tumor Microenvironment. <i>Methods and Protocols</i> , 2019, 2, 44.	0.9	19
2052	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	0.8	811
2053	From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2511-2513.	0.8	22
2054	Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. <i>Molecules</i> , 2019, 24, 2071.	1.7	106
2055	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 259-267.	0.9	28

#	ARTICLE	IF	CITATIONS
2056	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 54.	6.9	416
2057	<i>PD</i> and <i>PD</i> expression correlated genes in non-small cell lung cancer. <i>Cancer Communications</i> , 2019, 39, 1-14.	3.7	66
2058	Pathogenesis of fulminant type 1 diabetes: Genes, viruses and the immune mechanism, and usefulness of patient-derived induced pluripotent stem cells for future research. <i>Journal of Diabetes Investigation</i> , 2019, 10, 1158-1164.	1.1	30
2059	Liquid Biopsy in Hepatocellular Carcinoma. , 2019, , 87-95.		0
2060	Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 23-35.	2.0	52
2061	β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
2062	An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1267-1279.	1.6	92
2063	Alcoholic/Non-Alcoholic Digestive Diseases. , 2019, , .		0
2064	Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2019, 11, 287-291.	2.2	1
2065	Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. <i>BMC Cancer</i> , 2019, 19, 558.	1.1	106
2066	The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1419-1428.	1.0	15
2067	Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. <i>Cancer Letters</i> , 2019, 460, 1-9.	3.2	156
2068	EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1190-1192.	0.6	4
2069	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
2070	Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice. <i>Lung Cancer</i> , 2019, 133, 110-116.	0.9	34
2071	Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5061-5068.	3.2	60
2072	Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 690.	1.7	57
2073	Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients. <i>Scientific Reports</i> , 2019, 9, 7680.	1.6	36

#	ARTICLE	IF	CITATIONS
2074	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
2075	Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes. <i>British Journal of Cancer</i> , 2019, 121, 51-64.	2.9	33
2076	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
2077	Nivolumab plus ipilimumab in non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2287-2302.	1.1	42
2078	Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 374-387.	1.8	19
2079	Prognostic factors of advanced or postoperative recurrent non-small cell lung cancer targeted with immune check point inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, 1117-1123.	0.6	46
2080	Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 352-363.	1.8	28
2081	Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 640-647.	1.9	32
2082	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 517-529.	1.5	15
2083	Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies. <i>Histopathology</i> , 2019, 75, 526-536.	1.6	17
2084	The Drug-Diagnostic Codevelopment Model. , 2019, , 11-25.		0
2085	Comment on "Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer" "No support for de-escalation of immunotherapy. <i>European Journal of Cancer</i> , 2019, 115, 24-26.	1.3	0
2086	Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 2561-2567.	0.5	3
2087	Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report. <i>Lung Cancer Management</i> , 2019, 8, LMT10.	1.5	5
2088	Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition. <i>Frontiers in Immunology</i> , 2019, 10, 867.	2.2	36
2089	Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1087-1094.	2.0	22
2090	PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2019, 76, 51-56.	3.4	36
2091	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1021-1031.	0.5	79

#	ARTICLE	IF	CITATIONS
2092	First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non-small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. <i>Clinical Lung Cancer</i> , 2019, 20, 331-338.e4.	1.1	47
2093	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1 Expressing NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 793-801.	0.5	50
2094	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5015-5026.	3.2	143
2095	Abscopal Effects in Radio-Immunotherapy Response Analysis of Metastatic Cancer Patients With Progressive Disease Under Anti-PD-1 Immune Checkpoint Inhibition. <i>Frontiers in Pharmacology</i> , 2019, 10, 511.	1.6	56
2096	Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy. <i>Cancers</i> , 2019, 11, 624.	1.7	32
2097	High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC. <i>Molecular Medicine Reports</i> , 2019, 19, 4881-4889.	1.1	9
2098	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 193.	3.5	61
2099	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	37
2100	Updates in Local-Regionally Advanced Non-small Cell Lung Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 553-562.	1.8	13
2101	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
2102	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. <i>Journal of Pathology</i> , 2019, 249, 151-165.	2.1	80
2103	PD(L)1 inhibitors vs chemotherapy vs their combination in front-line treatment for NSCLC: An indirect comparison. <i>International Journal of Cancer</i> , 2019, 145, 3011-3021.	2.3	15
2104	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. <i>Cell Reports</i> , 2019, 27, 806-819.e5.	2.9	51
2105	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 811-827.	1.4	27
2106	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. <i>Cancer Immunology Research</i> , 2019, 7, 866-873.	1.6	23
2107	Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema. <i>Journal of Thoracic Disease</i> , 2019, 11, 382-385.	0.6	2
2108	Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 264.	1.3	87
2109	PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. <i>Frontiers in Oncology</i> , 2019, 9, 343.	1.3	47

#	ARTICLE	IF	CITATIONS
2110	Lazarus-Type Tumour Response to Therapy with Nivolumab for Sarcomatoid Carcinomas of the Lung. <i>Current Oncology</i> , 2019, 26, 270-273.	0.9	17
2111	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-“Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 4663-4673.	3.2	210
2112	Immunoprofiling of Colitis-associated and Sporadic Colorectal Cancer and its Clinical Significance. <i>Scientific Reports</i> , 2019, 9, 6833.	1.6	33
2113	Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials. <i>JAMA Oncology</i> , 2019, 5, 1008.	3.4	526
2114	The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point. <i>Current Treatment Options in Oncology</i> , 2019, 20, 33.	1.3	0
2115	Drug development using pancreatic and lung organoid models. , 2019, , 323-342.		0
2116	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019, 25, 759-766.	15.2	180
2117	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	2.9	180
2118	Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 270-277.e1.	1.1	39
2119	Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors. <i>Neuro-Oncology Practice</i> , 2019, 6, 340-345.	1.0	7
2120	The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?. <i>Clinical Oncology</i> , 2019, 31, 432-443.	0.6	48
2121	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. <i>BMC Cancer</i> , 2019, 19, 298.	1.1	24
2122	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 360.	1.1	52
2123	Reactions at Biomembrane Interfaces. <i>Chemical Reviews</i> , 2019, 119, 6162-6183.	23.0	29
2124	Optimizing Patient Selection to Maximize Drug Efficacy: the Expanding Role of Pharmacogenomics in the Clinical Development of Pembrolizumab for the Treatment of Non-small Cell Lung Cancer. <i>Clinical Therapeutics</i> , 2019, 41, 982-991.	1.1	1
2125	Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. <i>International Immunopharmacology</i> , 2019, 72, 374-384.	1.7	109
2126	Cancer nanomedicine for combination cancer immunotherapy. <i>Nature Reviews Materials</i> , 2019, 4, 398-414.	23.3	658
2127	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52

#	ARTICLE	IF	CITATIONS
2128	Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer, 2019, 19, 379.	1.1	14
2129	Emerging therapies for non-small cell lung cancer. Journal of Hematology and Oncology, 2019, 12, 45.	6.9	111
2130	Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. Cancer Cytopathology, 2019, 127, 447-457.	1.4	12
2131	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Medical Oncology, 2019, 36, 49.	1.2	16
2132	<p>Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma</p>. Cancer Management and Research, 2019, Volume 11, 1631-1640.	0.9	9
2133	Elevated Heme Synthesis and Uptake Underpin Intensified Oxidative Metabolism and Tumorigenic Functions in Non-small Cell Lung Cancer Cells. Cancer Research, 2019, 79, 2511-2525.	0.4	55
2134	PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 1405.	1.8	36
2135	Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. Clinical and Translational Oncology, 2019, 21, 1464-1471.	1.2	1
2136	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer, 2019, 131, 95-103.	0.9	40
2137	Immunotherapy in colorectal cancer: rationale, challenges and potential. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 361-375.	8.2	1,039
2138	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human Vaccines and Immunotherapeutics, 2019, 15, 1111-1122.	1.4	297
2139	MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers. Gastroenterology Research and Practice, 2019, 2019, 1-7.	0.7	21
2140	Management of Locally Advanced Lung Cancer. , 2019, , 57-86.		1
2141	Lung Adenocarcinoma. , 2019, , 103-114.		2
2142	<sc>KEYNOTE</sc> 025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small cell lung cancer. Cancer Science, 2019, 110, 1012-1020.	1.7	40
2143	Genomic correlates of response to immune checkpoint blockade. Nature Medicine, 2019, 25, 389-402.	15.2	346
2144	The neoepitope landscape of breast cancer: implications for immunotherapy. BMC Cancer, 2019, 19, 200.	1.1	68
2145	Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer. Cancers, 2019, 11, 298.	1.7	10

#	ARTICLE	IF	CITATIONS
2146	Radiotherapy enhances responses of lung cancer to CTLA-4 blockade. , 2019, 7, 64.		16
2147	Immunological and clinical implications of immune checkpoint blockade in human cancer. Archives of Pharmacal Research, 2019, 42, 567-581.	2.7	17
2148	A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. Annals of Surgical Oncology, 2019, 26, 1925-1933.	0.7	23
2149	Ongoing Phase I Studies of Immune Checkpoint Inhibitors in China. Oncologist, 2019, 24, S11-S20.	1.9	2
2150	First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. BioDrugs, 2019, 33, 159-171.	2.2	40
2151	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leukemia and Lymphoma, 2019, 60, 2498-2507.	0.6	21
2152	PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives. Frontiers of Medicine, 2019, 13, 438-450.	1.5	32
2153	Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung Adenocarcinoma. Clinical Lung Cancer, 2019, 20, e299-e308.	1.1	2
2154	The Immune Subtypes and Landscape of Squamous Cell Carcinoma. Clinical Cancer Research, 2019, 25, 3528-3537.	3.2	136
2155	Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy. Cancer Letters, 2019, 452, 51-58.	3.2	16
2156	Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. Lung Cancer, 2019, 132, 107-113.	0.9	40
2157	Antibody repertoire analysis of mouse immunization protocols using microfluidics and molecular genomics. MAbs, 2019, 11, 870-883.	2.6	29
2158	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. Annals of Oncology, 2019, 30, 884-896.	0.6	78
2159	Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterology, 2019, 10, 364-371.	0.9	65
2160	Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1613-1623.	1.2	66
2161	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. Molecular Therapy - Oncolytics, 2019, 13, 1-6.	2.0	26
2162	Targeting immune cells for cancer therapy. Redox Biology, 2019, 25, 101174.	3.9	151
2163	Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?. Translational Medicine Communications, 2019, 4, .	0.5	3

#	ARTICLE	IF	CITATIONS
2164	The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. <i>Nature Communications</i> , 2019, 10, 1125.	5.8	131
2165	PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory. <i>Journal of Clinical Pathology</i> , 2019, 72, 412-417.	1.0	26
2166	Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)., 2019, 7, 65.		108
2167	A Dual-Responsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade. <i>Advanced Materials</i> , 2019, 31, e1806957.	11.1	145
2168	Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2019, 9, 179.	1.3	34
2169	Canadian Consensus: Oligoprogressive, Pseudoprogressive, and Oligometastatic Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2019, 26, 81-93.	0.9	38
2170	Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 663-666.	0.6	8
2171	Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing. <i>Advances in Therapy</i> , 2019, 36, 766-785.	1.3	16
2172	Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas. <i>Scientific Reports</i> , 2019, 9, 3536.	1.6	11
2173	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Hormone and Metabolic Research</i> , 2019, 51, 145-156.	0.7	234
2174	Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies. <i>Molecular and Clinical Oncology</i> , 2019, 10, 391-396.	0.4	3
2175	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	5.2	137
2176	PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. <i>Scientific Reports</i> , 2019, 9, 4633.	1.6	37
2177	The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 435-447.	1.0	7
2178	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , 2019, 11, 515-529.	1.0	17
2179	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 917-926.	2.0	59
2180	Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?. <i>Lancet Respiratory Medicine</i> , 2019, 7, 291-292.	5.2	1
2181	Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2019, 37, 529-536.	0.8	8

#	ARTICLE	IF	CITATIONS
2182	Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2162-2170.	0.8	202
2183	A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia. <i>European Journal of Cancer</i> , 2019, 112, 94-97.	1.3	7
2184	PD-1 Tumor Suppressor Signaling in T Cell Lymphomas. <i>Trends in Immunology</i> , 2019, 40, 403-414.	2.9	24
2185	Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 65-71.	0.9	120
2186	Light/pH-Triggered Biomimetic Red Blood Cell Membranes Camouflaged Small Molecular Drug Assemblies for Imaging-Guided Combinational Chemo-Photothermal Therapy. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 15262-15275.	4.0	90
2187	Bowel obstruction caused by colonic metastasis of lung adenocarcinoma: a case report and literature review. <i>World Journal of Surgical Oncology</i> , 2019, 17, 63.	0.8	12
2188	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials. <i>Thoracic Cancer</i> , 2019, 10, 1176-1181.	0.8	8
2189	PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas. <i>Molecular Biology Reports</i> , 2019, 46, 3333-3347.	1.0	12
2190	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
2191	PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival. <i>Frontiers in Oncology</i> , 2019, 9, 189.	1.3	21
2192	Are we ready to describe response or progression to immunotherapy in lung cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 112-119.	2.0	10
2193	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. <i>Molecules</i> , 2019, 24, 1190.	1.7	163
2194	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019, 75, 39-51.	3.4	124
2195	Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer. <i>Journal of Immunotherapy</i> , 2019, 42, 23-28.	1.2	22
2196	Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy: The Galectin-3 Signature in NSCLCs. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1607.	1.8	40
2198	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	6.3	2,347
2199	Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells. <i>Cancer Cell International</i> , 2019, 19, 68.	1.8	22
2200	T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. <i>Journal of Clinical Oncology</i> , 2019, 37, 318-327.	0.8	656

#	ARTICLE	IF	CITATIONS
2201	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 52-60.	0.8	218
2202	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 332-344.	0.2	16
2203	Early Phase I Study of a ^{99m} Tc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1213-1220.	2.8	111
2204	Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics. <i>Current Oncology Reports</i> , 2019, 21, 19.	1.8	34
2205	Multiple sclerosis outcomes after cancer immunotherapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 1336-1342.	1.2	75
2206	Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. <i>Scientific Reports</i> , 2019, 9, 2636.	1.6	38
2207	Magnetic aerosol drug targeting in lung cancer therapy using permanent magnet. <i>Drug Delivery</i> , 2019, 26, 120-128.	2.5	37
2208	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43
2209	Breaking the Depth Dependence by Nanotechnology-Enhanced X-Ray-Excited Deep Cancer Theranostics. <i>Advanced Materials</i> , 2019, 31, e1806381.	11.1	125
2210	Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2019, 14, 553-559.	0.5	123
2211	<p></p>Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 523-538.	2.0	23
2212	A case of immune thrombocytopenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia. <i>European Journal of Cancer</i> , 2019, 110, 49-52.	1.3	3
2213	Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 269-276.	0.4	218
2214	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 341-352.	2.0	82
2215	PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data. <i>Lung Cancer</i> , 2019, 129, 41-47.	0.9	24
2216	PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer. <i>OncImmunology</i> , 2019, 8, e1544442.	2.1	51
2217	Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 510-525.	1.6	47
2218	Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort. <i>BMC Cancer</i> , 2019, 19, 142.	1.1	24

#	ARTICLE	IF	CITATIONS
2219	Phase I/II trial testing safety and immunogenicity of the multi-peptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. <i>Neuro-Oncology</i> , 2019, 21, 923-933.	0.6	89
2220	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. <i>Journal of Oncology</i> , 2019, 2019, 1-18.	0.6	76
2221	Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. <i>Clinical and Translational Oncology</i> , 2019, 21, 1270-1279.	1.2	38
2222	A Novel Approach to Detect Programmed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 186-197.	1.2	12
2223	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. <i>Cancers</i> , 2019, 11, 223.	1.7	18
2224	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	5.1	327
2225	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
2226	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	15.2	932
2227	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	15.2	569
2228	LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers. <i>Frontiers in Immunology</i> , 2019, 10, 6.	2.2	280
2229	Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. <i>International Journal of Cancer</i> , 2019, 145, 2433-2439.	2.3	26
2230	Conventional transbronchial needle aspiration is promising for identifying EGFR mutations in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2019, 10, 856-863.	0.8	1
2231	Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. <i>Gynecologic Oncology</i> , 2019, 153, 381-384.	0.6	28
2232	Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors. , 2019, , 151-171.		0
2233	PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 16824-16837.	2.0	279
2234	The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 21.	1.3	27
2235	Immunotherapy and radiotherapy for metastatic cancers. <i>Annals of Palliative Medicine</i> , 2019, 8, 312-325.	0.5	33
2236	Nanotechnology in the diagnosis and treatment of lung cancer. , 2019, 198, 189-205.		106

#	ARTICLE	IF	CITATIONS
2237	The pioneers behind immune checkpoint blockers awarded the Nobel Prize in physiology or medicine 2018. <i>Acta Oncologica</i> , 2019, 58, 1-8.	0.8	14
2238	Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. <i>Acta Biomaterialia</i> , 2019, 88, 1-14.	4.1	29
2239	Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases. <i>Modern Pathology</i> , 2019, 32, 929-942.	2.9	67
2240	Immunotherapy for skin cancer. <i>International Immunology</i> , 2019, 31, 465-475.	1.8	47
2241	Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	169
2242	Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. <i>Oncolmmunology</i> , 2019, 8, e1564505.	2.1	118
2243	Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 815-822.	0.8	20
2244	Blood tumor mutational burden: are we ready for clinical implementation?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1906-S1908.	0.6	6
2245	The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 3347-3360.	3.9	82
2247	Is first-line pembrolizumab appropriate for all patients with metastatic non-squamous histology non-small cell lung cancer patients?. <i>Translational Lung Cancer Research</i> , 2019, 8, S327-S330.	1.3	3
2248	Spontaneous Regression of Recurrent Undifferentiated Carcinoma of the Endometrium. <i>Internal Medicine</i> , 2019, 58, 1649-1653.	0.3	3
2249	Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries. <i>BioMed Research International</i> , 2019, 2019, 1-22.	0.9	9
2250	Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial. <i>Translational Cancer Research</i> , 2019, 8, S598-S602.	0.4	2
2251	PD-1 Inhibitors in the Advanced Esophageal Cancer. <i>Frontiers in Pharmacology</i> , 2019, 10, 1418.	1.6	22
2252	<p>T-Regulatory Cells In Tumor Progression And Therapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10731-10747.	0.9	57
2253	Traitements de première ligne dans les CBNPC avancés, en l'absence d'addiction oncogénique (incluant) Tj ETQq1 1 0.784 2019, 11, 342-354.	0.0	0
2254	Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. <i>Oncologist</i> , 2019, 24, 648-656.	1.9	60
2255	Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion. <i>Oncologist</i> , 2019, 24, 730-734.	1.9	9

#	ARTICLE	IF	CITATIONS
2256	New development of Immune checkpoints blockade in cancer immunotherapy. E3S Web of Conferences, 2019, 131, 01022.	0.2	1
2257	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. Hepatobiliary Surgery and Nutrition, 2019, 8, 604-614.	0.7	34
2258	Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open, 2019, 9, e031019.	0.8	16
2259	Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study. ESMO Open, 2019, 4, e000536.	2.0	26
2260	Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. Oncologist, 2019, 24, 96-102.	1.9	35
2261	KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit. Translational Lung Cancer Research, 2019, 8, S403-S406.	1.3	2
2262	Impact of pretherapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T cell therapy. Clinical and Translational Immunology, 2019, 8, e01088.	1.7	10
2263	Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Scientific Reports, 2019, 9, 17085.	1.6	12
2264	EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Molecular Cancer, 2019, 18, 165.	7.9	160
2266	Immunotherapy and Radiation. Hematology/Oncology Clinics of North America, 2019, 33, 1057-1069.	0.9	2
2267	Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Scientific Reports, 2019, 9, 16662.	1.6	33
2268	KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment. Translational Lung Cancer Research, 2019, 8, 706-709.	1.3	5
2269	Preface: More than two decades of modern tumor immunology. Methods in Enzymology, 2019, 629, xxi-xl.	0.4	1
2270	Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging. ACS Nano, 2019, 13, 13884-13898.	7.3	66
2271	Classifying Stage IV Lung Cancer From Health Care Claims: A Comparison of Multiple Analytic Approaches. JCO Clinical Cancer Informatics, 2019, 3, 1-19.	1.0	8
2272	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	58
2274	Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer. Medicine (United States), 2019, 98, e18310.	0.4	2
2275	Reliability of PD-L1 assays using small tissue samples compared with surgical specimens. Medicine (United States), 2019, 98, e14972.	0.4	15

#	ARTICLE	IF	CITATIONS
2276	An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-7.	0.2	3
2277	Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. <i>Radiology Imaging Cancer</i> , 2019, 1, e190031.	0.7	22
2278	Phase II/III Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6623-6632.	3.2	96
2279	Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer. <i>Journal of Cancer</i> , 2019, 10, 6703-6710.	1.2	16
2280	Immune-Checkpoint Inhibitors as the First Line Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Cancer</i> , 2019, 10, 6261-6268.	1.2	22
2281	Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor. <i>Scientific Reports</i> , 2019, 9, 17830.	1.6	13
2282	Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. <i>Journal of Immunology Research</i> , 2019, 2019, 1-7.	0.9	93
2283	Anti-programmed Death-1 Immunotherapy for Endometrial Cancer with Microsatellite Instability-High Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 83.	1.3	11
2284	Immune-Mediated Colitis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 506-523.	0.3	6
2285	Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, S339-S342.	1.3	13
2286	Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1. <i>Molecular Therapy - Oncolytics</i> , 2019, 15, 201-213.	2.0	20
2287	Can Bioactive Lipids Augment Anti-cancer Action of Immunotherapy and Prevent Cytokine Storm?. <i>Archives of Medical Research</i> , 2019, 50, 342-349.	1.5	23
2288	Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. <i>Scientific Reports</i> , 2019, 9, 17252.	1.6	20
2289	KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591988554.	1.4	25
2290	Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. , 2019, 7, 339.		65
2291	Misleading impaired liver function in a non-small-cell lung cancer patient treated with pembrolizumab. <i>Anti-Cancer Drugs</i> , 2019, 30, 757-761.	0.7	0
2292	Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4591-4601.	0.6	35
2293	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. <i>Melanoma Management</i> , 2019, 6, MMT30.	0.1	19

#	ARTICLE	IF	CITATIONS
2295	Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1. Biomarker Research, 2019, 7, 28.	2.8	22
2296	Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy, 2019, 11, 1445-1461.	1.0	37
2297	Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. Integrative Cancer Therapies, 2019, 18, 153473541989002.	0.8	33
2298	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 61.	7.1	436
2299	The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?. Translational Lung Cancer Research, 2019, 8, 731-737.	1.3	1
2300	Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report. OncoTargets and Therapy, 2019, Volume 12, 8595-8600.	1.0	23
2301	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 699-714.	0.6	36
2302	Management of Brain Metastases in Non-Small-Cell Lung Cancer. Journal of Oncology Practice, 2019, 15, 563-570.	2.5	91
2303	A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer. Cancer Management and Research, 2019, Volume 11, 9469-9481.	0.9	1
2304	Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. Current Oncology, 2019, 26, 24-32.	0.9	11
2305	Setting the scene – a future epidemic™ of immune-related adverse events in association with checkpoint inhibitor therapy. Rheumatology, 2019, 58, vii1-vii6.	0.9	3
2307	Predictive potential and need for standardization of PD-L1 immunohistochemistry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 475-484.	1.4	32
2308	Digital PCR After MALDI-Mass Spectrometry Imaging to Combine Proteomic Mapping and Identification of Activating Mutations in Pulmonary Adenocarcinoma. Proteomics - Clinical Applications, 2019, 13, e1800034.	0.8	19
2309	Principles of adoptive T cell therapy in cancer. Seminars in Immunopathology, 2019, 41, 49-58.	2.8	141
2310	PD-L1/PD-L1 immune checkpoint: Potential target for cancer therapy. Journal of Cellular Physiology, 2019, 234, 1313-1325.	2.0	288
2311	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
2312	The Current Status of Immunotherapy in Thoracic Malignancies. , 2019, , 45-75.		0
2313	Cancers of the Head and Neck. , 2019, , 103-114.		0

#	ARTICLE	IF	CITATIONS
2314	Gynecologic Malignancies. , 2019, , 135-155.		0
2315	Absolute Quantification of All Identified Plasma Proteins from SWATH Data for Biomarker Discovery. Proteomics, 2019, 19, e1800135.	1.3	11
2316	Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. Lung Cancer, 2019, 130, 59-66.	0.9	65
2317	The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. Lung Cancer, 2019, 128, 113-119.	0.9	11
2318	Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy. British Journal of Cancer, 2019, 120, 346-355.	2.9	16
2319	Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 376.	3.4	235
2320	Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. Physics in Medicine and Biology, 2019, 64, 025017.	1.6	22
2321	A novel approach to candidemia? The potential role of checkpoint inhibition. Medical Mycology, 2019, 57, 151-154.	0.3	9
2322	Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-L1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 105-115.	0.9	16
2323	Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: A systematic review and meta-analysis. Pathology Research and Practice, 2019, 215, 229-234.	1.0	33
2324	Promising immunotherapy: Highlighting cytokine-induced killer cells. Journal of Cellular Biochemistry, 2019, 120, 8863-8883.	1.2	11
2325	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. Journal of the National Cancer Institute, 2019, 111, 118-128.	3.0	49
2326	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224.	3.3	53
2327	Krüppel like factor 6 splice variant 1 (KLF6-SV1) overexpression recruits macrophages to participate in lung cancer metastasis by up-regulating TWIST1. Cancer Biology and Therapy, 2019, 20, 680-691.	1.5	13
2328	The complicated effects of obesity on cancer and immunotherapy. Immunotherapy, 2019, 11, 11-14.	1.0	10
2329	Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation. Respiratory Medicine Case Reports, 2019, 26, 168-170.	0.2	8
2330	Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression. Annals of Surgical Oncology, 2019, 26, 876-883.	0.7	74
2331	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Annals of Oncology, 2019, 30, 44-56.	0.6	1,742

#	ARTICLE	IF	CITATIONS
2332	Immunotherapy in advanced gastric cancer, is it the future?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 25-32.	2.0	97
2333	Cancer Immunotherapy: Beyond Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2019, 3, 55-75.	2.3	102
2334	Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. <i>Modern Pathology</i> , 2019, 32, 524-531.	2.9	13
2335	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. <i>Annals of Oncology</i> , 2019, 30, 405-411.	0.6	419
2336	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
2337	PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. <i>Thoracic Cancer</i> , 2019, 10, 103-110.	0.8	36
2338	The clinical role of the TME in solid cancer. <i>British Journal of Cancer</i> , 2019, 120, 45-53.	2.9	380
2339	Pembrolizumab: a case of drug-induced autoimmune diabetes mellitus and colitis. <i>Journal of Pharmacy Practice and Research</i> , 2019, 49, 50-54.	0.5	2
2340	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 141-151.	15.2	539
2341	Immuno-Oncology in Lung Cancer. , 2019, , 487-497.		1
2342	Immunological and Genetic Biomarkers of Sarcomas. , 2019, , 591-608.		0
2343	Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 17-22.	0.2	21
2344	Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. <i>Cancer Letters</i> , 2019, 442, 279-286.	3.2	34
2345	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	0.5	68
2346	Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 691-698.	0.6	12
2347	Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1564-1573.	3.2	33
2348	The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumourigenic function in non-small cell lung cancer. <i>Oncogene</i> , 2019, 38, 2291-2304.	2.6	19
2349	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. <i>European Journal of Cancer</i> , 2019, 106, 1-11.	1.3	37

#	ARTICLE	IF	CITATIONS
2350	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 57-67.	0.6	167
2351	High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. <i>Lung Cancer</i> , 2019, 127, 37-43.	0.9	60
2352	Cancer immunotherapy: challenges and clinical applications. <i>Journal of Medical Genetics</i> , 2019, 56, 1-3.	1.5	22
2353	Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors. <i>BMC Cancer</i> , 2019, 19, 19.	1.1	66
2354	Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. <i>Journal of Medical Economics</i> , 2019, 22, 344-349.	1.0	34
2355	Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1. <i>Annals of Thoracic Surgery</i> , 2019, 107, 418-424.	0.7	19
2356	Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies. <i>BMC Cancer</i> , 2019, 19, 72.	1.1	32
2357	Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. <i>Immunotherapy</i> , 2019, 11, 167-175.	1.0	33
2358	Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 225-232.	1.4	22
2359	Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. <i>Annals of Oncology</i> , 2019, 30, 281-289.	0.6	88
2360	The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 455-466.	2.0	31
2361	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 463-474.	1.4	16
2362	Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 443-454.	2.0	8
2363	Exploiting Fasting-mimicking Diet and Metformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019, 20, e413-e417.	1.1	27
2364	PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers. <i>Human Pathology</i> , 2019, 86, 108-114.	1.1	20
2365	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 127, 25-33.	0.9	13
2366	Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 861-867.	2.0	36
2367	Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. <i>Lung Cancer</i> , 2019, 127, 44-52.	0.9	52

#	ARTICLE	IF	CITATIONS
2368	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 2144-2154.	3.2	134
2369	Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 49.	1.1	21
2370	Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 128-134.	1.4	47
2371	Engineering Precision Medicine. <i>Advanced Science</i> , 2019, 6, 1801039.	5.6	55
2372	Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 19-24.	1.1	6
2373	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	8.9	349
2374	T lymphocyte subsets in cancer immunity: Friends or foes. <i>Journal of Leukocyte Biology</i> , 2019, 105, 243-255.	1.5	110
2375	Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophanâ€“Kynurenineâ€“Aryl Hydrocarbon Axis. <i>Clinical Cancer Research</i> , 2019, 25, 1462-1471.	3.2	271
2376	Tumour cellâ€“intrinsic <sc>CTLA</sc>4 regulates <sc>PD</sc>â€“1 expression in nonâ€“small cell lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 535-542.	1.6	68
2377	Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 85-95.	2.0	32
2378	Quality Control of Immunohistochemical and In Situ Hybridization Predictive Biomarkers for Patient Treatment: Experience from International Guidelines and International Quality Control Schemes. , 2019, , 525-537.		2
2379	The lung microenvironment: an important regulator of tumour growth and metastasis. <i>Nature Reviews Cancer</i> , 2019, 19, 9-31.	12.8	692
2380	Clinical significance of â‰¥ 50% PDâ€“1 expression with the SP263 monoclonal antibody in nonâ€“small cell lung cancer patients. <i>Thoracic Cancer</i> , 2019, 10, 175-182.	0.8	4
2381	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. <i>Annual Review of Cancer Biology</i> , 2019, 3, 385-408.	2.3	17
2382	Predictive value of oncogenic driver subtype, programmed deathâ€“1 ligand (PDâ€“1) score, and smoking status on the efficacy of PDâ€“1/PDâ€“1 inhibitors in patients with oncogeneâ€“driven nonâ€“small cell lung cancer. <i>Cancer</i> , 2019, 125, 1038-1049.	2.0	66
2383	Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms. <i>International Immunopharmacology</i> , 2019, 67, 160-175.	1.7	33
2384	Promising efficacy of SHRâ€“1210, a novel antiâ€“programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China. <i>Cancer</i> , 2019, 125, 742-749.	2.0	55
2385	Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. , 2019, 196, 105-116.		88

#	ARTICLE	IF	CITATIONS
2386	Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages. <i>Cancer Immunology Research</i> , 2019, 7, 193-207.	1.6	64
2387	Next generation sequencing-based gene panel tests for the management of solid tumors. <i>Cancer Science</i> , 2019, 110, 6-15.	1.7	107
2388	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 393, 156-167.	6.3	1,153
2389	Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay. <i>Cancer Cytopathology</i> , 2019, 127, 52-61.	1.4	49
2390	Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells. <i>International Immunopharmacology</i> , 2019, 66, 296-308.	1.7	15
2391	Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028. <i>Gynecologic Oncology</i> , 2019, 152, 243-250.	0.6	192
2392	Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor. <i>International Journal of Cancer</i> , 2019, 144, 1170-1179.	2.3	29
2393	Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 12-22.	1.5	11
2394	A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy. <i>Oncolmmunology</i> , 2019, 8, e1513440.	2.1	20
2395	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1715-1730.	2.9	92
2396	Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients. <i>Modern Pathology</i> , 2019, 32, 367-375.	2.9	31
2397	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. <i>Clinical Cancer Research</i> , 2019, 25, 946-956.	3.2	96
2398	Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. <i>Oncolmmunology</i> , 2019, 8, e1512943.	2.1	31
2399	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 41-54.	3.3	83
2400	Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 88-96.e6.	1.1	90
2401	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
2402	Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions. <i>Briefings in Functional Genomics</i> , 2019, 18, 147-156.	1.3	12
2403	RNA In Situ Hybridization for Epstein-Barr Virus and Cytomegalovirus: Comparison With In Situ Hybridization and Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 155-159.	0.6	17

#	ARTICLE	IF	CITATIONS
2404	Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. <i>Pathology and Oncology Research</i> , 2019, 25, 319-325.	0.9	2
2405	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , 2019, 25, 513-520.	0.9	5
2406	Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. <i>Journal of Drug Targeting</i> , 2019, 27, 244-256.	2.1	86
2407	The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay. <i>Pathology and Oncology Research</i> , 2020, 26, 79-89.	0.9	59
2408	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 64-77.	1.9	30
2409	Geriatric assessment and treatment outcomes in older adults with cancer receiving immune checkpoint inhibitors. <i>Journal of Geriatric Oncology</i> , 2020, 11, 523-528.	0.5	29
2410	Monitoring abscopal responses to radiation in mice. <i>Methods in Enzymology</i> , 2020, 635, 111-125.	0.4	2
2411	<i>Cancer Immunology.</i> , 2020, , 84-96.e5.		0
2412	Managing Lung Cancer with Comorbid Interstitial Pneumonia. <i>Internal Medicine</i> , 2020, 59, 163-167.	0.3	14
2413	Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis. <i>Modern Pathology</i> , 2020, 33, 380-390.	2.9	25
2414	Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. <i>Pharmacoeconomics - Open</i> , 2020, 4, 235-247.	0.9	19
2415	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <i>Annals of Emergency Medicine</i> , 2020, 75, 264-286.	0.3	3
2416	Tumour-intrinsic resistance to immune checkpoint blockade. <i>Nature Reviews Immunology</i> , 2020, 20, 25-39.	10.6	856
2417	Intraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer. <i>Medical Principles and Practice</i> , 2020, 29, 150-159.	1.1	7
2418	The impact of smoking on the effectiveness of immune checkpoint inhibitors – a systematic review and meta-analysis. <i>Acta Oncol</i> ³gica, 2020, 59, 96-100.	0.8	13
2419	Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. <i>Modern Pathology</i> , 2020, 33, 603-615.	2.9	34
2420	Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 18-27.	2.0	46
2421	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. <i>Oncologist</i> , 2020, 25, e147-e159.	1.9	220

#	ARTICLE	IF	CITATIONS
2422	Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma. <i>CEN Case Reports</i> , 2020, 9, 48-54.	0.5	9
2423	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
2424	Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. <i>Clinical and Translational Oncology</i> , 2020, 22, 759-771.	1.2	11
2425	Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. <i>Modern Pathology</i> , 2020, 33, 4-17.	2.9	135
2426	The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. <i>Modern Pathology</i> , 2020, 33, 109-117.	2.9	40
2427	Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 160-171.	1.2	30
2428	PGC-1 β activator-induced fatty acid oxidation in tumor-infiltrating CTLs enhances effects of PD-1 blockade therapy in lung cancer. <i>Tumori</i> , 2020, 106, 55-63.	0.6	29
2429	Current Development of Monoclonal Antibodies in Cancer Therapy. <i>Recent Results in Cancer Research</i> , 2020, 214, 1-70.	1.8	16
2430	Assessment of Adverse Events and Their Ability to Discriminate Response to Anti-PD-1/PD-L1 Antibody Immunotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 103-104.	0.8	9
2431	Platinum complexes of curcumin delivered by dual-responsive polymeric nanoparticles improve chemotherapeutic efficacy based on the enhanced anti-metastasis activity and reduce side effects. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1106-1121.	5.7	58
2432	Role of myeloid cells in the immunosuppressive microenvironment in gliomas. <i>Immunobiology</i> , 2020, 225, 151853.	0.8	50
2433	Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review. <i>Lung Cancer</i> , 2020, 139, 18-21.	0.9	7
2434	BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2643-2654.	1.2	22
2435	Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 390-402.	1.5	19
2436	Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens. <i>Journal of Cancer</i> , 2020, 11, 41-50.	1.2	3
2437	miR-146b Reverses epithelial-mesenchymal transition via targeting PTP1B in cisplatin-resistance human lung adenocarcinoma cells. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3901-3912.	1.2	20
2438	CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers. <i>Cancer Research</i> , 2020, 80, 444-457.	0.4	88
2439	Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1598-1610.e3.	0.4	23

#	ARTICLE	IF	CITATIONS
2440	Immune-related adverse reactions in the hepatobiliary system: second-generation checkpoint inhibitors highlight diverse histological changes. <i>Histopathology</i> , 2020, 76, 470-480.	1.6	52
2441	Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 265-272.	1.1	47
2442	Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. <i>Oral Oncology</i> , 2020, 101, 104525.	0.8	39
2444	ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. <i>Cancer Letters</i> , 2020, 473, 148-155.	3.2	31
2445	iRECIST: how to do it. <i>Cancer Imaging</i> , 2020, 20, 2.	1.2	41
2446	Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy. <i>Biomaterials Science</i> , 2020, 8, 1045-1057.	2.6	20
2447	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 457-466.	1.2	21
2448	The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151445.	0.6	5
2449	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 499-519.	0.5	203
2450	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020, 65, 51-64.	4.3	63
2451	Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1. <i>Translational Research</i> , 2020, 217, 11-22.	2.2	17
2452	Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 26-35.	0.9	69
2453	Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. <i>American Journal of Surgical Pathology</i> , 2020, 44, 378-386.	2.1	23
2454	Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e151-e163.	1.1	9
2455	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays TM and cross-validation with resections, in patients with, stage III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. <i>Modern Pathology</i> , 2020, 33, 792-801.	2.9	28
2456	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. <i>Theranostics</i> , 2020, 10, 1708-1718.	4.6	68
2457	Commentary: Breaking down non-small cell lung cancer tumor microenvironment heterogeneity and predicting response to immune checkpoint inhibitors. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 1612-1613.	0.4	2
2458	PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung Cancers. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 437-443.	0.6	1

#	ARTICLE	IF	CITATIONS
2459	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 2908-2920.	3.2	30
2460	Adverse kidney effects of immunotherapies. , 2020, , 166-182.e3.		0
2461	Mechanisms of immune evasion in bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 3-14.	2.0	127
2462	The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 137-147.	1.0	6
2463	PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells. <i>American Journal of Surgical Pathology</i> , 2020, 44, 174-181.	2.1	52
2464	The Cytosolic DNA-Sensing cGASâ€“STING Pathway in Cancer. <i>Cancer Discovery</i> , 2020, 10, 26-39.	7.7	558
2465	Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions. <i>Clinical Obstetrics and Gynecology</i> , 2020, 63, 48-63.	0.6	27
2466	Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Nonâ€“Small Cell Lung Adenocarcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 23-29.	0.6	6
2467	Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1168-1182.	3.3	115
2468	Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 127-134.	2.0	37
2469	Biomarkers that may predict response to immunotherapy in ovarian malignancies. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 84-90.	0.9	8
2470	Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 137-152.	1.2	17
2471	Brain immunology and immunotherapy in brain tumours. <i>Nature Reviews Cancer</i> , 2020, 20, 12-25.	12.8	389
2472	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2020, 122, 340-347.	2.9	24
2473	Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 15-22.	2.0	54
2474	Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 932-941.	1.3	33
2475	Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1147-1157.	3.3	103
2476	Systematic construction and validation of an immune prognostic model for lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1233-1244.	1.6	52

#	ARTICLE	IF	CITATIONS
2477	Combined Evaluation of Tumor-Infiltrating CD8 ⁺ and FoxP3 ⁺ Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2102-2109.	0.7	16
2478	Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. <i>European Journal of Cancer</i> , 2020, 124, 110-122.	1.3	56
2479	Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC. <i>Thoracic Cancer</i> , 2020, 11, 120-129.	0.8	23
2480	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 139, 207-215.	0.9	79
2481	Ethical and Policy Issues for Seamless Phase I Oncology Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 669-673.	0.8	11
2482	PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 161-165.	0.6	7
2483	PD-L1 Expression Correlates With Young Age and CD8 ⁺ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 428-435.	0.9	14
2484	The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. <i>Cells</i> , 2020, 9, 26.	1.8	29
2485	Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 741-749.	1.2	21
2486	Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. <i>International Immunopharmacology</i> , 2020, 79, 106088.	1.7	39
2487	Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2761.	1.7	24
2488	Extracellular Vesicles as Biomarkers in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 2825.	1.7	66
2489	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	1.1	11
2490	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2013770.	2.8	34
2491	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020, 140, 119-129.	1.3	37
2492	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. <i>AAPS Journal</i> , 2020, 22, 132.	2.2	27
2493	Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 273-280.	1.0	39
2494	A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas. <i>Annals of Translational Medicine</i> , 2020, 8, 930-930.	0.7	13

#	ARTICLE	IF	CITATIONS
2495	First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions. <i>Drugs</i> , 2020, 80, 1783-1797.	4.9	12
2496	Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. <i>Nature Communications</i> , 2020, 11, 4878.	5.8	27
2497	Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model. <i>Frontiers in Oncology</i> , 2020, 10, 1771.	1.3	7
2498	Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report. <i>Respiratory Medicine Case Reports</i> , 2020, 31, 101236.	0.2	1
2499	Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective. <i>Chinese Medical Journal</i> , 2020, 133, 2466-2475.	0.9	4
2500	Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. , 2020, 8, e001001.		143
2501	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	0.9	18
2502	Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. <i>Biomarkers in Medicine</i> , 2020, 14, 1383-1392.	0.6	16
2503	Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110621.	2.5	8
2504	Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 3337-3345.	0.8	12
2505	The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. <i>Cancers</i> , 2020, 12, 2983.	1.7	56
2506	Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?. <i>Carcinogenesis</i> , 2020, 41, 1671-1681.	1.3	18
2507	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. <i>Human Molecular Genetics</i> , 2020, 29, R214-R225.	1.4	3
2508	The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients. <i>Medicine (United States)</i> , 2020, 99, e22567.	0.4	5
2509	Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7378.	1.8	62
2510	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer. <i>Cell</i> , 2020, 183, 303-304.	13.5	4
2511	Using phage-assisted continuous evolution (PACE) to evolve human PD1. <i>Experimental Cell Research</i> , 2020, 396, 112244.	1.2	3
2512	Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188447.	3.3	97

#	ARTICLE	IF	CITATIONS
2513	Association of immune checkpoint inhibitors with respiratory infections: A review. <i>Cancer Treatment Reviews</i> , 2020, 90, 102109.	3.4	9
2514	The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung. <i>Translational Lung Cancer Research</i> , 2020, 9, 811-815.	1.3	3
2515	Development of adoptive immunotherapy with KLRG1-specific TCR-transduced β 1T cells against lung cancer cells. <i>Cancer Science</i> , 2020, 111, 4021-4030.	1.7	11
2516	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. <i>Cytotherapy</i> , 2020, 22, 204-213.	0.3	9
2519	Les CBNPC de stades avancés hors addiction oncogénique : les traitements systémiques de deuxième ligne. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S185-2S194.	0.0	0
2520	Isolation of DNA Aptamer Targeting PD-1 with an Antitumor Immunotherapy Effect. <i>ACS Applied Bio Materials</i> , 2020, 3, 7080-7086.	2.3	19
2521	Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 277-283.	0.3	2
2522	Immune reaction and regulation in transplantation based on pluripotent stem cell technology. <i>Inflammation and Regeneration</i> , 2020, 40, 12.	1.5	20
2523	Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110504.	2.5	26
2524	Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093688.	1.4	17
2525	Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2020, 9, 824-827.	1.3	0
2526	Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report. <i>Anticancer Research</i> , 2020, 40, 4123-4129.	0.5	9
2527	Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. <i>Clinical Cancer Research</i> , 2020, 26, 5153-5161.	3.2	58
2528	Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies. <i>Translational Lung Cancer Research</i> , 2020, 9, 906-916.	1.3	3
2529	Implementation of PD-L1 22C3 IHC pharmDx™;TM™; in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytolytA® Prefixation. <i>Acta Cytologica</i> , 2020, 64, 577-587.	0.7	14
2530	Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report. <i>Annals of Palliative Medicine</i> , 2020, 9, 3623-3628.	0.5	3
2531	Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2706-2712.	0.6	10
2532	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. <i>Annals of Gastroenterological Surgery</i> , 2020, 4, 369-378.	1.2	10

#	ARTICLE	IF	CITATIONS
2533	Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 568279.	1.3	11
2534	Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer immunotherapy. <i>European Journal of Immunology</i> , 2020, 50, 1871-1884.	1.6	6
2535	Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 270.	7.1	18
2536	Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 22, e555-e562.	1.1	1
2537	Using Machine Learning Modeling to Explore New Immune-Related Prognostic Markers in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 550002.	1.3	10
2538	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. <i>Nature Cancer</i> , 2020, 1, 1167-1175.	5.7	22
2539	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2059-2073.	1.3	9
2540	Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 584423.	2.2	39
2541	Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival. <i>Frontiers in Oncology</i> , 2020, 10, 571545.	1.3	12
2542	The Risk of Diarrhea and Colitis in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2020, 27, 486-494.	0.9	17
2543	ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 527750.	2.2	7
2544	HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8770.	1.8	6
2545	Prognostic Value of the Pretreatment Systemic Immune-Inflammation Index in Patients with Colorectal Cancer. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-8.	0.7	5
2546	Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis. <i>Annals of Translational Medicine</i> , 2020, 8, 1172-1172.	0.7	8
2547	A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient. <i>Translational Lung Cancer Research</i> , 2020, 9, 2157-2160.	1.3	5
2548	Sintilimab: A Promising Anti-Tumor PD-1 Antibody. <i>Frontiers in Oncology</i> , 2020, 10, 594558.	1.3	76
2549	Case Report: Pathologic Complete Response to Pembrolizumab in Combination With Neoadjuvant Chemotherapy in a Patient With Stage IIB Squamous Lung Cancer. <i>Frontiers in Surgery</i> , 2020, 7, 601805.	0.6	2
2550	Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy. <i>Frontiers in Immunology</i> , 2020, 8, e001392.		27

#	ARTICLE	IF	CITATIONS
2551	Tumors establish resistance to immunotherapy by regulating T _{reg} recruitment via CCR4. , 2020, 8, e000764.		66
2552	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. <i>Frontiers in Genetics</i> , 2020, 11, 548719.	1.1	18
2553	CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 6119.	5.8	53
2554	Unique genomic features and prognostic value of COSMIC mutational signature 4 in lung adenocarcinoma and lung squamous cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1176-1176.	0.7	8
2555	Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11. <i>Medicine (United States)</i> , 2020, 99, e22323.	0.4	12
2556	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 236.	3.5	44
2557	MELK is an oncogenic kinase essential for metastasis, mitotic progression, and programmed death in lung carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 279.	7.1	41
2558	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020, 99, 932-942.	1.2	30
2559	The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2020, 10, 569202.	1.3	22
2560	Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3574.	1.7	42
2561	Première ligne des CBNPC avancés sans addiction oncogénique : quel traitement pour quel patient ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S329-2S338.	0.0	0
2562	TGF- β 2 is a Prognostic Biomarker Correlated with Immune Cell Infiltration in Colorectal Cancer. <i>Medicine (United States)</i> , 2020, 99, e23024.	0.4	8
2563	Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2020, 2020, 1-13.	0.9	76
2564	Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy. <i>Cell Death and Disease</i> , 2020, 11, 964.	2.7	61
2565	Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency. <i>Frontiers in Immunology</i> , 2020, 11, 563622.	2.2	4
2566	First line Immunotherapy for Non-Small Cell Lung Cancer. <i>Pharmaceuticals</i> , 2020, 13, 373.	1.7	49
2567	Roles for the FCRL6 Immunoreceptor in Tumor Immunology. <i>Frontiers in Immunology</i> , 2020, 11, 575175.	2.2	16
2568	Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097004.	1.4	22

#	ARTICLE	IF	CITATIONS
2569	Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 7137-7145.	1.2	14
2570	Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 725-741.	12.5	701
2571	Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma. <i>Reproductive Sciences</i> , 2020, 27, 1848-1856.	1.1	10
2572	Reply to: Problems With the Recommendations for PD-L1 Biomarker Testing. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, e65-e67.	0.6	0
2573	Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. <i>BMC Cancer</i> , 2020, 20, 727.	1.1	17
2574	<p>Past, Present, and Future of Anticancer Nanomedicine</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5719-5743.	3.3	23
2575	<p>Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5893-5902.	0.9	13
2576	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	3.0	37
2577	Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. <i>Cancer</i> , 2020, 126, 4390-4399.	2.0	19
2578	Clinical burden of immune checkpoint inhibitor-induced pneumonitis. <i>Respiratory Investigation</i> , 2020, 58, 305-319.	0.9	11
2579	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , 2020, 89, 102085.	3.4	41
2580	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 672.	1.8	205
2581	Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2020, 40, 4001-4010.	0.5	5
2582	Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies. <i>Toxins</i> , 2020, 12, 416.	1.5	1
2583	Identification and Validation of the Immune Subtypes of Lung Adenocarcinoma: Implications for Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 550.	1.8	14
2584	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 69.	1.3	20
2585	SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges. <i>Journal of Hematology and Oncology</i> , 2020, 13, 105.	6.9	73
2586	Progress in Neoantigen Targeted Cancer Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 728.	1.8	28

#	ARTICLE	IF	CITATIONS
2587	PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5228.	1.8	19
2588	Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 3051-3061.	0.8	106
2589	High Expression of Programmed Death Ligand 1 and Programmed Death Ligand 2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors. <i>American Journal of Ophthalmology</i> , 2020, 220, 128-139.	1.7	8
2590	Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. <i>Oral Oncology</i> , 2020, 111, 104931.	0.8	16
2592	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1050-1060.	2.1	34
2593	Image-Guided Interventions in Oncology. , 2020, , .		1
2594	Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2413-2424.	2.0	21
2595	Immunological combination treatment holds the key to improving survival in pancreatic cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2897-2911.	1.2	14
2596	High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. <i>Scientific Reports</i> , 2020, 10, 12348.	1.6	48
2597	Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC. <i>Scientific Reports</i> , 2020, 10, 13160.	1.6	29
2598	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. <i>Cells</i> , 2020, 9, 1727.	1.8	8
2599	Programmed cell death ligand 1 and cytotoxic T cell infiltrates in metastatic cutaneous squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2020, 42, 3226-3234.	0.9	3
2600	Programmed cell death 1 (PD-1)/PD-ligand 1 (PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 299-304.	0.7	10
2601	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2020, 151, 141-148.	0.3	62
2602	The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. <i>BMC Cancer</i> , 2020, 20, 738.	1.1	9
2603	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. <i>Experimental Hematology and Oncology</i> , 2020, 9, 17.	2.0	21
2604	Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110626.	2.5	25
2605	Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. <i>Scientific Reports</i> , 2020, 10, 13773.	1.6	42

#	ARTICLE	IF	CITATIONS
2606	Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e160-e178.	0.7	6
2607	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30
2608	Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 930.	2.0	17
2609	Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma. <i>Immunotherapy</i> , 2020, 12, 293-298.	1.0	4
2610	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. <i>Frontiers in Pharmacology</i> , 2020, 11, 578091.	1.6	51
2611	Inflection of Akt/mTOR/STAT-3 cascade in TNF- α induced protein 8 mediated human lung carcinogenesis. <i>Life Sciences</i> , 2020, 262, 118475.	2.0	12
2612	Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma. <i>Journal of Bone Oncology</i> , 2020, 25, 100332.	1.0	19
2613	LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. <i>ESMO Open</i> , 2020, 5, e000748.	2.0	2
2614	Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. <i>Thoracic Cancer</i> , 2020, 11, 3585-3595.	0.8	32
2615	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 1952.	3.4	241
2616	Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	7
2617	The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 563044.	2.2	30
2618	Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells. <i>Cancers</i> , 2020, 12, 3169.	1.7	10
2619	Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy. <i>Radiation Oncology</i> , 2020, 15, 247.	1.2	18
2620	Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 769-783.	1.0	1
2621	Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. <i>Biomarker Research</i> , 2020, 8, 34.	2.8	266
2622	Modular design of Bi-specific nanoplatform engaged in malignant lymphoma immunotherapy. <i>Nanoscale</i> , 2020, 12, 18418-18428.	2.8	6
2623	Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). <i>British Journal of Cancer</i> , 2020, 123, 1535-1542.	2.9	42

#	ARTICLE	IF	CITATIONS
2624	Destrin Contributes to Lung Adenocarcinoma Progression by Activating Wnt/ β -Catenin Signaling Pathway. <i>Molecular Cancer Research</i> , 2020, 18, 1789-1802.	1.5	18
2625	Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular Carcinoma. <i>Cells</i> , 2020, 9, 2002.	1.8	25
2626	Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 866-872.	0.9	3
2627	Predictive value of ^{18}F -fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2020, 11, 3260-3268.	0.8	5
2628	Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2020, 9, 1053-1066.	1.3	7
2629	Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 213.	7.1	387
2630	Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration. , 2020, 8, e001224.		41
2631	Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity. <i>Immunology Letters</i> , 2020, 227, 96-101.	1.1	11
2632	29 immune-related genes pairs signature predict the prognosis of cervical cancer patients. <i>Scientific Reports</i> , 2020, 10, 14152.	1.6	27
2633	Personalized Immuno-Oncology. <i>Medical Principles and Practice</i> , 2021, 30, 1-16.	1.1	25
2634	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	157.7	93
2635	Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. <i>Cancer</i> , 2020, 126, 4788-4799.	2.0	14
2636	Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22910-22919.	3.3	32
2637	Metformin and cancer immunity. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1403-1409.	2.8	54
2638	Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. <i>Cancer</i> , 2020, 126, 4867-4877.	2.0	69
2639	The Combined Use of SBRT and Immunotherapy—a Literature Review. <i>Current Oncology Reports</i> , 2020, 22, 117.	1.8	13
2640	A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 509-511.	0.6	5
2641	Spontaneous Regression and Complete Response to Immune Checkpoint Blockade in a Case of High-Grade Neuroendocrine Carcinoma. <i>JCO Precision Oncology</i> , 2020, 4, 1006-1011.	1.5	2

#	ARTICLE	IF	CITATIONS
2642	ctDNA Concentration, MIK167 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC. <i>Frontiers in Oncology</i> , 2020, 10, 1706.	1.3	17
2644	The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. <i>Vaccines</i> , 2020, 8, 529.	2.1	9
2645	Revisiting the PD-1 pathway. <i>Science Advances</i> , 2020, 6, .	4.7	277
2646	Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications. <i>BMC Medicine</i> , 2020, 18, 275.	2.3	42
2647	Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 554313.	1.3	32
2648	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 6145-6157.	1.0	14
2649	Association Between the Efficacy of Pembrolizumab and Low STK11/LKB1 Expression in High-PD-L1-expressing Non-small-cell Lung Cancer. <i>In Vivo</i> , 2020, 34, 2997-3003.	0.6	11
2650	Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1167.	1.3	8
2651	Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. <i>Clinical and Translational Medicine</i> , 2020, 10, e118.	1.7	15
2652	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 2495.	1.7	12
2653	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. <i>Nature Communications</i> , 2020, 11, 4520.	5.8	218
2654	<p><p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy<p><p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3625-3649.	2.0	80
2655	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.4	17
2656	<p><p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer<p><p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7229-7241.	1.0	12
2657	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 325-334.	1.1	18
2658	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 70-80.	0.4	3
2659	Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. <i>Cancers</i> , 2020, 12, 2307.	1.7	40
2660	Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. <i>Cancer Control</i> , 2020, 27, 107327482097720.	0.7	5

#	ARTICLE	IF	CITATIONS
2661	PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	1.4	13
2662	PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype. <i>Frontiers in Oncology</i> , 2020, 10, 527385.	1.3	13
2663	Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382097970.	0.8	5
2664	Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP). <i>Frontiers in Oncology</i> , 2020, 10, 588932.	1.3	4
2665	The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>Disease Markers</i> , 2020, 2020, 1-14.	0.6	13
2666	Thymosin $\hat{\alpha}$ 210 promotes tumor-associated macrophages M2 conversion and proliferation via the PI3K/Akt pathway in lung adenocarcinoma. <i>Respiratory Research</i> , 2020, 21, 328.	1.4	18
2667	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. <i>Npj Precision Oncology</i> , 2020, 4, 29.	2.3	11
2668	Bone Scintigraphy in Pembrolizumab-Induced Inflammatory Arthritis. <i>Clinical Nuclear Medicine</i> , 2020, 45, 999-1000.	0.7	2
2669	Radiation and immunotherapy: emerging mechanisms of synergy. <i>Journal of Thoracic Disease</i> , 2020, 12, 7011-7023.	0.6	28
2670	Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9300.	1.8	23
2671	Budget Impact Analysis of Fixed Dose Versus Weight-Based Dosing Regimen of Nivolumab and Pembrolizumab in the Treatment of Non-Small Cell Lung Cancer. <i>Vaccines</i> , 2020, 8, 730.	2.1	6
2672	Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 517-524.	1.0	18
2673	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2020, 12, CD013257.	1.5	30
2674	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. <i>Cancers</i> , 2020, 12, 3173.	1.7	36
2675	Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101584.	1.9	15
2676	Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. <i>Lung Cancer</i> , 2020, 150, 159-163.	0.9	33
2677	Prise en charge des cancers bronchiques non À petites cellules oligomÃ©tastatiques. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, 2S94-2S103.	0.0	0
2678	Radiomics of ¹⁸ F Fluorodeoxyglucose PET/CT Images Predicts Severe Immune-related Adverse Events in Patients with NSCLC. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e190063.	3.0	24

#	ARTICLE	IF	CITATIONS
2679	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 568931.	2.2	100
2680	EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1781-1789.	1.2	13
2681	Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 961-973.	2.7	21
2682	Two Malignancies With Differential Responses to Immune Checkpoint Inhibitors: A Case Report. <i>Anticancer Research</i> , 2020, 40, 2821-2826.	0.5	3
2683	Stereotactic body radiation therapy (SBRT) in the management of pulmonary spindle cell carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e234779.	0.2	3
2684	Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition. <i>Annals of Translational Medicine</i> , 2020, 8, 555-555.	0.7	8
2685	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1221.	1.7	46
2686	Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review. <i>Translational Lung Cancer Research</i> , 2020, 9, 379-388.	1.3	4
2687	Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer. <i>Lung Cancer Management</i> , 2020, 9, LMT31.	1.5	19
2688	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. <i>British Journal of Cancer</i> , 2020, 123, 207-215.	2.9	50
2689	Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. <i>British Journal of Cancer</i> , 2020, 123, 392-402.	2.9	28
2690	Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2020, 80, 883-892.	4.9	5
2691	Intervention strategies for microbial therapeutics in cancer immunotherapy. <i>Immuno-Oncology Technology</i> , 2020, 6, 9-17.	0.2	8
2692	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
2693	The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 410-413.	1.3	0
2694	Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab. <i>Immunotherapy</i> , 2020, 12, 629-633.	1.0	6
2695	FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1612-1623.	1.0	19
2696	B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. <i>International Journal of Biological Sciences</i> , 2020, 16, 1767-1773.	2.6	148

#	ARTICLE	IF	CITATIONS
2697	Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in non-small-cell lung cancer. <i>Clinical and Translational Medicine</i> , 2020, 10, 331-336.	1.7	12
2698	Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 786-795.	5.1	419
2699	Immune Escape Mediated by Exosomal PD-L1 in Cancer. <i>Advanced Biology</i> , 2020, 4, e2000017.	3.0	19
2700	Multiplex digital spatial profiling of proteins and RNA in fixed tissue. <i>Nature Biotechnology</i> , 2020, 38, 586-599.	9.4	509
2701	Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. <i>Oncologist</i> , 2020, 25, 702-711.	1.9	17
2702	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	0.6	19
2703	The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. <i>Journal of Thoracic Disease</i> , 2020, 12, 1520-1528.	0.6	52
2704	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 372-381.	1.2	51
2705	Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1753-1768.	1.1	7
2706	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2209-2221.	2.0	60
2707	Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines. <i>Nature Biomedical Engineering</i> , 2020, 4, 636-648.	11.6	44
2708	Biomarkers for immunotherapy for treatment of glioblastoma. , 2020, 8, e000348.		33
2709	Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma. <i>Current Opinion in Immunology</i> , 2020, 64, 88-109.	2.4	14
2710	Acquired Resistance to Immune Checkpoint Blockade Therapies. <i>Cancers</i> , 2020, 12, 1161.	1.7	9
2711	Identification and Analysis of Dysfunctional Genes and Pathways in CD8+ T Cells of Non-Small Cell Lung Cancer Based on RNA Sequencing. <i>Frontiers in Genetics</i> , 2020, 11, 352.	1.1	6
2712	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. <i>Cancers</i> , 2020, 12, 1153.	1.7	4
2713	HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1425.	1.0	6
2714	Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer. , 2020, 8, e000349.		19

#	ARTICLE	IF	CITATIONS
2715	The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses. <i>Frontiers in Immunology</i> , 2020, 11, 940.	2.2	423
2716	Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors. <i>International Journal of Cancer</i> , 2020, 147, 2996-3006.	2.3	36
2717	The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer. <i>Current Oncology Reports</i> , 2020, 22, 54.	1.8	20
2718	Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 226-231.	1.0	21
2719	Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma. <i>European Journal of Cancer</i> , 2020, 132, 150-158.	1.3	28
2720	Immune checkpoint inhibitor-related dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1255-1268.	0.6	221
2721	Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 187-198.	0.4	19
2722	Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. <i>Experimental Hematology and Oncology</i> , 2020, 9, 10.	2.0	48
2724	Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 681-694.	2.1	7
2725	Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. <i>Thoracic Cancer</i> , 2020, 11, 1955-1962.	0.8	16
2726	RAS-targeted therapies: is the undruggable drugged?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 533-552.	21.5	569
2727	The efficacy and safety comparison of PD-1/PD-L1 antibody, chemotherapy and supportive treatment for pretreated advanced esophagogastric cancer: a network meta-analysis. <i>Annals of Palliative Medicine</i> , 2020, 9, 1770-1781.	0.5	5
2728	Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients' Profiles with Dynamic Mathematical Models. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 515-527.	2.3	14
2729	Design, synthesis and biological evaluation of 2-methyl-(1,1'-biphenyl)-pyrimidine conjugates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127328.	1.0	7
2730	Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer. <i>Lung Cancer</i> , 2020, 146, 36-41.	0.9	12
2731	Rational Cancer Treatment Combinations: An Urgent Clinical Need. <i>Molecular Cell</i> , 2020, 78, 1002-1018.	4.5	95
2732	Predicting tumour mutational burden from histopathological images using multiscale deep learning. <i>Nature Machine Intelligence</i> , 2020, 2, 356-362.	8.3	52
2733	Immuno-Oncology, Imaging Biomarkers and Response to Chemotherapy in Cancer Treatment. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
2734	Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16072-16082.	3.3	60
2735	Cardiac Monitoring for Thoracic Radiation Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 249-256.	0.6	5
2736	Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities. Critical Reviews in Oncology/Hematology, 2020, 152, 102983.	2.0	11
2737	Mitoribosome Defect in Hepatocellular Carcinoma Promotes an Aggressive Phenotype with Suppressed Immune Reaction. IScience, 2020, 23, 101247.	1.9	9
2738	Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2020, , .	0.7	5
2739	Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 4441.	1.8	20
2740	Imaging-Based Prediction of Molecular Therapy Targets in NSCLC by Radiogenomics and AI Approaches: A Systematic Review. Diagnostics, 2020, 10, 359.	1.3	51
2741	Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy. Diagnostic Pathology, 2020, 15, 67.	0.9	22
2742	Immunotherapy in Advanced Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 400-408.	0.8	4
2743	Long-term survivors with immunotherapy in advanced NSCLC: is "cure"™ within reach?. Translational Cancer Research, 2020, 9, 409-414.	0.4	3
2744	Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 4030.	1.8	7
2745	Advances in the Treatment of Non-Small Cell Lung Cancer. Clinics in Chest Medicine, 2020, 41, 237-247.	0.8	50
2746	Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden. Pathology Research and Practice, 2020, 216, 153043.	1.0	21
2747	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 386-399.	0.8	3
2748	Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature. Cancer Investigation, 2020, 38, 365-371.	0.6	8
2749	Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer: A Stimulating Partnership. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 360-368.	0.8	2
2750	MDSC subtypes and CD39 expression on CD8 ⁺ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. European Journal of Immunology, 2020, 50, 1810-1819.	1.6	57
2751	Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion. Clinical Colorectal Cancer, 2020, 19, 165-177.	1.0	15

#	ARTICLE	IF	CITATIONS
2752	Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2979-2988.	1.2	6
2753	The top 100 cited articles in lung cancer – a bibliometric analysis. <i>Wspolczesna Onkologia</i> , 2020, 24, 17-28.	0.7	7
2754	Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 748.	1.3	20
2755	Immunotherapy as a second-line or later treatment modality for advanced non-small cell lung cancer: A review of safety and efficacy. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 103009.	2.0	10
2756	Factors associated with ocular adverse event after immune checkpoint inhibitor treatment. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2441-2452.	2.0	13
2757	Diabetes mellitus type 2 is associated with increased tumor expression of programmed death-ligand 1 (PD-L1) in surgically resected non-small cell lung cancer – A matched case-control study. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100170.	0.7	5
2758	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
2759	ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. <i>Cancer Cell</i> , 2020, 37, 324-339.e8.	7.7	126
2760	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 364.	2.2	50
2761	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	0.8	710
2762	PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC. <i>Chinese Clinical Oncology</i> , 2020, 9, 60-60.	0.4	5
2763	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
2764	Immune-Based Approaches for the Treatment of Pediatric Malignancies. <i>Annual Review of Cancer Biology</i> , 2020, 4, 353-370.	2.3	7
2765	Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1229-1236.	2.0	18
2766	Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	229
2767	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β 2 and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1210-1222.	0.5	119
2768	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
2769	Drastic healing process after pembrolizumab monotherapy in a case of advanced squamous cell carcinoma with severe bronchial stenosis observed over a two-year period using continuous bronchoscopy: A case report. <i>Thoracic Cancer</i> , 2020, 11, 1339-1343.	0.8	3

#	ARTICLE	IF	CITATIONS
2770	KEYNOTE-032: A Randomized Phase I Study of Pembrolizumab in Chinese Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 650-e1145.	1.9	11
2771	ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, 609-618.	0.6	100
2772	Check point inhibitors and autoimmunity: Why endocrinopathies and who is prone to?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101411.	2.2	16
2773	Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 197.	1.3	9
2774	Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors. <i>Current Treatment Options in Oncology</i> , 2020, 21, 29.	1.3	11
2775	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
2776	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 895-904.	5.2	111
2777	A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 55-60.	1.3	18
2778	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. <i>Frontiers in Medicine</i> , 2020, 7, 90.	1.2	31
2779	Cost-Utility Analysis of Pembrolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer With Different PD-L1 Expression Levels. <i>Oncology Research</i> , 2020, 28, 117-125.	0.6	24
2780	PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 617-622.	0.6	14
2781	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
2782	Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2020, 21, 655-663.	5.1	335
2783	T cell-engaging therapies – BiTEs and beyond. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 418-434.	12.5	296
2784	Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2020, 235, 6496-6506.	2.0	19
2785	Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment. <i>Case Reports in Oncology</i> , 2020, 13, 85-90.	0.3	9
2786	Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications. <i>Future Oncology</i> , 2020, 16, 497-506.	1.1	16
2787	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 159.	2.2	73

#	ARTICLE	IF	CITATIONS
2788	The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2020, 19, 233-242.	1.0	7
2789	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. Frontiers in Immunology, 2020, 11, 223.	2.2	54
2790	Influence of Estrogen on the NSCLC Microenvironment: A Comprehensive Picture and Clinical Implications. Frontiers in Oncology, 2020, 10, 137.	1.3	53
2791	Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients – A systematic review. Critical Reviews in Oncology/Hematology, 2020, 153, 103035.	2.0	5
2792	Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma. American Journal of Clinical Pathology, 2020, 154, 517-524.	0.4	4
2793	–Analysis of Patient Preferences in Lung Cancer – Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects–. Patient Preference and Adherence, 2020, Volume 14, 927-937.	0.8	39
2794	Combination Therapies in Solid Tumour Oncology. , 2020, , 515-578.		0
2795	Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells. Chinese Journal of Natural Medicines, 2020, 18, 517-525.	0.7	13
2796	An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia. British Journal of Cancer, 2020, 123, 919-931.	2.9	0
2797	Limited MOMP, ATM, and their roles in carcinogenesis and cancer treatment. Cell and Bioscience, 2020, 10, 81.	2.1	8
2798	Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. Cancer Cell, 2020, 38, 400-411.e6.	7.7	70
2799	The immunotherapy revolution in genitourinary malignancies. Immunotherapy, 2020, 12, 819-831.	1.0	10
2800	Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020. Kidney360, 2020, 1, 130-140.	0.9	62
2801	Article Commentary: Cancer Immunotherapy for the General Surgeon. American Surgeon, 2020, 86, 284-292.	0.4	0
2802	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. Nanomaterials, 2020, 10, 1274.	1.9	26
2803	Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti-PD-1 Antibodies in the Treatment of Lung Cancer. Clinical Therapeutics, 2020, 42, 1612-1616.	1.1	4
2804	Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study. Lung Cancer, 2020, 147, 21-25.	0.9	10
2805	A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2020, 26, 5188-5197.	3.2	15

#	ARTICLE	IF	CITATIONS
2806	Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1763.	1.7	17
2807	Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review. <i>Frontiers in Immunology</i> , 2020, 11, 1036.	2.2	10
2808	Immunomodulatory effects of renin-angiotensin system inhibitors on T lymphocytes in mice with colorectal liver metastases. , 2020, 8, e000487.		20
2809	MiR-222-3p Promotes Cell Proliferation and Inhibits Apoptosis by Targeting PUMA (BBC3) in Non-Small Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382092255.	0.8	21
2810	Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
2811	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. <i>Cancers</i> , 2020, 12, 1826.	1.7	46
2812	Organoid Models of Tumor Immunology. <i>Trends in Immunology</i> , 2020, 41, 652-664.	2.9	210
2813	The 5-Ws of immunotherapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103041.	2.0	13
2814	Early stage triple negative breast cancer: Management and future directions. <i>Seminars in Oncology</i> , 2020, 47, 201-208.	0.8	23
2815	The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis. <i>Journal of Biomedical Science</i> , 2020, 27, 77.	2.6	89
2816	Is there hope in improving 5-year overall survival? a review of 5-year overall survival data from KEYNOTE-001. <i>Annals of Translational Medicine</i> , 2020, 8, 728-728.	0.7	0
2817	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. <i>Frontiers in Immunology</i> , 2020, 11, 1243.	2.2	30
2818	PET/CT and the Response to Immunotherapy in Lung Cancer. <i>Current Radiopharmaceuticals</i> , 2020, 13, 177-184.	0.3	17
2819	Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1217-1225.	1.2	42
2820	Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate. <i>Scientific Reports</i> , 2020, 10, 1852.	1.6	65
2821	Identification immunophenotyping of lung adenocarcinomas based on the tumor microenvironment. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 4569-4579.	1.2	13
2822	Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	3
2823	Introducing online multicolumn two-dimensional liquid chromatography screening for facile selection of stationary and mobile phase conditions in both dimensions. <i>Journal of Chromatography A</i> , 2020, 1622, 460895.	1.8	33

#	ARTICLE	IF	CITATIONS
2824	Blood and tissue biomarker analysis in dogs with osteosarcoma treated with palliative radiation and intra-tumoral autologous natural killer cell transfer. <i>PLoS ONE</i> , 2020, 15, e0224775.	1.1	15
2825	Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, e536-e544.	1.9	39
2826	Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e405-e414.	1.1	21
2827	Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 667-683.	1.0	24
2828	The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 519.	1.0	26
2829	Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. <i>Annals of Oncology</i> , 2020, 31, 599-608.	0.6	183
2830	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	0.9	17
2831	High Serum OX40 and OX40 Ligand (OX40L) Levels Correlate with Reduced Survival in Patients with Advanced Lung Adenocarcinoma. <i>Oncology</i> , 2020, 98, 303-310.	0.9	14
2832	Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. <i>Journal of Drug Targeting</i> , 2020, 28, 861-872.	2.1	11
2833	Oncolytic poxvirus CF33-hNIS- ¹²⁵ I-F14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model. <i>Oncolimmunology</i> , 2020, 9, 1729300.	2.1	29
2834	A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab. <i>Oncolimmunology</i> , 2020, 9, 1731072.	2.1	30
2835	Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. <i>Medicine (United States)</i> , 2020, 99, e19059.	0.4	30
2836	Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. <i>British Journal of Cancer</i> , 2020, 122, 1205-1210.	2.9	24
2837	Anticancer effects of chemokine-directed antigen delivery to a cross-presenting dendritic cell subset with immune checkpoint blockade. <i>British Journal of Cancer</i> , 2020, 122, 1185-1193.	2.9	14
2838	Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 601-610.	1.5	2
2839	Revisiting Immunotherapy: A Focus on Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 1615-1623.	0.4	120
2840	Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression $\geq 50\%$. <i>Annals of Oncology</i> , 2020, 31, 404-411.	0.6	79
2841	Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report. <i>Thoracic Cancer</i> , 2020, 11, 1094-1098.	0.8	10

#	ARTICLE	IF	CITATIONS
2843	Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1â€™Positive, Advanced Nonâ€™Small-Cell Lung Cancer in the KEYNOTE-010 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1580-1590.	0.8	189
2844	Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on <i>EGFR</i> Mutationâ€™Positive Lung Adenocarcinoma. <i>Tuberculosis and Respiratory Diseases</i> , 2020, 83, 51.	0.7	13
2845	Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies. <i>Journal of the American College of Cardiology</i> , 2020, 75, 620-628.	1.2	49
2846	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020, 8, 11-24.	0.6	68
2847	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. <i>Clinical Imaging</i> , 2020, 63, 35-49.	0.8	3
2848	PD-L1 expression and T cells infiltration in patients with uncommon <i>EGFR</i> -mutant non-small cell lung cancer and the response to immunotherapy. <i>Lung Cancer</i> , 2020, 142, 98-105.	0.9	52
2849	Association Between <i>RET</i> Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study. <i>Clinical Lung Cancer</i> , 2020, 21, e349-e354.	1.1	23
2850	The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents. <i>RSC Medicinal Chemistry</i> , 2020, 11, 293-296.	1.7	3
2851	Longâ€™term response with durvalumab after chemoradiotherapy for pulmonary pleomorphic carcinoma: A case report. <i>Thoracic Cancer</i> , 2020, 11, 1090-1093.	0.8	11
2852	Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report. <i>Internal Medicine</i> , 2020, 59, 1105-1109.	0.3	6
2853	Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer. <i>Medicine (United States)</i> , 2020, 99, e18332.	0.4	1
2854	Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 93-100.	1.7	27
2855	Prognostic Biomarkers for Melanoma Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 25.	1.8	13
2856	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
2857	Association of age with differences in immune related adverse events and survival of patients with advanced nonsmall cell lung cancer receiving pembrolizumab or nivolumab. <i>Journal of Geriatric Oncology</i> , 2020, 11, 807-813.	0.5	18
2858	Cytokines as potential combination agents with PDâ€™1/PDâ€™L1 blockade for cancer treatment. <i>Journal of Cellular Physiology</i> , 2020, 235, 5449-5460.	2.0	42
2859	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58
2860	Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma. <i>Acta Oto-Laryngologica</i> , 2020, 140, 175-180.	0.3	11

#	ARTICLE	IF	CITATIONS
2861	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020, 11, 805-809.	0.8	8
2862	Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3K ⁱ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. <i>Brain Tumor Pathology</i> , 2020, 37, 41-49.	1.1	37
2863	Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis. <i>Cancer Investigation</i> , 2020, 38, 130-138.	0.6	14
2864	Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments. <i>Cancers</i> , 2020, 12, 274.	1.7	53
2865	Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 207-217.	1.4	21
2866	Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 235-245.	0.7	7
2867	Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. <i>Diagnostic Pathology</i> , 2020, 15, 6.	0.9	55
2868	Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era. <i>Cancer Medicine</i> , 2020, 9, 2019-2029.	1.3	17
2869	Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study. <i>Journal of Cancer</i> , 2020, 11, 974-982.	1.2	10
2870	Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 182.	1.7	74
2871	Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1154-1163.	0.8	276
2872	Utility of PD-L1 immunocytochemistry using body fluid cell blocks in patients with non-small cell lung cancer. <i>Diagnostic Cytopathology</i> , 2020, 48, 291-299.	0.5	5
2873	Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma. <i>Pediatric Surgery International</i> , 2020, 36, 137-143.	0.6	14
2874	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <i>BioMed Research International</i> , 2020, 2020, 1-24.	0.9	38
2875	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
2876	Immune Checkpoint Inhibitor-induced Fatal Myositis in a Patient With Squamous Cell Carcinoma and a History of Thymoma. <i>Clinical Lung Cancer</i> , 2020, 21, e246-e249.	1.1	2
2877	Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer. <i>Medicine (United States)</i> , 2020, 99, e19013.	0.4	64
2878	<p></p>Circulating Tumor Cells as a Biomarker to Assist Molecular Diagnosis for Early Stage Non-Small Cell Lung Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 841-854.	0.9	26

#	ARTICLE	IF	CITATIONS
2879	Tumor Timeâ€‘Course Predicts Overall Survival in Nonâ€‘Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Followâ€‘Up Time. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 115-123.	1.3	8
2880	Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Nonâ€‘Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2020, 21, e315-e328.	1.1	29
2881	Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1000-1014.	0.5	68
2882	Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. <i>Medicine (United States)</i> , 2020, 99, e18726.	0.4	23
2883	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 305.	1.7	56
2884	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. <i>Cancer Gene Therapy</i> , 2020, 27, 841-853.	2.2	94
2885	Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3831-3842.	3.2	28
2886	5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 492.	1.3	33
2887	Neurological adverse effects due to programmed death 1 (PD-1) inhibitors. <i>Journal of Neuro-Oncology</i> , 2020, 148, 291-297.	1.4	8
2888	mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand) Tj ETQq1.1 0.784314 rgB / 1.6 10	1.6	10
2889	Design and Analysis of Subgroups with Biopharmaceutical Applications. <i>Emerging Topics in Statistics and Biostatistics</i> , 2020, , .	0.1	5
2890	Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2531.	1.8	56
2891	Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression. <i>International Immunopharmacology</i> , 2020, 83, 106478.	1.7	28
2892	Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment. <i>International Journal of Clinical Oncology</i> , 2020, 25, 801-809.	1.0	115
2893	Advances in theranostic biomarkers for tumor immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2020, 56, 79-90.	2.8	27
2894	Acquired Resistance to Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 37, 443-455.	7.7	444
2895	Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. <i>Current Opinion in Virology</i> , 2020, 40, 19-27.	2.6	14
2896	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. <i>Thyroid</i> , 2020, 30, 1458-1469.	2.4	44

#	ARTICLE	IF	CITATIONS
2897	Programmed Death Ligand 1 Testing of Endobronchial Ultrasoundâ€guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Nonâ€Small Cell Lung Cancer. Journal of Bronchology and Interventional Pulmonology, 2020, 27, 50-57.	0.8	19
2898	Master protocols in immuno-oncology: do novel drugs deserve novel designs?. , 2020, 8, e000475.		17
2899	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an antiâ€PD-1 antibody, in patients with advanced solid tumors. , 2020, 8, e000530.		54
2900	Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. Diagnostics, 2020, 10, 216.	1.3	13
2901	Talkinâ€™ Toxins: From Coleyâ€™s to Modern Cancer Immunotherapy. Toxins, 2020, 12, 241.	1.5	47
2902	A Case of Isolated Adrenocorticotrophic Hormone Deficiency Caused by Pembrolizumab. Case Reports in Oncology, 2020, 13, 200-206.	0.3	15
2903	Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e47-e57.	1.8	30
2904	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
2905	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. British Journal of Pharmacology, 2020, 177, 2889-2903.	2.7	10
2906	EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in nonâ€small cell lung cancer. Journal of the American Society of Cytopathology, 2020, 9, 485-493.	0.2	9
2907	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. Clinical Cancer Research, 2020, 26, 4805-4813.	3.2	12
2908	<scp>PDâ€L1</scp> and <scp>LAG</scp>â€3 expression in advanced cutaneous squamous cell carcinomas. Journal of Cutaneous Pathology, 2020, 47, 882-887.	0.7	14
2909	Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters. Chinese Clinical Oncology, 2020, 9, 19-19.	0.4	6
2910	<p>Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis</p>. OncoTargets and Therapy, 2020, Volume 13, 3085-3091.	1.0	25
2911	Prodrugâ€Based Versatile Nanomedicine for Enhancing Cancer Immunotherapy by Increasing Immunogenic Cell Death. Small, 2020, 16, e2000214.	5.2	73
2912	Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge. Science China Life Sciences, 2020, 63, 1499-1514.	2.3	20
2913	Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1328-1337.	0.5	19
2914	Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples. BMC Cancer, 2020, 20, 344.	1.1	13

#	ARTICLE	IF	CITATIONS
2915	Pembrolizumab for the treatment of programmed deathâ€“ligand 1â€“positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTEâ€“028 study. <i>Cancer</i> , 2020, 126, 3021-3030.	2.0	97
2916	A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. <i>European Journal of Cancer</i> , 2020, 131, 68-75.	1.3	103
2917	Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. <i>Cancer Communications</i> , 2020, 40, 135-153.	3.7	339
2919	Immunotherapy in Lung Cancer: From a Minor God to the Olympus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 69-92.	0.8	15
2920	Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. <i>European Journal of Cancer</i> , 2020, 130, 182-192.	1.3	46
2921	Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100020.	0.6	23
2922	PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 38.	7.1	75
2923	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , 2020, 87, E281-E288.	0.6	22
2924	Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. , 2020, 8, e000441.		28
2925	SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Antiâ€“PD-1â€“Resistant Model of Nonâ€“Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 883-894.	1.6	48
2926	Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. <i>Trials</i> , 2020, 21, 352.	0.7	7
2927	Hyperprogression Under Immune Checkpoint-Based Immunotherapyâ€“Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. <i>Cancers</i> , 2020, 12, 804.	1.7	19
2928	Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients. <i>Cancers</i> , 2020, 12, 863.	1.7	18
2929	RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1000.	1.0	6
2930	Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e511-e515.	1.1	10
2931	Nanoparticle mediated cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2021, 69, 307-324.	4.3	48
2932	Implementing â€“Goals of Careâ€™ discussion and palliative care referral for patients with advanced lung cancer: an outpatientâ€“based pilot project. <i>Internal Medicine Journal</i> , 2021, 51, 540-547.	0.5	1
2933	Emerging role of microbiota in immunomodulation and cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2021, 70, 37-52.	4.3	19

#	ARTICLE	IF	CITATIONS
2934	Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status. <i>Journal of Clinical Pathology</i> , 2021, 74, 123-128.	1.0	16
2935	ZFH3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 137-151.	2.0	69
2936	Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 28-36.	0.6	8
2937	Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided fine needle aspiration derived non-small cell lung carcinoma samples. <i>Diagnostic Cytopathology</i> , 2021, 49, 355-362.	0.5	6
2938	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
2939	Biomarkers for predicting the outcome of various cancer immunotherapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103161.	2.0	10
2940	Metabolic interventions: A new insight into the cancer immunotherapy. <i>Archives of Biochemistry and Biophysics</i> , 2021, 697, 108659.	1.4	8
2941	NAD ⁺ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. <i>Cell Metabolism</i> , 2021, 33, 110-127.e5.	7.2	137
2942	Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 299-309.	0.5	72
2943	Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). <i>Clinical and Translational Science</i> , 2021, 14, 277-287.	1.5	5
2944	Use of Multi-Site Radiation Therapy for Systemic Disease Control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 352-364.	0.4	34
2945	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101491.	0.7	18
2946	Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 350-359.	1.8	122
2947	Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1654.	3.3	21
2948	Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. <i>Science China Life Sciences</i> , 2021, 64, 548-562.	2.3	29
2949	Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 405-415.	2.0	8
2950	Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e125-e131.	0.7	3
2951	Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma. <i>Histopathology</i> , 2021, 78, 381-391.	1.6	13

#	ARTICLE	IF	CITATIONS
2952	Artificial Intelligence in Lung Cancer: Bridging the Gap Between Computational Power and Clinical Decision-Making. <i>Canadian Association of Radiologists Journal</i> , 2021, 72, 86-97.	1.1	24
2953	Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 245-251.	1.2	47
2954	PD-L1 expression in tongue squamous cell carcinoma. <i>Medical Molecular Morphology</i> , 2021, 54, 52-59.	0.4	6
2955	Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 140-149.	2.0	15
2956	Targeting metabolism to reverse Tâ€cell exhaustion in chronic viral infections. <i>Immunology</i> , 2021, 162, 135-144.	2.0	23
2957	Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Nonâ€Small-Cell Lung Cancer in the United States. <i>Clinical Lung Cancer</i> , 2021, 22, e35-e47.	1.1	6
2958	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2021, 219, 107694.		79
2959	Current Microsatellite Instability Testing in Management of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, e12-e20.	1.0	32
2960	Expression of PD-L1, cancer stem cell and epithelialâ€mesenchymal transition phenotype in non-small cell lung cancer. <i>Pathology</i> , 2021, 53, 239-246.	0.3	10
2961	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Antiâ€PD-(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1019-1028.	3.2	58
2962	Improving patient selection for immunoâ€oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center. <i>International Journal of Cancer</i> , 2021, 148, 2502-2511.	2.3	7
2963	The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PDâ€L1. <i>Advanced Science</i> , 2021, 8, 2001596.	5.6	34
2964	Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. <i>Pathology</i> , 2021, 53, 462-469.	0.3	11
2965	High expression of MYEOV reflects poor prognosis in non-small cell lung cancer. <i>Gene</i> , 2021, 770, 145337.	1.0	11
2966	Understanding the tumor microenvironment for effective immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 1474-1498.	5.0	130
2967	Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 1151-1158.	1.3	7
2968	Preâ€existing interstitial lung disease does not affect prognosis in nonâ€small cell lung cancer patients with <scp>PDâ€L1</scp> expression â‰¥50% on firstâ€line pembrolizumab. <i>Thoracic Cancer</i> , 2021, 12, 304-313.	0.8	17
2970	Pembrolizumabâ€induced vitiligo in a patient with lung adenocarcinoma: A case report. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2614-2618.	1.1	9

#	ARTICLE	IF	CITATIONS
2971	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 223-249.	9.6	956
2972	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103160.	2.0	26
2973	Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker. <i>AAPS Journal</i> , 2021, 23, 5.	2.2	22
2974	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory FoRECATT study. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1583-1592.	2.0	12
2975	Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1 positive locally advanced or metastatic non-small cell lung cancer: KEYNOTE-042 China Study. <i>International Journal of Cancer</i> , 2021, 148, 2313-2320.	2.3	60
2976	Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. <i>Modern Pathology</i> , 2021, 34, 532-541.	2.9	63
2977	Intrahepatic cholangiocarcinoma: MRI texture signature as predictive biomarkers of immunophenotyping and survival. <i>European Radiology</i> , 2021, 31, 3661-3672.	2.3	20
2978	Radiotherapy and Immunotherapy Combinations for Lung Cancer. <i>Current Oncology Reports</i> , 2021, 23, 4.	1.8	11
2979	Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113001.	2.6	27
2980	The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2021, 79, 783-792.	0.9	46
2981	2020 Innovation-Based Optimism for Lung Cancer Outcomes. <i>Oncologist</i> , 2021, 26, e454-e472.	1.9	17
2982	Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2021, 32, 395-403.	0.6	53
2983	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 419-427.	0.5	33
2984	The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis. <i>Frontiers in Oncology</i> , 2020, 10, 608609.	1.3	18
2985	The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. <i>Oncologist</i> , 2021, 26, e1036-e1049.	1.9	30
2986	KRAS G12V mutation upregulates PD-L1 expression via TGF β ² /EMT signaling pathway in human non-small cell lung cancer. <i>Cell Biology International</i> , 2021, 45, 795-803.	1.4	19
2987	How wide is the application of genetic big data in biomedicine. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111074.	2.5	5
2988	Comparative Efficacy and Safety of PD-1/PD-L1 Inhibitors for Patients with Solid Tumors: A Systematic Review and Bayesian Network Meta-analysis. <i>Journal of Cancer</i> , 2021, 12, 1133-1143.	1.2	14

#	ARTICLE	IF	CITATIONS
2989	Gastrointestinal tract metastasis of lung cancer: The PD-L1 expression and correlated clinicopathological variables. <i>Pathology International</i> , 2021, 71, 33-41.	0.6	6
2990	Self-Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002080.	3.9	20
2991	Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 229-238.	1.1	14
2992	Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 887-900.	2.1	24
2993	Institutional-Level Differences in Quality and Outcomes of Lung Cancer Resections in the United States. <i>Chest</i> , 2021, 159, 1630-1641.	0.4	10
2994	Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 580045.	1.3	2
2995	A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. <i>Kidney International Reports</i> , 2021, 6, 66-77.	0.4	84
2996	CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50 . <i>Cancer Science</i> , 2021, 112, 72-80.	1.7	9
2997	Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials. <i>Cancer</i> , 2021, 127, 777-786.	2.0	21
2998	Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice. <i>Cancer Letters</i> , 2021, 498, 121-129.	3.2	35
2999	In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. <i>Molecular Imaging and Biology</i> , 2021, 23, 241-249.	1.3	23
3000	Interstitial nephritis with pembrolizumab: A case report and review. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1046-1051.	0.5	3
3001	<i>SMARCA4</i> mutations in <i>KRAS</i> mutant lung adenocarcinoma: a multicohort analysis. <i>Molecular Oncology</i> , 2021, 15, 462-472.	2.1	29
3002	Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens. <i>Diagnostic Cytopathology</i> , 2021, 49, 219-225.	0.5	10
3003	Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model. <i>Cancer Letters</i> , 2021, 498, 111-120.	3.2	5
3004	Statistical Considerations for Sequential Analysis of the Restricted Mean Survival Time for Randomized Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 210-218.	0.6	7
3005	Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater. <i>International Journal of Clinical Oncology</i> , 2021, 26, 78-86.	1.0	3
3006	Predictive Biomarker Identification for Biopharmaceutical Development. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 239-247.	0.6	3

#	ARTICLE	IF	CITATIONS
3007	Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 713-720.	2.0	44
3008	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 867-887.	2.4	9
3009	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. <i>Clinical Cancer Research</i> , 2021, 27, 665-679.	3.2	69
3010	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. <i>Oncology</i> , 2021, 99, 365-372.	0.9	6
3011	The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 757-764.	0.9	0
3012	Targeted Therapies in Cancer Treatment. , 2021, , 57-78.		1
3013	Metastatic cancer: How one can address the therapeutic challenge. , 2021, , 485-514.		0
3014	Medical costs of Japanese lung cancer patients during end-of-life care. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 769-777.	0.6	4
3015	Modulation of Signaling Pathways by Immunotherapeutics in Lung Cancer. , 2021, , 241-261.		0
3016	Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study. <i>Journal of Cancer</i> , 2021, 12, 4478-4487.	1.2	0
3017	Combining radiation therapy and immunotherapy for lung cancers: a narrative review. <i>Shanghai Chest</i> , 2021, 5, 10-10.	0.3	4
3018	Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100297.	0.7	4
3019	Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100427.	0.7	5
3020	Immunotherapy-related pneumonitis and bacterial pneumonia after the successful treatment of metastatic malignant melanoma with pembrolizumab. <i>Medicine (United States)</i> , 2021, 100, e24018.	0.4	3
3021	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
3022	Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 31-44.	1.4	23
3023	Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. <i>Gastroenterology Report</i> , 2021, 9, 560-570.	0.6	10
3024	Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors. <i>Journal of Veterinary Science</i> , 2021, 22, e75.	0.5	3

#	ARTICLE	IF	CITATIONS
3025	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab012.	1.4	16
3026	Development of a prognostic model based on an immunogenomic landscape analysis of medulloblastoma. <i>Bioscience Reports</i> , 2021, 41, .	1.1	3
3027	Immun-Checkpoint-Blockade bei fortgeschrittenem kutanen Plattenepithelkarzinom: Was wissen wir derzeit im Jahr 2020?. <i>Karger Kompass Dermatologie</i> , 2021, 9, 114-128.	0.0	0
3028	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. <i>Oncolmunology</i> , 2021, 10, 1950411.	2.1	22
3029	Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 778-785.	0.6	4
3030	The optimal design of clinical trials with potential biomarker effects: A novel computational approach. <i>Statistics in Medicine</i> , 2021, 40, 1752-1766.	0.8	4
3031	LncRNA GAS6-AS2 promotes non-small-cell lung cancer cell proliferation via regulating miR-144-3p/ MAPK6 axis. <i>Cell Cycle</i> , 2021, 20, 179-193.	1.3	9
3032	Cancer of Unknown Primary: Challenges and Progress in Clinical Management. <i>Cancers</i> , 2021, 13, 451.	1.7	24
3033	CXCR4 uses STAT3-mediated slug expression to maintain radioresistance of non-small cell lung cancer cells: emerges as a potential prognostic biomarker for lung cancer. <i>Cell Death and Disease</i> , 2021, 12, 48.	2.7	16
3034	Core needle biopsy for screening detected lung cancer“ does it capture all in light of tumor heterogeneity?“a narrative review. <i>Shanghai Chest</i> , 0, .	0.3	0
3035	Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492110355.	0.6	45
3036	Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101390.	0.2	3
3037	Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. <i>Oncolmunology</i> , 2021, 10, 1957603.	2.1	10
3038	Immunotherapy for glioblastoma as a means to overcome resistance to standard therapy. , 2021, , 635-665.		0
3039	Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2389-2400.	2.0	11
3040	Clinical pattern of failure after a durable response to immune checkpoint inhibitors in non-small cell lung cancer patients. <i>Scientific Reports</i> , 2021, 11, 2514.	1.6	17
3041	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
3042	Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression. <i>MAbs</i> , 2021, 13, 1868066.	2.6	2

#	ARTICLE	IF	CITATIONS
3043	Recent advances in drug formulation development for targeting lung cancer. , 2021, , 75-100.		0
3044	PET-Based Volumetric Biomarkers for Risk Stratification of Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2021, 11, 210.	1.3	14
3045	Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget's Disease. <i>Anticancer Research</i> , 2021, 41, 219-226.	0.5	3
3046	Update on the role of pembrolizumab in patients with unresectable or metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110244.	1.4	8
3047	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , 2021, 9, 33-33.	0.7	16
3048	Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. <i>Translational Lung Cancer Research</i> , 2021, 10, 2614-2624.	1.3	11
3049	High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2021, 10, 304-313.	1.3	23
3050	The role of second-generation EGFR inhibitors in lung cancer therapy in the realities of modern clinical practice. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2021, 10, 75.	0.0	0
3051	Turning cold tumors into hot tumors by improving T-cell infiltration. <i>Theranostics</i> , 2021, 11, 5365-5386.	4.6	324
3052	Pan-Cancer Molecular Characterization of m6A Regulators and Immunogenomic Perspective on the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 618374.	1.3	28
3053	Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon. <i>SAGE Open Medicine</i> , 2021, 9, 205031212110437.	0.7	1
3054	Recent applications and strategies in nanotechnology for lung diseases. <i>Nano Research</i> , 2021, 14, 2067-2089.	5.8	49
3055	Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2021, 8, 18.	0.7	3
3056	Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports. <i>Respiratory Medicine Case Reports</i> , 2021, 33, 101469.	0.2	0
3057	Efficacy and safety of immune checkpoint inhibitor monotherapy in elderly patients with non-small cell lung cancer. <i>Aging Medicine (Milton (N S W))</i> , 2021, 4, 42-46.	0.9	4
3059	Gold digging: Searching for gut microbiota that enhances antitumor immunity. <i>Journal of Cellular Physiology</i> , 2021, 236, 5495-5511.	2.0	2
3060	Association of acute interstitial nephritis with nivolumab in renal cell carcinoma: A case report. <i>Indian Journal of Nephrology</i> , 2021, 31, 303.	0.2	1
3061	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0

#	ARTICLE	IF	CITATIONS
3062	Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 355-367.	1.3	26
3063	Immuno-Oncology in Pancreatic Cancer. , 2021, , 287-304.		2
3064	Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma. <i>Oncotarget</i> , 2021, 12, 2177-2187.	0.8	7
3065	Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. <i>Theranostics</i> , 2021, 11, 4957-4974.	4.6	4
3066	Innovative immunotherapy targeting at PD-1/PD-L1 signaling pathway: mechanism, efficacy and safety analysis of monotherapy and combination therapies in non-small cell lung cancer (NSCLC) treatment. <i>E3S Web of Conferences</i> , 2021, 267, 02026.	0.2	0
3067	Severe colitis induced by pembrolizumab in a patient with advanced hypopharyngeal squamous cell carcinoma: A case report of an immune-related adverse event. <i>Journal of Cancer Research and Practice</i> , 2021, 8, 113.	0.2	1
3068	Immunotherapy in colorectal cancer. <i>Advances in Cancer Research</i> , 2021, 151, 137-196.	1.9	18
3069	Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry. <i>Cancer Medicine</i> , 2021, 10, 2054-2062.	1.3	1
3070	Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection. <i>Nature Nanotechnology</i> , 2021, 16, 538-548.	15.6	165
3071	Progress of exosomes in the diagnosis and treatment of lung cancer. <i>Biomedicine and Pharmacotherapy</i> , 2021, 134, 111111.	2.5	89
3072	Lights and Shadows in Immuno-Oncology Drug Development. <i>Cancers</i> , 2021, 13, 691.	1.7	0
3073	Analysis of Molecular Mechanism of YiqiChutan Formula Regulating DLL4-Notch Signaling to Inhibit Angiogenesis in Lung Cancer. <i>BioMed Research International</i> , 2021, 2021, 1-10.	0.9	4
3074	Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 776-789.	1.3	6
3075	Tislelizumab uniquely binds to the CC α 2 loop of PD α 1 with slow ϵ dissociated rate and complete PD α 1 blockage. <i>FEBS Open Bio</i> , 2021, 11, 782-792.	1.0	32
3076	ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	107
3077	Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential. <i>Frontiers in Oncology</i> , 2020, 10, 593848.	1.3	12
3078	The evolving landscape of immunotherapy in solid tumors. <i>Journal of Surgical Oncology</i> , 2021, 123, 798-806.	0.8	17
3079	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	4.3	21

#	ARTICLE	IF	CITATIONS
3080	Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. <i>Lancet</i> , The, 2021, 397, 592-604.	6.3	441
3081	Immunotherapy for the treatment of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 760-774.	0.8	18
3082	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. <i>Blood Advances</i> , 2021, 5, 1069-1080.	2.5	20
3083	Development and validation of a multigene variant profiling assay to guide targeted and immunotherapy selection in solid tumors. <i>PLoS ONE</i> , 2021, 16, e0246048.	1.1	0
3084	Systemic Immune-Inflammation Index Is a Prognostic Predictor in Patients with Intrahepatic Cholangiocarcinoma Undergoing Liver Transplantation. <i>Mediators of Inflammation</i> , 2021, 2021, 1-7.	1.4	11
3085	Immunotherapeutic advances in gastric cancer. <i>Surgery Today</i> , 2021, 51, 1727-1735.	0.7	14
3086	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
3087	Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. <i>Cancers</i> , 2021, 13, 729.	1.7	3
3088	Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. , 2021, 9, e001999.		26
3089	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. <i>Frontiers in Oncology</i> , 2020, 10, 600573.	1.3	100
3090	Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 623424.	1.1	20
3091	The Effectiveness and Safety of Cinobufotalin Injection as an Adjunctive Treatment for Lung Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-17.	0.5	7
3092	Clinical impact of postâ€progression survival on overall survival in patients receiving nivolumab monotherapy as a secondâ€line treatment for advanced nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 1171-1179.	0.8	1
3093	Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune-Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. <i>American Journal of Roentgenology</i> , 2021, , 1-9.	1.0	7
3094	Combination immunotherapy strategies for glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 151, 375-391.	1.4	38
3095	PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. <i>Npj Precision Oncology</i> , 2021, 5, 10.	2.3	57
3096	Smoking status during firstâ€line immunotherapy and chemotherapy in <sc>NSCLC</sc> patients: A caseâ€control matched analysis from a large multicenter study. <i>Thoracic Cancer</i> , 2021, 12, 880-889.	0.8	30
3097	Role of EIF4G1 network in nonâ€small cell lung cancers (NSCLC) cell survival and disease progression. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 2795-2805.	1.6	11

#	ARTICLE	IF	CITATIONS
3098	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	1.6	71
3099	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	1.7	7
3100	Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100140.	0.6	11
3101	CD38 and Regulation of the Immune Response Cells in Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	25
3102	Immunotherapy of gastric cancer: Past, future perspective and challenges. <i>Pathology Research and Practice</i> , 2021, 218, 153322.	1.0	51
3103	Combination of radiation therapy for brain metastasis and anti-PD-1/PD-L1 treatment in non-small cell lung cancer: two cases and review of the literature. <i>Anti-Cancer Drugs</i> , 2021, 32, 460-464.	0.7	1
3104	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 72.	7.1	191
3105	Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade. <i>Cancer Research</i> , 2021, 81, 1775-1787.	0.4	25
3106	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 144-150.	0.6	8
3107	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15
3108	Immunotherapy in lung cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 718-729.	0.8	7
3109	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021, 152, 165-173.	0.9	23
3110	Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1181-1200.	1.4	68
3111	BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 603223.	1.3	9
3112	Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma. <i>Cancers</i> , 2021, 13, 1065.	1.7	5
3113	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 501-509.	1.5	4
3114	Inmunoterapia, cáncer y PET. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.0	0
3115	Long-term efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients harboring MET exon 14 skipping mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1065-1072.	1.0	3

#	ARTICLE	IF	CITATIONS
3116	Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113170.	2.6	32
3117	The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 975-985.	1.9	79
3118	Low-dose pembrolizumab in the treatment of advanced non-small cell lung cancer. <i>International Journal of Cancer</i> , 2021, 149, 169-176.	2.3	24
3119	Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway. <i>BioMed Research International</i> , 2021, 2021, 1-6.	0.9	4
3120	An in vivo method for diversifying the functions of therapeutic antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	3
3121	Oncolytic vaccinia virus induces a novel phenotype of CD8+ effector T cells characterized by high ICOS expression. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 422-432.	2.0	5
3122	A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer. <i>Journal of Pancreatic Cancer</i> , 2021, 7, 8-19.	1.6	8
3123	Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways. , 2021, 9, e002355.		6
3124	Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma. <i>SKIN the Journal of Cutaneous Medicine</i> , 2021, 5, 108-117.	0.1	1
3125	Immunotherapy and predictive immunologic profile: the tip of the iceberg. <i>Medical Oncology</i> , 2021, 38, 51.	1.2	4
3126	Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2259-2263.	0.2	5
3127	Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 639947.	1.3	24
3128	Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. <i>Neoplasia</i> , 2021, 23, 281-293.	2.3	18
3129	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 537-547.	1.0	9
3130	Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component. <i>Translational Lung Cancer Research</i> , 2021, 10, 1292-1304.	1.3	7
3132	iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 20, 572-586.	1.8	21
3133	Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2881-2892.	2.0	14
3134	T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). <i>Anticancer Research</i> , 2021, 41, 1123-1141.	0.5	6

#	ARTICLE	IF	CITATIONS
3135	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
3136	ITGB1-DT Facilitates Lung Adenocarcinoma Progression via Forming a Positive Feedback Loop With ITGB1/Wnt/ β -Catenin/MYC. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 631259.	1.8	24
3137	STK1p as a prognostic biomarker for overall survival in non-small-cell lung carcinoma, based on real-world data. <i>Future Science OA</i> , 2021, 7, FSO661.	0.9	3
3138	Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs. <i>Biomaterials</i> , 2021, 270, 120685.	5.7	29
3139	Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002104.	3.9	47
3140	Recent advances in preclinical models for lung squamous cell carcinoma. <i>Oncogene</i> , 2021, 40, 2817-2829.	2.6	26
3141	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. <i>Nanomaterials</i> , 2021, 11, 661.	1.9	23
3142	Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison. <i>Annals of Palliative Medicine</i> , 2021, 10, 2766-2775.	0.5	8
3144	Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 611012.	1.3	16
3145	Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2021, 13, 1760-1768.	0.6	36
3146	The role of immunotherapy in fusion-driven lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 461-464.	1.1	3
3147	Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. <i>Bone Marrow Transplantation</i> , 2021, 56, 1784-1793.	1.3	5
3148	Immunotherapy, cancer and PET. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 123-135.	0.1	1
3150	Clinical impact of probiotics on the efficacy of anti-PD-1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting. <i>International Journal of Cancer</i> , 2021, 149, 473-482.	2.3	35
3151	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. <i>Journal of Korean Neurosurgical Society</i> , 2021, 64, 271-281.	0.5	8
3152	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 1402.	5.8	85
3153	Does Reproducibility Drive Clinical Accuracy?. <i>American Journal of Clinical Pathology</i> , 2021, 156, 577-585.	0.4	1
3154	PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1365.	1.0	13

#	ARTICLE	IF	CITATIONS
3156	The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity. <i>BMC Cancer</i> , 2021, 21, 240.	1.1	14
3157	Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 628124.	1.3	39
3158	Harmonization across programmed death ligand 1 (PD-L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing. <i>Thoracic Cancer</i> , 2021, 12, 1187-1194.	0.8	3
3159	Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 657615.	1.3	29
3160	Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer. <i>Cancers</i> , 2021, 13, 1145.	1.7	13
3161	Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia. <i>Future Oncology</i> , 2021, 17, 1069-1081.	1.1	5
3162	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	0.8	83
3163	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 617335.	1.3	49
3164	Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function. <i>JCI Insight</i> , 2021, 6, .	2.3	47
3165	A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients. <i>Aging</i> , 2021, 13, 10034-10057.	1.4	12
3166	Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. <i>Scientific Reports</i> , 2021, 11, 9080.	1.6	6
3167	Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 633685.	2.2	4
3168	Association between programmed cell death ligand 1 expression and thyroid cancer. <i>Medicine (United States)</i> , 2021, 100, e27477.	0.4	7
3169	Efficacy of Combination Docetaxel and Nintedanib in Advanced Non-Small Cell Lung Cancer in Thailand: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 572740.	1.3	4
3170	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 499-511.	5.1	260
3171	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. <i>BMC Cancer</i> , 2021, 21, 425.	1.1	16
3172	Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 562315.	1.3	38
3173	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. <i>Lung Cancer</i> , 2021, 154, 76-83.	0.9	16

#	ARTICLE	IF	CITATIONS
3174	Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC). <i>Human Genomics</i> , 2021, 15, 21.	1.4	8
3175	CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3235-3248.	2.0	23
3176	Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4618.	1.8	30
3177	Trials and tribulations of pancreatic cancer immunotherapy. <i>Cancer Letters</i> , 2021, 504, 1-14.	3.2	37
3178	Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience. <i>Cancers</i> , 2021, 13, 1634.	1.7	23
3179	Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, e833-e841.	1.1	3
3180	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70
3181	The need for immunotherapy when neoadjuvant chemoradiotherapy achieves pathologic complete response in stage IIIB non-small cell lung cancer: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 4965-4969.	0.5	0
3182	Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2021, 81, 3295-3308.	0.4	51
3183	Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. <i>Oral Oncology</i> , 2021, 115, 105133.	0.8	1
3184	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
3185	Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 7830.	1.6	50
3186	Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. <i>International Immunopharmacology</i> , 2021, 93, 107403.	1.7	30
3187	Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, .	0.6	2
3188	Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 2021, 8, 640515.	1.2	13
3189	Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors. <i>Scientific Reports</i> , 2021, 11, 9381.	1.6	9
3190	IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3557-3571.	2.0	11
3191	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. <i>The Cochrane Library</i> , 2021, 2021, CD013257.	1.5	35

#	ARTICLE	IF	CITATIONS
3192	Biomarkers and Target Therapy for Lung Cancer. <i>Physical and Rehabilitation Medicine Medical Rehabilitation</i> , 2021, 3, 74-94.	0.1	1
3193	Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC. <i>Frontiers in Oncology</i> , 2021, 11, 659321.	1.3	11
3194	Tumour neoantigen mimicry by microbial species in cancer immunotherapy. <i>British Journal of Cancer</i> , 2021, 125, 313-323.	2.9	29
3195	Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer. <i>International Immunopharmacology</i> , 2021, 93, 107395.	1.7	12
3196	Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1639.	1.7	13
3197	Radiation and Modulation of the Tumor Immune Microenvironment in Non-Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 133-139.	1.0	6
3198	Therapeutic Targeting of the Tumor Microenvironment. <i>Cancer Discovery</i> , 2021, 11, 933-959.	7.7	646
3199	Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 95-105.	3.0	33
3200	Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed. <i>Cells</i> , 2021, 10, 928.	1.8	13
3201	Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 645352.	1.3	2
3202	Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 646874.	2.2	6
3203	A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. <i>BMC Cancer</i> , 2021, 21, 441.	1.1	25
3204	Myelopoiesis during Solid Cancers and Strategies for Immunotherapy. <i>Cells</i> , 2021, 10, 968.	1.8	7
3206	Resistance mechanisms to checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 47-55.	2.4	19
3207	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	0.5	62
3208	Metformin impairs cisplatin resistance effects in A549 lung cancer cells through mTOR signaling and other metabolic pathways. <i>International Journal of Oncology</i> , 2021, 58, .	1.4	15
3209	Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1006.	1.8	45
3210	TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	135

#	ARTICLE	IF	CITATIONS
3211	PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective. <i>Pathology Research and Practice</i> , 2021, 228, 153497.	1.0	9
3212	Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 674558.	1.6	10
3214	Challenges and Opportunities for Immunotherapy in Gynecologic Cancer. <i>Advances in Oncology</i> , 2021, 1, 113-123.	0.1	0
3215	Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma. <i>European Journal of Cancer</i> , 2021, 148, 1-13.	1.3	9
3216	Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy. <i>Gut</i> , 2022, 71, 734-745.	6.1	177
3217	Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom. <i>BMC Cancer</i> , 2021, 21, 515.	1.1	17
3218	Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 621639.	1.3	12
3219	The Role of Programmed Death-1 in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 20.	1.7	11
3220	Design of PD-1-decorated nanocages targeting tumor-draining lymph node for promoting T cell activation. <i>Journal of Controlled Release</i> , 2021, 333, 328-338.	4.8	12
3221	Neurological complications of immune checkpoint inhibitor cancer immunotherapy. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117424.	0.3	14
3222	Challenges in bioinformatics approaches to tumor mutation burden analysis. <i>Oncology Letters</i> , 2021, 22, 555.	0.8	4
3223	MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method. <i>Medicine (United States)</i> , 2021, 100, e26068.	0.4	1
3224	Cancer microenvironment and genomics: evolution in process. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 85-99.	1.7	11
3225	Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis. <i>BMC Cancer</i> , 2021, 21, 634.	1.1	15
3226	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2111113.	2.8	17
3227	Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 678753.	1.6	16
3228	A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab. <i>American Journal of Case Reports</i> , 2021, 22, e931702.	0.3	10
3229	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	3.0	5

#	ARTICLE	IF	CITATIONS
3230	Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2953-2965.	1.0	6
3231	Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells. <i>Oncology Letters</i> , 2021, 22, 542.	0.8	2
3232	Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. <i>Clinical and Translational Oncology</i> , 2021, 23, 2237-2252.	1.2	7
3233	Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2021, 13, 2290.	1.7	17
3234	Precision medicine and the principle of equal treatment: a conjoint analysis. <i>BMC Medical Ethics</i> , 2021, 22, 55.	1.0	7
3235	PD-L1 as a prognostic and predictive biomarker in neuroendocrine tumors of the lung: state of the art and future perspectives. <i>Minerva Respiratory Medicine</i> , 2021, 60, .	0.1	4
3237	Who's Driving? Switch of Drivers in Immunotherapy-Treated Progressing Sinonasal Melanoma. <i>Cancers</i> , 2021, 13, 2725.	1.7	7
3238	Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB harmonization project comparing three NGS panels. , 2021, 9, e001904.		16
3239	Role of immunotherapy in oligometastatic nonsmall cell lung cancer. <i>BMJ Case Reports</i> , 2021, 14, e241070.	0.2	1
3240	PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma. <i>Anticancer Research</i> , 2021, 41, 2501-2509.	0.5	1
3241	Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence. <i>Histopathology</i> , 2021, 79, 139-159.	1.6	9
3242	Phosphor-signal transducers and activator of transcription 1 signaling in mucosal lichen planus developing from metastatic bladder cancer treated with pembrolizumab. <i>Dermatologic Therapy</i> , 2021, 34, e14961.	0.8	2
3243	Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. <i>Bioscience Reports</i> , 2021, 41, .	1.1	39
3244	Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 628243.	1.3	1
3245	In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 650486.	2.2	26
3246	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers. <i>Science Advances</i> , 2021, 7, .	4.7	12
3247	Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology. <i>Global Journal of Cancer Therapy</i> , 2021, , 035-042.	0.4	1
3248	Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2021, 19, 145.	0.8	17

#	ARTICLE	IF	CITATIONS
3249	Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. <i>Cell Reports</i> , 2021, 35, 109071.	2.9	35
3250	Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies. <i>International Journal of Cancer</i> , 2021, 149, 1189-1198.	2.3	17
3251	Genome profiling of mismatch repair genes in eight types of tumors. <i>Cell Cycle</i> , 2021, 20, 1-16.	1.3	0
3252	Dual-scale categorization based deep learning to evaluate programmed cell death ligand 1 expression in non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e25994.	0.4	6
3253	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. <i>Oncologist</i> , 2021, 26, e1226-e1239.	1.9	17
3254	Analysis of the Gut Microbiota: An Emerging Source of Biomarkers for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2514.	1.7	19
3255	An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 445-454.	1.5	4
3256	Precision Oncology. <i>Advances in Oncology</i> , 2021, 1, 97-112.	0.1	0
3257	Signature based on metabolic-related gene pairs can predict overall survival of osteosarcoma patients. <i>Cancer Medicine</i> , 2021, 10, 4493-4509.	1.3	9
3258	Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative. <i>BMJ Open</i> , 2021, 11, e043442.	0.8	7
3259	Prognosis of Patients With Interstitial Lung Disease Induced by Different Pharmacological Types of Anticancer Drugs. <i>Anticancer Research</i> , 2021, 41, 2563-2568.	0.5	2
3260	Targeting Solid Tumors Using CD3 Bispecific Antibodies. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1350-1358.	1.9	8
3261	Moving Beyond 3+3: The Future of Clinical Trial Design. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e133-e144.	1.8	33
3262	Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 14-14.	1.8	3
3263	Integration of Salmonella into Combination Cancer Therapy. <i>Cancers</i> , 2021, 13, 3228.	1.7	15
3264	Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer. <i>Journal of Pancreatology</i> , 2021, 4, 106-114.	0.3	3
3265	Explant Modeling of the Immune Environment of Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 611365.	1.3	6
3266	Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. , 2021, 9, e002349.		16

#	ARTICLE	IF	CITATIONS
3267	Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2779-2787.	1.3	4
3268	Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1761-1769.	3.0	27
3269	Clinical management of immune-related adverse events following immunotherapy treatment in patients with non-small cell lung cancer. <i>Journal of Investigative Medicine</i> , 2021, 69, 1281-1286.	0.7	0
3270	Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma. <i>Aging</i> , 2021, 13, 15126-15138.	1.4	8
3271	Cocktail strategy for "cold" tumors therapy via active recruitment of CD8+ T cells and enhancing their function. <i>Journal of Controlled Release</i> , 2021, 334, 413-426.	4.8	18
3272	Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 202.	3.5	14
3273	Approaches for Handling Immunopathological and Clinical Data Using Deep Learning Methodology: Multiplex IHC/IF Data as a Paradigm. , 0, , .		0
3274	The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning. <i>Frontiers in Immunology</i> , 2021, 12, 685992.	2.2	33
3275	Immune checkpoint analysis in lip cancer. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2021, 49, 950-958.	0.7	4
3276	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32
3277	A Case of Pulmonary Adenocarcinoma Continuously Treated with Immune Checkpoint Inhibitor Despite Repeated Checkpoint Inhibitor Pneumonitis. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 201-207.	0.0	1
3278	Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. <i>Pharmaceutics</i> , 2021, 13, 912.	2.0	2
3279	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 672521.	2.2	13
3280	Guidelines for clinical evaluation of anti-cancer drugs. <i>Cancer Science</i> , 2021, 112, 2563-2577.	1.7	17
3281	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2752-2765.	1.3	5
3282	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. <i>Annals of Translational Medicine</i> , 2021, 9, 1033-1033.	0.7	23
3283	Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration. <i>Frontiers in Oncology</i> , 2021, 11, 670927.	1.3	9
3284	The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types. <i>Frontiers in Oncology</i> , 2021, 11, 645159.	1.3	10

#	ARTICLE	IF	CITATIONS
3285	PD-1 Expression Status on CD8+ Tumour Infiltrating Lymphocytes Associates With Survival in Cervical Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 678758.	1.3	9
3286	Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 684098.	1.3	41
3287	PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer. <i>Scientific Reports</i> , 2021, 11, 13077.	1.6	7
3288	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
3289	Recent Advances and Future Perspective of DC-Based Therapy in NSCLC. <i>Frontiers in Immunology</i> , 2021, 12, 704776.	2.2	13
3290	First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2021, 10, 2917-2936.	1.3	18
3291	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021, 2, 207-222.	0.5	0
3292	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 625-644.	12.5	148
3293	Prediction of overall survival and response to immune checkpoint inhibitors: An immune-related signature for gastric cancer. <i>Translational Oncology</i> , 2021, 14, 101082.	1.7	2
3294	The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2021, 41, 3193-3204.	0.5	3
3295	TMB in NSCLC: A Broken Dream?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6536.	1.8	31
3296	Microarrays and NGS for Drug Discovery. , 0, , .		0
3297	Current Development of Glioblastoma Therapeutic Agents. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1521-1532.	1.9	15
3298	Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 658690.	1.3	15
3299	Thromboembolic risk in patients with lung cancer receiving systemic therapy. <i>British Journal of Haematology</i> , 2021, 194, 179-190.	1.2	9
3300	Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3020.	1.7	11
3301	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4369-4376.	3.3	23
3302	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Non-small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4566-4573.	3.2	13

#	ARTICLE	IF	CITATIONS
3303	A Ferroptosis-Related lncRNAs Signature Predicts Prognosis and Immune Microenvironment for Breast Cancer. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 678877.	1.6	43
3304	The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 2539-2550.	1.3	6
3305	Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation. <i>Translational Lung Cancer Research</i> , 2021, 10, 2858-2864.	1.3	12
3306	Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment. <i>Biotechnology Journal</i> , 2021, 16, e2100041.	1.8	65
3307	Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non-“small cell lung cancer treated with first-line pembrolizumab. <i>European Journal of Cancer</i> , 2021, 150, 99-107.	1.3	36
3308	Study of ⁸⁹ Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-“Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 362-367.	2.8	44
3309	The incidence of gastrointestinal adverse events in patients with advanced non-small cell lung cancer (NSCLC) treated with PD-1 inhibitors: a meta-analysis. <i>Translational Cancer Research</i> , 2021, 10, 3389-3403.	0.4	1
3310	Intrapulmonic Cavity or Necrosis on Baseline CT Scan Serves as an Efficacy Predictor of Anti-PD-(L)1 Inhibitor in Advanced Lung Squamous Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 5931-5939.	0.9	2
3311	Novel strategies for immuno-oncology breakthroughs with cell therapy. <i>Biomarker Research</i> , 2021, 9, 62.	2.8	18
3312	Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. <i>Annals of Oncology</i> , 2021, 32, 881-895.	0.6	213
3313	Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3279-3288.	1.2	3
3314	Combining liquid biopsy and radiomics for personalized treatment of lung cancer patients. State of the art and new perspectives. <i>Pharmacological Research</i> , 2021, 169, 105643.	3.1	13
3315	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	10
3316	Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia. <i>Brain Tumor Pathology</i> , 2021, 38, 189-200.	1.1	15
3317	Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-20.	0.6	3
3318	Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. <i>Scientific Reports</i> , 2021, 11, 14999.	1.6	5
3319	A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-“Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 268-273.	1.1	16
3320	Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1099-1117.	0.5	64

#	ARTICLE	IF	CITATIONS
3321	Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3001-3013.	2.0	17
3322	Spine eburnation in a metastatic lung cancer patient treated with immunotherapy and radiotherapy. The first case report of bystander effect on bone. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 237-241.	0.5	16
3323	Radiotherapy for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 3420-3431.	1.3	5
3324	Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. <i>Communications Biology</i> , 2021, 4, 906.	2.0	12
3325	Is more better? An analysis of toxicity and response outcomes from dose-finding clinical trials in cancer. <i>BMC Cancer</i> , 2021, 21, 777.	1.1	3
3326	Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2022, 114, 1505-1515.	0.7	20
3327	Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy. <i>Frontiers in Genetics</i> , 2021, 12, 646362.	1.1	9
3328	Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2339-2344.	0.8	6
3329	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 39-47.	0.1	3
3330	Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7201.	1.8	8
3331	Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes. <i>Frontiers in Oncology</i> , 2021, 11, 674328.	1.3	1
3332	Cemiplimab: a new option for the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2021, 17, 2559-2562.	1.1	3
3333	Immunotherapy in rare ovarian cancer. <i>Current Opinion in Oncology</i> , 2021, 33, 447-456.	1.1	3
3334	Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1086-1098.	0.5	53
3335	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. <i>Frontiers in Pharmacology</i> , 2021, 12, 714483.	1.6	9
3336	The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells. <i>Frontiers in Oncology</i> , 2021, 11, 662010.	1.3	4
3337	Predictive value of ¹⁸ F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer. , 2021, 9, e003079.		5
3338	ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer. , 2021, 9, e001758.		10

#	ARTICLE	IF	CITATIONS
3339	OX40-targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in mice. <i>FASEB BioAdvances</i> , 2021, 3, 829-840.	1.3	0
3340	Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 3828.	1.7	6
3341	Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. <i>Translational Lung Cancer Research</i> , 2021, 10, 3071-3078.	1.3	11
3342	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. <i>Lung Cancer Management</i> , 2021, 10, LMT51.	1.5	10
3343	Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. <i>Frontiers in Immunology</i> , 2021, 9, e002723.		92
3344	The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis. <i>Journal of Thoracic Disease</i> , 2021, 13, 4301-4310.	0.6	6
3345	Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 679095.	1.3	7
3346	Nanomaterials-Based Photodynamic Therapy with Combined Treatment Improves Antitumor Efficacy Through Boosting Immunogenic Cell Death. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4693-4712.	3.3	42
3347	Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 1244-1256.	0.9	4
3348	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5131-5140.	3.2	40
3349	Immune checkpoints and cancer development: Therapeutic implications and future directions. <i>Pathology Research and Practice</i> , 2021, 223, 153485.	1.0	29
3350	Prognostic significance of pre-treatment ALBI grade in advanced non-small cell lung cancer receiving immune checkpoint therapy. <i>Scientific Reports</i> , 2021, 11, 15057.	1.6	17
3351	Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2021, 31, 1076-1085.	2.4	96
3352	A clinical variable-based nomogram could predict the survival for advanced NSCLC patients receiving second-line atezolizumab. <i>Cancer Medicine</i> , 2021, 10, 6218-6226.	1.3	2
3353	Case Report: SAPHO Syndrome Mimicking Bone Metastases During Treatment With Pembrolizumab for Non-small Cell Lung Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 679111.	1.2	1
3354	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. <i>Nature Communications</i> , 2021, 12, 4172.	5.8	16
3355	Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2021, 12, 2360-2368.	0.8	4
3356	Efficacy and safety of pembrolizumab/carrelizumab, alone or in combination with chemotherapy in treatment of patients with non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e26672.	0.4	1

#	ARTICLE	IF	CITATIONS
3357	Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer. <i>Cancers</i> , 2021, 13, 3595.	1.7	1
3358	Update on recent key publications in lung oncology: picking up speed. <i>European Respiratory Review</i> , 2021, 30, 200300.	3.0	1
3359	Ultra-Small Platinum Nanoparticle-Enabled Catalysis and Corrosion Susceptibility Reverse Tumor Hypoxia for Cancer Chemoimmunotherapy. <i>ACS Applied Bio Materials</i> , 2021, 4, 6527-6538.	2.3	5
3360	Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1739.	3.3	19
3361	The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. <i>Cancer Cell</i> , 2021, 39, 945-957.e10.	7.7	124
3362	Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
3363	GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors. , 2021, 9, e003005.		22
3364	Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4217-4228.	1.6	20
3365	18F-FDG PET/CT for monitoring anti-PD-1 therapy in patients with non-small cell lung cancer using SUV harmonization of results obtained with various types of PET/CT scanners used at different centers. <i>Annals of Nuclear Medicine</i> , 2021, 35, 1253-1263.	1.2	5
3366	Infiltration of NK and plasma cells is associated with a distinct immune subset in non-small cell lung cancer. <i>Journal of Pathology</i> , 2021, 255, 243-256.	2.1	17
3367	A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma. <i>BMC Cancer</i> , 2021, 21, 901.	1.1	20
3368	Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review. <i>International Immunopharmacology</i> , 2021, 97, 107703.	1.7	1
3369	FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. <i>Frontiers in Endocrinology</i> , 2021, 12, 712107.	1.5	16
3370	Lung cancer. <i>Lancet, The</i> , 2021, 398, 535-554.	6.3	896
3371	Activation or exhaustion of CD8+ T cells in patients with COVID-19. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2325-2333.	4.8	106
3372	Advances in immune therapies for the treatment of microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	4
3373	Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors. <i>PLoS ONE</i> , 2021, 16, e0256416.	1.1	5
3374	Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. <i>Frontiers in Oncology</i> , 2021, 11, 620246.	1.3	38

#	ARTICLE	IF	CITATIONS
3375	Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. <i>Vaccines</i> , 2021, 9, 894.	2.1	9
3376	Immunotherapy Treatment for Triple Negative Breast Cancer. <i>Pharmaceuticals</i> , 2021, 14, 763.	1.7	30
3377	Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues. <i>ELife</i> , 2021, 10, .	2.8	17
3378	Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients. <i>Frontiers in Oncology</i> , 2021, 11, 725292.	1.3	28
3379	PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain. <i>Nature Communications</i> , 2021, 12, 5106.	5.8	38
3380	Mutational burden and immune recognition of gliomas. <i>Current Opinion in Oncology</i> , 2021, 33, 626-634.	1.1	5
3381	N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer. <i>Molecular Cancer</i> , 2021, 20, 105.	7.9	150
3382	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. <i>Cells</i> , 2021, 10, 2250.	1.8	6
3383	Engineering a High-Affinity PD-1 Peptide for Optimized Immune Cell-Mediated Tumor Therapy. <i>Cancer Research and Treatment</i> , 2022, 54, 362-374.	1.3	5
3384	Cancer immunotherapy: current opportunities and perspectives. <i>Practical Oncology</i> , 2021, 4, 25-38.	0.1	1
3385	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100208.	0.6	0
3386	Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC. <i>Cancer Discovery</i> , 2022, 12, 47-61.	7.7	58
3387	Incidence, risk factors and clinical outcome of venous thromboembolism in non-small cell lung cancer patients receiving immune checkpoint inhibition. <i>Thrombosis Update</i> , 2021, 4, 100056.	0.4	4
3388	Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small cell lung cancer with high-level PD-L1 expression in China. <i>Cancer Medicine</i> , 2021, 10, 6344-6353.	1.3	9
3389	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
3390	Role of Ezrin/Radixin/Moesin in the Surface Localization of Programmed Cell Death Ligand-1 in Human Colon Adenocarcinoma LS180 Cells. <i>Pharmaceuticals</i> , 2021, 14, 864.	1.7	13
3391	Preliminary Report on Computed Tomography Radiomics Features as Biomarkers to Immunotherapy Selection in Lung Adenocarcinoma Patients. <i>Cancers</i> , 2021, 13, 3992.	1.7	44
3392	Evaluation of TTV replication as a biomarker of immune checkpoint inhibitors efficacy in melanoma patients. <i>PLoS ONE</i> , 2021, 16, e0255972.	1.1	1

#	ARTICLE	IF	CITATIONS
3393	Clinical decision support algorithm based on machine learning to assess the clinical response to anti- PD-L1 therapy in patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2021, 153, 179-189.	1.3	16
3394	BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 682007.	1.3	29
3395	Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab. <i>Scientific Reports</i> , 2021, 11, 16992.	1.6	13
3397	Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100205.	0.6	32
3398	Immune Checkpoint Inhibitors and Neurotoxicity. <i>Current Neuropharmacology</i> , 2021, 19, 1246-1263.	1.4	10
3399	Novel and Promising Systemic Treatment Approaches in Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 89.	1.3	2
3400	Immunotherapy for locally advanced non-small cell lung cancer: current evidence and future perspectives. <i>Current Challenges in Thoracic Surgery</i> , 0, 3, 25-25.	0.2	0
3401	Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. <i>Immunotherapy</i> , 2021, 13, 1031-1051.	1.0	14
3402	The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC. <i>Medicine (United States)</i> , 2021, 100, e27038.	0.4	9
3403	Challenges of Immunotherapy in Stage IV Non-small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 465-471.	1.4	6
3404	Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 704336.	1.3	29
3405	Pembrolizumab-induced autoimmune side effects of colon and pancreas in a patient with lung cancer. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1692-1699.	0.4	12
3406	Chemokine $\text{CXCL}21$ synergized with programmed death-ligand 1 blockade restrains tumor growth. <i>Cancer Science</i> , 2021, 112, 4457-4469.	1.7	10
3407	Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. <i>Nature Communications</i> , 2021, 12, 5547.	5.8	31
3408	Adjuvant PD-L1 blockade in non-small-cell lung cancer. <i>Lancet, The</i> , 2021, 398, 1281-1283.	6.3	4
3409	Radiation-activated secretory proteins of $\text{Scgb1a1}+$ club cells increase the efficacy of immune checkpoint blockade in lung cancer. <i>Nature Cancer</i> , 2021, 2, 919-931.	5.7	26
3410	Immune-Related Adverse Events Associated With Outcomes in Patients With NSCLC Treated With Anti-PD-1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 708195.	1.3	16
3411	Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies. <i>Oncologist</i> , 2021, 26, e2227-e2238.	1.9	23

#	ARTICLE	IF	CITATIONS
3412	Inflammation–nutritional markers of peripheral blood could predict survival in advanced non–small–cell lung cancer patients treated with <sc>PD</sc>–1 inhibitors. Thoracic Cancer, 2021, 12, 2914-2923.	0.8	13
3413	Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead. Journal of Personalized Medicine, 2021, 11, 971.	1.1	5
3414	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. Frontiers in Oncology, 2021, 11, 744889.	1.3	19
3415	Molecular Pathology of Lung Cancer. Surgical Pathology Clinics, 2021, 14, 369-377.	0.7	9
3416	PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. International Immunopharmacology, 2021, 98, 107870.	1.7	13
3417	A Novel Prognostic Biomarker LPAR6 in Hepatocellular Carcinoma via Associating with Immune Infiltrates. Journal of Clinical and Translational Hepatology, 2022, 10, 90-103.	0.7	9
3418	From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1–Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific?. Journal of Personalized Medicine, 2021, 11, 914.	1.1	2
3419	Ezrin Modulates the Cell Surface Expression of Programmed Cell Death Ligand-1 in Human Cervical Adenocarcinoma Cells. Molecules, 2021, 26, 5648.	1.7	10
3420	External Validation of ALK and ROS1 Fusions Detected Using an Oncomine Comprehensive Assay. Anticancer Research, 2021, 41, 4609-4617.	0.5	5
3421	Metabolic Modifications, Inflammation, and Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 703681.	1.3	8
3422	Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 4734.	1.7	13
3423	Contribution of Ezrin on the Cell Surface Plasma Membrane Localization of Programmed Cell Death Ligand-1 in Human Choriocarcinoma JEG-3 Cells. Pharmaceuticals, 2021, 14, 963.	1.7	9
3424	PD-1 inhibition in advanced myeloproliferative neoplasms. Blood Advances, 2021, 5, 5086-5097.	2.5	16
3425	Biomarkers of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer: Beyond PD-L1. Clinical Lung Cancer, 2021, 22, 381-389.	1.1	4
3426	CD8+ T effector and immune checkpoint signatures predict prognosis and responsiveness to immunotherapy in bladder cancer. Oncogene, 2021, 40, 6223-6234.	2.6	42
3427	A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer. International Journal of General Medicine, 2021, Volume 14, 5771-5785.	0.8	2
3428	Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer. Modern Pathology, 2022, 35, 403-411.	2.9	28
3429	Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer. Journal of Oncology, 2021, 2021, 1-7.	0.6	10

#	ARTICLE	IF	CITATIONS
3430	TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 667875.	2.2	11
3431	Engineering Nanorobots for Tumor-Targeting Drug Delivery: From Dynamic Control to Stimuli-Responsive Strategy. <i>ChemBioChem</i> , 2021, 22, 3369-3380.	1.3	10
3432	Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with chemo-immunotherapy or immunotherapy as first-line therapy. <i>Heliyon</i> , 2021, 7, e07916.	1.4	4
3433	Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab. <i>Annals of Oncology</i> , 2021, 32, 1618-1625.	0.6	15
3434	PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?. <i>Cancers</i> , 2021, 13, 4520.	1.7	8
3435	First-line pembrolizumab vs chemotherapy in metastatic non-small cell lung cancer: KEYNOTE-024 Japan subset*. <i>Cancer Science</i> , 2021, 112, 5000-5010.	1.7	6
3436	Tumor microenvironment is associated with clinical and genetic properties of diffuse gliomas and predicts overall survival. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 953-966.	2.0	8
3437	MRTF-A-NF- κ B/p65 axis-mediated PDL1 transcription and expression contributes to immune evasion of non-small-cell lung cancer via TGF- β . <i>Experimental and Molecular Medicine</i> , 2021, 53, 1366-1378.	3.2	22
3438	Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100230.	0.6	8
3439	Nivolumab-Related Dry Mouth and Dry Eye: Cross-Sectional Study. <i>Cancer Investigation</i> , 2021, 39, 1-11.	0.6	3
3440	Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1475-1475.	0.7	3
3441	A Calcium-Related Immune Signature in Prognosis Prediction of Patients With Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723103.	1.8	1
3442	Current strategies for intratumoural immunotherapy — Beyond immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 157, 493-510.	1.3	28
3443	Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 717601.	1.8	6
3444	Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1351.	3.4	113
3445	Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 723172.	2.2	11
3446	Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists. <i>Modern Pathology</i> , 2022, 35, 142-151.	2.9	7
3447	Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12). <i>Journal of Thoracic Oncology</i> , 2021, 16, 1501-1511.	0.5	158

#	ARTICLE	IF	CITATIONS
3448	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 37, 102415.	1.7	16
3449	Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. <i>International Immunopharmacology</i> , 2021, 99, 108017.	1.7	5
3450	Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study. <i>Surgery Open Science</i> , 2021, 6, 10-14.	0.5	4
3451	Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. <i>Cells</i> , 2021, 10, 2620.	1.8	10
3452	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 57-70.	3.2	30
3453	Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. <i>Lung Cancer</i> , 2021, 161, 34-41.	0.9	7
3454	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. <i>Lung Cancer</i> , 2021, 161, 60-67.	0.9	2
3455	Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. <i>Lung Cancer</i> , 2021, 161, 163-170.	0.9	6
3456	Anti-tumor effects of valproate zinc complexes on a lung cancer cell line. <i>Polyhedron</i> , 2021, 208, 115415.	1.0	0
3457	Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. <i>Lung Cancer</i> , 2021, 161, 180-188.	0.9	14
3458	New insights into exosome mediated tumor-immune escape: Clinical perspectives and therapeutic strategies. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188624.	3.3	29
3459	Personalized cancer immunotherapy. , 2022, , 399-426.		0
3460	Local immunotherapy of cancer and metastasis. , 2022, , 483-528.		1
3461	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
3462	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
3463	Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 542140.	1.3	21
3464	Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. <i>Scientific Reports</i> , 2021, 11, 1324.	1.6	38
3465	Expanded human NK cells from lung cancer patients sensitize patients'™ PDL1™negative tumors to PD1-blockade therapy. , 2021, 9, e001933.		22

#	ARTICLE	IF	CITATIONS
3466	Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 619-630.	0.8	8
3467	Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review. <i>Current Challenges in Thoracic Surgery</i> , 0, .	0.2	2
3468	Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. <i>Cancers</i> , 2021, 13, 373.	1.7	18
3469	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 39-52.	1.0	9
3470	Typical Tumor Immune Microenvironment Status Determine Prognosis in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3471	Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?. <i>Current Cancer Research</i> , 2021, , 27-54.	0.2	0
3472	A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer. <i>PharmacoEconomics - Open</i> , 2021, 5, 365-383.	0.9	9
3473	The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. <i>Annals of Palliative Medicine</i> , 2021, 10, 34-34.	0.5	3
3474	Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 603701.	1.6	7
3475	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). <i>Clinical Cancer Research</i> , 2021, 27, 5038-5048.	3.2	13
3476	PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms. <i>Scientific Reports</i> , 2021, 11, 1982.	1.6	24
3477	Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. <i>Oncolmmunology</i> , 2021, 10, 1865653.	2.1	24
3478	Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100433.	0.7	5
3479	The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. <i>Clinical Medicine Insights: Oncology</i> , 2021, 15, 117955492199628.	0.6	33
3480	Immune-Checkpoint Inhibitors in B-Cell Lymphoma. <i>Cancers</i> , 2021, 13, 214.	1.7	29
3481	Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 659-669.	1.0	1
3482	PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity. <i>Oncolmmunology</i> , 2021, 10, 1943180.	2.1	54
3483	The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199296.	1.4	40

#	ARTICLE	IF	CITATIONS
3484	Immune Resistance in Lung Adenocarcinoma. <i>Cancers</i> , 2021, 13, 384.	1.7	82
3485	Immunotherapy in Colorectal Cancer: Current and Future Strategies. <i>Journal of the Anus, Rectum and Colon</i> , 2021, 5, 11-24.	0.4	59
3486	PD-L1 testing in advanced stage lung cancer using cytology samples: Suitability and reporting issues. Comparison between two tertiary referral centers. <i>Annals of Cytology and Pathology</i> , 2021, , 001-006.	0.3	0
3487	A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab. <i>Journal of Immunotherapy</i> , 2021, 44, 175-178.	1.2	6
3488	Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system. <i>Cancer Medicine</i> , 2020, 9, 2122-2133.	1.3	14
3489	Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. <i>Cancer Medicine</i> , 2020, 9, 2106-2112.	1.3	28
3490	Overview of Tissue Imaging Methods. <i>Methods in Molecular Biology</i> , 2020, 2055, 455-465.	0.4	23
3491	High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research. <i>Methods in Molecular Biology</i> , 2020, 2055, 563-583.	0.4	79
3492	Measuring Tumor Mutational Burden Using Whole-Exome Sequencing. <i>Methods in Molecular Biology</i> , 2020, 2055, 63-91.	0.4	6
3493	Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. , 2020, , 1187-1214.		2
3494	Predictive Subgroup/Biomarker Identification and Machine Learning Methods. , 2019, , 1-22.		2
3495	CCL21 Programs Immune Activity in Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1231, 67-78.	0.8	15
3496	Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors. <i>Cancer Treatment and Research</i> , 2020, 180, 251-279.	0.2	15
3497	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 235-246.	0.8	7
3498	Gastrointestinal Tract Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 247-253.	0.8	5
3499	Drug-Induced Gastrointestinal Tract Injury. , 2021, , 267-287.		1
3501	Spatiotemporal Changes in Checkpoint Molecule Expression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 167-200.	0.8	5
3502	Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura. <i>Annals of Thoracic Surgery</i> , 2020, 112, 1862-1869.	0.7	1

#	ARTICLE	IF	CITATIONS
3503	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. <i>British Journal of Anaesthesia</i> , 2020, 124, 251-260.	1.5	35
3504	A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 421-427.e2.	1.1	30
3505	Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors. <i>Clinical Skin Cancer</i> , 2017, 2, 59-65.	0.1	3
3506	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1449-1459.	0.5	109
3507	Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses. <i>Lung Cancer</i> , 2020, 145, 40-47.	0.9	7
3508	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	24
3509	Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis. <i>Oncogene</i> , 2017, 36, 6863-6872.	2.6	53
3510	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 80-88.	2.9	74
3511	Dramatic enhancement of the detection limits of bioassays via ultrafast deposition of polydopamine. <i>Nature Biomedical Engineering</i> , 2017, 1, .	11.6	93
3512	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 341-355.	12.5	347
3513	Genomic landscape of lung adenocarcinoma in East Asians. <i>Nature Genetics</i> , 2020, 52, 177-186.	9.4	281
3514	Therapeutic targeting of protein S-acylation for the treatment of disease. <i>Biochemical Society Transactions</i> , 2020, 48, 281-290.	1.6	19
3515	p110 β PI3K as a therapeutic target of solid tumours. <i>Clinical Science</i> , 2020, 134, 1377-1397.	1.8	15
3516	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1047-1059.	1.4	9
3517	TAM kinase inhibition and immune checkpoint blockade: a winning combination in cancer treatment?. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 141-151.	1.5	17
3518	Computational modelling of modern cancer immunotherapy. <i>Physics in Medicine and Biology</i> , 2020, 65, 24TR01.	1.6	14
3519	Immune checkpoint inhibitors for the management of advanced non-small-cell lung carcinoma: a meta-analysis. <i>Anti-Cancer Drugs</i> , 2020, 31, 637-645.	0.7	5
3520	Bilateral Corneal Perforation in a Patient Under Anti-PD1 Therapy. <i>Cornea</i> , 2021, 40, 245-247.	0.9	10

#	ARTICLE	IF	CITATIONS
3521	Pilot Study of the Performance of 19-G Needle in Endobronchial Ultrasound-guided Transbronchial Aspiration for the Diagnosis and Testing of Molecular Markers in Lung Cancer. <i>Journal of Bronchology and Interventional Pulmonology</i> , 2021, 28, 209-214.	0.8	6
3522	Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 49-55.	0.6	4
3523	PD-L1 Expression in Endocervical Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 742-752.	2.1	10
3535	Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas. <i>Thoracic Cancer</i> , 2020, 11, 993-1004.	0.8	56
3536	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1969-1978.	1.7	13
3537	Advanced Merkel cell carcinoma—A focus on medical drug therapy. <i>Dermatologic Therapy</i> , 2020, 33, e13675.	0.8	3
3538	Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016217454.	0.2	56
3539	Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-224485.	0.2	6
3540	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. <i>ESMO Open</i> , 2016, 1, e000118.	2.0	6
3541	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	3.2	132
3542	Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. <i>JCI Insight</i> , 2018, 3, .	2.3	25
3543	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , 2019, 4, .	2.3	345
3544	Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. <i>JCI Insight</i> , 2016, 1, e89014.	2.3	110
3545	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 3209-3218.	3.9	170
3546	U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. <i>Journal of Clinical Investigation</i> , 2019, 130, 374-388.	3.9	43
3547	cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. <i>Journal of Clinical Investigation</i> , 2019, 129, 4850-4862.	3.9	136
3548	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
3549	Transcription factor c-Maf is a checkpoint that programs macrophages in lung cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 2081-2096.	3.9	108

#	ARTICLE	IF	CITATIONS
3550	Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. <i>Journal of Clinical Investigation</i> , 2020, 130, 2560-2569.	3.9	77
3551	Metabolic regulation of immune responses: therapeutic opportunities. <i>Journal of Clinical Investigation</i> , 2016, 126, 2031-2039.	3.9	78
3552	Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 2334-2340.	3.9	312
3553	Pyruvate controls the checkpoint inhibitor PD-L1 and suppresses T cell immunity. <i>Journal of Clinical Investigation</i> , 2017, 127, 2725-2738.	3.9	75
3554	Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. <i>Journal of Clinical Investigation</i> , 2017, 127, 1218-1220.	3.9	15
3555	Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. <i>Journal of Clinical Investigation</i> , 2018, 128, 644-654.	3.9	144
3556	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018, 128, 805-815.	3.9	423
3557	LINC00922 Accelerates the Proliferation, Migration and Invasion of Lung Cancer Via the miRNA-204/CXCR4 Axis. <i>Medical Science Monitor</i> , 2019, 25, 5075-5086.	0.5	25
3558	Construction and Validation of a 7-Immune Gene Model for Prognostic Assessment of Esophageal Carcinoma. <i>Medical Science Monitor</i> , 2020, 26, e927392.	0.5	6
3559	Recent advances in understanding antitumor immunity. <i>F1000Research</i> , 2016, 5, 2545.	0.8	29
3560	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. <i>PLoS Medicine</i> , 2016, 13, e1002196.	3.9	21
3561	Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients. <i>PLoS ONE</i> , 2017, 12, e0179744.	1.1	33
3562	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. <i>PLoS ONE</i> , 2017, 12, e0189848.	1.1	190
3563	PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade. <i>PLoS ONE</i> , 2020, 15, e0234218.	1.1	10
3564	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. <i>Journal of Clinical Medicine Research</i> , 2016, 8, 63-75.	0.6	49
3565	Management of Immunotherapy Related Adverse Effects. <i>Journal of Cancer Prevention & Current Research</i> , 2016, 6, .	0.1	1
3566	Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 339-347.	0.2	6
3567	The Effect of Concurrent Stereotactic Body Radiation and Anti-PD-1 Therapy for Recurrent Metastatic Sarcoma. <i>Radiation Research</i> , 2020, 194, 124.	0.7	11

#	ARTICLE	IF	CITATIONS
3568	The combination of immunotherapy and radiation therapy for non-small cell lung cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2018, 7, 90.	0.0	1
3569	Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases. <i>Bosnian Journal of Basic Medical Sciences</i> , 2020, 20, 329-335.	0.6	12
3570	An Update on Immune Checkpoint Inhibitor-related Hypophysitis. <i>US Endocrinology</i> , 2020, 16, 117.	0.3	3
3571	FAM83A signaling induces epithelial-mesenchymal transition by the PI3K/AKT/Snail pathway in NSCLC. <i>Aging</i> , 2019, 11, 6069-6088.	1.4	48
3572	Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer. <i>Aging</i> , 2019, 11, 12270-12277.	1.4	11
3573	Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. <i>Aging</i> , 2020, 12, 3312-3339.	1.4	103
3574	High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations. <i>Aging</i> , 2020, 12, 10827-10843.	1.4	16
3575	Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients. <i>Aging</i> , 2020, 12, 22906-22926.	1.4	15
3576	Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 47252-47264.	0.8	79
3577	Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. <i>Oncotarget</i> , 2017, 8, 8807-8817.	0.8	68
3578	Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. <i>Oncotarget</i> , 2016, 7, 80426-80434.	0.8	42
3579	Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model. <i>Oncotarget</i> , 2016, 7, 76891-76901.	0.8	9
3580	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. <i>Oncotarget</i> , 2016, 7, 76604-76612.	0.8	93
3581	SCIB1, a hulgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. <i>Oncotarget</i> , 2016, 7, 83088-83100.	0.8	16
3582	Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 8315-8329.	0.8	19
3583	PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 26845-26857.	0.8	55
3584	Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. <i>Oncotarget</i> , 2017, 8, 47400-47411.	0.8	21
3585	Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the <i>JAK2</i> gene in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 60975-60986.	0.8	15

#	ARTICLE	IF	CITATIONS
3586	Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN. <i>Oncotarget</i> , 2017, 8, 53068-53083.	0.8	19
3587	Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. <i>Oncotarget</i> , 2017, 8, 97671-97682.	0.8	254
3588	Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 59901-59914.	0.8	64
3589	Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 97920-97927.	0.8	69
3590	Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. <i>Oncotarget</i> , 2017, 8, 91841-91859.	0.8	28
3591	Secreted protein acidic and rich in cysteine (SPARC) induces cell migration and epithelial mesenchymal transition through WNK1/snail in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 63691-63702.	0.8	52
3592	PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment. <i>Oncotarget</i> , 2017, 8, 59677-59689.	0.8	7
3593	Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes. <i>Oncotarget</i> , 2017, 8, 64283-64293.	0.8	9
3594	PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors. <i>Oncotarget</i> , 2017, 8, 89465-89474.	0.8	13
3595	The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China. <i>Oncotarget</i> , 2017, 8, 87442-87454.	0.8	6
3596	Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 103117-103128.	0.8	84
3597	Radiotherapy: the key to immunotherapy ignition?. <i>Oncotarget</i> , 2017, 8, 93307-93308.	0.8	3
3598	Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 111130-111143.	0.8	34
3599	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	0.8	44
3600	Implications of KRAS mutations in acquired resistance to treatment in NSCLC. <i>Oncotarget</i> , 2018, 9, 6630-6643.	0.8	42
3601	Targeted drugs for systemic therapy of lung cancer with brain metastases. <i>Oncotarget</i> , 2018, 9, 5459-5472.	0.8	47
3602	A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. <i>Oncotarget</i> , 2018, 9, 6993-7009.	0.8	31
3603	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284.	0.8	12

#	ARTICLE	IF	CITATIONS
3604	Correlation of <i>MET</i> gene amplification and <i>TP53</i> mutation with PD-L1 expression in non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 13682-13693.	0.8	39
3605	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
3606	Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of <i>EGFR</i> or <i>HER2</i> . <i>Oncotarget</i> , 2018, 9, 21132-21140.	0.8	24
3607	Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2018, 9, 20034-20047.	0.8	32
3608	PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy. <i>Oncotarget</i> , 2018, 9, 27460-27470.	0.8	53
3609	PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263. <i>Oncotarget</i> , 2018, 9, 30465-30471.	0.8	26
3610	STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNF \pm mediated immune responses in a model of NSCLC. <i>Oncotarget</i> , 2018, 9, 37157-37172.	0.8	10
3611	Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab. <i>Oncotarget</i> , 2019, 10, 3302-3311.	0.8	6
3612	Evaluation of a ConvitVax/anti-PD-1 combined immunotherapy for breast cancer treatment. <i>Oncotarget</i> , 2019, 10, 6546-6560.	0.8	2
3613	Tumor mutational burden in lung cancer: a systematic literature review. <i>Oncotarget</i> , 2019, 10, 6604-6622.	0.8	72
3614	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2092-2105.	0.8	64
3615	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <i>Oncotarget</i> , 2015, 6, 19393-19404.	0.8	61
3616	Vesicular stomatitis virus expressing interferon- β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 33165-33177.	0.8	87
3617	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. <i>Oncotarget</i> , 2016, 7, 1486-1499.	0.8	212
3618	PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 15901-15914.	0.8	125
3619	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	0.8	134
3620	Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of <i>Kras</i> mutation-positive, non-small cell lung cancer. <i>Oncotarget</i> , 0, 7, 42385-42392.	0.8	16
3621	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9

#	ARTICLE	IF	CITATIONS
3622	Resistance to chemoimmunotherapy in non-small-cell lung cancer. , 2020, 3, 445-453.		3
3623	A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. , 2020, 3, 252-275.		18
3624	Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?. , 2020, 3, 276-286.		3
3625	Tobacco, air pollution, environmental carcinogenesis, and thoughts on conquering strategies of lung cancer. Cancer Biology and Medicine, 2019, 16, 700-713.	1.4	33
3626	The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series. Cancer Biology and Medicine, 2019, 16, 811-821.	1.4	14
3627	Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma. Cancer Biology and Medicine, 2020, 17, 555-568.	1.4	14
3628	The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biology and Medicine, 2020, 17, 599-611.	1.4	45
3629	T Cell Metabolism in Cancer Immunotherapy. Immunometabolism, 2020, 2, .	0.7	16
3630	Bronchopleural fistula following a video-assisted thoracoscopic surgery lobectomy after neoadjuvant therapy of pembrolizumab: a case report and literature review. Annals of Translational Medicine, 2020, 8, 1691-1691.	0.7	4
3631	What does the future hold for immunotherapy in cancer?. Annals of Translational Medicine, 2016, 4, 177-177.	0.7	9
3632	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Annals of Translational Medicine, 2016, 4, 267-267.	0.7	17
3633	DNA damage, tumor mutational load and their impact on immune responses against cancer. Annals of Translational Medicine, 2016, 4, 264-264.	0.7	35
3634	Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies. Annals of Translational Medicine, 2016, 4, 529-529.	0.7	11
3635	The KEY to the end of chemotherapy in non-small cell lung cancer?. Annals of Translational Medicine, 2017, 5, 166-166.	0.7	4
3636	Novel immunotherapy clinical trials in malignant pleural mesothelioma. Annals of Translational Medicine, 2017, 5, 245-245.	0.7	6
3637	Neopterin as a biomarker of immune response in cancer patients. Annals of Translational Medicine, 2017, 5, 280-280.	0.7	42
3638	PD-L1 as a biomarker in NSCLC: challenges and future directions. Annals of Translational Medicine, 2017, 5, 375-375.	0.7	35
3639	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Annals of Translational Medicine, 2018, 6, 160-160.	0.7	22

#	ARTICLE	IF	CITATIONS
3640	Is the onset of adverse effects of immunotherapy always bad news for the patientsâ€ ?â€”certainly not!. Annals of Translational Medicine, 2019, 7, S5-S5.	0.7	5
3641	Are we facing a cure in lung cancer?â€”KEYNOTE-001 insights. Annals of Translational Medicine, 2019, 7, S215-S215.	0.7	7
3642	JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. Annals of Translational Medicine, 2019, 7, 435-435.	0.7	17
3643	Pre-treatment systemic immune-inflammation represents a prognostic factor in patients with advanced non-small cell lung cancer. Annals of Translational Medicine, 2019, 7, 572-572.	0.7	28
3644	Challenges of PD-L1 testing in non-small cell lung cancer and beyond. Journal of Thoracic Disease, 2020, 12, 4541-4548.	0.6	13
3645	Tissue-specific tumour microenvironments are an emerging determinant of immunotherapy responses. Journal of Thoracic Disease, 2020, 12, 4504-4509.	0.6	3
3646	Perioperative immunotherapy for muscle-invasive bladder cancer. Translational Andrology and Urology, 2020, 9, 2976-2985.	0.6	5
3647	Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study. Translational Cancer Research, 2018, 7, S16-S20.	0.4	4
3648	Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 2020, 9, 2391-2400.	1.3	19
3649	Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?â€”a literature review. Translational Lung Cancer Research, 2020, 9, 2674-2685.	1.3	2
3650	PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS. Siberian Journal of Oncology, 2020, 19, 123-131.	0.1	4
3651	Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation. Immunohematology, 2017, 33, 15-21.	0.2	29
3652	Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers. Future Science OA, 2020, 6, FSO616.	0.9	10
3653	<p>PD-1/PD-L1 Inhibitor Combined with Chemotherapy Can Improve the Survival of Non-Small Cell Lung Cancer Patients with Brain Metastases</p>. OncoTargets and Therapy, 2020, Volume 13, 12777-12786.	1.0	7
3654	Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Current Medicinal Chemistry, 2019, 26, 3026-3041.	1.2	142
3655	Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer. Combinatorial Chemistry and High Throughput Screening, 2019, 21, 711-717.	0.6	5
3656	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2019, 19, 595-630.	0.8	61
3657	Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients. Current Cancer Drug Targets, 2019, 19, 896-905.	0.8	34

#	ARTICLE	IF	CITATIONS
3658	Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 768-776.	0.9	6
3659	Cancer Immunology and Immunotherapy. <i>Anticancer Research</i> , 2016, 36, 5593-5606.	0.5	69
3660	Immune Blockade Inhibition in Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 5607-5622.	0.5	37
3661	Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. <i>Anticancer Research</i> , 2017, 37, 21-33.	0.5	105
3662	Immune-based Therapies for Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 377-388.	0.5	66
3663	Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE. <i>Anticancer Research</i> , 2017, 37, 1321-1328.	0.5	6
3664	Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab. , 2017, 37, 5713-5717.		24
3665	Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 7073-7082.	0.5	32
3666	Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 671-677.	0.5	4
3667	The Positive Relationship Between γ H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. In <i>Vivo</i> , 2018, 32, 171-177.	0.6	10
3668	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 162-174.	0.4	38
3669	Updates to Clinical Information on Anticancer Immunotherapy. <i>Korean Journal of Clinical Pharmacy</i> , 2018, 28, 65-75.	0.0	3
3670	Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. <i>Journal of Medical Biochemistry</i> , 2019, 38, 332-341.	0.7	21
3671	Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. <i>Radiology and Oncology</i> , 2018, 52, 281-288.	0.6	22
3672	Two Patients with Non-small Cell Lung Cancer Developed Thyroid Dysfunction Accompanied by the Emergence of Anti-thyroglobulin Antibodies During Nivolumab Therapy. <i>Japanese Journal of Lung Cancer</i> , 2017, 57, 308-314.	0.0	1
3673	A Case of Exacerbation of Postinfectious Organizing Pneumonia by Pembrolizumab. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 1162-1166.	0.0	1
3674	Tumor-intrinsic response to IFN γ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. <i>Life Science Alliance</i> , 2019, 2, e201900328.	1.3	38
3675	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. <i>Cancer Biology and Medicine</i> , 2016, 13, 87-100.	1.4	21

#	ARTICLE	IF	CITATIONS
3676	Neoadjuvant immunotherapy in breast cancer: a paradigm shift?. <i>Ecancermedalscience</i> , 2020, 14, 1147.	0.6	12
3677	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. <i>Frontiers in Endocrinology</i> , 2020, 11, 576027.	1.5	20
3678	Microenvironment-Dependent Gradient of CTL Exhaustion in the AE17sOVA Murine Mesothelioma Tumor Model. <i>Frontiers in Immunology</i> , 2019, 10, 3074.	2.2	6
3679	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
3680	PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. <i>Frontiers in Immunology</i> , 2020, 11, 596825.	2.2	53
3681	PCOLCE Is Potent Prognostic Biomarker and Associates With Immune Infiltration in Gastric Cancer. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 544895.	1.6	16
3683	Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives. <i>Cancers</i> , 2021, 13, 47.	1.7	106
3684	Use of a Cancer Registry to Evaluate Patient-Reported Outcomes of Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 103.	1.7	7
3685	Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images. <i>Journal of Clinical Medicine</i> , 2021, 10, 118.	1.0	14
3686	Severe Cytomegalovirus Gastritis after Pembrolizumab in a Patient with Melanoma. <i>Current Oncology</i> , 2020, 27, 436-439.	0.9	15
3687	Immunotherapy in human colorectal cancer: Challenges and prospective. <i>World Journal of Gastroenterology</i> , 2016, 22, 6362.	1.4	41
3690	M2 tumor-associated macrophages promote tumor progression in non-small cell lung cancer. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 4490-4498.	0.8	83
3691	Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 762-770.	0.8	11
3692	Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 3150-3158.	0.8	5
3693	Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 13, 43-47.	0.4	12
3694	Use of immunotherapy in the treatment of gastric cancer (Review). <i>Oncology Letters</i> , 2019, 18, 5681-5690.	0.8	31
3695	Nomogram construction for predicting survival of patients with non-small cell lung cancer with malignant pleural or pericardial effusion based on SEER analysis of 10,268½ patients. <i>Oncology Letters</i> , 2020, 19, 449-459.	0.8	8
3696	POLR1B is upregulated and promotes cell proliferation in non-small cell lung cancer. <i>Oncology Letters</i> , 2020, 19, 671-680.	0.8	11

#	ARTICLE	IF	CITATIONS
3697	Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors. <i>Oncology Letters</i> , 2020, 19, 2817-2824.	0.8	13
3698	The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study. <i>Oncology Letters</i> , 2020, 19, 3400-3410.	0.8	6
3699	Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy. <i>Oncology Letters</i> , 2020, 20, 517-524.	0.8	12
3700	Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. <i>Oncology Letters</i> , 2020, 20, 14.	0.8	10
3701	Biomarkers of immunotherapy in non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	8
3702	Plasma platinin-3: A tumor marker in patients with non-small-cell lung cancer treated with nivolumab. <i>Oncology Letters</i> , 2020, 21, 1-1.	0.8	4
3703	Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation (Review). <i>Oncology Reports</i> , 2020, 44, 424-437.	1.2	18
3704	Role of DNA mismatch repair genes in lung and head and neck cancer (Review). <i>World Academy of Sciences Journal</i> , 0, , .	0.4	5
3705	Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials-are we in a new era?. <i>Translational Lung Cancer Research</i> , 2015, 4, 804-8.	1.3	15
3706	New strategies in immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 553-9.	1.3	35
3707	Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. <i>Translational Lung Cancer Research</i> , 2015, 4, 560-75.	1.3	303
3708	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015, 4, 721-7.	1.3	26
3709	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. <i>Translational Lung Cancer Research</i> , 2015, 4, 728-42.	1.3	48
3710	Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 756-62.	1.3	8
3711	Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 743-51.	1.3	31
3712	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , 2016, 5, 2-15.	1.3	52
3713	The inflammatory microenvironment in brain metastases: potential treatment target?. <i>Chinese Clinical Oncology</i> , 2015, 4, 21.	0.4	51
3714	Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. <i>Chinese Clinical Oncology</i> , 2015, 4, 48.	0.4	5

#	ARTICLE	IF	CITATIONS
3715	Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer. <i>Journal of Breast Cancer</i> , 2020, 23, 303.	0.8	25
3716	Saudi lung cancer management guidelines 2017. <i>Annals of Thoracic Medicine</i> , 2017, 12, 221.	0.7	16
3717	Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens. <i>CytoJournal</i> , 2018, 15, 29.	0.8	14
3718	Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line. <i>Indian Journal of Cancer</i> , 2017, 54, 89.	0.2	5
3719	Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 59-64.	0.6	8
3720	Immunotherapy in oral cancer. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2019, 11, 107.	0.2	37
3721	Immune checkpoint inhibitors: Real-world experience from India in advanced solid cancers that have progressed on chemotherapy. <i>South Asian Journal of Cancer</i> , 2019, 08, 65-68.	0.2	4
3722	Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line “ Indian consensus statement update. <i>South Asian Journal of Cancer</i> , 2019, 08, 01-17.	0.2	8
3723	Immune landscape and biomarkers for immuno-oncology in colorectal cancers. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 351-360.	0.4	9
3724	Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Research and Treatment</i> , 2016, 48, 527-536.	1.3	104
3725	Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 95-102.	1.3	22
3726	Higher Age Puts Lung Cancer Patients at Risk for Not Receiving Anti-cancer Treatment. <i>Cancer Research and Treatment</i> , 2019, 51, 1241-1248.	1.3	7
3727	High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment. <i>Cancer Research and Treatment</i> , 2020, 52, 98-108.	1.3	18
3728	Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response. <i>Cancer Research and Treatment</i> , 2020, 52, 594-603.	1.3	55
3729	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2019, 10, 17-28.	0.5	26
3730	Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer. <i>Turkish Thoracic Journal</i> , 2017, 18, 101-107.	0.2	2
3731	Advanced oropharyngeal squamous cell carcinoma: Pathogenesis, treatment, and novel therapeutic approaches. <i>World Journal of Clinical Oncology</i> , 2016, 7, 15.	0.9	14
3732	Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>World Journal of Clinical Oncology</i> , 2017, 8, 320.	0.9	8

#	ARTICLE	IF	CITATIONS
3733	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1278-1285.	2.3	185
3734	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 329-354.	2.3	383
3735	Role of Immunotherapy in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 479-489.	2.3	295
3736	Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biology and Medicine, 2015, 12, 87-95.	1.4	35
3737	Advances in immunotherapy for treatment of lung cancer. Cancer Biology and Medicine, 2015, 12, 209-22.	1.4	50
3738	Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs in Context, 2015, 4, 1-7.	1.0	32
3739	The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors. Cureus, 2017, 9, e1774.	0.2	17
3740	Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis. Cureus, 2019, 11, e5997.	0.2	5
3741	Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies. Cureus, 2020, 12, e8095.	0.2	19
3742	Targeting PD-L1 (Programmed death-ligand 1) and inhibiting the expression of IGF2BP2 (Insulin-like) Tj ETQq1 1 0.784314 rgBT /Over carcinoma cells. Bioengineered, 2021, 12, 7755-7764.	1.4	10
3743	Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation. Journal of Gastrointestinal Oncology, 2021, 12, 2287-2309.	0.6	3
3744	Costs of Extended Use of the Immune Check Point Inhibitors in 1st-line Non-Small Cell Lung Cancer. Journal of Clinical and Medical Research, 0, , .	0.0	0
3745	Algorithme thérapeutique des CBNPC sans anomalie moléculaire actionnable. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S121-2S134.	0.0	0
3746	Prise en charge des cancers bronchiques non À petites cellules oligométastatiques. Revue Des Maladies Respiratoires Actualites, 2021, 13, 2S109-2S120.	0.0	0
3747	Digital pathology and artificial intelligence in translational medicine and clinical practice. Modern Pathology, 2022, 35, 23-32.	2.9	179
3748	Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma. International Journal of Environmental Research and Public Health, 2021, 18, 11038.	1.2	3
3749	The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Communications, 2021, 41, 1314-1330.	3.7	19
3750	Improved Immunotherapy Efficacy by Vascular Modulation. Cancers, 2021, 13, 5207.	1.7	12

#	ARTICLE	IF	CITATIONS
3751	Molecular and genomic characterisation of a panel of human anal cancer cell lines. <i>Cell Death and Disease</i> , 2021, 12, 959.	2.7	3
3752	Case Report: Severe Immune-Related Cholestatic Hepatitis and Subsequent Pneumonia After Pembrolizumab Therapy in a Geriatric Patient With Metastatic Gastric Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 719236.	1.2	3
3753	Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. <i>BMC Medicine</i> , 2021, 19, 239.	2.3	11
3754	Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 42-56.	0.6	56
3755	Gallbladder cancer: Historical treatment and new management options. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1317-1335.	0.8	14
3756	A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 891-901.	2.5	38
3757	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1355-1370.	1.1	6
3758	Toripalimab in an advanced non-small cell lung cancer patient with poor general condition after multiline treatment: a case report. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110429.	0.4	3
3759	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
3760	Differential expression of programmed cell death ligand 1 (PD-L1) and inflammatory cells in basal cell carcinoma subtypes. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	3
3761	Recent advances in primary resistance mechanisms against immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 95-106.	1.1	9
3762	Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 415.	1.8	25
3763	Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. <i>Nanomaterials</i> , 2021, 11, 2792.	1.9	8
3764	Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 388-397.	0.4	3
3765	Camrelizumab in different PD-L1 expression cohorts of pre-treated advanced or metastatic non-small cell lung cancer: a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1393-1402.	2.0	11
3766	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. <i>Biomedicines</i> , 2021, 9, 1484.	1.4	10
3767	Immunotherapy in Cancer Management: A Literature Review of Clinical Efficacy of Pembrolizumab in the Non-small Cell Lung Cancer Treatment. <i>Advanced Pharmaceutical Bulletin</i> , 2021, , .	0.6	3
3768	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 20059.	1.6	53

#	ARTICLE	IF	CITATIONS
3769	Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1530-1540.	5.1	130
3771	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. <i>Nature Communications</i> , 2021, 12, 5955.	5.8	25
3772	Is there a role for neoadjuvant anti-PD-1 therapies in glioma?. <i>Current Opinion in Neurology</i> , 2021, Publish Ahead of Print, 834-839.	1.8	0
3773	Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. <i>Frontiers in Oncology</i> , 2021, 11, 763468.	1.3	10
3774	Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors. <i>Pathology Research and Practice</i> , 2021, 227, 153651.	1.0	1
3775	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188636.	3.3	27
3776	A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. <i>Cancer Treatment Reviews</i> , 2021, 101, 102300.	3.4	8
3777	Structure-activity relationship and biological evaluation of 12ÅN-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway. <i>Bioorganic Chemistry</i> , 2021, 117, 105432.	2.0	1
3778	Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. , 2015, , 85-101.		0
3780	CCL-21. , 2016, , 1-9.		0
3781	FBXW7 Pathway Functions as a Promising Therapeutic Target of Cholangiocarcinoma. <i>Chemotherapy</i> , 2016, 05, .	0.0	0
3782	Translational Research and Immunotherapy in Lung Cancer. , 2016, , 255-296.		0
3783	Treatment of Advanced and Metastatic Squamous Non-small Cell Lung Cancer. <i>Korean Journal of Medicine</i> , 2016, 90, 1-6.	0.1	1
3784	Present status and perspectives of immunotherapy in NSCLC. <i>Onkologie (Czech Republic)</i> , 2016, 10, 26-30.	0.0	0
3785	TG4010 immunotherapy: a novel weapon against advanced non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 185-185.	0.7	0
3786	2015 Review of Newly Approved Oncologic Therapies. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 268-270.	0.2	0
3787	Advances in lung cancer with a focus on ATS 2016 updates. <i>Journal of Thoracic Disease</i> , 2016, 8, S566-S568.	0.6	0
3788	Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 514-524.	0.2	1

#	ARTICLE	IF	CITATIONS
3789	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, .	0.2	3
3790	Surgical Emergencies in Gynecologic Oncology. , 2017, , 219-231.		0
3792	Natural Products & Complementary Medicines: where are we up to?. <i>British Journal of Pharmacy</i> , 2016, 1, .	0.1	1
3793	Eosinophilic Lung Diseases. , 2017, , 239-249.		0
3794	Translational Aspects in Drug Discovery. , 2017, , 495-529.		1
3795	Companion Diagnostics. , 2017, , 117-136.		0
3796	The Current Status of Immunotherapy Using anti PD-1 or PD-L1 Antibodies. <i>Japanese Journal of Lung Cancer</i> , 2017, 57, 75-80.	0.0	0
3797	Immune-Checkpoint Inhibitors. <i>Journal of the Nihon University Medical Association</i> , 2017, 76, 8-10.	0.0	0
3798	Patient-Derived Xenografts From Lung Cancer and Their Potential Applications. , 2017, , 273-289.		0
3799	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2017, , 1-45.		0
3800	PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer. <i>Precision and Future Medicine</i> , 2017, 1, 3-9.	0.5	0
3801	Radio-Immunotherapy: A Promising Weapon to Consider in the Fight against NSCLC. <i>International Journal of Radiology & Radiation Therapy</i> , 2017, 3, .	0.2	0
3803	Immunotherapy and Lung Cancer: Programmed Death 1 and Its Ligand as a Target for Therapy. <i>Molecular Pathology Library</i> , 2018, , 257-273.	0.1	0
3804	Immunoterapia en c�ncer : ciencia ficci�n convertida en realidad.. <i>Revista Colombiana De Hematolog�a Y Oncolog�a</i> , 2017, 4, 8-9.	0.0	0
3805	CCL-21. , 2018, , 790-799.		0
3806	Clinical Observation of Immunization Maintenance Treatment with Thymosin Alpha-1 (T�1) on Postoperative Lung Cancer with High Risk Recurrence. <i>Asian Case Reports in Oncology</i> , 2018, 07, 68-72.	0.0	0
3807	Delayed Immune-Related Erythrodermia in a Squamous NSCLC Patient Treated with Nivolumab: A Case Report. <i>Journal of Cancer Research and Immuno-Oncology</i> , 2018, 04, .	0.0	0
3808	Immune Checkpoint Inhibition. , 2018, , 315-353.		0

#	ARTICLE	IF	CITATIONS
3809	The efficacy and safety of atezolizumab, nivolumab, and pembrolizumab as second-line therapy for non-small-cell lung cancer: preliminary data. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2018, 7, 80.	0.0	0
3810	Competing Immune Biomarkers in the Selection of First-line Therapy in Non-small Cell Lung Cancer. <i>Oncology & Hematology Review</i> , 2018, 14, 67.	0.2	0
3811	ALK and Others: How Important Are ALK and Other Mutations in the Management of Lung Cancer?. <i>Respiratory Disease Series</i> , 2018, , 295-315.	0.1	0
3812	PD-1/PD-L1: A novel target for immunotherapy in patients with advanced and metastatic non-small cell lung cancer. <i>Medicinski Podmladak</i> , 2018, 69, 57-64.	0.2	0
3813	Anticorps monoclonaux en oncologie : d'occlencher une r�ponse immunitaire en plus de la r�duction tumorale sp�cifique.. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 707-735.	0.0	0
3815	A clinical case of 3-year highly efficient pembrolizumab therapy of metastatic lung adenocarcinoma. <i>Meditsinskiy Sovet</i> , 2018, , 9-10.	0.1	1
3816	Tratamiento de c�ncer de pulm�n metast�sico (estadio IV) de c�lula no peque�a : consenso de expertos, Asociaci�n Colombiana de Hematolog�a y Oncolog�a (ACHO).. <i>Revista Colombiana De Hematolog�a Y Oncolog�a</i> , 2018, 5, 61-71.	0.0	1
3817	Are lung adenocarcinoma mutations shaping the immune microenvironment?. <i>Translational Cancer Research</i> , 2018, 7, S740-S742.	0.4	2
3819	The Role of Predictive Markers in Outcome and Value of Anticancer Drugs in Non-small Cell Lung Cancer. <i>Journal of Exploratory Research in Pharmacology</i> , 2018, 3, 102-104.	0.2	0
3820	Personalized Cancer Immunotherapy: Today's Challenge and Tomorrow's Promise. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 56-67.	0.6	4
3821	Genomics Role in Cancer Immunosurveillance: Impact on Immunotherapy Response. <i>International Journal of Cancer Management</i> , 2018, In Press, .	0.2	1
3822	Two Cases of Pulmonary Pleomorphic Carcinoma Treated with Pembrolizumab. <i>Japanese Journal of Lung Cancer</i> , 2018, 58, 969-974.	0.0	2
3823	Managing Checkpoint Inhibitor Symptoms and Toxicity. , 2019, , 1-28.		0
3824	A Phase II Clinical Trial Design for Associated Co-primary Efficacy and Toxicity Outcomes with Baseline Covariates. <i>Springer Proceedings in Mathematics and Statistics</i> , 2019, , 125-133.	0.1	0
3825	IMMUNOTHERAPY FOR NSCLC: THE RIGHT TREATMENT FOR THE RIGHT PERSON. <i>Voprosy Onkologii</i> , 2019, 65, 27-41.	0.1	0
3826	A Case of Colon Perforation during the Treatment with an Immune Checkpoint Inhibitor. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2019, 80, 1715-1720.	0.0	0
3827	Immunotherapy with subcutaneous injection of immunomodulatory agent (OK-432) elicits durable response in locally advanced or relapsed cervical cancer. <i>Gynecology and Minimally Invasive Therapy</i> , 2019, 8, 80.	0.2	2
3828	T Cell Senescence and Tumor Immunotherapy. , 2019, , 2091-2114.		0

#	ARTICLE	IF	CITATIONS
3829	Unmet Needs and Future Outlook of Mesothelioma Management. , 2019, , 331-340.		0
3830	Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. JMA Journal, 2019, 3, 58-66.	0.6	13
3831	Molecular mechanisms of resistance to monoclonal antibodies therapy patients with squamous cell carcinoma of the tongue and mucosa of the oral cavity. Malignant Tumours, 2019, 8, 13-25.	0.1	1
3832	Immunoproteomic Biomarkers: From Publication to Personalized Medicine. Methods in Molecular Biology, 2019, 2024, 371-377.	0.4	0
3833	Targeting the "undruggable" RAS - new strategies - new hope?. , 2019, 2, 813-826.		2
3834	Advances in Research on Immunological Checkpoint Inhibitors in Immunotherapy of Liver Cancer. International Journal of Clinical Medicine, 2019, 10, 62-69.	0.1	0
3836	An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer. Annals of Translational Medicine, 2019, 7, S53-S53.	0.7	5
3837	Complete Disappearance of Numerous Hepatic and Adrenal Metastases after One Dose of Pembrolizumab in a Patient with Metastatic Malignant Melanoma. American Journal of Medical Case Reports, 2019, 7, 22-23.	0.1	0
3840	Analysis of PD-L1 expression in salivary duct carcinoma with its efficacy as a tumor marker. Korean Society for Head and Neck Oncology, 2019, 35, 13-20.	0.1	0
3841	Biomarkers in immuno-oncology: A review article. International Journal of Molecular and Immuno Oncology, 2019, 4, 41-49.	0.0	1
3842	Programmed death ligand 1 (PD-L1) expression in parathyroid tumors. Endocrine Connections, 2019, 8, 887-897.	0.8	7
3843	Chronic nicotine exposure affects programmed death-ligand 1 expression and sensitivity to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. Translational Cancer Research, 2019, 8, S378-S388.	0.4	3
3844	Pembrolizumab and Nivolumab in the treatment of Non-small cell lung cancer (NSCLC).. Revista Bionatura, 2019, 4, 942-947.	0.1	0
3845	Traditional Korean Medicine for Non-Small Cell Lung Cancer Patient Undergoing Pembrolizumab Immunotherapy: A Case Report. The Journal of Internal Korean Medicine, 2019, 40, 709-722.	0.0	2
3846	Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises. Annals of Urologic Oncology, 2019, , 1-18.	0.0	0
3847	PD-L1 testing as a way of personalizing the treatment of non-small cell lung cancer. Likars'ka Sprava, 2019, , 40-45.	0.2	0
3849	Tratamiento de cncer de pulmn metastsico (estadio IV) : segundo consenso de expertos, Asociacin Colombiana de Hematologa y Oncologa (ACHO), 2019.. Revista Colombiana De Hematologa Y Oncologa, 2019, 6, 10-22.	0.0	0
3850	Les CBNPC de stades avances hors addiction oncognique: les traitements systmiques de deuxime ligne. Revue Des Maladies Respiratoires Actualites, 2019, 11, 355-363.	0.0	0

#	ARTICLE	IF	CITATIONS
3851	Proteínas de checkpoint imunológico como novo alvo da imunoterapia contra o câncer: revisão da literatura. HU Revista, 2019, 45, 325-333.	0.3	3
3854	Does Induction Immunotherapy Confer Increased Operative Risk for Lung Resection?. Difficult Decisions in Surgery: an Evidence-based Approach, 2020, , 205-214.	0.0	0
3857	Combination of pembrolizumab and 125I attenuates the aggressiveness of non-small cell lung cancer. Oncology Letters, 2020, 19, 4142-4150.	0.8	1
3859	Radiation induces iatrogenic immunosuppression by indirectly affecting hematopoiesis in bone marrow. Oncotarget, 2020, 11, 1681-1690.	0.8	7
3860	β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas. International Journal of Gynecological Cancer, 2020, 30, 993-999.	1.2	6
3862	Comprehensive investigation of T and B cell receptor repertoires in an MC38 tumor model following murine anti-PD-1 administration. Molecular Medicine Reports, 2020, 22, 975-985.	1.1	3
3866	Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review. American Journal of Dermatopathology, 2021, 43, 321-330.	0.3	2
3867	SNAIL is a prognostic biomarker and correlated with immune infiltrates in gastrointestinal cancers. Aging, 2020, 12, 17167-17208.	1.4	12
3869	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
3870	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
3871	Technical aspects of the use of cytopathological specimens for diagnosis and predictive testing in malignant epithelial neoplasms of the lung.. Cytopathology, 2021, , .	0.4	3
3872	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermuted cancers. Science Translational Medicine, 2021, 13, eabe6201.	5.8	19
3873	Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers, 2021, 13, 5415.	1.7	13
3874	Cutaneous adverse reactions in a lung cancer patient treated with pembrolizumab: A case report. Experimental and Therapeutic Medicine, 2021, 23, 15.	0.8	0
3875	The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. Journal of Controlled Release, 2021, 340, 168-187.	4.8	20
3876	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. Disease Markers, 2021, 2021, 1-10.	0.6	2
3877	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clinical Immunology, 2021, 232, 108873.	1.4	19
3878	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	0.8	580

#	ARTICLE	IF	CITATIONS
3879	CRISPR/Cas9 for the Clinician: Current uses of gene editing and applications for new therapeutics in oncology. , 2020, 24, 1-3.		3
3880	Immune-related Adverse Effects Associated with Programmed Death-1 Inhibitor Therapy in the Treatment of Non-Small Cell Lung Cancer: Incidence, Management, and Effect on Outcomes. , 2021, 25, 1-1.		4
3881	Hepatobiliary Adverse Events. Advances in Experimental Medicine and Biology, 2020, 1244, 271-276.	0.8	3
3882	Exploratory Subgroup Identification for Biopharmaceutical Development. Emerging Topics in Statistics and Biostatistics, 2020, , 245-270.	0.1	1
3884	Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients. Engineering Biology, 2020, 4, 37-42.	0.8	0
3885	Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers. Epigenomics, 2020, 12, 2155-2171.	1.0	4
3886	Applications of Antibodies in Therapy, Diagnosis, and Science. Learning Materials in Biosciences, 2021, , 129-159.	0.2	0
3887	Personalized Immuno-Oncology. , 2021, , 479-508.		2
3890	Prognostic Hub Genes in the Immune Microenvironment of Lung Adenocarcinoma by Estimation. Combinatorial Chemistry and High Throughput Screening, 2021, 25, 77-89.	0.6	0
3891	A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player. Translational Lung Cancer Research, 2020, 9, 2479-2493.	1.3	10
3892	Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer – predictors of response and impact of previous radiotherapy. Acta OncolÁgica, 2021, 60, 149-156.	0.8	5
3893	What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches. Applied Health Economics and Health Policy, 2021, 19, 389-401.	1.0	3
3894	Vaccines as Immunotherapy. , 2021, , 31-61.		1
3895	Immunotherapy of Lung Tumors. , 2020, , 427-450.		0
3896	Models for Monocytic Cells in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1224, 87-115.	0.8	8
3897	Cancer Treatment Infusion Reactions. , 2020, , 107-112.		0
3898	The prevalence of tumour markers in malignant pleural effusions associated with primary pulmonary adenocarcinoma: a retrospective study. European Clinical Respiratory Journal, 2021, 8, 1984375.	0.7	0
3899	Tratamiento de cÁncer de pulmÁn metastÁsico (estadio IV) : segundo consenso de expertos, AsociaciÁn Colombiana de HematologÁa y OncologÁa (ACHO), 2019.. Revista Colombiana De HematologÁa Y OncologÁa, 2019, 6, 10-22.	0.0	0

#	ARTICLE	IF	CITATIONS
3900	Therapy Response Imaging in Thoracic Malignancy. <i>Medical Radiology</i> , 2020, , 79-97.	0.0	0
3902	Efficacy Considerations in Phase I Trials. , 2020, , 159-183.		0
3903	CHAPTER 14. Cell and Immune Therapy. <i>RSC Detection Science</i> , 2020, , 303-344.	0.0	0
3904	Facing the First-line in Metastatic Non-small-cell Lung Cancer “ Immunotherapy and Chemotherapy. <i>European Oncology and Haematology</i> , 2020, 16, 39.	0.0	0
3905	Incidence of Invasive Pneumococcal Disease Among Adults With Hematological and Solid Organ Malignancies in the Netherlands: A Population Based Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3906	Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy. , 2020, , 55-82.		0
3907	History of Oncotherapies in Cancer Biology. , 2020, , 1-13.		1
3908	Tumor Profiling. , 2020, , 319-327.		0
3909	Immune Targets in Colorectal Cancer. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 205-230.	0.2	0
3910	A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. <i>Euroasian Journal of Hepato-gastroenterology</i> , 2021, 10, 56-63.	0.1	5
3911	Molecular Events Behind Adverse Effects. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 119-141.	0.8	0
3912	Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience. <i>World Journal of Oncology</i> , 2020, 11, 150-157.	0.6	3
3913	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0
3916	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. <i>JCO Precision Oncology</i> , 2021, 5, 1625-1638.	1.5	10
3917	Advances in systemic therapy for non-small cell lung cancer. <i>BMJ, The</i> , 2021, 375, n2363.	3.0	134
3918	Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies. <i>Cancer Cell International</i> , 2021, 21, 589.	1.8	17
3919	Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients. <i>Anticancer Research</i> , 2021, 41, 5739-5747.	0.5	4
3920	Moving towards the Future of Radio-Immunotherapy: Could We “Tailor”the Abscopal Effect on Head and Neck Cancer Patients?. <i>Immuno</i> , 2021, 1, 410-423.	0.6	1

#	ARTICLE	IF	CITATIONS
3921	Advances in Pancreatic Ductal Adenocarcinoma Treatment. <i>Cancers</i> , 2021, 13, 5510.	1.7	28
3922	Comparison of programmed death ligand 1 immunostaining for pancreatic ductal adenocarcinoma between paired cytological and surgical samples. <i>CytoJournal</i> , 2021, 18, 28.	0.8	1
3925	Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. <i>ELife</i> , 2021, 10, .	2.8	8
3926	Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy. <i>Radiology and Oncology</i> , 2020, 54, 353-363.	0.6	3
3927	Immunotherapy in Nonsmall Cell Lung Cancer (Basket of Choices). <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 587-590.	0.1	0
3928	Metastatic Anaplastic Lymphoma Kinase Rearrangement-Positive Adenocarcinoma of Occult Primary Mimicking Ovarian Cancer. <i>Cureus</i> , 2020, 12, e9437.	0.2	1
3931	Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. <i>Radiology and Oncology</i> , 2018, .	0.6	0
3932	Predictive and Prognosis Factors of Clinical Utility in Mesothelioma. , 0, , .		0
3933	Clinical implications of WNT/ β -catenin signaling for hepatocellular carcinoma. <i>Global Health & Medicine</i> , 2020, 2, 269-272.	0.6	4
3934	Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-“Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 507-516.	1.0	4
3935	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors. <i>Onkologie (Czech Republic)</i> , 2020, 14, 205-212.	0.0	0
3936	Updates in Staging and Management of Malignant Pleural Mesothelioma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 603-612.	0.6	6
3937	Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. <i>Translational Lung Cancer Research</i> , 2015, 4, 678-88.	1.3	16
3939	Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 704-12.	1.3	8
3940	Immunotherapy for lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 675-7.	1.3	2
3941	Shedding light on the molecular determinants of response to anti-PD-1 therapy. <i>Translational Lung Cancer Research</i> , 2015, 4, 816-9.	1.3	18
3942	PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2016, 4, 1-8.	0.4	22
3943	Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?. <i>Translational Lung Cancer Research</i> , 2016, 5, 138-42.	1.3	14

#	ARTICLE	IF	CITATIONS
3945	MafB silencing in macrophages does not influence the initiation and growth of lung cancer induced by urethane. EXCLI Journal, 2017, 16, 914-920.	0.5	2
3946	Altered miR-223 Expression in Sputum for Diagnosis of Non-Small Cell Lung Cancer. Avicenna Journal of Medical Biotechnology, 2017, 9, 189-195.	0.2	25
3948	Immunotherapy and the Treatment of Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 304-306.	0.2	1
3949	Optimizing peptide epitope-based autoantibody detection in cancer patients. American Journal of Clinical and Experimental Immunology, 2017, 6, 84-91.	0.2	0
3950	The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer. Ochsner Journal, 2017, 17, 379-387.	0.5	6
3951	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, 498-509.	0.2	6
3961	New advances in immunotherapy for non-small cell lung cancer. American Journal of Translational Research (discontinued), 2018, 10, 2234-2245.	0.0	26
3962	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. American Journal of Cancer Research, 2018, 8, 1837-1846.	1.4	26
3963	Promising clinical application of ctDNA in evaluating immunotherapy efficacy. American Journal of Cancer Research, 2018, 8, 1947-1956.	1.4	6
3964	Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring. American Journal of Translational Research (discontinued), 2018, 10, 3911-3923.	0.0	13
3967	PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors. American Journal of Clinical and Experimental Urology, 2019, 7, 159-169.	0.4	13
3968	Highlight report: Role of PD-L1 in never-smokers. EXCLI Journal, 2019, 18, 439-441.	0.5	0
3970	Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2019, 12, 774-786.	0.5	8
3971	Serum miR-10a-5p and miR-196a-5p as non-invasive biomarkers in non-small cell lung cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 773-780.	0.5	12
3972	Preliminary data on circulating tumor cells in metastatic NSCLC patients candidate to immunotherapy. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 282-295.	1.0	4
3973	Prognostic value of immune related genes in lung adenocarcinoma. Oncology Letters, 2020, 20, 259.	0.8	2
3975	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clinical Advances in Hematology and Oncology, 2017, 15, 543-551.	0.3	6
3976	Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer. American Journal of Cancer Research, 2020, 10, 2878-2894.	1.4	6

#	ARTICLE	IF	CITATIONS
3977	Down-regulation of ULL16-binding protein 3 mediated by interferon-gamma impairs immune killing in nasopharyngeal carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 6509-6523.	0.0	1
3978	POU2F1 induces the immune escape in lung cancer by up-regulating PD-L1. American Journal of Translational Research (discontinued), 2021, 13, 672-683.	0.0	4
3980	Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. American Journal of Cancer Research, 2021, 11, 2319-2330.	1.4	3
3982	Oligometastatic non-small cell lung cancer: Current management. Journal of Clinical and Translational Research, 2021, 7, 311-319.	0.3	2
3983	Laboratory biomarkers of an effective antitumor immune response. Clinical significance.. Cancer Treatment and Research Communications, 2021, 29, 100489.	0.7	2
3984	Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110396.	0.8	4
3985	When Should Neuroendovascular Care for Patients With Acute Stroke Be Palliative?. AMA Journal of Ethics, 2021, 23, E783-793.	0.4	7
3987	The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature. Clinical Lung Cancer, 2022, 23, 108-115.	1.1	8
3988	Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. Journal of Hematology and Oncology, 2021, 14, 200.	6.9	68
3989	Among Multiple Needle Core Biopsy Samples, the One with the Highest Tumor Proportion Score Best Represents the PD-L1 Status of the Whole Surgical Specimen in Non-Small Cell Lung Cancer. Applied Immunohistochemistry and Molecular Morphology, 2022, 30, 190-196.	0.6	0
3990	The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed. Frontiers in Immunology, 2021, 12, 764596.	2.2	31
3991	The Role of Neutrophil-to-Lymphocyte Ratio in Predicting Pathological Response for Resectable Non-Small Cell Lung Cancer Treated with Neoadjuvant Chemotherapy Combined with PD-1 Checkpoint Inhibitors. Cancer Research and Treatment, 2022, 54, 1017-1029.	1.3	7
3992	Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma. BMC Pulmonary Medicine, 2021, 21, 373.	0.8	1
3993	Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Archives of Dermatological Research, 2021, , 1.	1.1	1
3994	Pan-cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors. Cancer Medicine, 2021, , .	1.3	10
3995	Kinase Inhibitors™ Effects on Innate Immunity in Solid Cancers. Cancers, 2021, 13, 5695.	1.7	5
3997	A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. Journal of Experimental Medicine, 2022, 219, .	4.2	37
3998	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2022, 181, 114033.	6.6	5

#	ARTICLE	IF	CITATIONS
3999	CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer. <i>MedComm</i> , 2021, 2, 514-530.	3.1	12
4000	BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint. <i>Statistics in Medicine</i> , 2022, 41, 1205-1224.	0.8	4
4001	IL-34, the rationale for its expression in physiological and pathological conditions. <i>Seminars in Immunology</i> , 2021, 54, 101517.	2.7	12
4002	Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. <i>Thoracic Cancer</i> , 2021, , .	0.8	5
4003	Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer. <i>Histopathology</i> , 2022, 80, 635-647.	1.6	21
4004	Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 5773.	1.7	0
4005	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. <i>Cell Communication and Signaling</i> , 2021, 19, 117.	2.7	25
4006	DL-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling. <i>Cancer Management and Research</i> , 2021, Volume 13, 8513-8524.	0.9	3
4007	Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12126.	1.8	8
4008	Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation. <i>Frontiers in Oncology</i> , 2021, 11, 739090.	1.3	19
4009	Complete and durable response of pulmonary large-cell neuroendocrine carcinoma to pembrolizumab. <i>Cancer Reports</i> , 2022, 5, e1589.	0.6	5
4010	B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. <i>Oncogene</i> , 2022, 41, 704-717.	2.6	15
4011	Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients. <i>Human Cell</i> , 2021, , 1.	1.2	0
4012	Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids. <i>Oncotarget</i> , 2021, 12, 2375-2387.	0.8	12
4013	Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110578.	0.5	3
4014	CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. <i>Life</i> , 2021, 11, 1282.	1.1	18
4015	LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 711928.	1.6	2
4016	The Epithelial-Mesenchymal Transition Influences the Resistance of Oral Squamous Cell Carcinoma to Monoclonal Antibodies via Its Effect on Energy Homeostasis and the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 5905.	1.7	9

#	ARTICLE	IF	CITATIONS
4017	The current landscape of systemic therapy for recurrent glioblastoma: A systematic review of randomized-controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103540.	2.0	11
4018	Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers. <i>PLoS ONE</i> , 2021, 16, e0260500.	1.1	2
4019	Dual inhibition of TGF β 2 and PD-L1: a novel approach to cancer treatment. <i>Molecular Oncology</i> , 2022, 16, 2117-2134.	2.1	53
4020	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. <i>Scientific Reports</i> , 2021, 11, 23284.	1.6	3
4021	Metabolic reprogramming and cancer precision medicine: a narrative review. <i>Precision Cancer Medicine</i> , 0, 4, 35-35.	1.8	5
4022	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 319-330.	0.8	3
4023	PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study. <i>Journal of Cancer</i> , 2021, 12, 7390-7398.	1.2	6
4024	Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110565.	1.0	5
4025	BOLA3 Is a Prognostic-Related Biomarker and Correlated with Immune Infiltrates in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4026	Hepatobiliary and Pancreatic Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 339-355.	0.8	6
4027	Pulmonary Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 357-375.	0.8	4
4028	A Systematic Analysis of Post-Protocol Therapy in First Line Checkpoint Inhibitor Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4029	Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 113-142.	0.8	5
4030	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	1.3	12
4031	Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy. <i>BMC Cancer</i> , 2022, 22, 46.	1.1	6
4032	A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 688679.	1.3	13
4033	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	15.2	53
4034	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 55-63.	0.3	2

#	ARTICLE	IF	CITATIONS
4035	Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 2.	7.9	14
4036	The anti-programmed cell death 1 antibody immunotherapy: A paradigm shift in the treatment of nonsmall-cell lung cancer. <i>Nigerian Journal of Cardiovascular & Thoracic Surgery</i> , 2020, 5, 29.	0.1	0
4037	Prognostic value of immune related genes in lung adenocarcinoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	5
4038	Localized release of extracellular ATP by ultrasound and microbubbles for enhancing cancer immunotherapy. , 2020, , .		0
4039	Neoadjuvant chemotherapy for upper tract urothelial carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 6576-6582.	0.4	2
4040	Pembrolizumab Induced Acute Tubulointerstitial Nephritis. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, .	0.5	2
4041	Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups. <i>Immunologic Research</i> , 2022, 70, 256-268.	1.3	4
4042	PHD3 as a Prognosis Marker and its relationship with Immune Infiltration in Lung Adenocarcinoma. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	0
4043	Correlation between Programmed Death Ligand-1 (PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 131-142.	0.5	0
4044	Research progress of tumor targeted drug delivery based on PD-1/PD-L1. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121527.	2.6	16
4045	Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. <i>Npj Precision Oncology</i> , 2022, 6, 2.	2.3	17
4046	XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
4047	Identification of potential key molecular biomarkers in lung adenocarcinoma by bioinformatics analysis. <i>Translational Cancer Research</i> , 2022, 11, 227-241.	0.4	0
4048	Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells. <i>Theranostics</i> , 2022, 12, 747-766.	4.6	28
4049	Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression $\geq 50\%$. <i>Frontiers in Pharmacology</i> , 2021, 12, 803626.	1.6	1
4050	Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy. <i>Clinical and Translational Immunology</i> , 2022, 11, e1363.	1.7	2
4051	PET/CT Imaging of Activated Cancer-Associated Fibroblasts Predict Response to PD-1 Blockade in Gastric Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 802257.	1.3	9
4052	Perspectives of future lung toxicology studies using human pluripotent stem cells. <i>Archives of Toxicology</i> , 2022, 96, 389-402.	1.9	8

#	ARTICLE	IF	CITATIONS
4053	Effects of Different Factors on the Efficacy of Anti PD-(L)1 Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer: An Observational, Retrospective Cohort Study. SSRN Electronic Journal, 0, , .	0.4	0
4054	The B7H4-PDL1 classifier stratifies immuno-phenotype in cervical cancer. Cancer Cell International, 2022, 22, 3.	1.8	2
4055	Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. Frontiers in Immunology, 2021, 12, 730666.	2.2	31
4056	Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment. Patient Preference and Adherence, 2022, Volume 16, 123-135.	0.8	2
4057	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics. Chinese Chemical Letters, 2022, , .	4.8	3
4058	Clinical Effectiveness And Safety Of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, , .	1.1	2
4059	Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 806963.	1.3	14
4060	Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer. PLoS ONE, 2022, 17, e0262455.	1.1	12
4061	GBE1 Is an Independent Prognostic Marker and Associated With CD163+ Tumor-Associated Macrophage Infiltration in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 781344.	1.3	4
4062	<sc>PD-1</sc> and <sc>PD-L2</sc> expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and <sc>DNA</sc> damage response molecules. Journal of Pathology: Clinical Research, 2022, 8, 257-267.	1.3	9
4063	Microsatellite Instability, Epstein-Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer. Cancers, 2022, 14, 218.	1.7	13
4064	Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non-small cell lung cancer. Thoracic Cancer, 2022, 13, 624-630.	0.8	9
4065	Prognostic and Predictive Value of BGN in Colon Cancer Outcomes and Response to Immunotherapy. Frontiers in Oncology, 2021, 11, 761030.	1.3	6
4066	The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (United States), 2022, 101, e28617.	0.4	22
4067	Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study. Cancers, 2022, 14, 751.	1.7	5
4068	T cell subtype profiling measures exhaustion and predicts anti-PD-1 response. Scientific Reports, 2022, 12, 1342.	1.6	7
4069	Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology, 2023, 77, 109-123.	3.6	31
4070	Biomarkers related to immune checkpoint inhibitors therapy. Biomedicine and Pharmacotherapy, 2022, 147, 112470.	2.5	14

#	ARTICLE	IF	CITATIONS
4071	Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab. <i>Annals of Nuclear Medicine</i> , 2022, 36, 224-234.	1.2	13
4072	CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120089.	0.3	10
4073	Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study. <i>Oncotarget</i> , 2022, 13, 257-270.	0.8	0
4074	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 798474.	2.2	10
4075	DNA damage response inhibitor and anti-PD-L1 therapy for prostate cancer: Development of predictive biomarkers. <i>Engineering</i> , 2022, , .	3.2	0
4076	Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. <i>Blood Advances</i> , 2022, 6, 1143-1151.	2.5	21
4077	Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types. <i>Immunity</i> , 2022, 55, 56-64.e4.	6.6	19
4078	Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead. <i>Frontiers in Oncology</i> , 2022, 12, 789728.	1.3	2
4079	Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 268-278.	1.3	12
4080	Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report. <i>Cureus</i> , 2022, 14, e21770.	0.2	5
4081	Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. , 2022, 10, e003091.		67
4082	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. <i>Oncologist</i> , 2022, 27, e273-e285.	1.9	22
4083	Predicting treatment outcomes using ¹⁸ F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110687.	1.4	7
4084	Anti-PD-L1/TGF- β 2R fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-L1/PD-L1 inhibitors in lung cancer. <i>Cancer Communications</i> , 2022, 42, 17-36.	3.7	30
4085	Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab. <i>Journal of Immunotherapy</i> , 2022, 45, 167-179.	1.2	7
4086	PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 390-400.	2.0	8
4087	Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-L1/PD-L1 immune checkpoint inhibitors as second-line monotherapy. <i>Cancer Reports</i> , 2022, 5, e1578.	0.6	8
4088	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. <i>Frontiers in Immunology</i> , 2021, 12, 806043.	2.2	7

#	ARTICLE	IF	CITATIONS
4089	First-Line Immunotherapy for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 586-597.	0.8	312
4090	Identification and Characterization of Immunogene-Related Alternative Splicing Patterns and Tumor Microenvironment Infiltration Patterns in Breast Cancer. <i>Cancers</i> , 2022, 14, 595.	1.7	2
4092	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 203-213.	1.1	4
4093	Suppressive effects of the obese tumor microenvironment on CD8 T cell infiltration and effector function. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	33
4094	The Prognostic Value of Albumin-Globulin Ratio and Eosinophil-Neutrophil Ratio in Patients with Advanced Tumors Undergoing Treatment with PD-1/PD-L1 Inhibitors. <i>Nutrition and Cancer</i> , 2022, 74, 2815-2828.	0.9	4
4095	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis. <i>Molecular Diagnosis and Therapy</i> , 2022, , 1.	1.6	2
4096	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
4097	First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Annals of Oncology</i> , 2022, 33, 488-499.	0.6	99
4098	Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	38
4099	Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. <i>Biomedicines</i> , 2022, 10, 360.	1.4	17
4100	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
4101	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
4102	Current Immunotherapeutic Approaches for Malignant Gliomas. <i>Brain Tumor Research and Treatment</i> , 2022, 10, 1.	0.4	5
4103	Terelizumab Combined with Hypofractionated Radiation Therapy and GM-CSF as Dyspnea with Stage IV Lung Squamous Cell Carcinoma: A Case Report. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4104	<i>cfTrack</i>: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. <i>Clinical Cancer Research</i> , 2022, 28, 1841-1853.	3.2	4
4105	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. <i>BioDrugs</i> , 2022, 36, 137-151.	2.2	6
4106	Programmed Death-Ligand 1 Copy Number Loss in NSCLC Associates With Reduced Programmed Death-Ligand 1 Tumor Staining and a Cold Immunophenotype. <i>Journal of Thoracic Oncology</i> , 2022, 17, 675-687.	0.5	11
4107	Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 840313.	2.2	19

#	ARTICLE	IF	CITATIONS
4108	Immunotherapy in Lung Cancer: Current Landscape and Future Directions. <i>Frontiers in Immunology</i> , 2022, 13, 823618.	2.2	105
4109	The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner. <i>Clinical Cancer Research</i> , 2022, 28, 3387-3399.	3.2	24
4110	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. <i>Lung Cancer</i> , 2022, 166, 84-93.	0.9	7
4111	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. <i>Porto Biomedical Journal</i> , 2022, 7, e162.	0.4	3
4112	Pericardial effusion with pembrolizumab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1664-1670.	0.5	3
4113	Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy. <i>Biochemical and Biophysical Research Communications</i> , 2022, 599, 31-37.	1.0	13
4116	Immuno-PET imaging of PD-L1 expression in patient-derived lung cancer xenografts with [⁶⁸ Ga]Ga-NOTA-Nb109. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 3300-3313.	1.1	5
4117	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
4118	Effects of PD-1 Signaling on Immunometabolic Reprogramming. <i>Immunometabolism</i> , 2022, 4, .	0.7	10
4119	Clinical Impact of <i>STK11</i> Mutation in Advanced-Stage Non-Small-Cell Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4120	Neurological complications of lung cancer. , 2022, , 243-276.		0
4121	Evaluation of Pembrolizumab Monotherapy Efficacy in Advanced Non-Small-Cell Lung Cancer by Serial Monitoring of Circulating Tumor DNA Using Next-Generation Sequencing. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210753.	0.6	1
4123	Investigation of Unprecedented Sites and Proposition of New Ligands for Programmed Cell Death Protein 1 through Molecular Dynamics with Probes and Virtual Screening. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 1236-1248.	2.5	2
4124	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
4125	Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. <i>Cancers</i> , 2022, 14, 1253.	1.7	69
4126	High farnesoid X receptor expression predicts favorable clinical outcomes in PD ^{low/negative} non-small cell lung cancer patients receiving anti-PD ¹ -based chemo-immunotherapy. <i>International Journal of Oncology</i> , 2022, 60, .	1.4	2
4127	Analysis of Gene Co-Expression Network to Identify the Role of CD8 + T Cell Infiltration-Related Biomarkers in High-Grade Glioma. <i>International Journal of General Medicine</i> , 2022, Volume 15, 1879-1890.	0.8	4
4128	A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1104-1119.	0.7	5

#	ARTICLE	IF	CITATIONS
4129	Role of Base Excision Repair in Innate Immune Cells and Its Relevance for Cancer Therapy. <i>Biomedicines</i> , 2022, 10, 557.	1.4	1
4130	Pembrolizumab weight based dosing – A call for policy change. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2022, 43, 306-310.	0.1	2
4131	Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Medicine</i> , 2022, 9, 860733.	1.2	2
4132	DNA-PK Inhibition and Radiation Promote Antitumoral Immunity through RNA Polymerase III in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1137-1150.	1.5	8
4133	Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2631-2643.	2.0	23
4134	Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. <i>Immunotherapy</i> , 2022, , .	1.0	4
4135	Immunomodulatory Properties of Immune Checkpoint Inhibitors – More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710.	1.7	13
4136	The prognostic value of the derived neutrophil-to-lymphocyte ratio (dNLR) in patients treated with immune checkpoint inhibitors. <i>Irish Journal of Medical Science</i> , 2022, , 1.	0.8	2
4137	Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 844260.	1.3	7
4138	An Oxidative Stress-Related Genes Signature for Predicting Survival in Bladder Cancer: Based on TCGA Database and Bioinformatics. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2645-2667.	0.8	9
4139	Immune-related gene signature predicts clinical outcomes and immunotherapy response in acute myeloid leukemia. <i>Cancer Medicine</i> , 2022, 11, 3364-3380.	1.3	3
4140	MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer. , 2022, 10, e004241.		11
4141	The evolutionary legacy of immune checkpoint inhibitors. <i>Seminars in Cancer Biology</i> , 2022, 86, 491-498.	4.3	37
4142	Comprehensive Analysis and Validation of Competing Endogenous RNA Network and Tumor-infiltrating Immune Cells in Lung Adenocarcinoma. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2240-2254.	0.6	2
4143	NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens. <i>Journal of Immunology</i> , 2022, 208, 1813-1827.	0.4	4
4144	Surgery for Control of Brain Metastases After Previous Checkpoint Inhibitor Immunotherapy. <i>World Neurosurgery</i> , 2022, 162, e235-e245.	0.7	2
4145	Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1627.	1.0	14
4146	Identification of Biomarkers Related to Regulatory T Cell Infiltration in Oral Squamous Cell Carcinoma Based on Integrated Bioinformatics Analysis. <i>International Journal of General Medicine</i> , 2022, Volume 15, 2361-2376.	0.8	3

#	ARTICLE	IF	CITATIONS
4147	CMTM6 as a master regulator of PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2325-2340.	2.0	7
4148	Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	0
4149	Reduced CCR2 Can Improve the Prognosis of Sarcoma by Remodeling the Tumor Microenvironment. <i>International Journal of General Medicine</i> , 2022, Volume 15, 3043-3053.	0.8	4
4150	TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression. <i>Oncogene</i> , 2022, 41, 2357-2371.	2.6	4
4151	Risk of Immune-Related Pneumonitis with PD-1/PD-L1 Inhibitors in Different Cancer Types and Treatment Regimens: A Systematic Review and Meta-Analysis of 22 Randomized Controlled Trials. <i>Chemotherapy</i> , 2023, 68, 1-15.	0.8	0
4152	Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis. <i>Cancer Science</i> , 2022, , .	1.7	3
4153	Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas. <i>Scientific Reports</i> , 2022, 12, 5457.	1.6	3
4154	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	5.8	31
4155	Safety of salvage lung resection after immunotherapy for unresectable non-small cell lung cancer. <i>General Thoracic and Cardiovascular Surgery</i> , 2022, 70, 812-817.	0.4	10
4156	Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy. <i>Molecular Cancer</i> , 2022, 21, 64.	7.9	45
4157	dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score $\geq 50\%$. <i>Clinical Lung Cancer</i> , 2022, 23, 122-134.	1.1	8
4158	5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2022, 10, 259-259.	0.7	15
4159	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	3.3	29
4160	Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1916-1928.	0.8	94
4161	Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors. <i>Nature Biomedical Engineering</i> , 2022, 6, 310-324.	11.6	16
4162	Comprehensive Characterization of Human Lung Large Cell Carcinoma Identifies Transcriptomic Signatures with Potential Implications in Response to Immunotherapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 1500.	1.0	3
4163	Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3207.	1.8	7
4164	The clinical and prognostic significance of CMTM6/PD-L1 in oncology. <i>Clinical and Translational Oncology</i> , 2022, 24, 1478-1491.	1.2	2

#	ARTICLE	IF	CITATIONS
4165	Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, , 1.	1.2	2
4166	Should the control arms of randomized trials have an expiry date?. <i>Nature Reviews Clinical Oncology</i> , 2022, , .	12.5	5
4167	Using deep learning to predict tumor mutational burden in lung squamous cell carcinoma from 20 centers. , 2022, , .		0
4168	Efficacy of Cytokine-Induced Killer Cell Immunotherapy for Patients With Pathologically Pure Glioblastoma. <i>Frontiers in Oncology</i> , 2022, 12, 851628.	1.3	4
4169	Larotrectinib in TRK fusion-positive, metastatic non-small cell lung cancer (NSCLC) after treatment with entrectinib in a patient with a history of coronary artery disease. <i>Current Problems in Cancer Case Reports</i> , 2022, , 100158.	0.1	0
4170	Artificial Intelligenceâ€‘Powered Hematoxylin and Eosin Analyzer Reveals Distinct Immunologic and Mutational Profiles among Immune Phenotypes in Nonâ€‘Small-Cell Lung Cancer. <i>American Journal of Pathology</i> , 2022, 192, 701-711.	1.9	6
4171	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
4172	Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated nonâ€‘small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 1479-1489.	0.8	6
4173	Typical tumor immune microenvironment status determine prognosis in lung adenocarcinoma. <i>Translational Oncology</i> , 2022, 18, 101367.	1.7	10
4174	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	2.2	28
4175	An evaluation of pembrolizumab for classical Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2022, 15, 285-293.	1.0	1
4176	Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. <i>BMC Endocrine Disorders</i> , 2022, 22, 89.	0.9	14
4177	Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 406-416.e11.	2.3	31
4178	BOLA3 is a prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma. <i>International Immunopharmacology</i> , 2022, 107, 108652.	1.7	5
4179	Image classification of immune checkpoint inhibitorâ€‘related pneumonia in lung cancer patients. <i>Clinical Imaging</i> , 2022, 86, 31-37.	0.8	0
4180	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. <i>Translational Oncology</i> , 2022, 20, 101405.	1.7	25
4181	Case report of a patient with metastatic melanoma treated with several lines of systemic treatment. <i>Onkologie (Czech Republic)</i> , 2021, 15, 179-181.	0.0	0
4182	Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives. <i>Cancers</i> , 2022, 14, 122.	1.7	16

#	ARTICLE	IF	CITATIONS
4183	Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 75.	1.7	3
4184	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 245.	1.8	6
4185	Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. , 2021, 9, e002780.		15
4186	High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter. <i>Anticancer Research</i> , 2022, 42, 407-417.	0.5	1
4187	B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma. <i>Cancer Medicine</i> , 2022, 11, 479-491.	1.3	5
4188	A Novel Kinase Inhibitor AX-0085 Inhibits Interferon- β -Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. <i>Cells</i> , 2022, 11, 19.	1.8	3
4189	Differentially Expressed Genes in Clear Cell Renal Cell Carcinoma as a Potential Marker for Prognostic and Immune Signatures. <i>Frontiers in Oncology</i> , 2021, 11, 776824.	1.3	7
4190	Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer. <i>Aging</i> , 2021, 13, 25518-25549.	1.4	3
4191	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 793831.	2.2	16
4192	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
4193	Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. <i>Aging Pathobiology and Therapeutics</i> , 2021, 3, 84-94.	0.3	0
4194	Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials. <i>Journal of Chemotherapy</i> , 2021, , 1-9.	0.7	0
4195	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729.	3.1	38
4196	Immunotherapy against Gliomas. , 0, , .		0
4197	A Pan-Cancer Analysis of Predictive Methylation Signatures of Response to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 796647.	2.2	16
4198	NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 162-181.	1.6	26
4199	Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience. <i>South Asian Journal of Cancer</i> , 2022, 11, 058-061.	0.2	1
4200	Chamaejasmin B, an Inhibitor for Metastatic Outgrowth, Reversed M2-Dominant Macrophage Polarization in Breast Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2021, 12, 774230.	2.2	1

#	ARTICLE	IF	CITATIONS
4201	Effectiveness and safety of pembrolizumab monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 138-144.	0.5	1
4202	Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. <i>Journal of Translational Medicine</i> , 2021, 19, 529.	1.8	8
4204	p40/PD-L1 and TTF1/PD-L1 Immunohistochemical Double Staining Contributes to Intraindividual Variability Associated With PD-L1 Staining Interpretation in Lung Cancer Samples. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 165-170.	0.6	0
4205	Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient. <i>Thoracic Cancer</i> , 2022, 13, 510-513.	0.8	2
4206	Tumor Endothelial Marker TEM7 is a Prognostic Biomarker and Correlating with Immune Infiltrates in Gastric Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10155-10171.	0.8	1
4210	Applications of Quantitative System Pharmacology Modeling to Model-Informed Drug Development. <i>Methods in Molecular Biology</i> , 2022, 2486, 71-86.	0.4	0
4211	The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer. <i>Frontiers in Surgery</i> , 2022, 9, 895982.	0.6	1
4212	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	5.8	37
4213	Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy. <i>Thoracic Cancer</i> , 2022, 13, 1631-1641.	0.8	8
4214	A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. <i>Nature Nanotechnology</i> , 2022, 17, 531-540.	15.6	125
4215	Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab. <i>International Journal of Cancer</i> , 2022, 151, 473-480.	2.3	24
4216	Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 862084.	2.2	18
4217	Incidence of Elevated Aminotransferases With or Without Bilirubin Elevation During Treatment With Immune Checkpoint Inhibitors: A Retrospective Study of Patients From Community Oncology Clinics in the United States. <i>Cureus</i> , 2022, 14, e24053.	0.2	1
4219	The role of cellular proteostasis in antitumor immunity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101930.	1.6	6
4220	Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. <i>BMC Cancer</i> , 2022, 22, 407.	1.1	9
4221	Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic. <i>Journal of Personalized Medicine</i> , 2022, 12, 624.	1.1	9
4272	Development of an immunohistochemical assay for Siglec-15. <i>Laboratory Investigation</i> , 2022, 102, 771-778.	1.7	8
4273	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabl9171.	4.7	30

#	ARTICLE	IF	CITATIONS
4274	Squamous cell carcinoma of the lung presenting as a fungating ulcerated skin lesion: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, 172.	0.4	0
4295	The side effects of immune checkpoint inhibitor therapy on the endocrine system. <i>Indian Journal of Medical Research</i> , 2021, 154, 559.	0.4	7
4296	Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 140-146.	0.3	2
4298	Effect of pretreatment with dexamethasone on the efficacy and immune-related adverse events of immunotherapy in first-line treatment for advanced non-small cell lung cancer: a network meta-analysis of randomized control trials.. <i>American Journal of Clinical and Experimental Immunology</i> , 2021, 10, 93-102.	0.2	0
4299	De-glycosylated membrane PD-L1 in tumor tissues as a biomarker for responsiveness to atezolizumab (Tecentriq) in advanced breast cancer patients.. <i>American Journal of Cancer Research</i> , 2022, 12, 123-137.	1.4	1
4300	Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. <i>International Journal of Biological Sciences</i> , 2022, 18, 3019-3033.	2.6	54
4301	Wnt2b and Wnt5a Expressions are Highly Associated with M2 TAMs in Non-Small Cell Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4302	Expression and Prognostic Significance of c-Myc, ALK, ROS1, BRAF, and PD-L1 Among Patients With Non-Small Cell Lung Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210927.	0.6	1
4303	The Single-Cell Level Perspective of the Tumor Microenvironment and Its Remodeling by CAR-T Cells. <i>Cancer Treatment and Research</i> , 2022, 183, 275-285.	0.2	1
4304	Integrative Analysis Constructs an Extracellular Matrix-Associated Gene Signature for the Prediction of Survival and Tumor Immunity in Lung Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 835043.	1.8	4
4305	Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma. <i>Cancer Immunology Research</i> , 2022, 10, 728-744.	1.6	27
4306	DNA Hypermethylation-Regulated CX3CL1 Reducing T Cell Infiltration Indicates Poor Prognosis in Wilms Tumour. <i>Frontiers in Oncology</i> , 2022, 12, 882714.	1.3	7
4307	Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 863796.	1.1	0
4308	Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond. <i>Current Drug Targets</i> , 2022, 23, .	1.0	1
4309	A State-of-the-Art Roadmap for Biomarker-Driven Drug Development in the Era of Personalized Therapies. <i>Journal of Personalized Medicine</i> , 2022, 12, 669.	1.1	1
4310	Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. <i>Frontiers in Immunology</i> , 2022, 13, 849515.	2.2	15
4311	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. <i>Cancers</i> , 2022, 14, 2241.	1.7	26
4312	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. <i>Cancers</i> , 2022, 14, 2177.	1.7	2

#	ARTICLE	IF	CITATIONS
4313	The value of AI in the Diagnosis, Treatment, and Prognosis of Malignant Lung Cancer. <i>Frontiers in Radiology</i> , 2022, 2, .	1.2	1
4314	<sc>Realâ€World</sc> longitudinal practice patterns in the use of <sc>PD</sc> â€1 and <sc>PDâ€L1</sc> inhibitors as <sc>Firstâ€Line</sc> therapy in patients with <sc>Nonâ€Small</sc> cell lung cancer in the United States. <i>Cancer Medicine</i> , 2022, , .	1.3	2
4315	Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer. <i>International Journal of Biological Markers</i> , 2022, 37, 149-157.	0.7	10
4316	OX40 and 4-1BB delineate distinct immune profiles in sarcoma. <i>Oncolmmunology</i> , 2022, 11, 2066050.	2.1	6
4317	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 315-324.	0.4	2
4318	Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2279.	1.7	5
4319	Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy. <i>Journal of Oncology</i> , 2022, 2022, 1-11.	0.6	2
4320	LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of TÂcells through dendritic cell activation. <i>Molecular Therapy</i> , 2022, 30, 2800-2816.	3.7	29
4321	Anti-tumor effects of Skp2 inhibitor AAA-237 on NSCLC by arresting cell cycle at G0/G1 phase and inducing senescence. <i>Pharmacological Research</i> , 2022, 181, 106259.	3.1	9
4322	Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. <i>Clinical Cancer Research</i> , 2022, 28, 3021-3031.	3.2	32
4323	Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
4324	Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. <i>Frontiers in Immunology</i> , 2022, 13, 874589.	2.2	71
4325	Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	31
4326	A peptide-AIEgen nanocomposite mediated whole cancer immunity cycle-cascade amplification for improved immunotherapy of tumor. <i>Biomaterials</i> , 2022, 285, 121528.	5.7	21
4327	Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma. <i>Lung Cancer</i> , 2022, 168, 50-58.	0.9	4
4328	CD39 â€“ A bright target for cancer immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113066.	2.5	20
4329	Programmed death ligand 1 expression in lung adenocarcinoma: An analysis of the histomorphological features. <i>Journal of Microscopy and Ultrastructure</i> , 2022, .	0.1	0
4330	High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. , 2022, 10, e004197.		5

#	ARTICLE	IF	CITATIONS
4332	Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5999.	1.2	3
4333	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT). <i>Oncology and Therapy</i> , 2022, , 1.	1.0	0
4334	Tumor-Derived Lactate Creates a Favorable Niche for Tumor via Supplying Energy Source for Tumor and Modulating the Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	14
4335	Artificial intelligence“powered programmed death ligand1 analyser reduces interobserver variation in tumour proportion score for non“small cell lung cancer with better prediction of immunotherapy response. <i>European Journal of Cancer</i> , 2022, 170, 17-26.	1.3	21
4337	An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, 8230.	1.6	9
4338	Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 1348-1361.	1.8	75
4339	A novel four“gene signature predicts immunotherapy response of patients with different cancers. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24494.	0.9	2
4340	T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T. <i>Thyroid</i> , 2022, 32, 789-798.	2.4	3
4342	Combination of CRAFTY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.. <i>American Journal of Cancer Research</i> , 2022, 12, 1899-1911.	1.4	0
4343	Molecular Signatures of <i>KRAS</i>-Mutated Lung Adenocarcinoma: Analysis of Concomitant <i>EGFR</i>, <i>ALK</i>, <i>STK11</i>, and PD-L1 Status. <i>BMC Clinical Pathology</i> , 2022, 15, 2632010X2211020.	0.7	2
4345	Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non“small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. <i>Clinical Lung Cancer</i> , 2022, 23, e415-e427.	1.1	7
4346	Pembrolizumab Weight-Based Dosing: Conviction and Lacunae in Adopting a Cost-Saving Approach“ A Survey Report. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2022, 43, 298-303.	0.1	1
4347	The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	13
4348	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> , 2022, 28, 1199-1206.	15.2	88
4349	Individualized Treatment for Advanced Non-Small Cell Lung Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
4350	Immunoexpression of Programmed Death-1 Receptor (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Non-Small-Cell Lung Carcinoma and Its Correlation With Other Clinicopathological Parameters: A Cross-Sectional Study From North India. <i>Cureus</i> , 2022, , .	0.2	0
4351	Comprehensive Analysis of the Function, Immune Profiles, and Clinical Implication of m1A Regulators in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4353	Platelets Increase the Expression of PD-L1 in Ovarian Cancer. <i>Cancers</i> , 2022, 14, 2498.	1.7	12

#	ARTICLE	IF	CITATIONS
4355	New Achievements for the Treatment of Triple-Negative Breast Cancer. Applied Sciences (Switzerland), 2022, 12, 5554.	1.3	11
4356	Classification of <sc>PD-L1</sc> expression in various cancers and macrophages based on immunohistocytological analysis. Cancer Science, 2022, 113, 3255-3266.	1.7	8
4357	<sc>PSC</sc> subtyping based on <sc>TTF-1</sc> and p40 expression reveals distinct molecular characteristics and therapeutic strategies. International Journal of Cancer, 2022, 151, 717-729.	2.3	2
4358	Prediction of lung cancer immunotherapy response via machine learning analysis of immune cell lineage and surface markers. Cancer Biomarkers, 2022, 34, 681-692.	0.8	2
4359	<sc>TIGIT</sc> / <sc>CD47</sc> dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma. Thoracic Cancer, 0, .	0.8	4
4360	HLA analysis of immune checkpoint inhibitor-induced and idiopathic isolated ACTH deficiency. Pituitary, 2022, 25, 615-621.	1.6	6
4361	Strategies for developing PD-1 inhibitors and future directions. Biochemical Pharmacology, 2022, 202, 115113.	2.0	12
4363	A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments. Journal of Thoracic Disease, 2022, 14, 2131-2146.	0.6	2
4364	Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression $\geq 50\%$. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211050.	1.4	1
4365	Recurrent squamous cell carcinoma of the skin treated with immunotherapy. Journal of Cancer Research and Therapeutics, 2022, 18, 495.	0.3	1
4366	CD8+ T Cell/Cancer-Associated Fibroblasts Ratio Stratifies Prognostic and Predictive Responses to Immunotherapy Across Multiple Cancer Types. SSRN Electronic Journal, 0, .	0.4	0
4367	VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment. International Journal of Biological Sciences, 2022, 18, 3845-3858.	2.6	64
4368	Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor. Targeted Oncology, 2022, 17, 329-341.	1.7	2
4369	When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. Targeted Oncology, 2022, 17, 253-270.	1.7	5
4370	The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework. Frontiers in Oncology, 0, 12, .	1.3	0
4371	Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	28
4372	Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab. Current Drug Metabolism, 2022, 23, 460-472.	0.7	6
4373	Radiopharmaceuticals as Novel Immune System Tracers. Advances in Radiation Oncology, 2022, , 100936.	0.6	1

#	ARTICLE	IF	CITATIONS
4374	First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score $\geq 50\%$) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 91-99.	2.0	7
4375	Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 1193-1199.	1.2	1
4376	Symptom clusters and their predictors in patients with lung cancer and treated with programmed cell death protein 1 immunotherapy. <i>Asia-Pacific Journal of Oncology Nursing</i> , 2022, 9, 100103.	0.7	3
4377	PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	13
4378	A Single-Cell Atlas of Tumor-Infiltrating Immune Cells in Pancreatic Ductal Adenocarcinoma. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100258.	2.5	3
4379	Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
4380	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
4381	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	1.6	18
4382	Pembrolizumab-induced Stevens-Johnson syndrome in advanced squamous cell carcinoma of the lung: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2022, 10, 6110-6118.	0.3	3
4383	Prognostic and Immunological Significance of Rhomboid Domain Containing Protein 1 in Multiple Primary Cancers. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, .	0.6	0
4384	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
4385	Spontaneous xenogeneic GvHD in Wilms' tumor Patient-Derived xenograft models and potential solutions. <i>Animal Models and Experimental Medicine</i> , 2022, 5, 389-396.	1.3	3
4386	Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	15
4387	Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. <i>Thorax</i> , 2022, 77, 1163-1174.	2.7	5
4388	Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation. <i>Medicine (United States)</i> , 2022, 101, e29381.	0.4	0
4389	Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
4390	Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. <i>Cancer Management and Research</i> , 0, Volume 14, 2079-2090.	0.9	3
4391	Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement. <i>Cancers</i> , 2022, 14, 2995.	1.7	5

#	ARTICLE	IF	CITATIONS
4392	Predicting Tumor Mutational Burden From Lung Adenocarcinoma Histopathological Images Using Deep Learning. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
4393	Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 172, 85-95.	1.3	20
4394	Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 3449-3460.	1.9	3
4396	The Impact of Tertiary Lymphoid Structures on Clinicopathological, Genetic and Gene Expression Characteristics in Lung Adenocarcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4397	The PD-L1/22C3 assay for primary lung cancer is feasible for daily clinical practice irrespective of the diagnostic procedure. <i>The Showa University Journal of Medical Sciences</i> , 2022, 34, 64-77.	0.1	0
4398	Immune checkpoint inhibitorsâ€™ combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	4
4399	Ferroptosis in Glioma Immune Microenvironment: Opportunity and Challenge. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
4400	Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant. <i>Journal of Clinical Oncology</i> , 2022, 40, 3808-3816.	0.8	19
4401	Clinical Efficacy and Safety Analysis of PD-1/PD-L1 Inhibitor vs. Chemotherapy in the Treatment of Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	2
4402	Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives. <i>Cancers</i> , 2022, 14, 3138.	1.7	0
4403	Nivolumab Retreatment in Nonâ€™Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). <i>Clinical Cancer Research</i> , 2022, 28, 3207-3213.	3.2	7
4404	A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
4405	Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets. <i>Anticancer Research</i> , 2022, 42, 3275-3284.	0.5	3
4406	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 3480-3488.	3.2	8
4407	Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
4408	Advanced non-small-cell lung cancer: how to manage non-oncogene disease. <i>Drugs in Context</i> , 0, 11, 1-14.	1.0	2
4409	Ferroptosis-Related lncRNA Signature Correlates with the Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity of Esophageal Squamous Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-29.	1.9	8
4410	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	1.1	6

#	ARTICLE	IF	CITATIONS
4411	Pulmonary adverse events following immune checkpoint inhibitors. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 391-398.	1.2	9
4412	Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. <i>Genome Medicine</i> , 2022, 14, .	3.6	20
4413	Comprehensive Analysis Identifies and Validates the Tumor Microenvironment Subtypes to Predict Anti-Tumor Therapy Efficacy in Hepatocellular Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
4414	Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3440.	1.7	1
4415	DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis. <i>International Journal of General Medicine</i> , 0, Volume 15, 6127-6143.	0.8	1
4416	Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
4417	Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched caseâ€“control study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1445-1452.	0.5	17
4418	Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer. <i>Cureus</i> , 2022, , .	0.2	1
4419	Association of thyroid transcription factorâ€“1 with the efficacy of <scp>immuneâ€“checkpoint</scp> inhibitors in patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , 2022, 13, 2309-2317.	0.8	7
4420	Exploring immunotherapy in colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	104
4421	Comparing VIP and PDâ€“L1 expression as cancer biomarkers. <i>Immunomedicine</i> , 0, , .	0.7	0
4422	Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. <i>PLoS ONE</i> , 2022, 17, e0270950.	1.1	5
4423	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
4424	Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114421.	6.6	18
4425	Temporal Trend in an Initial Treatment, Survival, and Medical Costs Among Patients With Lung Cancer Between 2013 and 2018 in Kyoto City, Japan. <i>Value in Health Regional Issues</i> , 2022, 31, 163-168.	0.5	1
4426	TIMP2 is associated with prognosis and immune infiltrates of gastric and colon cancer. <i>International Immunopharmacology</i> , 2022, 110, 109008.	1.7	6
4427	Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
4428	Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Nodeâ€“Negative, p53â€“Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 465-473.	1.2	2

#	ARTICLE	IF	CITATIONS
4448	A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 351-369.	2.0	6
4449	Overexpression of 14-3-3 σ primes disease recurrence, metastasis and resistance to chemotherapy by inducing epithelial-mesenchymal transition in NSCLC. <i>Aging</i> , 2022, 14, 5838-5854.	1.4	3
4450	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	142
4452	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
4453	High interobserver and intraobserver reproducibility among pathologists assessing <scp>PD-L1 CPS</scp> across multiple indications. <i>Histopathology</i> , 2022, 81, 732-741.	1.6	9
4454	Low-dose anlotinib confers improved survival in combination with immune checkpoint inhibitor in advanced non-small cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 437-448.	2.0	4
4455	Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 449-459.	2.0	2
4456	Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma. <i>Chinese Chemical Letters</i> , 2023, 34, 107762.	4.8	11
4457	Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
4458	Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
4459	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. <i>Life</i> , 2022, 12, 1229.	1.1	4
4460	Stocky/Packed Pancreas: A Case of Focal Drug-Induced Acute Pancreatitis Mimicking Cancer. <i>Tomography</i> , 2022, 8, 2073-2082.	0.8	1
4461	Participation in phase 1 trials for patients with cancer. <i>Lancet, The</i> , 2022, 400, 473-475.	6.3	0
4463	Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2022, 8, 1456.	3.4	60
4464	Development and validation of the potential biomarkers based on m6A-related lncRNAs for the predictions of overall survival in the lung adenocarcinoma and differential analysis with cuproptosis. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	4
4465	Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
4466	Assessing the robustness of radiomics/deep learning approach in the identification of efficacy of anti-PD-1 treatment in advanced or metastatic non-small cell lung carcinoma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
4467	Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	2

#	ARTICLE	IF	CITATIONS
4468	Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
4469	The epiphany derived from T-cell "inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
4470	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
4471	Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential. <i>Cancer Letters</i> , 2022, 547, 215887.	3.2	24
4472	Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3469-3483.	1.2	9
4473	Current treatments for non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	18
4474	Solving the puzzle of what makes immunotherapies work. <i>Trends in Cancer</i> , 2022, 8, 890-900.	3.8	7
4475	Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	1
4476	Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs. <i>Science Advances</i> , 2022, 8, .	4.7	16
4477	Image-guided intratumoral immunotherapy: Developing a clinically practical technology. <i>Advanced Drug Delivery Reviews</i> , 2022, 189, 114505.	6.6	15
4478	Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report. <i>Medicine (United States)</i> , 2022, 101, e30094.	0.4	1
4479	PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. <i>Clinics and Practice</i> , 2022, 12, 653-671.	0.6	8
4481	A Response to the Letter to the Editor: "Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic Non-Small Cell Lung Cancer". <i>Journal of Thoracic Oncology</i> , 2022, 17, e72-e73.	0.5	0
4483	Comprehensive analysis of the effects of KIF2C on prognosis, biological functions and immune infiltration in PAAD. <i>Tissue and Cell</i> , 2022, 78, 101900.	1.0	3
4484	Pneumocystis pneumonia in patient with lung adenocarcinoma: early side effects from pembrolizumab. <i>Radiology Case Reports</i> , 2022, 17, 3979-3981.	0.2	3
4485	Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy. <i>Neoplasia</i> , 2022, 32, 100824.	2.3	4
4486	Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. <i>Lung Cancer</i> , 2022, 172, 65-74.	0.9	5
4487	Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study. <i>BMC Cancer</i> , 2022, 22, .	1.1	5

#	ARTICLE	IF	CITATIONS
4488	Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolamine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	1
4489	Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
4490	<i>EGFR</i> Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. <i>Oncologist</i> , 0, , .	1.9	1
4491	Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review. <i>European Journal of Cancer</i> , 2022, 175, 60-76.	1.3	12
4492	Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature. <i>Current Problems in Cancer Case Reports</i> , 2022, 8, 100190.	0.1	0
4493	Hepatology (Liver and Bile Duct). , 2022, , 119-165.		0
4494	Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
4495	EZH2 inhibition activates dsRNA-interferon axis stress and promotes response to PD-1 checkpoint blockade in NSCLC. <i>Journal of Cancer</i> , 2022, 13, 2893-2904.	1.2	5
4496	Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody. <i>Cancer Control</i> , 2022, 29, 107327482211112.	0.7	17
4497	Pulmonology (Lung). , 2022, , 275-299.		1
4498	Predictive signature development based on maximizing the area between receiver operating characteristic curves. <i>Statistics in Medicine</i> , 2022, 41, 5242-5257.	0.8	2
4499	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <i>Diagnostics</i> , 2022, 12, 2091.	1.3	5
4500	CC Chemokine Ligand-2: A Promising Target for Overcoming Anticancer Drug Resistance. <i>Cancers</i> , 2022, 14, 4251.	1.7	4
4501	Efficacy and Safety of Pembrolizumab Monotherapy for Recurrent/Unresectable/Metastatic Oral Squamous Cell Carcinoma: A Single-Center Study in China. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	1
4502	Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 1151-1164.	5.7	79
4503	MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
4504	What does radiomics do in <sc>PDâ€1</sc> blockade therapy of <sc>NSCLC</sc> patients?. <i>Thoracic Cancer</i> , 2022, 13, 2669-2680.	0.8	2
4505	Dynamic host immunity and PD-L1/PD-1 blockade efficacy: developments after â€œIFN-Î³ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancerâ€. <i>British Journal of Cancer</i> , 2023, 128, 461-467.	2.9	9

#	ARTICLE	IF	CITATIONS
4506	Wnt2b and Wnt5a expression is highly associated with M2 TAMs in non-small cell lung cancer. <i>Oncology Reports</i> , 2022, 48, .	1.2	6
4507	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
4508	Transient Systemic Autophagy Inhibition Is Selectively and Irreversibly Deleterious to Lung Cancer. <i>Cancer Research</i> , 2022, 82, 4429-4443.	0.4	10
4509	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
4510	Inpatient utilization of immune checkpoint inhibitors and clinical outcomes. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211239.	0.5	1
4511	The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	1
4512	Clinical implications of immune checkpoint markers and immune infiltrates in patients with thymic neuroendocrine neoplasms. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4513	Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. , 2022, 10, e005068.		6
4514	Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
4515	The immune landscape of hepatocellular carcinoma—where we are? (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	6
4516	A single-center analysis of 71 patients with thymic carcinoma: the chronological changes in the surgical procedure and prognosis. <i>Journal of Thoracic Disease</i> , 2022, 14, 3211-3220.	0.6	0
4517	Manufacturing-dependent change in biological activity of the <sc>TLR4</sc> agonist <sc>GSK1795091</sc> and implications for lipid A analog development. <i>Clinical and Translational Science</i> , 2022, 15, 2625-2639.	1.5	6
4518	Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
4519	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 4481.	1.7	3
4520	Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
4521	Beyond <sc>PD-1</sc>: Assessment of <sc>LAG-3</sc> and other predictive biomarkers in non-small cell lung carcinoma. <i>Cancer Cytopathology</i> , 2023, 131, 151-153.	1.4	0
4522	Tobacco carcinogen induces tryptophan metabolism and immune suppression via induction of indoleamine 2,3-dioxygenase 1. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	10
4523	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	83

#	ARTICLE	IF	CITATIONS
4524	V-Set and immunoglobulin domain containing (VSIg) proteins as emerging immune checkpoint targets for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
4525	Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
4526	Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 112-122.	1.9	3
4527	A Bayesian phase I/II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapy. <i>Pharmaceutical Statistics</i> , 2023, 22, 143-161.	0.7	2
4528	Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 5136-5148.	3.2	8
4529	An immunogold single extracellular vesicular RNA and protein (Au-SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	16
4530	Investigation of the efficacy and safety of cryoablation and intra-arterial PD-1 inhibitor in patients with advanced disease not responding to checkpoint inhibitors: An exploratory study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
4531	Molecular Biomarkers of Response to Cancer Immunotherapy. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 469-484.	0.7	3
4532	Anti-PD-1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review. <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	3
4534	Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
4535	Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment. <i>Translational Lung Cancer Research</i> , 2022, 11, 1866-1876.	1.3	1
4537	Protocol of the TREASURE study: Thoracic Radiotherapy with Atezolizumab in Small cell Lung cancer Extensive disease – a randomized, open-label, multicenter phase II trial. <i>BMC Cancer</i> , 2022, 22, .	1.1	7
4538	Dynamic monitoring of PD-L1 and Ki67 in circulating tumor cells of metastatic non-small cell lung cancer patients treated with pembrolizumab. <i>Molecular Oncology</i> , 2023, 17, 792-809.	2.1	8
4539	Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate. <i>Molecular Diagnosis and Therapy</i> , 2022, 26, 679-688.	1.6	3
4540	Clinical significance for diagnosis and prognosis of POP1 and its potential role in breast cancer: a comprehensive analysis based on multiple databases. <i>Aging</i> , 2022, 14, 6936-6956.	1.4	3
4541	First-in-human study of ONO-4578, an antagonist of prostaglandin E ₂ receptor 4, alone and with nivolumab in solid tumors. <i>Cancer Science</i> , 2023, 114, 211-220.	1.7	4
4542	Small-Molecule Drugs in Immunotherapy. <i>Mini-Reviews in Medicinal Chemistry</i> , 2023, 23, 1341-1359.	1.1	6
4543	The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. <i>Pathology</i> , 2023, 55, 19-30.	0.3	3

#	ARTICLE	IF	CITATIONS
4544	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
4545	High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. <i>Nature Biotechnology</i> , 2022, 40, 1794-1806.	9.4	144
4546	There Is an Unmet Need for Another Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Inhibitor. <i>Journal of Thoracic Oncology</i> , 2022, 17, 1175-1177.	0.5	0
4547	Anlotinib Benefits the ±PDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-18.	1.9	3
4548	Efficacy of first-line systemic treatment regimens for recurrent/metastatic head and neck squamous cell carcinoma: a network meta-analysis. <i>European Archives of Oto-Rhino-Laryngology</i> , 2023, 280, 1391-1401.	0.8	1
4549	Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
4550	Construction of a 5-methylcytosine-Related Molecular Signature to Inform the Prognosis and Immunotherapy of Lung Squamous Cell Carcinoma. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 905-913.	1.5	10
4551	Onco-biome in pharmacotherapy for lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2022, 11, 2332-2345.	1.3	1
4552	Ká³¼T QUá¢ Äá»EU TRá»Š UNG THÆ PHá»I KHÃ”NG Tá³¼ BÃEO NHá»Ž GIAI ÄOá²N IV Bá²NG PEMBROLIZUMAB Ká³¼T H á»CP HÃ“ 2022, 519, .	0.0	0
4553	Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
4554	An exploration of <sc>LAFâ€bTMB</sc> as a predictor for the efficacy of immunotherapy combined with chemotherapy in <sc>nonâ€”small cell lung cancer</sc>. <i>Thoracic Cancer</i> , 0, , .	0.8	1
4555	The gut microbiota modulates responses to antiâ€”PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
4556	Decreased Tertiary Lymphoid Structures in Lung Adenocarcinomas with ALK Rearrangements. <i>Journal of Clinical Medicine</i> , 2022, 11, 5935.	1.0	1
4557	Translational Research in Cancer Immunotherapies. <i>Japanese Journal of Lung Cancer</i> , 2022, 62, 363-370.	0.0	0
4558	Immune-infiltrating signature-based classification reveals CD103+CD39+ T cells associate with colorectal cancer prognosis and response to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
4560	Liver metastases and the efficacy of immune checkpoint inhibitors in advanced lung cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
4561	Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
4563	Review on Advanced Cancer Modeling for a Cancer Study. <i>Current Issues in Molecular Biology</i> , 2022, 44, 5352-5362.	1.0	0

#	ARTICLE	IF	CITATIONS
4564	The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. <i>Cancers</i> , 2022, 14, 5144.	1.7	8
4565	Immunophenotyping of pulmonary sarcomatoid carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
4567	Ká¼T QUÁc Äá»EU TRÁ»Š BÆá»ŠC HAI PEMBROLIZUMAB LUNG THÆ PHÁ»I KHÃ”NG Tá¼ BÃEO NHÁ»Ž GIAI ÄÖN IV. <i>Hoc Viet N</i>		
4570	Effectiveness of immunological agents in non-small cell lung cancer. <i>Cancer Reports</i> , 2023, 6, .	0.6	3
4571	Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 5401.	1.7	7
4573	Selection of a <sc>PD</sc>á blocking antibody from a novel fully human phage display library. <i>Protein Science</i> , 2022, 31, .	3.1	7
4574	Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-small-Cell Lung Cancer: The Phase III POSEIDON Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 1213-1227.	0.8	107
4575	Validation of E1L3N antibody for PD-L1 detection and prediction of pembrolizumab response in non-small-cell lung cancer. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
4576	Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-small Cell Lung Cancer. <i>Radiographics</i> , 2022, 42, 1956-1974.	1.4	4
4577	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1572.	0.8	5
4578	Delivery of aPD-L1 antibody to i.p. tumors via direct penetration by i.p. route: Beyond EPR effect. <i>Journal of Controlled Release</i> , 2022, 352, 328-337.	4.8	4
4579	IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model. <i>Lung Cancer</i> , 2022, 174, 14-26.	0.9	2
4580	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. <i>Life Sciences</i> , 2022, 310, 121138.	2.0	14
4581	RAS: Circuitry and therapeutic targeting. <i>Cellular Signalling</i> , 2023, 101, 110505.	1.7	1
4582	Development of models for predicting the objective response of immune checkpoint inhibitor therapy in patients with nonsmall-cell lung cancer. <i>Digital Medicine</i> , 2022, 8, 27.	0.1	0
4583	Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
4584	Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
4585	Engaging stemness improves cancer immunotherapy. <i>Cancer Letters</i> , 2023, 554, 216007.	3.2	13

#	ARTICLE	IF	CITATIONS
4586	Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non-Small Cell Lung Cancer in the Irish Healthcare Setting. <i>Value in Health</i> , 2023, 26, 402-410.	0.1	1
4587	CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
4588	Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
4589	A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	3
4590	Scope and Consistency of Cancer Outcomes Reported in Randomized Trials in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2023, 8, 274-281.	0.4	1
4591	Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	7
4592	Ferroptosis: a double-edged sword mediating immune tolerance of cancer. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	20
4593	Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. <i>Clinical Radiology</i> , 2022, , .	0.5	0
4594	Self-Cooperative Prodrug Nanovesicles Migrate Immune Evasion to Potentiate Chemoradiotherapy in Head and Neck Cancer. <i>Advanced Science</i> , 2022, 9, .	5.6	5
4595	CAR T-cells for colorectal cancer immunotherapy: Ready to go?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
4596	Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 906-920.	1.4	4
4597	Comparison of 22C3-PD-L1 Expression Between Paired Tumor Paraffin Blocks of Surgical Resection Specimens of Non-small Cell Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 0, Publish Ahead of Print, .	0.6	0
4599	Boosting the Immunoactivity of T Cells by Resonant Thermal Radiation from Electric Graphene Films for Improved Cancer Immunotherapy. <i>Advanced Therapeutics</i> , 2023, 6, .	1.6	3
4600	The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma. <i>Lung Cancer</i> , 2022, 174, 125-132.	0.9	8
4601	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. <i>Advances in Clinical Chemistry</i> , 2022, , .	1.8	0
4602	Perioperative Immune Checkpoint Inhibition in Early-Stage Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2023, 9, 135.	3.4	10
4603	Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments. <i>Translational Cancer Research</i> , 2021, .	0.4	0
4604	Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy. <i>Clinical Immunology</i> , 2023, 246, 109204.	1.4	7

#	ARTICLE	IF	CITATIONS
4605	Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114057.	2.5	5
4606	Association between serum levels of 12 different cytokines and short-term efficacy of anti-PD-1 monoclonal antibody combined with chemotherapy in advanced gastric cancer. <i>International Immunopharmacology</i> , 2023, 114, 109553.	1.7	3
4607	Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry. <i>European Journal of Cancer</i> , 2023, 180, 71-84.	1.3	6
4608	Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients. <i>Current Problems in Cancer Case Reports</i> , 2023, 9, 100209.	0.1	0
4609	Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy. <i>European Medical Journal (Chelmsford, England)</i> , 0, , 100-107.	3.0	0
4610	The Right Therapy Starts with the Right Test: Novel Therapeutic Approaches in Oncology Foster the Need for an Appropriate Molecular Profiling Strategy. <i>European Medical Journal Oncology</i> , 0, , 42-48.	0.0	0
4611	Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy. <i>Seminars in Immunopathology</i> , 0, , .	2.8	2
4612	Immune landscape and immunotherapy for penile cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
4613	How to Manage a Patient with Ocular Metastases?. <i>Biomedicines</i> , 2022, 10, 3044.	1.4	2
4614	Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Cancers</i> , 2022, 14, 5931.	1.7	6
4615	Initial clinical and experimental analyses of ALDOA in gastric cancer, as a novel prognostic biomarker and potential therapeutic target. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	1
4616	Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
4617	Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. , 2022, 10, e005517.		5
4618	Therapeutic Antibodies in Cancer Treatment in the UK. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14589.	1.8	1
4619	Advances in the Lung Cancer Immunotherapy Approaches. <i>Vaccines</i> , 2022, 10, 1963.	2.1	6
4620	Experimental in vitro, exÂvivo and in vivo models in prostate cancer research. <i>Nature Reviews Urology</i> , 2023, 20, 158-178.	1.9	11
4621	Prognostic role of modified Glasgow Prognostic score in elderly non-small cell lung cancer patients treated with anti-PD-1 antibodies. <i>Respiratory Investigation</i> , 2023, 61, 74-81.	0.9	2
4622	<i>SERPINB9</i> is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. <i>Oncimmunology</i> , 2022, 11, .	2.1	10

#	ARTICLE	IF	CITATIONS
4623	Development of therapeutic antibodies for the treatment of diseases. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	19
4624	Bronchoalveolar Lavage Fluid-Isolated Biomarkers for the Diagnostic and Prognostic Assessment of Lung Cancer. <i>Diagnostics</i> , 2022, 12, 2949.	1.3	4
4625	Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
4626	Immune-related colitis and pancreatitis treated with infliximab. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 73-80.	0.4	3
4627	<scp>RASAL3</scp> predicts overall survival and <scp>CD8</scp> + T lymphocyte infiltration in lung adenocarcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 6056-6065.	1.6	1
4628	Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2022, 11, 2170-2174.	1.3	0
4630	Imaging of Activated T Cells. <i>Journal of Nuclear Medicine</i> , 2023, 64, 30-33.	2.8	1
4631	Case report: Durable response after pembrolizumab in combination with radiation - induced abscopal effect in platinum - refractory metastatic endometrial clear cell carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
4632	<i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1077-1085.	3.2	9
4633	Discovery and Chemical Development of Uvelostinag (MK-1454): A Therapeutic Cyclic Dinucleotide Agonist of the Stimulator of Interferon Gene. <i>ACS Symposium Series</i> , 0, , 1-94.	0.5	0
4634	Local therapy treatment conditions for oligometastatic non-small cell lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
4635	The Current Treatment Landscape of Cutaneous Squamous Cell Carcinoma. <i>American Journal of Clinical Dermatology</i> , 2023, 24, 25-40.	3.3	4
4636	Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models. <i>Cancers</i> , 2022, 14, 6146.	1.7	3
4638	Impact of Corticosteroids for IrAEs on the Clinical Outcome of Immunotherapy in Patients With NSCLC. <i>Anticancer Research</i> , 2022, 42, 5961-5969.	0.5	0
4639	Evolutionary Characteristics and Immunologic Divergence of Lung and Brain Metastasis Lesions in NSCLC. <i>Molecular Cancer Research</i> , 2023, 21, 374-385.	1.5	0
4640	Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
4641	The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy. <i>Biomedicines</i> , 2022, 10, 3154.	1.4	4
4642	Suppression of PD-1 release from small extracellular vesicles promotes systemic anti-tumor immunity by targeting ORAI1 calcium channels. <i>Journal of Extracellular Vesicles</i> , 2022, 11, .	5.5	7

#	ARTICLE	IF	CITATIONS
4643	Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. <i>Diagnostics</i> , 2022, 12, 3157.	1.3	6
4644	Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. <i>Cancers</i> , 2022, 14, 6145.	1.7	10
4645	Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. <i>British Journal of Cancer</i> , 2023, 128, 1196-1207.	2.9	28
4646	Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
4647	Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2023, 41, 1735-1746.	0.8	19
4648	ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	0
4649	A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma. <i>Medicina (Lithuania)</i> , 2023, 59, 23.	0.8	1
4650	A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. <i>ESMO Open</i> , 2022, 7, 100639.	2.0	21
4651	ALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	15
4653	Model-based meta-analysis of non-small cell lung cancer with standard of care ^{PD} inhibitors and chemotherapy for early development decision making. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1751-1763.	1.3	0
4654	Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
4655	Investigation of racial differences in survival from non-small cell lung cancer with immunotherapy use: A Texas study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
4656	Traditional Herbal Medicine: A Potential Therapeutic Approach for Adjuvant Treatment of Non-small Cell Lung Cancer in the Future. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211443.	0.8	6
4658	⁶⁸ Ga-HBED-CC-WL-12 PET in Diagnosing and Differentiating Pancreatic Cancers in Murine Models. <i>Pharmaceuticals</i> , 2023, 16, 80.	1.7	3
4659	Drastic transformation of visceral adipose tissue and peripheral CD4 T cells in obesity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
4660	Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. <i>Cureus</i> , 2023, , .	0.2	1
4661	Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	0
4662	Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6

#	ARTICLE	IF	CITATIONS
4663	The regulation of N6-methyladenosine modification in PD-L1-induced anti-tumor immunity. <i>Immunology and Cell Biology</i> , 0, , .	1.0	2
4664	Impact of mouse model tumor implantation site on acquired resistance to anti-PD-1 immune checkpoint therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
4665	Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver. <i>Translational Lung Cancer Research</i> , 2023, 12, 158-167.	1.3	2
4666	Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
4667	AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1290-1303.	2.8	3
4668	Case report: Identification of acute promyelocytic leukemia during osimertinib resistance followed by granulocyte colony-stimulating factor and pembrolizumab. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
4669	Upregulation of complement proteins in lung cancer cells mediates tumor progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
4670	Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
4672	Strahlentherapie und Immuntherapie. <i>Springer Reference Medizin</i> , 2023, , 1-20.	0.0	0
4673	Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 974.	1.8	3
4674	Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?. , 2023, , 269-287.		1
4675	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. <i>Biomedicines</i> , 2023, 11, 107.	1.4	4
4676	Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. <i>Gene</i> , 2023, 857, 147177.	1.0	2
4677	Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. <i>Targeted Oncology</i> , 0, , .	1.7	1
4678	Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non-Small Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 197.	1.7	1
4679	CTHRC1 Is Associated With Immune Escape and Poor Prognosis in Gastric Cancer. <i>Anticancer Research</i> , 2023, 43, 115-126.	0.5	3
4681	Construction and Preclinical Evaluation of a ¹²⁴ I- ¹²⁵ I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer. <i>Molecular Pharmaceutics</i> , 2023, 20, 1365-1374.	2.3	1
4682	PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer. <i>Lung</i> , 2023, 201, 95-101.	1.4	1

#	ARTICLE	IF	CITATIONS
4683	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. <i>PLoS ONE</i> , 2023, 18, e0281143.	1.1	4
4684	Gastric adenocarcinoma with high-level microsatellite instability: A case report. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	0
4685	Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis. <i>Immunotherapy</i> , 2023, 15, 189-207.	1.0	3
4686	Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
4687	Tumor immunology. , 2023, , 245-452.		0
4688	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. <i>Molecular Cell</i> , 2023, 83, 660-680.	4.5	10
4689	Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2023, 15, 209-220.	1.0	5
4690	[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. , 2023, , 1-40.		0
4691	Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review. <i>Cancers</i> , 2023, 15, 682.	1.7	2
4692	Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. , 2023, 11, e005007.		3
4693	Comparison of <scp>ASCL1</scp>, <scp>NEUROD1</scp>, and <scp>POU2F3</scp> expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. <i>Histopathology</i> , 2023, 82, 860-869.	1.6	8
4694	Assessing PD-L1 Expression in Different Tumor Types. , 2023, , 1-21.		0
4695	Whole-Transcriptome Sequencing Combined with High-Dimensional Proteomic Technologies Reveals the Potential Value of miR-135b-5p as a Biomarker for Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2023, 2023, 1-22.	0.9	0
4696	Introduction on Cancer Immunotherapy. , 2023, , 1-27.		0
4697	A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
4698	The application of patient-derived organoid in the research of lung cancer. <i>Cellular Oncology (Dordrecht)</i> , 2023, 46, 503-519.	2.1	9
4699	A Review on Anticancer Profile of Flavonoids: Sources, Chemistry, Mechanisms, Structure-activity Relationship and Anticancer Activity. <i>Current Drug Research Reviews</i> , 2023, 15, 122-148.	0.7	4
4700	High PD-L2 Predicts Early Recurrence of ER-Positive Breast Cancer. <i>JCO Precision Oncology</i> , 2023, , .	1.5	6

#	ARTICLE	IF	CITATIONS
4701	Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. <i>Life Sciences</i> , 2023, 318, 121459.	2.0	6
4703	Immune-Related Adverse Events of the Gastrointestinal System. <i>Cancers</i> , 2023, 15, 691.	1.7	1
4704	Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. <i>Annals of Oncology</i> , 2023, 34, 377-388.	0.6	18
4705	Association between <sc>PD</sc> Æ inhibitorÆ-related adverse events and frailty assessed by frailty index in lung cancer patients. <i>Cancer Medicine</i> , 0, , .	1.3	1
4706	Upregulated SSB Is Involved in Hepatocellular Carcinoma Progression and Metastasis through the Epithelial-Mesenchymal Transition, Antiapoptosis, and Altered ROS Level Pathway. <i>Oxidative Medicine and Cellular Longevity</i> , 2023, 2023, 1-16.	1.9	0
4707	Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
4708	Pyroptosis-based risk score predicts prognosis and drug sensitivity in lung adenocarcinoma. <i>Open Medicine (Poland)</i> , 2023, 18, .	0.6	0
4709	Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311563.	1.4	1
4710	PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma. <i>Journal of Biomedical Science</i> , 2023, 30, .	2.6	4
4711	Diagnosis and Management of Pembrolizumab-Associated Pericardial Effusion in a Non-small Cell Lung Cancer Patient. <i>Cureus</i> , 2023, , .	0.2	0
4712	Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. <i>Cancer Letters</i> , 2023, 562, 216167.	3.2	5
4713	Targeting PD-1/PD-L1 in biliary tract cancer: role and available data. <i>Immunotherapy</i> , 0, , .	1.0	0
4714	The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade. <i>Biomedicine and Pharmacotherapy</i> , 2023, 161, 114436.	2.5	2
4715	Biomarkers of response to immunotherapy in early stage non-small cell lung cancer. <i>European Journal of Cancer</i> , 2023, 184, 179-196.	1.3	4
4716	Organoids as an Enabler of Precision Immuno-Oncology. <i>Cells</i> , 2023, 12, 1165.	1.8	2
4717	Qualitative analysis of PD-L1 expression in non-small-cell lung cancer based on chest CT radiomics. <i>Biomedical Signal Processing and Control</i> , 2023, 84, 104815.	3.5	0
4719	Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 182, 103913.	2.0	7
4720	SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers. <i>IScience</i> , 2023, 26, 106027.	1.9	6

#	ARTICLE	IF	CITATIONS
4721	Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	0
4723	Management of papillary thyroid cancer with tracheal invasion and lung cancer: A case report. <i>Oncology Letters</i> , 2023, 25, .	0.8	0
4724	Association between Loss of Immune Checkpoint Programmed Cell Death Protein 1 and Active ANCA-Associated Renal Vasculitis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2975.	1.8	3
4725	A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives. <i>AME Medical Journal</i> , 0, 8, 6-6.	0.4	1
4726	Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance. <i>Cancers</i> , 2023, 15, 971.	1.7	3
4727	Modulation of oxidative phosphorylation and mitochondrial biogenesis by cigarette smoke influence the response to immune therapy in NSCLC patients. <i>Lung Cancer</i> , 2023, 178, 37-46.	0.9	0
4728	Tumor-immune microenvironment lab chip integrating liquid-dielectrophoresis operation. <i>Japanese Journal of Applied Physics</i> , 2023, 62, SC1049.	0.8	0
4730	Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial. <i>Lung Cancer</i> , 2023, 178, 96-102.	0.9	1
4731	Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
4732	Long-Term Response of Pembrolizumab in a Patient with Metastatic Squamous Non-Small Cell Lung Cancer on Hemodialysis: Case Report and Review of the Literature. <i>Medicina (Lithuania)</i> , 2023, 59, 325.	0.8	3
4733	Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2023, 4, 100474.	0.6	0
4734	Prediction of CD3 T cells and CD8 T cells expression levels in non-small cell lung cancer based on radiomic features of CT images. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
4735	Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3618.	1.8	6
4736	TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
4737	Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
4738	<it>Salmonella typhimurium</it> may support cancer treatment: a review. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 331-342.	0.9	2
4739	The Gut Microbiome and Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2023, 12, 1502.	1.0	3
4740	Progression patterns and site-specific responses in advanced gastric cancer patients treated with nivolumab. <i>Cancer Medicine</i> , 0, , .	1.3	1

#	ARTICLE	IF	CITATIONS
4741	ALK-positive lung cancer: a moving target. <i>Nature Cancer</i> , 2023, 4, 330-343.	5.7	24
4742	Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
4743	Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	6
4744	The past, present, and future of immunotherapy for colorectal cancer. , 2023, 40, .		3
4745	Adjuvant and neoâ€adjvant immunotherapy in resectable nonâ€small cell lung cancer (NSCLC): Current status and perspectives. , 2023, 2, 65-78.		0
4746	NLRC3 is a potential prognostic biomarker that is correlated with immune cell infiltration in lung adenocarcinoma. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
4747	MTSS1 curtails lung adenocarcinoma immune evasion by promoting AIP4-mediated PD-L1 monoubiquitination and lysosomal degradation. <i>Cell Discovery</i> , 2023, 9, .	3.1	5
4748	The role of LncRNAs in tumor immunotherapy. <i>Cancer Cell International</i> , 2023, 23, .	1.8	11
4749	Using deep learning to predict tumor mutational burden from scans of H&E-stained multicenter slides of lung squamous cell carcinoma. <i>Journal of Medical Imaging</i> , 2023, 10, .	0.8	1
4750	Lung cancer immunotherapy: progress, pitfalls, and promises. <i>Molecular Cancer</i> , 2023, 22, .	7.9	104
4751	PD-L1 and MHC Class I Expression in High-grade Ovarian Cancers, Including Platinum-resistant Recurrences Treated With Checkpoint Inhibitor Therapy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2023, 31, 197-203.	0.6	2
4752	Killer to cure: Expression and production costs calculation of tobacco plantâ€made cancerâ€immune checkpoint inhibitors. <i>Plant Biotechnology Journal</i> , 2023, 21, 1254-1269.	4.1	4
4753	Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
4754	Non-small cell lung cancer: news from immunotherapy. <i>Journal of Lung, Pulmonary & Respiratory Research</i> , 2022, 9, 8-10.	0.3	0
4755	⁺ CD169</sup> sinus macrophages in regional lymph nodes do not predict mismatchâ€repair status of patients with colorectal cancer. <i>Cancer Medicine</i> , 2023, 12, 10199-10211.	1.3	5
4756	Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study (CAP29). <i>Translational Lung Cancer Research</i> , 2023, 12, 266-276.	1.3	2
4757	Proteomics: A modern tool for identifying therapeutic targets in different types of carcinomas. , 2023, , 333-362.		0
4758	Myeloid cells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1

#	ARTICLE	IF	CITATIONS
4760	Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer. <i>Cancers</i> , 2023, 15, 1532.	1.7	6
4761	Correlation of 18F-FDG PET/CT metabolic parameters with the expression of immune biomarkers in the tumour microenvironment in lung adenocarcinoma. <i>Clinical Radiology</i> , 2023, , .	0.5	0
4762	Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC). <i>Praxis</i> , 2023, 112, 143-147.	0.2	1
4763	Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
4764	Diversity of immune checkpoints in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
4766	Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
4767	Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
4768	PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitorsâ€™ Response and Survival in Advanced Melanoma Patients in Brazil. <i>Diagnostics</i> , 2023, 13, 1041.	1.3	1
4769	Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy. <i>JAMA Oncology</i> , 2023, 9, 627.	3.4	15
4770	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
4771	Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2023, 23, 231-241.	1.5	1
4772	Anti-PD-(L)1 therapy of non-small cell lung cancerâ€™A summary of clinical trials and current progresses. <i>Heliyon</i> , 2023, 9, e14566.	1.4	2
4773	Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 â‰¥ 50% in Patients Treated in Quebecâ€™s University Teaching Hospitals (DALP-First Study). <i>Current Oncology</i> , 2023, 30, 3251-3262.	0.9	0
4774	The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. , 2023, , 1-32.		0
4775	Trends in Survival Rates of Nonâ€™Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. <i>JAMA Network Open</i> , 2023, 6, e232002.	2.8	7
4776	NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know. <i>Diagnostics</i> , 2023, 13, 1117.	1.3	1
4777	Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review. <i>Journal of Cosmetic Dermatology</i> , 2023, 22, 2150-2157.	0.8	3
4778	Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311614.	1.4	8

#	ARTICLE	IF	CITATIONS
4779	Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2023, .	1.3	1
4780	Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer. <i>Journal of Materials Chemistry B</i> , 2023, 11, 3453-3472.	2.9	9
4781	Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2023, 15, 1909.	1.7	4
4782	Towards a consensus definition of immune exclusion in cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
4783	Hsa_circ_0003528 promotes cell malignant transformation and immune escape via increasing oncogene <i>PDL1</i> through sponging <i>miR-5113p</i> in non-small cell lung cancer. <i>Environmental Toxicology</i> , 0, .	2.1	1
4784	Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 361-368.	1.1	1
4785	Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
4786	Ganglioglioma deep transcriptomics reveals primitive neuroectoderm neural precursor-like population. <i>Acta Neuropathologica Communications</i> , 2023, 11, .	2.4	0
4787	Immune Checkpoint Blockade Response Biomarkers. , 2023, , 1-34.		0
4788	Personalized Immuno-Oncology with Immunodeficiency Mouse Models. , 2023, , .		0
4789	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. <i>Biomedicines</i> , 2023, 11, 1020.	1.4	6
4790	Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2023, 15, 1968.	1.7	7
4791	APC mutation correlated with poor response of immunotherapy in colon cancer. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	1
4792	Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapy. <i>Cancer Nanotechnology</i> , 2023, 14, .	1.9	2
4793	Immunogenic hypofractionated radiotherapy sensitising head and neck squamous cell carcinoma to anti-PD-L1 therapy in MDSC-dependent manner. <i>British Journal of Cancer</i> , 2023, 128, 2126-2139.	2.9	5
4794	Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	14
4795	Newly developed 3D in vitro models to study tumor-immune interaction. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	11
4796	Advancing Cancer Immunotherapy Through Integrating Molecular and Computational Approaches. , 2023, , 1-22.		0

#	ARTICLE	IF	CITATIONS
4797	Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2023, 221, 409-424.	1.0	2
4799	Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2023, , .	1.5	3
4800	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. <i>Healthcare (Switzerland)</i> , 2023, 11, 1073.	1.0	0
4801	Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?. <i>Nature Reviews Clinical Oncology</i> , 0, , .	12.5	0
4802	Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. <i>British Journal of Cancer</i> , 2023, 129, 185-203.	2.9	6
4803	Cuproptosis-related molecular subtypes direct T cell exhaustion phenotypes and therapeutic strategies for patients with lung adenocarcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
4804	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. <i>Cancer Reports</i> , 2023, 6, .	0.6	4
4805	Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. <i>Cancers</i> , 2023, 15, 2273.	1.7	2
4806	Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. <i>Pharmaceutics</i> , 2023, 15, 1252.	2.0	7
4807	Prediction of Radiation-induced Lymphopenia following Exposure of the Thoracic Region and Associated Risk of Infections and Mortality. <i>Clinical Oncology</i> , 2023, 35, e434-e444.	0.6	1
4808	Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. <i>World Journal of Cancer Research</i> , 2023, 13, 37-43.	0.1	0
4809	PD-L1 and PD-L2 immune checkpoint protein induction by type III interferon in non-small cell lung cancer cells. <i>Immunobiology</i> , 2023, 228, 152389.	0.8	4
4810	Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	8
4811	Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies. <i>Cancers</i> , 2023, 15, 2366.	1.7	3
4812	Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring. <i>Diagnostic Pathology</i> , 2023, 18, .	0.9	3
4813	Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311638.	1.4	0
4814	Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7577.	1.8	2
4815	Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. <i>Pathology Research and Practice</i> , 2023, 246, 154470.	1.0	0

#	ARTICLE	IF	CITATIONS
4816	Baseline neutrophil-to- ratio combined with the change during treatment provides risk stratification for metastatic malignant melanoma patients treated with PD-1 inhibitors in a Chinese population. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
4817	Survival and medical costs of non-small cell lung cancer patients according to the first-line treatment: An observational study using the Kyoto City Integrated Database. <i>Thoracic Cancer</i> , 0, , .	0.8	0
4818	The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma. <i>Journal of Neuro-Oncology</i> , 2023, 163, 1-14.	1.4	2
4820	Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. , 2023, , 1-34.		0
4825	Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 408-422.	12.5	9
4840	Immunotherapy and Cancer: The Pharmacists'™ Perspective. , 2023, , 1-34.		0
4845	Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. , 2023, , 1-33.		0
4852	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
4856	Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma. <i>BioDrugs</i> , 2023, 37, 489-503.	2.2	1
4863	Emerging evidence for adapting radiotherapy to immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 543-557.	12.5	36
4916	Monoclonal Antibodies in Oncology: A Decade of Novel Options. <i>Cell Biochemistry and Biophysics</i> , 0, , .	0.9	1
4934	Aggregation-Induced Emission (AIE), Life and Health. <i>ACS Nano</i> , 2023, 17, 14347-14405.	7.3	48
4948	Roles of RIPK1 as a stress sentinel coordinating cell survival and immunogenic cell death. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 835-852.	16.1	3
4950	Small-Molecule Inhibitors of Protein-Protein Interactions as Therapeutics. , 2023, , 343-428.		0
4970	TAM family kinases as therapeutic targets at the interface of cancer and immunity. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 755-779.	12.5	2
4982	Polymer-mediated nanoformulations: a promising strategy for cancer immunotherapy. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2024, 397, 1311-1326.	1.4	0
5017	Second-line therapy in advanced non-small cell lung cancer. , 2024, , 195-216.		0
5019	First-line therapy. , 2024, , 175-194.		0

#	ARTICLE	IF	CITATIONS
5044	Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with liver metastases. British Journal of Cancer, 0, , .	2.9	0
5097	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
5105	Neuroimmune Interactions. , 2024, , 59-71.		0
5148	Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors. International Review of Cell and Molecular Biology, 2024, , .	1.6	0
5173	Neurologic manifestations of autoimmunity with immune checkpoint inhibitors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 449-465.	1.0	0